analysis_id	phenotype	Lek	BNF_indication_codes	BNF_indication_description	ICD10	ICD10_PL	ICD10_EN	SYMBOL	rsID	Variant_ID	IMPACT	A1_FREQ	BETA_regenie	SE_regenie	LOG10P_disc	OR_plink2	LOG_OR_SE	P_test_PLINK2	A1_CASE_CT	BETA_ICD10	SE_ICD10	LOG10P_ICD10	Z_diff_BETA	AMP_RATIO	N_INDEPENDENT	FAERS_signal	FAERS_PRR	FAERS_IC025	Tissue_call	Tissue_rank	Druggability	PheWAS_call	PheWAS_atlas_traits	PheWAS_top_traits	PheWAS_n_gwas_hits	GWAS_lit_summary	GO_terms	Curator_assessment	TEMP_pct_after	TEMP_pct_before	TEMP_median_days_after	TEMP_n_total	TIER	TIER_NAME	TIER_RATIONALE	NOVELTY_SCORE	RESEARCH_SCORE	APPLICATION_SCORE	TOTAL_GEOMEAN	FLAGS	BETA_dose	SE_dose	LOG10P_dose	BETA_prescribed	SE_prescribed	LOG10P_prescribed	Tissue_tau	Tissue_tau_HPA	Tissue_concordance	Tissue_disagreement_flag	Tissue_zscore_max_GTEx	Tissue_zscore_max_HPA	Tissue_n_mapped	Tissue_map_source	Tissue_MAGMA_minFDR	best_tissue	n_tissues_tested	Tissue_MAGMA_minFDR_magma	best_tissue_magma	n_tissues_tested_magma	Tissue_abs_logTPM_disease	beta_disc_valid_consistency	locus_multiplicity	OT_gene_disease_score	latent_pgx_score	latent_pgx_candidate	internal_pleiotropy	n_collapsed	collapsed_genes	track2_pv_score	track2_pv_candidate	expert_downweight_reason	latent_confidence	TEMP_n_before_exposure	TEMP_n_after_exposure	TEMP_median_years_after	TEMP_median_years_before_exposure	TEMP_q25_days_after	TEMP_q75_days_after	TEMP_pct_missing_dx_date	TEMP_pct_missing_rx_date	Z_STAT	A1_CASE_FREQ	A1_CTRL_FREQ	CASE_HET_A1_CT	CASE_HOM_A1_CT	CTRL_HET_A1_CT	CTRL_HOM_A1_CT	Consequence	BIOTYPE	SIFT	PolyPhen	AF	gmm	gmm_state	gmm_name	epic_unsup	epic_final	epic_source	epic_sup
dzesikahoinkis_plinktestset_2026_04_20_18_24_11_simvastatin__I831	simvastatin__I831	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I831	Żylaki kończyn dolnych z zapaleniem	Varicose veins of lower extr. with inflammation	ABHD14B	rs114011542	3-51964935-G-A	MODIFIER	0.00587682	4.74358	0.915542	6.65659	25.9885	0.836709	9.88437e-05	1.0	-0.0569537	0.287285	0.0742493	5.0	83.29	3	STRONG (ROR+PRR+IC)	2.82	1.09	enriched	46.0	Database Ubiquitination	trait_unrelated		2: body height; 1: level of putative protein-lysine deacylase ABHD14B in blood; 1: protein measurement; 1: N-formylmethionine measurement; 1: N-acetylserine measurement	8.0	Brak asocjacji GWAS Catalog ABHD14B (3p21.1) z żylakami kończyn dolnych (I83.x). Top loci VV: CASZ1, EBF1, PIEZO1, HFE, PPP3R1. ABHD14B ma marginalne sygnały w GWAS cech biochemicznych (głównie cQTL/pQTL); brak GWS dla fenotypów naczyniowych.	GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005730:nucleolus,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0016740:transferase_activity,GO:0016746:acyltransferase_activity	Nie wskazanie. Wspólne czynniki ryzyka naczyniowego (wiek, otyłość, siedzący tryb życia) – słaba komorbidalność. Statyny mają nieznaczne pleiotropowe efekty przeciwzapalne/endotelialne, ale nie leczą varices.	89.683	10.317	1574	126	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.82 + replikacja OR+P_test OR=25.99/P_test=0.000 + tissue enriched)	10	9	8	8.96	LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n8; CURATOR_NOT_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[ABHD14B|DUSP7|PCBP4|RPL29|RRP9]	-0.0148154	0.019688	0.345107	-0.0857839	0.0607496	0.801554	0.4578632054170726	0.7189280829724185	0.7802447127461307	0.0	0.4576070025426964	-0.023556090639889126	2	curated	0.36641	Artery - Tibial	2.0	0.36641	Artery - Tibial	2.0	3.941168129883823	-0.5027864051178873	7	0.0	0.19374308011002656	0	1	7	-;ABHD14B;DUSP7;PCBP4;RPL29;RRP9	0.16355997880084336	0	comorbidity: statins protective for varicose in large studies; age co-occurrence with the CV indication	HIGH replicated	13	113	4.3094	5.6947	806	2644	0.0	0	3.89341	0.0357143	0.00519974	1	0	63	0	downstream_gene_variant	protein_coding	-	-	0.003	C3	E	Replicated drug-triggered signal	E	C	confounder	E
dzesikahoinkis_plinktestset_2026_04_20_18_24_11_simvastatin__I831	simvastatin__I831	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I831	Żylaki kończyn dolnych z zapaleniem	Varicose veins of lower extr. with inflammation	DOCK3	rs115598170	3-51070309-T-C	MODIFIER	0.00647519	4.31753	0.881183	6.01779	21.436	0.816947	0.000175529	1.0	0.127389	0.280821	0.187023	4.53	33.89	3	STRONG (ROR+PRR+IC)	2.82	1.09	enriched	42.0	GO CC med conf	trait_unrelated		20: body height; 12: eosinophil count; 9: body mass index; 7: BMI-adjusted waist circumference; 6: hematological measurement	181.0	DOCK3 / Varicose veins (I83.1). Brak asocjacji GWAS Catalog DOCK3 (3p21.2) z żylakami. DOCK3 (Dedicator of Cytokinesis 3) - znany z Mendlowskiej intellectual disability z cerebellar atrofią (biallelic LoF), rola w wzroście axonów i Rho-GTPase signaling. Top loci GWAS VV: CASZ1, EBF1, PIEZO1, HFE, PPP3R1 (Fukaya 2018, Ahmed 2023) - bez DOCK3.	GO:0005085:guanyl-nucleotide_exchange_factor_activity,GO:0005096:GTPase_activator_activity,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0007264:small_GTPase-mediated_signal_transduction,GO:0017124:,GO:0031267:small_GTPase_binding,GO:0048011:neurotrophin_TRK_receptor_signaling_pathway,GO:0051056:regulation_of_small_GTPase_mediated_signal_transduction	Nie wskazanie. Wspólne czynniki ryzyka naczyniowego (wiek, otyłość, siedzący tryb życia) – słaba komorbidalność. Statyny mają nieznaczne pleiotropowe efekty przeciwzapalne/endotelialne, ale nie leczą varices.	89.683	10.317	1574	126	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.82 + replikacja OR+P_test OR=21.44/P_test=0.000 + tissue enriched)	9	9	8	8.65	LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n181; CURATOR_NOT_INDICATION	0.00606229	0.0190844	0.124507	-0.1123	0.0585683	1.25818	0.8499823607103993	0.8168754119973634	0.9084352969775543	0.0	0.07690061182647828	-0.07186979691726393	2	curated	0.36641	Artery - Tibial	2.0	0.36641	Artery - Tibial	2.0	1.7483351332191996	-0.47925038664895	1	0.03788193510518193	0.19101989729513966	0	1	1	DOCK3	0.1535936777551983	0	comorbidity: statins protective for varicose in large studies; age co-occurrence with the CV indication	HIGH replicated	13	113	4.3094	5.6947	806	2644	0.0	0	3.75186	0.0357143	0.00693298	1	0	84	0	intron_variant	protein_coding	-	-	0.0024	C3	E	Replicated drug-triggered signal	E	C	confounder	E
dzesikahoinkis_plinktestset_2026_04_20_18_24_11_simvastatin__I831	simvastatin__I831	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I831	Żylaki kończyn dolnych z zapaleniem	Varicose veins of lower extr. with inflammation	CHRM2	rs55761735	7-137009844-C-T	MODIFIER	0.0209429	3.08079	0.54719	7.7447	7.49114	0.60407	0.000857338	2.0	0.200809	0.157845	0.691852	5.06	15.34	2	STRONG (ROR+PRR+IC)	2.82	1.09	expressed	47.0	Approved Drug	trait_unrelated		9: heart rate; 7: vaginal microbiome measurement; 7: bone tissue density; 6: heart rate response to recovery post exercise; 4: pulse pressure measurement	62.0	Brak asocjacji GWAS Catalog dla CHRM2 (7q33) z varicose veins (I83.x). Top loci VV: CASZ1, EBF1, PIEZO1, HFE (Fukaya 2018, Ahmed 2023). CHRM2 natomiast GWS dla: heart rate recovery po wysiłku, heart rate variability (van de Vegte 2023), cognitive ability/IQ, EEG oscillations, alcohol dependence (COGA), blood pressure.	GO:0004930:G_protein-coupled_receptor_activity,GO:0005730:nucleolus,GO:0005794:Golgi_apparatus,GO:0005886:plasma_membrane,GO:0005929:cilium,GO:0006940:regulation_of_smooth_muscle_contraction,GO:0007165:signal_transduction,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007187:G_protein-coupled_receptor_signaling_pathway_-_coupled_to_cyclic_nucleotide_second_messenger,GO:0007188:adenylate_cyclase-modulating_G_protein-coupled_receptor_signaling_pathway,GO:0007197:adenylate_cyclase-inhibiting_G_protein-coupled_acetylcholine_receptor_signaling_pathway,GO:0007207:phospholipase_C-activating_G_protein-coupled_acetylcholine_receptor_signaling_pathway,GO:0007213:G_protein-coupled_acetylcholine_receptor_signaling_pathway,GO:0007268:chemical_synaptic_transmission,GO:0007399:nervous_system_development,GO:0008016:regulation_of_heart_contraction,GO:0009615:response_to_virus,GO:0016020:membrane,GO:0016907:G_protein-coupled_acetylcholine_receptor_activity,GO:0030054:cell_junction,GO:0030425:dendrite,GO:0030669:clathrin-coated_endocytic_vesicle_membrane,GO:0036064:ciliary_basal_body,GO:0045202:synapse,GO:0045211:postsynaptic_membrane,GO:0098793:presynapse,GO:1990763:arrestin_family_protein_binding	Nie wskazanie. Wspólne czynniki ryzyka naczyniowego (wiek, otyłość, siedzący tryb życia) – słaba komorbidalność. Statyny mają nieznaczne pleiotropowe efekty przeciwzapalne/endotelialne, ale nie leczą varices.	89.683	10.317	1574	126	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	6	10	7	7.49	LIT_NO_PRIOR_HIT; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs55761735; LOCUS_HETEROGENEOUS_SAME_GENE	-0.0031462	0.0105358	0.116208	0.0209202	0.0339046	0.269853	0.9637294514500008	0.9131187761581757	0.7465359371201684	0.0	-0.5306357653995358	-0.6351125489877948	2	curated	0.36641	Artery - Tibial	2.0	0.36641	Artery - Tibial	2.0	0.019172919267767655	-0.2709729288153355	2	0.0	0.19638950614739586	0	1	2	CHRM2;ENSG00000234352	0.19429901207518066	0	comorbidity: statins protective for varicose in large studies; age co-occurrence with the CV indication	HIGH replicated	13	113	4.3094	5.6947	806	2644	0.0	0	3.33359	0.0714286	0.0216243	2	0	256	3	intron_variant	protein_coding	-	-	0.006	C3	E	Replicated drug-triggered signal	E	C	confounder	C
dzesikahoinkis_plinktestset_2026_04_20_17_24_26_ramipril__H931	ramipril__H931	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	H931	Szumy uszne	Tinnitus	AGTPBP1	rs148133930	9-85557777-A-G	MODIFIER	0.00488736	10.4616	1.51815	11.2565	8.4441	1.36484	0.118013	0.0	-0.0800995	0.228442	0.139145	6.87	130.61	3	STRONG (ROR+PRR+IC)	2.52	1.15	enriched	43.0	GO CC high conf	trait_unrelated		3: gut microbiome measurement, allergen exposure measurement; 1: breast carcinoma; 1: colorectal cancer; 1: CCL3 measurement; 1: facial pigmentation	12.0	Brak bezpośredniej asocjacji GWAS Catalog z tinnitus (H93.1). AGTPBP1 (CCP1) związany głównie z rzadką chorobą Mendlowską CONDCA (OMIM 618276) - autosomalnie recesywną neurodegeneracją z atrofią móżdżku i neuropatią motoryczną. Brak GWAS-level common-variant signals z fenotypami słuchowymi.	GO:0004180:carboxypeptidase_activity,GO:0004181:metallocarboxypeptidase_activity,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005739:mitochondrion,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0005929:cilium,GO:0006508:proteolysis,GO:0008233:peptidase_activity,GO:0008237:metallopeptidase_activity,GO:0008270:zinc_ion_binding,GO:0016787:hydrolase_activity,GO:0034451:centriolar_satellite,GO:0036064:ciliary_basal_body,GO:0046872:metal_ion_binding	Nie wskazanie. Tinnitus opisywany w SmPC ACEi jako rzadkie działanie niepożądane; sygnał rzadki, ale obecny w pharmacovigilance (WHO-UMC VigiBase).	88.889	11.111	1107	99	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.52 + replikacja OR-based OR=8.44/P_test=0.118 + tissue enriched)	10	10	8	9.28	LOW_POWER_HIGH_OR; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n12; CURATOR_NOT_INDICATION	-0.0402997	0.0445723	0.436614	-0.0216735	0.0799038	0.104465	0.6559488568770191	0.8344641016832702	0.6390892148124138	0.0	0.714529787750964	1.3700777078092943	2	curated_weak							2.8213788864092133	-0.23568264573083508	1	0.0	0.557923121388643	0	1	1	AGTPBP1	0.6359789701817539	0		MED repl-underpowered	11	88	3.0308	4.0821	497	2292	0.0	0	1.56317	0.0	0.00500589	0	0	34	0	intron_variant	protein_coding	-	-	0.0024	C4	I	Pre-existing condition (timing only)	I	I	model	E
dzesikahoinkis_plinktestset_2026_04_20_17_24_26_ramipril__H931	ramipril__H931	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	H931	Szumy uszne	Tinnitus	RAB9A	rs191504316	X-13687533-T-A	MODIFIER	0.00714013	5.91045	1.14819	6.5787	3.44393	0.727168	0.0890202	0.0	0.105916	0.145169	0.331957	5.02	55.8	3	STRONG (ROR+PRR+IC)	2.52	1.15	enriched	102.0	UniProt loc high conf	trait_unrelated		1: Red cell distribution width	1.0		-	Nie wskazanie. Tinnitus opisywany w SmPC ACEi jako rzadkie działanie niepożądane; sygnał rzadki, ale obecny w pharmacovigilance (WHO-UMC VigiBase).	88.889	11.111	1107	99	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.52 + replikacja OR-based OR=3.44/P_test=0.089 + tissue enriched)	9	9	8	8.65	LOW_POWER_HIGH_OR; LOW_PLEIOTROPY_n1; CURATOR_NOT_INDICATION	0.0270194	0.0299753	0.434882	-0.0702637	0.0527822	0.737258	0.6587553947111631	0.5219696620406657	0.5318045539259378	0.0	0.9606926288920775	-0.9268829772862417	2	curated_weak							3.4708726869048787	-0.1572357659238264	1	0.0	0.5569153432931004	1	1	1	RAB9A	0.5265330132878795	1		HIGH replicated	11	88	3.0308	4.0821	497	2292	0.0	0	1.70059	0.0	0.00853946	0	0	16	21	upstream_gene_variant	protein_coding	-	-	0.0016	C4	I	Pre-existing condition (timing only)	I	I	model	E
dzesikahoinkis_plinktestset_2026_04_20_14_30_54_citalopram__K317	citalopram__K317	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	K317	Polip żołądka/dwunastnicy	Polyp of stomach and duodenum	N4BP3	rs151112840	5-178113919-G-A	MODIFIER	0.0113313	4.26555	0.819467	6.71286	4.98657	0.73517	0.0288489	1.0	0.059844	0.116946	0.215494	5.08	71.28	3	STRONG (ROR+PRR+IC)	5.26	1.89	enriched	36.0	Database Ubiquitination	trait_unrelated		2: body height; 1: cystine measurement; 1: bone tissue density; 1: blood protein amount; 1: health trait	6.0		GO:0002376:immune_system_process,GO:0005515:protein_binding,GO:0007399:nervous_system_development,GO:0030424:axon,GO:0030425:dendrite,GO:0031410:cytoplasmic_vesicle,GO:0042995:cell_projection,GO:0045087:innate_immune_response	Brak wskazania.	100.0	0.0	1579	102	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=5.26 + replikacja OR-based OR=4.99/P_test=0.029 + tissue enriched)	9	9	8	8.65	LOW_PLEIOTROPY_n6	0.0138851	0.0195893	0.320172	0.0354414	0.0619685	0.246133	0.8617999034458919	0.7693288697592858	0.5865813143181264	0.0	0.06606286743208736	-0.39813266074313597	2	curated							1.3060112078749677	-0.06848676103935283	1	0.0	0.6498553798692331	1	1	1	N4BP3	0.5813787576667371	1		HIGH replicated	0	102	4.3231		636	2817	0.0	0	2.18555	0.0277778	0.0088047	1	0	31	1	intron_variant	protein_coding	-	-	0.0038	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_14_30_54_citalopram__K317	citalopram__K317	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	K317	Polip żołądka/dwunastnicy	Polyp of stomach and duodenum	NFIB	rs142651685	9-14115218-G-C	MODIFIER	0.00644592	4.95252	1.00414	6.08963	10.6332	0.699483	0.00072587	2.0	-0.0869122	0.142232	0.266674	4.97	56.98	3	STRONG (ROR+PRR+IC)	5.26	1.89	enriched	36.0	Database Ubiquitination	trait_unrelated		17: educational attainment; 14: self reported educational attainment; 14: memory impairment; 12: body height; 10: body mass index	196.0	NFIB / Polyp of stomach and duodenum (K31.7). Brak asocjacji GWAS Catalog NFIB (9p23-p22.3) z polipami żołądka/dwunastnicy. NFIB (Nuclear Factor IB) - czynnik transkrypcyjny; GWAS głównie: cechy płucne (FEV1/FVC, COPD), rak piersi, glioma, schizofrenia. Brak GWS dla fenotypów GI/polipowych.	GO:0003700:DNA-binding_transcription_factor_activity,GO:0005634:nucleus,GO:0006355:regulation_of_DNA-templated_transcription	Brak wskazania.	100.0	0.0	1579	102	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=6.1<7.5 (artefakt opposite-sign)	8	9	6	7.56	LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n196	0.0276937	0.0247198	0.58073	-0.0180461	0.076387	0.08978	0.6524493047817229	0.583484691229891	0.5139777975852847	0.0	0.1368697828736977	-0.2640721333243362	2	curated							2.657605669220852	-0.2334271107373602	1	0.0022174791281082107	0.6769535580393076	0	1	1	NFIB	0.5294157961392639	0		HIGH replicated	0	102	4.3231		636	2817	0.0	0	3.37962	0.0555556	0.00747065	2	0	28	0	intron_variant	protein_coding	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_26_33_atenolol__R634	atenolol__R634	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R634	Nieprawidłowa utrata masy ciała	Abnormal weight loss	PPP1R12B	rs143365951	1-202410290-A-G	MODIFIER	0.00564703	4.66079	0.906782	6.56091	9.28621	0.800542	0.00537302	2.0	-0.0132266	0.135645	0.0351173	5.1	352.38	3	STRONG (ROR+PRR+IC)	2.06	0.96	enriched	74.0	Human Protein Atlas loc	trait_unrelated		3: acne; 2: open-angle glaucoma; 2: cerebral cortex area attribute; 1: sex ratio; 1: estradiol measurement	19.0		GO:0001725:stress_fiber,GO:0004857:enzyme_inhibitor_activity,GO:0005515:protein_binding,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0005856:cytoskeleton,GO:0006937:regulation_of_muscle_contraction,GO:0007165:signal_transduction,GO:0008047:enzyme_activator_activity,GO:0017020:,GO:0019208:phosphatase_regulator_activity,GO:0019901:protein_kinase_binding,GO:0030018:Z_disc,GO:0031672:A_band,GO:0048812:neuron_projection_morphogenesis	Brak wskazania.	100.0	0.0	2654	153	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.06 + replikacja OR+P_test OR=9.29/P_test=0.005 + tissue enriched)	10	8	8	8.62	LOW_PLEIOTROPY_n19	0.0198706	0.0331626	0.260389	-0.128298	0.0857041	0.871609	0.8119157512087639	0.8173976448284663	0.7533425168138723	0.0	0.2025318805246732	0.07466730765332048	3	curated							3.3957693431465548	-0.21629256502782288	1	0.0	0.6211495665634291	0	1	1	PPP1R12B	0.5187787379057726	0		HIGH replicated	0	153	7.2663		1180	4451	0.0	0	2.78378	0.037037	0.00638468	2	0	32	0	intron_variant	protein_coding	-	-	0.0018	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_14_17_29_citalopram__A099	citalopram__A099	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	A099	Zapalenie żołądka i jelit	Gastroenteritis	ADAM22	rs145737307	7-88134075-A-G	MODIFIER	0.00508889	4.1888	0.819367	6.49709	6.90762	0.670542	0.0039493	2.0	0.150926	0.133328	0.588989	4.86	27.75	3	STRONG (ROR+PRR+IC)	2.33	0.93	enriched	51.0	UniProt loc high conf	trait_unrelated		8: level of disintegrin and metalloproteinase domain-containing protein 22 in blood; 3: body height; 3: gut microbiome measurement; 2: blood protein amount; 2: protein measurement	31.0		GO:0004222:metalloendopeptidase_activity,GO:0005178:integrin_binding,GO:0005515:protein_binding,GO:0005886:plasma_membrane,GO:0006508:proteolysis,GO:0007155:cell_adhesion,GO:0007162:negative_regulation_of_cell_adhesion,GO:0007417:central_nervous_system_development,GO:0008237:metallopeptidase_activity,GO:0016020:membrane,GO:0030424:axon,GO:0038023:signaling_receptor_activity,GO:0042995:cell_projection,GO:0050806:positive_regulation_of_synaptic_transmission,GO:0098839:	Nie wskazanie. Zaburzenia GI (nudności, biegunka) – najczęstsze ADR SSRI (>20%), ale gastroenteritis jako kod koincydencja.	100.0	0.0	1604	183	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.33 + replikacja OR+P_test OR=6.91/P_test=0.004 + tissue enriched)	9	8	8	8.32	CURATOR_NOT_INDICATION	-0.0201994	0.0278168	0.329994	-0.00420298	0.0850445	0.0174647	0.9414149279441909	0.8786054043113045	0.7956405477676038	0.0	-0.44201173014212086	-0.7159445736707402	4	curated							0.9693233128255242	-0.16674937242717536	1	0.0	0.6167277005209721	1	1	1	ADAM22	0.5040380849628652	1		HIGH replicated	0	183	4.3915		674	2872	0.0	0	2.88218	0.0416667	0.00642398	2	0	24	0	intron_variant	protein_coding	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_15_35_35_fluoxetine__R55	fluoxetine__R55	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	R55	Omdlenie i zapaść	Syncope and collapse	CDH22	rs192620892	20-46262088-G-A	MODIFIER	0.00968962	3.60741	0.695956	6.66175	4.9653	0.737416	0.0297734	2.0	0.0312998	0.1034	0.11798	5.08	115.25	3	STRONG (ROR+PRR+IC)	2.18	0.99	enriched	12.0	UniProt loc med conf	trait_unrelated		9: body mass index; 4: body height; 4: tumor necrosis factor, receptor superfamily, member 5 measurement; 3: diet measurement; 3: mathematical ability	67.0		GO:0000902:cell_morphogenesis,GO:0005509:calcium_ion_binding,GO:0005886:plasma_membrane,GO:0005912:adherens_junction,GO:0007043:cell-cell_junction_assembly,GO:0007155:cell_adhesion,GO:0007156:homophilic_cell_adhesion_via_plasma_membrane_adhesion_molecules,GO:0008013:beta-catenin_binding,GO:0016020:membrane,GO:0016339:,GO:0016342:,GO:0016477:cell_migration,GO:0034332:adherens_junction_organization,GO:0044331:cell-cell_adhesion_mediated_by_cadherin,GO:0045296:cadherin_binding,GO:0046872:metal_ion_binding,GO:0098609:cell-cell_adhesion	Nie wskazanie. SSRI → SIADH/hiponatremia (szczególnie u starszych) + ortostaza → omdlenia. Udokumentowany związek.	95.0	0.83333	1519	120	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.18 + replikacja OR-based OR=4.97/P_test=0.030 + tissue enriched)	9	8	8	8.32	CURATOR_NOT_INDICATION	-0.0192131	0.0117389	0.992707	0.0468585	0.0747048	0.275318	0.9572690950366141	0.9262860557336086	0.83372498176809	0.0	2.240314036428488	2.058037532919885	5	curated	0.89852	Whole Blood	1.0	0.89852	Whole Blood	1.0	3.0975575476025647	-0.11548505388254471	1	0.0	0.5873893559907976	1	1	1	CDH22	0.5261379353808899	1		HIGH replicated	1	114	4.1588	0.065708	450	3228	4.1667	0	2.17309	0.0526316	0.0115783	2	0	34	2	intron_variant	protein_coding	-	-	0.0046	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_17_06_17_ramipril__A099	ramipril__A099	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	A099	Zapalenie żołądka i jelit	Gastroenteritis	PTPRD	rs72698987	9-10425290-A-G	MODIFIER	0.0163039	1.82066	0.337182	7.17538	2.74614	0.487701	0.0383269	5.0	0.126916	0.0767521	1.00784	4.9	14.35	3	STRONG (ROR+PRR+IC)	2.93	1.25	enriched	28.0	GO CC high conf	trait_unrelated		20: restless legs syndrome; 19: insomnia; 17: body mass index; 13: systolic blood pressure; 12: body height	438.0		GO:0004721:phosphoprotein_phosphatase_activity,GO:0004725:protein_tyrosine_phosphatase_activity,GO:0005001:transmembrane_receptor_protein_tyrosine_phosphatase_activity,GO:0005102:signaling_receptor_binding,GO:0005515:protein_binding,GO:0005886:plasma_membrane,GO:0006470:protein_dephosphorylation,GO:0006796:phosphate-containing_compound_metabolic_process,GO:0007157:heterophilic_cell-cell_adhesion_via_plasma_membrane_cell_adhesion_molecules,GO:0007165:signal_transduction,GO:0007185:cell_surface_receptor_protein_tyrosine_phosphatase_signaling_pathway,GO:0007399:nervous_system_development,GO:0016020:membrane,GO:0016311:dephosphorylation,GO:0016787:hydrolase_activity,GO:0030182:neuron_differentiation,GO:0042734:presynaptic_membrane,GO:0046426:negative_regulation_of_receptor_signaling_pathway_via_JAK-STAT,GO:0050775:positive_regulation_of_dendrite_morphogenesis,GO:0050776:regulation_of_immune_response,GO:0050804:modulation_of_chemical_synaptic_transmission,GO:0050839:cell_adhesion_molecule_binding,GO:0051965:positive_regulation_of_synapse_assembly,GO:0061003:positive_regulation_of_dendritic_spine_morphogenesis,GO:0070062:,GO:0097105:presynaptic_membrane_assembly,GO:0098685:,GO:0098686:,GO:0098978:glutamatergic_synapse,GO:0099054:,GO:0099151:regulation_of_postsynaptic_density_assembly,GO:0099537:trans-synaptic_signaling,GO:0099545:,GO:0099560:	Brak wskazania.	100.0	0.0	1961	401	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.93 + replikacja OR-based OR=2.75/P_test=0.038 + tissue enriched)	8	9	8	8.32	HIGH_PLEIOTROPY_n438	-0.0224254	0.0249914	0.432333	0.056461	0.0458047	0.662127	0.8821271229467128	0.8142589118198873	0.8671096345514949	0.0	0.2179782120484331	0.11503647725865776	4	curated							1.9007125239826015	-0.07800492764282485	1	0.0	0.5937983517782971	1	1	1	PTPRD	0.537152163541798	1		HIGH replicated	0	401	5.3361		899	3233	0.0	0	2.07134	0.0438596	0.0163886	5	0	110	0	intron_variant	protein_coding	-	-	0.0048	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_17_43_56_ramipril__R35	ramipril__R35	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	R35	Wielomocz	Polyuria	UBR5	rs138518996	8-102263442-A-C	MODIFIER	0.00767468	4.32851	0.823407	6.834	7.06354	0.65141	0.00269007	1.0	0.427454	0.176895	1.80483	4.63	10.13	3	STRONG (ROR+PRR+IC)	4.52	1.85	enriched	86.0	Structure with Ligand	trait_unrelated		10: erythrocyte volume; 4: mean corpuscular hemoglobin; 4: insomnia; 3: mean corpuscular hemoglobin concentration; 2: mathematical ability	40.0	UBR5 / Polyuria (R35). Brak asocjacji GWAS Catalog UBR5 (8q22.3) z wielomoczem. UBR5 (E3 ubiquitin ligase) - somatyczne mutacje w chłoniaku Mantle cell, niektórych rakach; GWAS głównie dla cech antropometrycznych. Brak GWS dla R35 ani dla ADR ramiprylu.	GO:0000209:protein_polyubiquitination,GO:0000785:chromatin,GO:0003723:RNA_binding,GO:0004842:ubiquitin-protein_transferase_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0006281:DNA_repair,GO:0006974:DNA_damage_response,GO:0006979:response_to_oxidative_stress,GO:0008270:zinc_ion_binding,GO:0010498:proteasomal_protein_catabolic_process,GO:0010628:positive_regulation_of_gene_expression,GO:0016020:membrane,GO:0016567:protein_ubiquitination,GO:0016740:transferase_activity,GO:0030520:estrogen_receptor_signaling_pathway,GO:0032991:protein-containing_complex,GO:0033696:heterochromatin_boundary_formation,GO:0034450:ubiquitin-ubiquitin_ligase_activity,GO:0035519:protein_K29-linked_ubiquitination,GO:0042307:,GO:0043130:ubiquitin_binding,GO:0043161:proteasome-mediated_ubiquitin-dependent_protein_catabolic_process,GO:0045879:negative_regulation_of_smoothened_signaling_pathway,GO:0046872:metal_ion_binding,GO:0048384:retinoic_acid_receptor_signaling_pathway,GO:0048471:perinuclear_region_of_cytoplasm,GO:0050847:progesterone_receptor_signaling_pathway,GO:0061630:ubiquitin_protein_ligase_activity,GO:0070561:,GO:0070936:protein_K48-linked_ubiquitination,GO:0070979:protein_K11-linked_ubiquitination,GO:0071629:cytoplasm_protein_quality_control_by_the_ubiquitin-proteasome_system,GO:0071630:nuclear_protein_quality_control_by_the_ubiquitin-proteasome_system,GO:0090263:positive_regulation_of_canonical_Wnt_signaling_pathway,GO:0140455:cytoplasm_protein_quality_control,GO:0140861:DNA_repair-dependent_chromatin_remodeling,GO:0141198:protein_branched_polyubiquitination	Nie wskazanie. Poliuria nie jest ADR ACEi. Koincydencja z DM nieleczoną.	96.667	0.0	1283	120	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=4.52 + replikacja OR+P_test OR=7.06/P_test=0.003 + tissue enriched)	7	9	9	8.28	LIT_NO_PRIOR_HIT; CURATOR_NOT_INDICATION	-0.0214275	0.0362086	0.256492	0.0174115	0.0650698	0.102911	0.7765665503608771	0.4437639791245074	0.5745887691435053	0.0	0.7783671275163581	0.5614294836516488	3	curated							3.615983439550521	-0.16286007277717254	1	0.0	0.6078853059163769	1	1	1	UBR5	0.5172024855503946	1		HIGH replicated	0	116	3.5127		606	2688	3.3333	0	3.0011	0.0357143	0.00779641	1	0	51	1	intron_variant	protein_coding	-	-	0.0028	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_11_00_04_amlodipine__E86	amlodipine__E86	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	E86	Zmniejszenie objętości płynu	Volume depletion	XPO6	rs77625269	16-28093273-T-C	MODIFIER	0.0120658	2.65167	0.523073	6.39899	5.46936	0.532044	0.00140487	4.0	0.142187	0.111632	0.693006	4.69	18.65	3	STRONG (ROR+PRR+IC)	2.1	0.99	enriched	89.0	GO CC high conf	trait_unrelated		4: monocyte count; 3: leukocyte quantity; 3: apolipoprotein A 1 measurement; 3: alkaline phosphatase measurement; 3: glomerular filtration rate	39.0	XPO6 / Volume depletion (E86). Brak asocjacji GWAS Catalog XPO6 (16p11.2) z odwodnieniem. XPO6 (exportin 6) - transporter jądrowy aktyny; brak GWS hitów dla fenotypów metabolicznych/płynowych. E86 jako ADR amlodypiny - złożony fenotyp odnoszący się do różnych mechanizmów (stary wiek, odwodnienie, hiponatremia).	GO:0005049:nuclear_export_signal_receptor_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005730:nucleolus,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0006611:protein_export_from_nucleus,GO:0006886:intracellular_protein_transport,GO:0015031:protein_transport,GO:0031267:small_GTPase_binding,GO:0032991:protein-containing_complex	Nie wskazanie. CCB nie powodują odwodnienia bezpośrednio.	98.324	0.0	1703	179	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.10 + replikacja OR+P_test OR=5.47/P_test=0.001 + tissue enriched)	8	8	8	8.0	LIT_NO_PRIOR_HIT; CURATOR_NOT_INDICATION	-0.0104954	0.0123749	0.401897	-0.0774033	0.0493967	0.931366	0.8974446437118075	0.6598251851391842	0.3086459768252167	1.0	-0.5983887203755037	-0.5671180047517597	2	curated	0.96614	Adipose - Subcutaneous	3.0	0.96614	Adipose - Subcutaneous	3.0	3.2872108800414352	-0.2129862432589725	1	0.0	0.6025680277937382	1	1	1	XPO6	0.5002951362692025	1		HIGH replicated	0	176	4.6626		673	3307	1.676	0	3.19365	0.0740741	0.0144389	4	0	99	3	downstream_gene_variant	protein_coding	-	-	0.0034	C3	E	Replicated drug-triggered signal	E	E	model	E
dzesikahoinkis_plinktestset_2026_04_20_15_00_02_diazepam__J449	diazepam__J449	diazepam	F41.1, F10.3, R56.8, G40, M62.4, F51.0, Z51.4	Krótkotrwałe leczenie lęku (F41.1), zespół odstawienny alkoholu (F10.3), drgawki/stan padaczkowy (G40/R56.8), spastyczność mięśni (M62.4), bezsenność krótkotrwała (F51.0), premedykacja (Z51.4)	J449	POChP, nieokreślona	COPD, unspecified	PDE1C	rs150509789	7-32069723-A-C	MODIFIER	0.00810868	5.21149	0.946805	7.43102	8.87036	0.781247	0.00520788	1.0	0.227193	0.109783	1.41451	5.23	22.94	3	STRONG (ROR+PRR+IC)	2.57	1.16	enriched	34.0	Approved Drug	trait_match	3: FEV/FVC ratio	20: body mass index; 13: intelligence; 8: cigarettes per day measurement; 8: PHF-tau measurement; 7: smoking cessation	179.0	Brak asocjacji GWAS Catalog PDE1C (7p14.3) z COPD (J44.9). PDE1C znane z Mendlowskiej autosomalnie dominującej niesyndromowej niedosłuchu (ADNSHL, Wang 2018), ekspresja w komórkach rzęsatych ślimaka. Brak GWS hitów dla funkcji płuc/COPD. Top loci COPD (ICGC 2019, 82 loci): FAM13A, HHIP, CHRNA3/5, TGFB2 - brak PDE1C.	GO:0004114:3'-5'-cyclic-nucleotide_phosphodiesterase_activity,GO:0004115:3'-5'-cyclic-AMP_phosphodiesterase_activity,GO:0004117:calmodulin-activated_dual_specificity_3'-5'-cyclic-GMP_-_3'-5'-cyclic-AMP_phosphodiesterase_activity,GO:0005516:calmodulin_binding,GO:0005764:lysosome,GO:0005829:cytosol,GO:0007165:signal_transduction,GO:0008081:phosphoric_diester_hydrolase_activity,GO:0016787:hydrolase_activity,GO:0043025:neuronal_cell_body,GO:0046872:metal_ion_binding,GO:0047555:3'-5'-cyclic-GMP_phosphodiesterase_activity,GO:0048101:calmodulin-activated_3'-5'-cyclic-GMP_phosphodiesterase_activity,GO:0141162:negative_regulation_of_cAMP/PKA_signal_transduction	Nie wskazanie. BDZ względnie przeciwwskazane w POChP (depresja oddechowa), ALE często stosowane w lęku u pacjentów z POChP/duszności paliatywnej – znaczące nadużywanie w tej populacji. Komorbidalność silniejsza niż sugerowało.	92.929	7.0707	1500	99	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.57 + replikacja OR+P_test OR=8.87/P_test=0.005 + tissue enriched)	4	10	10	7.37	PHEWAS_ATLAS_MATCH; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n179; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs150509789	-0.00600664	0.0237677	0.0966481	-0.0122204	0.0614095	0.0745518	0.7753777719751137	0.8818319387573437	0.8171947167976662	0.0	0.6275626797243153	0.128656959851763	1	curated	0.066645	Lung	1.0	0.066645	Lung	1.0	1.6815539019070291	-0.1629255436946186	2	0.0	0.6159701002211541	1	1	2	PDE1C	0.5738602294784613	1		HIGH replicated	7	92	4.1068	6.8063	99	3889	0.0	0	2.79389	0.0416667	0.00712191	1	0	34	0	intron_variant	protein_coding	-	-	0.0022	C4	I	Pre-existing condition (timing only)	I	I	model	E
dzesikahoinkis_plinktestset_2026_04_20_15_00_02_diazepam__J449	diazepam__J449	diazepam	F41.1, F10.3, R56.8, G40, M62.4, F51.0, Z51.4	Krótkotrwałe leczenie lęku (F41.1), zespół odstawienny alkoholu (F10.3), drgawki/stan padaczkowy (G40/R56.8), spastyczność mięśni (M62.4), bezsenność krótkotrwała (F51.0), premedykacja (Z51.4)	J449	POChP, nieokreślona	COPD, unspecified	CXCL13	rs116032776	4-77601109-C-T	MODIFIER	0.0132161	3.61746	0.69361	6.73657	7.55543	0.606092	0.000848208	2.0	0.0621439	0.0910444	0.305499	5.08	58.21	2	STRONG (ROR+PRR+IC)	2.57	1.16	expressed	34.0	UniProt loc med conf	trait_unrelated		2: rheumatoid arthritis; 2: tonsillectomy risk measurement; 2: neurofibrillary tangles measurement; 1: carotid artery thickness; 1: BMI-adjusted waist circumference	16.0	Brak bezpośredniej asocjacji GWAS Catalog CXCL13 (4q21.1) z COPD w pozycji cechy wiodącej. CXCL13 (B-lymphocyte chemoattractant) - pQTL/cQTL w GWAS plasma proteins; silnie implikowany biologicznie w tworzeniu trzeciorzędowych struktur limfoidalnych w płucach pacjentów z ciężką COPD. Najbliższe GWS loci GWAS: RA, SLE, Sjögren, IgG levels.	GO:0002467:,GO:0002518:lymphocyte_chemotaxis_across_high_endothelial_venule,GO:0002544:,GO:0002920:regulation_of_humoral_immune_response,GO:0005125:cytokine_activity,GO:0005576:extracellular_region,GO:0005615:extracellular_space,GO:0006935:chemotaxis,GO:0006952:defense_response,GO:0006954:inflammatory_response,GO:0006955:immune_response,GO:0007165:signal_transduction,GO:0007166:cell_surface_receptor_signaling_pathway,GO:0007204:positive_regulation_of_cytosolic_calcium_ion_concentration,GO:0007267:cell-cell_signaling,GO:0008009:chemokine_activity,GO:0008201:heparin_binding,GO:0010820:,GO:0017134:,GO:0030593:neutrophil_chemotaxis,GO:0031724:CXCR5_chemokine_receptor_binding,GO:0031735:CCR10_chemokine_receptor_binding,GO:0032487:,GO:0033625:positive_regulation_of_integrin_activation,GO:0033634:positive_regulation_of_cell-cell_adhesion_mediated_by_integrin,GO:0035754:B_cell_chemotaxis,GO:0035768:endothelial_cell_chemotaxis_to_fibroblast_growth_factor,GO:0042742:defense_response_to_bacterium,GO:0045236:CXCR_chemokine_receptor_binding,GO:0045765:regulation_of_angiogenesis,GO:0048018:receptor_ligand_activity,GO:0048248:CXCR3_chemokine_receptor_binding,GO:0060326:cell_chemotaxis,GO:0061844:antimicrobial_humoral_immune_response_mediated_by_antimicrobial_peptide,GO:0070098:chemokine-mediated_signaling_pathway,GO:0071222:cellular_response_to_lipopolysaccharide,GO:2000545:negative_regulation_of_endothelial_cell_chemotaxis_to_fibroblast_growth_factor	Nie wskazanie. BDZ względnie przeciwwskazane w POChP (depresja oddechowa), ALE często stosowane w lęku u pacjentów z POChP/duszności paliatywnej – znaczące nadużywanie w tej populacji. Komorbidalność silniejsza niż sugerowało.	92.929	7.0707	1500	99	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	7	9	5	6.8	LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n16; CURATOR_NOT_INDICATION	0.0323917	0.0203195	0.955033	-0.0121086	0.0509453	0.0903745	0.9976443865372142	0.9611473448595245	0.34316505955757226	1.0	-0.029747988859457557	0.02626835855605776	1	curated	0.066645	Lung	1.0	0.066645	Lung	1.0	0.4684236317067466	-0.2340873246456087	1	0.0	0.6207676126328626	1	1	1	CXCL13	0.5504793917309673	1		HIGH replicated	7	92	4.1068	6.8063	99	3889	0.0	0	3.33656	0.0833333	0.0123586	2	0	59	0	intron_variant	protein_coding	-	-	0.0036	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_48_36_lisinopril__R739	lisinopril__R739	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	R739	Hiperglikemia	Hyperglycaemia	RYR2	rs138333572	1-237808852-T-C	MODIFIER	0.00654664	6.51104	1.24251	6.79482	9.35419	1.40613	0.111822	1.0	0.710159	0.216642	2.98074	4.6	9.17	3	STRONG (ROR+PRR+IC)	2.23	1.09	enriched	19.0	Structure with Ligand	trait_partial	1: type 2 diabetes mellitus	21: nightmare; 6: pain measurement; 5: smoking initiation; 4: protein measurement; 4: color vision disorder	123.0		GO:0001666:response_to_hypoxia,GO:0002027:regulation_of_heart_rate,GO:0003143:embryonic_heart_tube_morphogenesis,GO:0003220:left_ventricular_cardiac_muscle_tissue_morphogenesis,GO:0003300:cardiac_muscle_hypertrophy,GO:0005216:monoatomic_ion_channel_activity,GO:0005219:ryanodine-sensitive_calcium-release_channel_activity,GO:0005262:calcium_channel_activity,GO:0005509:calcium_ion_binding,GO:0005513:detection_of_calcium_ion,GO:0005515:protein_binding,GO:0005516:calmodulin_binding,GO:0005790:smooth_endoplasmic_reticulum,GO:0005886:plasma_membrane,GO:0006811:monoatomic_ion_transport,GO:0006816:calcium_ion_transport,GO:0006874:intracellular_calcium_ion_homeostasis,GO:0006941:striated_muscle_contraction,GO:0010460:positive_regulation_of_heart_rate,GO:0010881:,GO:0010882:,GO:0014701:junctional_sarcoplasmic_reticulum_membrane,GO:0014808:release_of_sequestered_calcium_ion_into_cytosol_by_sarcoplasmic_reticulum,GO:0014850:response_to_muscle_activity,GO:0015278:intracellularly_gated_calcium_channel_activity,GO:0016020:membrane,GO:0016529:,GO:0019722:calcium-mediated_signaling,GO:0019899:enzyme_binding,GO:0019901:protein_kinase_binding,GO:0030017:sarcomere,GO:0030018:Z_disc,GO:0031000:response_to_caffeine,GO:0032991:protein-containing_complex,GO:0033017:sarcoplasmic_reticulum_membrane,GO:0034220:monoatomic_ion_transmembrane_transport,GO:0034236:protein_kinase_A_catalytic_subunit_binding,GO:0034237:protein_kinase_A_regulatory_subunit_binding,GO:0034704:calcium_channel_complex,GO:0035994:response_to_muscle_stretch,GO:0042383:,GO:0042802:identical_protein_binding,GO:0043924:suramin_binding,GO:0044325:transmembrane_transporter_binding,GO:0048763:calcium-induced_calcium_release_activity,GO:0051209:release_of_sequestered_calcium_ion_into_cytosol,GO:0051284:positive_regulation_of_sequestering_of_calcium_ion,GO:0051480:regulation_of_cytosolic_calcium_ion_concentration,GO:0051649:establishment_of_localization_in_cell,GO:0051775:response_to_redox_state,GO:0055085:transmembrane_transport,GO:0055117:regulation_of_cardiac_muscle_contraction,GO:0060048:cardiac_muscle_contraction,GO:0060402:calcium_ion_transport_into_cytosol,GO:0070296:sarcoplasmic_reticulum_calcium_ion_transport,GO:0070588:calcium_ion_transmembrane_transport,GO:0071313:cellular_response_to_caffeine,GO:0071872:cellular_response_to_epinephrine_stimulus,GO:0072599:establishment_of_protein_localization_to_endoplasmic_reticulum,GO:0086005:ventricular_cardiac_muscle_cell_action_potential,GO:0086029:Purkinje_myocyte_to_ventricular_cardiac_muscle_cell_signaling,GO:0086064:cell_communication_by_electrical_coupling_involved_in_cardiac_conduction,GO:0097050:type_B_pancreatic_cell_apoptotic_process,GO:0097553:calcium_ion_transmembrane_import_into_cytosol,GO:0098735:,GO:0098904:regulation_of_AV_node_cell_action_potential,GO:0098907:regulation_of_SA_node_cell_action_potential,GO:0098910:regulation_of_atrial_cardiac_muscle_cell_action_potential,GO:0098911:regulation_of_ventricular_cardiac_muscle_cell_action_potential	Nie wskazanie. ACEi raczej poprawiają wrażliwość insulinową. Hipoglikemia (nie hiperglikemia) opisywana z ACEi + insulina. Kierunek niespójny z ADR – raczej confounding DM.	88.462	11.538	1657	78	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.23 + replikacja OR-based OR=9.35/P_test=0.112 + tissue enriched)	4	10	9	7.11	PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n123; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs138333572	0.0207353	0.0592061	0.138961	-0.151653	0.0907241	1.02408	0.932211887124897	0.9536603052760042	0.860789239121627	0.0	-0.20461600594805174	0.8405180835545811	2	curated	0.36548	Whole Blood	1.0	0.36548	Whole Blood	1.0	1.102162645353129	-0.08282199852929265	8	0.0	0.48238893151197787	1	1	8	RYR2	0.4722127824993644	1		MED repl-underpowered	9	69	4.5366	1.5359	916	3252	0.0	0	1.59006	0.05	0.0076442	1	0	22	0	intron_variant	protein_coding	-	-	0.0092	C4	I	Pre-existing condition (timing only)	I	I	model	E
dzesikahoinkis_plinktestset_2026_04_20_14_31_13_citalopram__M819	citalopram__M819	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	M819	Osteoporoza, nieokreślona	Osteoporosis, unspecified	DLEU1	rs138921674	13-50464150-A-T	MODIFIER	0.007328	4.93377	0.927375	6.98427	10.1483	0.873774	0.00800007	2.0	0.325108	0.118142	2.22723	4.93	15.18	3	STRONG (ROR+PRR+IC)	2.09	0.88	low		Unknown	trait_match	7: heel bone mineral density; 6: bone tissue density; 4: heel bone mineral density, sex hormone-binding globulin measurement; 1: heel bone mineral density, urate measurement	130: body height; 68: BMI-adjusted hip circumference; 50: BMI-adjusted waist-hip ratio; 26: electrocardiography; 20: health trait	857.0	DLEU1 / Osteoporosis unspecified (M81.9). DLEU1 (13q14.3, 'deleted in lymphocytic leukemia 1') to lncRNA - delecja w CLL jest najczęstszą aberracją chromosomalną w tej chorobie. Brak asocjacji GWAS Catalog z osteoporozą. Top loci GWAS BMD/osteoporozy (Morris 2019, Estrada 2012): WNT16, ESR1, TNFSF11 (RANKL), LRP5, DKK1, SOST - brak DLEU1. GWAS cat Bone mineral density mean -300	-	Nie wskazanie (odwrotnie). SSRI + spadek BMD udokumentowane w meta-analizach (RR fraktury 1.61; Wu et al., Zhou et al.). FDA/EMA ostrzegają. Mechanizm: 5-HT w osteoblastach, efekty serotoninergiczne na kość.	86.364	13.636	1366	132	4	T4: PGx-ADR	Kandydat PGx-ADR: n_independent=3/3 (FAERS STRONG PRR=2.09 + replikacja OR+P_test OR=10.15/P_test=0.008 + tissue low)	1	9	6	3.78	PHEWAS_ATLAS_MATCH; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n857; TISSUE_RESCUE_BY_LIT_n7; CURATOR_NOT_INDICATION	0.00707298	0.0230533	0.119765	0.00859887	0.0719294	0.0434269	0.7145376499200601				-0.7238610455493776		2	curated_weak	0.71393	Muscle - Skeletal	1.0	0.71393	Muscle - Skeletal	1.0	0.16530255162435983	-0.22153194082343697	1	0.0	0.5341713559457654	1	1	1	DLEU1	0.49529996228519896	1		HIGH replicated	18	114	3.7399	4.2656	715	2782	0.0	0	2.65207	0.0526316	0.00774159	2	0	29	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C7	P	Sub-threshold predisposition	P	P	model	E
dzesikahoinkis_plinktestset_2026_04_20_16_29_27_lisinopril__J449	lisinopril__J449	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	J449	POChP	COPD	P4HA3		P4HA3_mpc		0.00332501	28.8216	5.58497	6.6087	7192260000.0	13.0362	0.0816812	0.339172	0.641627	0.829489	0.357323	4.99	44.92	3	STRONG (ROR+PRR+IC)	2.62	1.27	enriched	25.0	UniProt SigP or TMHMM	trait_unrelated		4: hematocrit; 1: Alzheimer disease, polygenic risk score; 1: vaginal microbiome measurement; 1: tumor necrosis factor receptor superfamily member 19L amount; 1: alcohol consumption quality	13.0			Nie wskazanie. Kaszel ACEi (10–12%) może być mylony z POChP lub imitować zaostrzenie. Confounding diagnostyczny + komorbidalność.	92.04	7.9602	2548	201	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched + FAERS STRONG (PRR=2.62); replikacja PLINK2 nie aplikuje się	9	9	7	8.28	BURDEN; RARE_VARIANT_LARGE_EFFECT; LOW_PLEIOTROPY_n13; CURATOR_NOT_INDICATION	0.0255813	0.391818	0.0232173	-0.0416943	0.693282	0.0213431	0.8609700502297767	0.8642192607493087	0.5778299975690786	0.0	0.3805864808221305	0.18919274959976914	1	curated	0.3431	Lung	1.0	0.3431	Lung	1.0	0.9626818301086479	-0.7917968843184326	1	0.0	0.5719264125592411	1	1	1	P4HA3	0.578824865494634	1		HIGH replicated	16	185	6.976	2.527	1148	3926	0.0	0	1.74101	0.00434836	0.00312125	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_13_45_24_bisoprolol__E872	bisoprolol__E872	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	E872	Kwasica	Acidosis	PAPPA2	rs111858596	1-176461865-T-C	MODIFIER	0.00913743	4.58482	0.80227	7.95929	2.14803	1.25019	0.540838	0.0	0.316961	0.213631	0.86046	5.14	14.46	2	STRONG (ROR+PRR+IC)	4.37	1.97	specific	2.0	UniProt loc med conf	trait_unrelated		56: body height; 10: IGF-1 measurement; 9: myocardial infarction; 7: appendicular lean mass; 5: BMI-adjusted hip circumference	148.0		GO:0001558:regulation_of_cell_growth,GO:0004222:metalloendopeptidase_activity,GO:0005576:extracellular_region,GO:0005615:extracellular_space,GO:0006508:proteolysis,GO:0007166:cell_surface_receptor_signaling_pathway,GO:0008233:peptidase_activity,GO:0008237:metallopeptidase_activity,GO:0008270:zinc_ion_binding,GO:0016787:hydrolase_activity,GO:0046872:metal_ion_binding,GO:0070062:	Brak wskazania.	99.029	0.97087	1094	103	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue specific)	10	8	7	8.24	HIGH_CONFIDENCE_T3; LOW_POWER_HIGH_OR; HIGH_PLEIOTROPY_n148	0.0255155	0.0410446	0.27232	0.0955641	0.0790557	0.644487	0.8643415402646242	0.9808166620992053	0.7128271614942062	0.0	3.0614722223080215	1.7168829989762062	2	curated	0.60905	Adipose - Subcutaneous	3.0	0.60905	Adipose - Subcutaneous	3.0	1.6481989045472403	-0.1943214802502714	1	0.0	0.5433379167933234	1	1	1	PAPPA2	0.5886622281885239	1		MED repl-underpowered	1	102	2.9952	0.0	280	1745	0.0	0	0.611547	0.0	0.00911271	0	0	38	0	upstream_gene_variant	protein_coding	-	-	0.0056	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_13_45_24_bisoprolol__E872	bisoprolol__E872	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	E872	Kwasica	Acidosis	MYSM1	rs115667126	1-58676108-G-A	MODIFIER	0.0067617	6.07605	1.09166	7.58361	4.35317	1.13001	0.193029	0.0	0.153594	0.243126	0.277734	5.3	39.56	2	STRONG (ROR+PRR+IC)	4.37	1.97	enriched	96.0	UniProt Ubiquitination	trait_unrelated		14: tumor-associated calcium signal transducer 2 measurement; 1: diabetic retinopathy; 1: serum iron amount; 1: Stuttering; 1: aortic stenosis, aortic valve calcification	24.0		-	Brak wskazania.	99.029	0.97087	1094	103	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	9	8	7	7.96	HIGH_CONFIDENCE_T3; LOW_POWER_HIGH_OR; LOW_PLEIOTROPY_n24	-0.0195439	0.0467759	0.170002	0.000270992	0.0852847	0.00110245	0.527417407643836	0.6685144124168515	0.4313264727331658	1.0	-0.43604373732268453	-0.007133137213765343	2	curated	0.60905	Adipose - Subcutaneous	3.0	0.60905	Adipose - Subcutaneous	3.0	2.3788912901370107	-0.10276299681578288	1	0.0	0.5895045586357365	1	1	1	MYSM1	0.5854359529523123	1		MED repl-underpowered	1	102	2.9952	0.0	280	1745	0.0	0	1.30167	0.0	0.0088729	0	0	37	0	intron_variant,non_coding_transcript_variant	protein_coding_CDS_not_defined	-	-	0.0022	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_14_15_03_bisoprolol__R410	bisoprolol__R410	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	R410	Dezorientacja	Disorientation	SPRTN		SPRTN_mpc		0.00255244	90.2338	15.1219	8.61701	262.259	23.1248	0.80968	0.113281	7.49165	2.68864	2.27331	5.39	12.04	3	STRONG (ROR+PRR+IC)	3.32	1.65	enriched	41.0	Structure with Ligand	trait_unrelated		4: hematocrit; 2: hemoglobin measurement; 1: wellbeing measurement	7.0			Nie wskazanie. β-blokery lipofilne (propranolol) silniej CNS; bisoprolol mniej. Hipotensja/bradykardia jako mechanizm.	99.259	0.74074	850	135	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched + FAERS STRONG (PRR=3.32); replikacja PLINK2 nie aplikuje się	7	10	8	8.24	BURDEN; RARE_VARIANT_LARGE_EFFECT; LOW_PLEIOTROPY_n7; CURATOR_NOT_INDICATION	-0.157678	0.716235	0.0831484	-0.680786	1.31578	0.218334	0.7316594041245942	0.676829268292683	0.34932339356616154	1.0	-1.1382369756083615	-0.07702656418661849	2	curated	0.89176	Brain - Cortex	2.0	0.89176	Brain - Cortex	2.0	1.0186343011224028	-0.7917968843184326	1	0.0	0.3756847405695898	1	4	1	SPRTN	0.4983425116481966	1		MED repl-underpowered	1	134	2.3272	0.2601	221	1890	0.0	0	0.240838	0.00257457	0.0025995	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_30_04_atorvastatin__E162	atorvastatin__E162	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	E162	Hipoglikemia, nieokreślona	Hypoglycaemia, unspecified	TRIM11		TRIM11_mpc		0.000522172	65.3042	6.93616	20.3252	517.468	2.5382	0.013818	0.0	5.73785	2.32974	1.86066	8.14	11.38	3	STRONG (ROR+PRR+IC)	2.52	1.22	enriched	40.0	UniProt Ubiquitination	trait_unrelated		1: psychosocial stress measurement, hip circumference; 1: progressive supranuclear palsy; 1: bone tissue density; 1: hepatocellular carcinoma	4.0	Brak asocjacji GWAS Catalog dla hipoglikemii (E16.x) w locus TRIM11 (1q42.13). Duże GWAS hipoglikemii u diabetyków (Million Veteran Program, Chung et al. 2023) nie raportują TRIM11. Top asocjacja genu: progressive supranuclear palsy (PSP/Richardson syndrome) - rs564309 OR=5.5, p=1.7e-9. Brak dowodów na związek z ADR hipoglikemii po atorwastatynie.		Nie wskazanie. Statyny związane z dysglikemią/T2D (JUPITER, FDA label update 2012), ale hipoglikemia jako izolowana ADR bardzo rzadka – raczej koincydencja z chorymi leczonymi sulfonylomocznikami/insuliną. FAERS ROR dla statyn w hipoglikemii nieistotny.	93.793	6.2069	2079	145	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched + FAERS STRONG (PRR=2.52); replikacja PLINK2 nie aplikuje się	7	10	7	7.88	BURDEN; LOW_POWER_HIGH_OR; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n4; CURATOR_NOT_INDICATION	0.262231	0.235304	0.576605	0.37799	0.510828	0.337879	0.833790650304696	0.7627748900439824	0.6625881208978202	0.0	-1.340364334303002	-0.3624657285260774	2	curated							1.240806054371285	-0.7917968843184326	1	0.0	0.573074948316493	1	1	1	TRIM11	0.5917973191519822	1		HIGH replicated	9	136	5.692	2.2423	765	3800	0.0	0	2.46196	0.0	0.000597508	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_43_57_ramipril__R410	ramipril__R410	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	R410	Dezorientacja	Disorientation, unspecified	GJB6	rs142230271	13-20231113-C-T	MODIFIER	0.00832379	4.7194	0.7306	9.97896	0.986601	1.17824	0.990865	0.0	0.275275	0.169524	0.981232	5.93	17.14	2	STRONG (ROR+PRR+IC)	6.47	2.61	enriched	17.0	UniProt loc med conf	trait_partial	1: Alzheimer disease, dementia, family history of Alzheimerâ_x0080__x0099_s disease	2: glucagon measurement; 1: deafness; 1: thrombin generation potential measurement; 1: thrombin generation potential measurement, thrombomodulin measurement; 1: fish oil supplement exposure measurement, triglyceride measurement	14.0		GO:0003163:sinoatrial_node_development,GO:0005243:gap_junction_channel_activity,GO:0005515:protein_binding,GO:0005884:actin_filament,GO:0005886:plasma_membrane,GO:0005921:gap_junction,GO:0005922:connexin_complex,GO:0007154:cell_communication,GO:0007267:cell-cell_signaling,GO:0007605:sensory_perception_of_sound,GO:0008017:microtubule_binding,GO:0010644:cell_communication_by_electrical_coupling,GO:0016020:membrane,GO:0016264:,GO:0030054:cell_junction,GO:0035633:maintenance_of_blood-brain_barrier,GO:0048487:beta-tubulin_binding,GO:0051015:actin_filament_binding,GO:0055085:transmembrane_transport,GO:0070161:anchoring_junction,GO:1903763:gap_junction_channel_activity_involved_in_cell_communication_by_electrical_coupling,GO:1990349:gap_junction-mediated_intercellular_transport	Nie wskazanie. Może odzwierciedlać hipotensję/hiponatremię (znane ADR ACEi).	98.684	1.3158	2020	152	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	7	10	7	7.88	HIGH_CONFIDENCE_T3; PHEWAS_ATLAS_MATCH; LOW_PLEIOTROPY_n14; CURATOR_NOT_INDICATION	0.0234979	0.035604	0.293055	0.073102	0.0648724	0.585357	0.9376317447083827	0.8258807588075879	0.7470221213840045	0.0	1.6775301499047897	1.0902018179752988	2	curated	0.52137	Brain - Cortex	2.0	0.52137	Brain - Cortex	2.0	3.9514052439970335	-0.4253614936456763	1	0.0	0.5377663003784054	1	1	1	GJB6	0.6499561014772482	1		MED repl-underpowered	2	150	5.5305	2.9295	678	3189	0.0	0	-0.0114489	0.0	0.00826202	0	0	52	2	5_prime_UTR_variant	protein_coding	-	-	0.0028	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_59_08_zopiclone__K297	zopiclone__K297	zopiclone	F51.0	Krótkotrwałe leczenie bezsenności (F51.0) - max 4 tygodnie	K297	Zapalenie żołądka	Gastritis, unspecified	POU2AF2	rs117631852	11-111249271-G-A	MODIFIER	0.0056066	5.64273	0.981646	8.04488	2.2721	1.30645	0.529877	0.0	0.0542	0.104075	0.220028	5.66	104.11	2	STRONG (ROR+PRR+IC)	2.64	1.11	specific	2.0	Unknown	trait_unrelated		7: colorectal cancer; 2: polyp of colon; 2: peptide yy measurement; 1: colorectal cancer, colorectal adenoma; 1: rectal cancer	22.0		GO:0003677:DNA_binding,GO:0003713:transcription_coactivator_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0043565:sequence-specific_DNA_binding,GO:0045893:positive_regulation_of_DNA-templated_transcription,GO:0070974:POU_domain_binding	Brak wskazania.	96.124	3.876	1036	129	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue specific)	10	8	6	7.83	HIGH_CONFIDENCE_T3; LOW_POWER_HIGH_OR; LOW_PLEIOTROPY_n22	0.0241505	0.0294049	0.385661	-0.025291	0.085923	0.114359						2.209039805811263	1	curated								-0.2558577094396869	1	0.0	0.5447989361301419	1	1	1	POU2AF2	0.5908829125641502	1		MED repl-underpowered	5	124	2.8364	1.2211	154	2838	0.0	0	0.628193	0.0	0.00552147	0	0	18	0	intron_variant	protein_coding	-	-	0.0012	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_14_53_atenolol__K760	atenolol__K760	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	K760	Stłuszczenie wątroby	Fatty liver NEC	CDKL5	rs187564951	X-18600498-G-A	MODIFIER	0.00543593	4.34344	0.788022	7.44962	2.26525	0.864621	0.344293	0.0	0.358745	0.181862	1.31391	4.93	12.11	2	STRONG (ROR+PRR+IC)	4.81	2.05	enriched	88.0	Structure with Ligand	trait_unrelated		4: glomerular filtration rate; 2: serum creatinine amount; 1: blood urea nitrogen amount; 1: blood protein amount; 1: microbiome measurement	11.0		GO:0000166:nucleotide_binding,GO:0001764:neuron_migration,GO:0004672:protein_kinase_activity,GO:0004674:protein_serine/threonine_kinase_activity,GO:0004693:cyclin-dependent_protein_serine/threonine_kinase_activity,GO:0005515:protein_binding,GO:0005524:ATP_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005813:centrosome,GO:0005856:cytoskeleton,GO:0006468:protein_phosphorylation,GO:0016301:kinase_activity,GO:0016740:transferase_activity,GO:0031267:small_GTPase_binding,GO:0032587:,GO:0032839:dendrite_cytoplasm,GO:0035022:positive_regulation_of_Rac_protein_signal_transduction,GO:0036064:ciliary_basal_body,GO:0042995:cell_projection,GO:0044294:dendritic_growth_cone,GO:0045773:positive_regulation_of_axon_extension,GO:0050773:regulation_of_dendrite_development,GO:0050775:positive_regulation_of_dendrite_morphogenesis,GO:0050804:modulation_of_chemical_synaptic_transmission,GO:0051726:regulation_of_cell_cycle,GO:0097542:ciliary_tip,GO:0098978:glutamatergic_synapse,GO:0099175:regulation_of_postsynapse_organization,GO:0106310:,GO:1902017:regulation_of_cilium_assembly	Brak wskazania. Koincydencja metaboliczna.	100.0	0.0	3325	102	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	8	7	8	7.65	HIGH_CONFIDENCE_T3; LOW_POWER_HIGH_OR; LOW_PLEIOTROPY_n11	0.025965	0.0286765	0.437433	0.0234458	0.0778441	0.117321	0.6961236684366912	0.764672256097561	0.6157523701482861	0.0	-2.0995672656021007	-0.7579266309495839	1	curated	0.75928	Liver	1.0	0.75928	Liver	1.0	0.4858062327893776	-0.16153376121836402	1	0.0	0.5735819062212616	1	1	1	CDKL5	0.5555773474554732	1		MED repl-underpowered	0	102	9.1034		1397	5059	0.0	0	0.945717	0.0	0.00457438	0	0	11	6	intron_variant	protein_coding	-	-	0.0024	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_14_53_atenolol__K760	atenolol__K760	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	K760	Stłuszczenie wątroby	Fatty liver NEC	CNBD1	rs77074962	8-87498680-C-T	MODIFIER	0.0088136	4.75165	0.862431	7.44413	4.09737	1.08385	0.193178	1.0	-0.0744486	0.180774	0.167196	5.48	63.82	1	STRONG (ROR+PRR+IC)	4.81	2.05	low	101.0	Unknown	trait_partial	1: gut microbiome measurement, breastfeeding duration	8: educational attainment; 6: bone tissue density; 4: COVID-19; 4: socioeconomic status; 3: optic disc area	70.0		-	Brak wskazania. Koincydencja metaboliczna.	100.0	0.0	3325	102	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	3	8	4	4.58	PHEWAS_ATLAS_MATCH	-0.0205036	0.0268718	0.351198	0.00120591	0.073487	0.00572359	0.9996329627238659	0.9979242345614946	0.966129162952759	0.0	-0.14588768133629765	-0.18684475903401127	1	curated	0.75928	Liver	1.0	0.75928	Liver	1.0	0.0	-0.02295689988216537	1	0.1847899273423509	0.5983127207467079	0	1	1	CNBD1	0.5883735004306099	0		MED repl-underpowered	0	102	9.1034		1397	5059	0.0	0	1.30124	0.0263158	0.00755768	1	0	38	0	intron_variant	protein_coding	-	-	0.0018	C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_56_16_furosemide__R040	furosemide__R040	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	R040	Krwawienie z nosa	Epistaxis	TBC1D4	rs117678777	13-75352809-G-T	MODIFIER	0.00569068	4.92229	0.934146	6.86344	4.90005	1.07639	0.139821	1.0	0.139405	0.218833	0.280587	4.99	35.31	2	STRONG (ROR+PRR+IC)	2.81	1.38	enriched	98.0	Database Ubiquitination	trait_unrelated		15: erythrocyte volume; 15: erythrocyte count; 8: mean corpuscular hemoglobin; 8: mean corpuscular hemoglobin concentration; 4: platelet volume	88.0		GO:0005096:GTPase_activator_activity,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005794:Golgi_apparatus,GO:0005829:cytosol,GO:0016192:vesicle-mediated_transport,GO:0032869:	Brak wskazania.	94.949	5.0505	984	99	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	9	7	7	7.61	HIGH_CONFIDENCE_T3	-0.00647529	0.0418189	0.0570269	-0.106779	0.106911	0.497697	0.8347278082075585	0.7880094413847365	0.6251519325824486	0.0	0.28261002104528526	1.2161699414728182	2	curated	0.37659	Artery - Aorta	2.0	0.37659	Artery - Aorta	2.0	2.875145310564873	-0.015400139010459973	1	0.0	0.5536536782574297	1	1	1	TBC1D4	0.5131730230069723	1		MED repl-underpowered	5	94	2.694	3.3539	379	2346	0.0	0	1.47646	0.0238095	0.00758956	1	0	23	1	intron_variant	protein_coding	-	-	0.0014	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_57_04_tramadol__R33	tramadol__R33	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	R33	Zatrzymanie moczu	Retention of urine	TBPL1		TBPL1_mpc		0.000756109	15.506	2.92263	6.94934	327.452	3.89302	0.13685	0.281067	0.730274	0.623962	0.616459	4.94	21.23	2	STRONG (ROR+PRR+IC)	3.2	1.47	enriched	78.0	Database Ubiquitination	trait_unrelated		1: prostate carcinoma; 1: mean corpuscular hemoglobin; 1: depressive symptom measurement, social risk factor; 1: C-reactive protein measurement; 1: treatment-resistant hypertension	5.0			Nie wskazanie. Retencja moczu – udokumentowana ADR opioidów w tym tramadolu (mechanizm µ-opioidowy w pęcherzu).	98.496	0.0	509	266	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched + FAERS STRONG (PRR=3.20); replikacja PLINK2 nie aplikuje się	9	7	7	7.61	BURDEN; LOW_PLEIOTROPY_n5; CURATOR_NOT_INDICATION	0.143227	0.157314	0.440588	-0.423527	0.371779	0.594101	0.8890093494566935	0.8891315095583389	0.48691354023174777	1.0	0.8448664862322108	0.14618602702471337	2	curated	0.46475	Bladder	2.0	0.46475	Bladder	2.0	2.8570849597495407	-0.4346375560967197	1	0.0	0.5772652081528533	1	1	1	TBPL1	0.5060780842793361	1		MED repl-underpowered	0	262	1.3936		71	1801	1.5038	0	1.48762	0.00270257	0.000719477	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_15_55_54_furosemide__K922	furosemide__K922	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	K922	Krwawienie z przewodu pokarmowego	GI haemorrhage, unspecified	DNM3	rs553821737	1-172136588-A-G	MODIFIER	0.0078734	4.74492	0.732359	10.0345	0.899856	1.22791	0.931518	0.0	0.118315	0.129126	0.444275	6.22	40.1	2	STRONG (ROR+PRR+IC)	2.86	1.41	enriched	63.0	Structure with Ligand	trait_match	38: platelet volume; 37: platelet count	74: body height; 39: BMI-adjusted waist-hip ratio; 38: platelet volume; 37: platelet count; 35: BMI-adjusted hip circumference	619.0		GO:0000166:nucleotide_binding,GO:0003924:GTPase_activity,GO:0005515:protein_binding,GO:0005525:GTP_binding,GO:0005737:cytoplasm,GO:0005856:cytoskeleton,GO:0005874:microtubule,GO:0005886:plasma_membrane,GO:0006897:endocytosis,GO:0007416:synapse_assembly,GO:0008017:microtubule_binding,GO:0014069:postsynaptic_density,GO:0016185:,GO:0016787:hydrolase_activity,GO:0043197:dendritic_spine,GO:0045202:synapse,GO:0046847:filopodium_assembly,GO:0048471:perinuclear_region_of_cytoplasm,GO:0070062:,GO:0098793:presynapse	Nie wskazanie. Diuretyki pętlowe mogą nasilać krwawienie przez hipokalemię/alkalozę i interakcje. Słaby sygnał.	100.0	0.0	1466	139	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	5	10	8	7.37	HIGH_CONFIDENCE_T3; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n619; CURATOR_NOT_INDICATION	-0.0214212	0.0348169	0.268905	-0.0859301	0.0900589	0.468515	0.9169716052987862	0.8545754630478636	0.854468843691759	0.0	-0.4698291033195957	-0.5527565204518367	4	curated							0.9588673461484527	-0.4533935338661048	1	0.0	0.5157812993327375	1	1	1	DNM3	0.6388212399873247	1		MED repl-underpowered	0	139	4.0137		476	3613	0.0	0	-0.0859353	0.0	0.00939964	0	0	31	0	intron_variant	protein_coding	-	-	0.0008	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_18_25_27_simvastatin__J310	simvastatin__J310	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	J310	Przewlekły nieżyt nosa	Chronic rhinitis	DENND1C		DENND1C_mpc		0.00405275	25.2219	5.0678	6.18969	2166170.0	3.09842	2.4973e-06	0.402649	3.38043	1.56502	1.51182	4.12	7.46	3	STRONG (ROR+PRR+IC)	2.15	0.73	enriched	23.0	Database Ubiquitination	trait_unrelated		2: monocyte count; 2: CD70 antigen measurement; 1: response to cyclophosphamide, response to antineoplastic agent; 1: caffeine measurement; 1: theophylline measurement	9.0	Brak bezpośredniej asocjacji GWAS Catalog DENND1C (19p13.11) z przewlekłym nieżytem nosa (J31.0). DENND1C - GDP-GTP exchange factor dla Rab35, rola w endocytozie. Pojedyncze doniesienia (bez GWS) o asocjacji z allergic rhinitis/astmą w kandydackich studiach; warto zweryfikować w katalogu EBI-NHGRI.		Brak wskazania i brak znanej biologii. Koincydencja populacyjna.	86.364	13.636	1120	198	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched + FAERS STRONG (PRR=2.15); replikacja PLINK2 nie aplikuje się	7	8	7	7.32	BURDEN; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n9	-0.0307962	0.120548	0.0978009	0.0849737	0.403896	0.0791636	0.9187756665417576	0.9175581229496507	0.6809010615023092	0.0	1.6434540148049612	1.1325522560649364	1	curated	0.63491	Lung	1.0	0.63491	Lung	1.0	3.2170301226072326	-0.7917968843184326	1	0.0	0.5103385612557024	1	1	1	DENND1C	0.4771314913841765	1		HIGH replicated	27	171	3.0664	6.1958	484	2174	0.0	0	4.70835	0.00559235	0.00377696	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_16_27_44_gabapentin__R42	gabapentin__R42	gabapentin	G40, G50.0, M79.7, R52, G62.9	Padaczka - napady ogniskowe (G40), neuralgia (G50.0), ból neuropatyczny w tym poherpetyczny i cukrzycowy (M79.7/G62.9)	R42	Zawroty głowy	Dizziness and giddiness	ELOVL5	rs141310150	6-53274512-T-A	MODIFIER	0.0140703	4.09744	0.71447	8.01079	1.86411	1.12374	0.579439	1.0	0.0208804	0.0799224	0.100238	5.67	196.23	2	STRONG (ROR+PRR+IC)	2.03	0.97	enriched	98.0	UniProt SigP or TMHMM	trait_unrelated		4: platelet volume; 4: lymphocyte count; 2: mean reticulocyte volume; 2: Red cell distribution width; 2: metastasis measurement, survival time, colorectal cancer	22.0		GO:0005515:protein_binding,GO:0005783:endoplasmic_reticulum,GO:0005789:endoplasmic_reticulum_membrane,GO:0006629:lipid_metabolic_process,GO:0006631:fatty_acid_metabolic_process,GO:0006633:fatty_acid_biosynthetic_process,GO:0006636:unsaturated_fatty_acid_biosynthetic_process,GO:0009922:,GO:0009922:fatty_acid_elongase_activity,GO:0016020:membrane,GO:0016740:transferase_activity,GO:0019367:fatty_acid_elongation_-_saturated_fatty_acid,GO:0030148:sphingolipid_biosynthetic_process,GO:0030425:dendrite,GO:0030497:fatty_acid_elongation,GO:0034625:fatty_acid_elongation_-_monounsaturated_fatty_acid,GO:0034626:fatty_acid_elongation_-_polyunsaturated_fatty_acid,GO:0035338:long-chain_fatty-acyl-CoA_biosynthetic_process,GO:0036109:,GO:0042759:long-chain_fatty_acid_biosynthetic_process,GO:0042761:very_long-chain_fatty_acid_biosynthetic_process,GO:0042995:cell_projection,GO:0043025:neuronal_cell_body,GO:0043651:linoleic_acid_metabolic_process,GO:0045723:positive_regulation_of_fatty_acid_biosynthetic_process,GO:0097447:dendritic_tree,GO:1901570:fatty_acid_derivative_biosynthetic_process	Nie wskazanie. Zawroty – FLAGOWE ADR gabapentyny (>15% użytkowników; FDA label). Jeden z najsilniejszych oczekiwanych sygnałów.	66.055	0.91743	814	109	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	9	6	7	7.23	HIGH_CONFIDENCE_T3; LOW_PLEIOTROPY_n22; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs141310150; LOCUS_HETEROGENEOUS_SAME_GENE	0.0568247	0.0501579	0.589646	-0.0712566	0.0683499	0.526999	0.680896768264473	0.7453396829482808	0.62742079248035	0.0	1.0631638516043114	-1.0513894294385144	2	curated	0.65355	Brain - Cortex	2.0	0.65355	Brain - Cortex	2.0	4.436662773027508	-0.19891898160770616	2	0.0	0.38083538445642723	1	1	2	ELOVL5;ENSG00000296254	0.5004287780478227	1		MED repl-underpowered	1	72	2.2286	1.9603	262	1974	33.028	0	0.554204	0.025	0.013665	1	0	39	0	intron_variant	protein_coding	-	-	0.0026	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_18_00_amlodipine__I959	amlodipine__I959	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	I959	Hipotensja, nieokreślona	Hypotension, unspecified	TWIST1	rs537752533	7-19099338-G-A	MODIFIER	0.00665575	4.41601	0.7071	9.3735	1.81266	1.02662	0.562336	1.0	0.0563225	0.144354	0.157134	6.04	78.41	2	STRONG (ROR+PRR+IC)	3.49	1.72	enriched	36.0	Database Ubiquitination	trait_match	17: systolic blood pressure; 3: diastolic blood pressure; 2: diastolic blood pressure change measurement; 1: blood pressure trait	17: systolic blood pressure; 14: coronary artery disorder; 14: pulse pressure measurement; 11: large artery stroke; 7: body height	158.0		GO:0007517:muscle_organ_development,GO:0030154:cell_differentiation,GO:0046983:protein_dimerization_activity,GO:0048511:rhythmic_process	Nie wskazanie (przeciwnie). Hipotensja to najczęstsze oczekiwane ADR CCB. FAERS silny sygnał dla amlodypiny.	99.005	0.99502	1896	201	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	5	10	7	7.05	HIGH_CONFIDENCE_T3; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n158; CURATOR_NOT_INDICATION	-0.0170522	0.0170324	0.499283	0.000634861	0.0678681	0.00325354	0.944644698120409	0.7949484237925383	0.8183291467466168	0.0	1.478545630950282	0.17165626683522978	4	curated	0.3428199999999999	Artery - Aorta	3.0	0.3428199999999999	Artery - Aorta	3.0	3.3046277424049695	-0.230213030515512	1	0.0942948378432198	0.5545168707066939	1	1	1	TWIST1	0.6147272973927259	1		MED repl-underpowered	2	199	5.191	1.8891	534	3251	0.0	0	0.579375	0.0116279	0.00745856	1	0	52	1	intron_variant,NMD_transcript_variant	nonsense_mediated_decay	-	-	0.0004	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_04_28_simvastatin__R600	simvastatin__R600	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	R600	Obrzęk zlokalizowany	Localised oedema	SPRTN		SPRTN_mpc		0.00258852	46.5296	7.41411	9.45868	276.006	5.03916	0.264701	0.265625	3.68853	2.28526	0.972585	5.52	12.61	2	STRONG (ROR+PRR+IC)	4.0	1.86	icd_not_mapped		Structure with Ligand	icd_not_mapped		4: hematocrit; 2: hemoglobin measurement; 1: wellbeing measurement	7.0	Brak asocjacji GWAS Catalog SPRTN (1q42.13) z localized oedema (R60.0). SPRTN (replication stress response) - znany głównie z Mendlowskiego Ruijs-Aalfs syndrome (przedwczesne starzenie, HCC). Brak GWS hitów dla angioobrzęku.		Nie wskazanie. Statyny nie powodują typowego obrzęku. Koincydencja z chorobą CV.	86.984	13.016	1407	315	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=icd_not_mapped; wymagana walidacja carrier frequency	5	10	7	7.05	BURDEN; RARE_VARIANT_LARGE_EFFECT; TISSUE_UNCERTAIN; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n7; CURATOR_NOT_INDICATION	0.0916029	0.23554	0.156552	0.115966	0.781399	0.0545215	0.7316594041245942	0.676829268292683	0.34932339356616154	1.0	1.0116448575449968	0.7021186042845707	2	curated							1.7825908993867692	-0.7917968843184326	1	0.0	0.3829007816348767	1	4	1	SPRTN	0.4817704138343711	1		MED repl-underpowered	41	274	3.8522	1.4565	609	2628	0.0	0	1.11535	0.00241477	0.00265398	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_04_28_simvastatin__R600	simvastatin__R600	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	R600	Obrzęk zlokalizowany	Localised oedema	chr2:97000001-97100001_cnv_region_up		chr2:97000001-97100001_cnv_region_up		0.00222251	3.99797	0.752868	6.96087	2.55078	0.697645	0.179522	0.0	0.373359	0.239209	0.926028	4.59	10.71	1	STRONG (ROR+PRR+IC)	4.0	1.86	no_gene_symbol		Unknown	no_gene_symbol						Nie wskazanie. Statyny nie powodują typowego obrzęku. Koincydencja z chorobą CV.	86.984	13.016	1407	315	2	T2: Komorbidalność	Komorbidalność: tissue=no_gene_symbol (brak biologii w tkance ADR)	3	7	4	4.38	BURDEN; CURATOR_NOT_INDICATION	-0.0111603	0.0237582	0.194813	0.11602	0.0799415	0.833592							2	curated								-0.1024776282298657	1	0.0	0.5100500335136354	1	1	1	chr2:97000001-97100001_cnv_region_up	0.46032035964485785	1		MED repl-underpowered	41	274	3.8522	1.4565	609	2628	0.0	0	1.34223	0.0	0.00257818	0	0	3	14						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_35_49_furosemide__E871	furosemide__E871	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	E871	Hipoosmolarność/hiponatremia	Hypo-osmolality and hyponatraemia	SMAD3	rs188879376	15-67164634-A-G	MODIFIER	0.0110695	3.97021	0.750754	6.90846	4.57694	0.885291	0.0857759	2.0	0.273002	0.13844	1.31327	4.84	14.54	2	STRONG (ROR+PRR+IC)	6.02	2.47	enriched	57.0	High-Quality Ligand	trait_unrelated		42: body height; 41: asthma; 27: eosinophil count; 15: coronary artery disorder; 15: BMI-adjusted waist circumference	459.0		GO:0000122:negative_regulation_of_transcription_by_RNA_polymerase_II,GO:0000165:MAPK_cascade,GO:0000785:chromatin,GO:0000976:transcription_cis-regulatory_region_binding,GO:0000977:RNA_polymerase_II_transcription_regulatory_region_sequence-specific_DNA_binding,GO:0000978:RNA_polymerase_II_cis-regulatory_region_sequence-specific_DNA_binding,GO:0000981:DNA-binding_transcription_factor_activity_-_RNA_polymerase_II-specific,GO:0000987:cis-regulatory_region_sequence-specific_DNA_binding,GO:0001217:DNA-binding_transcription_repressor_activity,GO:0001222:transcription_corepressor_binding,GO:0001223:transcription_coactivator_binding,GO:0001228:DNA-binding_transcription_activator_activity_-_RNA_polymerase_II-specific,GO:0001501:skeletal_system_development,GO:0001649:osteoblast_differentiation,GO:0001657:ureteric_bud_development,GO:0001666:response_to_hypoxia,GO:0001701:in_utero_embryonic_development,GO:0001707:mesoderm_formation,GO:0001756:somitogenesis,GO:0001836:release_of_cytochrome_c_from_mitochondria,GO:0001889:liver_development,GO:0001947:heart_looping,GO:0002076:osteoblast_development,GO:0002520:,GO:0003677:DNA_binding,GO:0003682:chromatin_binding,GO:0003690:double-stranded_DNA_binding,GO:0003700:DNA-binding_transcription_factor_activity,GO:0005160:transforming_growth_factor_beta_receptor_binding,GO:0005515:protein_binding,GO:0005518:collagen_binding,GO:0005634:nucleus,GO:0005637:nuclear_inner_membrane,GO:0005654:nucleoplasm,GO:0005667:transcription_regulator_complex,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0006355:regulation_of_DNA-templated_transcription,GO:0006357:regulation_of_transcription_by_RNA_polymerase_II,GO:0006915:apoptotic_process,GO:0006955:immune_response,GO:0007179:transforming_growth_factor_beta_receptor_signaling_pathway,GO:0007254:JNK_cascade,GO:0007369:gastrulation,GO:0007492:endoderm_development,GO:0008013:beta-catenin_binding,GO:0008270:zinc_ion_binding,GO:0008283:cell_population_proliferation,GO:0008285:negative_regulation_of_cell_population_proliferation,GO:0009653:anatomical_structure_morphogenesis,GO:0009880:embryonic_pattern_specification,GO:0010332:,GO:0010628:positive_regulation_of_gene_expression,GO:0010629:negative_regulation_of_gene_expression,GO:0010718:positive_regulation_of_epithelial_to_mesenchymal_transition,GO:0016202:regulation_of_striated_muscle_tissue_development,GO:0016922:nuclear_receptor_binding,GO:0017015:regulation_of_transforming_growth_factor_beta_receptor_signaling_pathway,GO:0017151:,GO:0019899:enzyme_binding,GO:0019901:protein_kinase_binding,GO:0019902:phosphatase_binding,GO:0023019:signal_transduction_involved_in_regulation_of_gene_expression,GO:0030154:cell_differentiation,GO:0030279:negative_regulation_of_ossification,GO:0030308:negative_regulation_of_cell_growth,GO:0030325:adrenal_gland_development,GO:0030335:positive_regulation_of_cell_migration,GO:0030501:positive_regulation_of_bone_mineralization,GO:0030878:thyroid_gland_development,GO:0031053:primary_miRNA_processing,GO:0031490:chromatin_DNA_binding,GO:0031625:ubiquitin_protein_ligase_binding,GO:0031962:nuclear_mineralocorticoid_receptor_binding,GO:0032332:positive_regulation_of_chondrocyte_differentiation,GO:0032502:developmental_process,GO:0032731:,GO:0032810:,GO:0032909:regulation_of_transforming_growth_factor_beta2_production,GO:0032916:positive_regulation_of_transforming_growth_factor_beta3_production,GO:0032924:activin_receptor_signaling_pathway,GO:0033689:negative_regulation_of_osteoblast_proliferation,GO:0035259:nuclear_glucocorticoid_receptor_binding,GO:0036064:ciliary_basal_body,GO:0036120:,GO:0038092:nodal_signaling_pathway,GO:0042060:wound_healing,GO:0042110:T_cell_activation,GO:0042177:negative_regulation_of_protein_catabolic_process,GO:0042220:response_to_cocaine,GO:0042307:,GO:0042802:identical_protein_binding,GO:0042803:protein_homodimerization_activity,GO:0043066:negative_regulation_of_apoptotic_process,GO:0043130:ubiquitin_binding,GO:0043161:proteasome-mediated_ubiquitin-dependent_protein_catabolic_process,GO:0043235:receptor_complex,GO:0043425:bHLH_transcription_factor_binding,GO:0043565:sequence-specific_DNA_binding,GO:0045216:cell-cell_junction_organization,GO:0045429:positive_regulation_of_nitric_oxide_biosynthetic_process,GO:0045596:negative_regulation_of_cell_differentiation,GO:0045599:negative_regulation_of_fat_cell_differentiation,GO:0045668:,GO:0045893:positive_regulation_of_DNA-templated_transcription,GO:0045944:positive_regulation_of_transcription_by_RNA_polymerase_II,GO:0046872:metal_ion_binding,GO:0048340:paraxial_mesoderm_morphogenesis,GO:0048589:developmental_growth,GO:0048617:embryonic_foregut_morphogenesis,GO:0048701:embryonic_cranial_skeleton_morphogenesis,GO:0050678:regulation_of_epithelial_cell_proliferation,GO:0050728:negative_regulation_of_inflammatory_response,GO:0050776:regulation_of_immune_response,GO:0050821:protein_stabilization,GO:0050927:positive_regulation_of_positive_chemotaxis,GO:0051481:negative_regulation_of_cytosolic_calcium_ion_concentration,GO:0051496:positive_regulation_of_stress_fiber_assembly,GO:0051881:regulation_of_mitochondrial_membrane_potential,GO:0051894:positive_regulation_of_focal_adhesion_assembly,GO:0060039:pericardium_development,GO:0060290:transdifferentiation,GO:0060391:positive_regulation_of_SMAD_protein_signal_transduction,GO:0060395:SMAD_protein_signal_transduction,GO:0061001:regulation_of_dendritic_spine_morphogenesis,GO:0061045:negative_regulation_of_wound_healing,GO:0061450:trophoblast_cell_migration,GO:0061629:RNA_polymerase_II-specific_DNA-binding_transcription_factor_binding,GO:0061767:negative_regulation_of_lung_blood_pressure,GO:0070306:,GO:0070410:,GO:0070411:,GO:0070412:,GO:0071141:SMAD_protein_complex,GO:0071144:heteromeric_SMAD_protein_complex,GO:0071333:cellular_response_to_glucose_stimulus,GO:0071363:cellular_response_to_growth_factor_stimulus,GO:0071559:,GO:0071560:,GO:0090263:positive_regulation_of_canonical_Wnt_signaling_pathway,GO:0097190:apoptotic_signaling_pathway,GO:0097191:extrinsic_apoptotic_signaling_pathway,GO:0097305:response_to_alcohol,GO:0098586:cellular_response_to_virus,GO:0140297:DNA-binding_transcription_factor_binding,GO:0141091:transforming_growth_factor_beta_receptor_superfamily_signaling_pathway,GO:1901203:positive_regulation_of_extracellular_matrix_assembly,GO:1902893:regulation_of_miRNA_transcription,GO:1902894:negative_regulation_of_miRNA_transcription,GO:1902895:positive_regulation_of_miRNA_transcription,GO:1903243:negative_regulation_of_cardiac_muscle_hypertrophy_in_response_to_stress,GO:1990776:response_to_angiotensin,GO:1990841:promoter-specific_chromatin_binding	Nie wskazanie (przeciwnie). Hiponatremia – KLASYCZNE ADR diuretyków pętlowych, jeden z najlepiej udokumentowanych sygnałów.	96.226	3.7736	944	106	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	6	7	8	6.95	HIGH_CONFIDENCE_T3; HIGH_PLEIOTROPY_n459; CURATOR_NOT_INDICATION	0.0292227	0.0281256	0.524617	0.112603	0.0806201	0.789148	0.5919455312224307	0.5661054889707596	0.6206142127866461	0.0	0.3164406012973143	0.6088157965325312	2	curated	0.481905	Adipose - Subcutaneous	3.0	0.481905	Adipose - Subcutaneous	3.0	3.265350930403741	-0.06575475749276544	1	0.0	0.6207989846195908	1	1	1	SMAD3	0.57425667182747	1		HIGH replicated	4	102	2.5845	1.8645	120	2662	0.0	0	1.71811	0.0555556	0.0118182	2	0	39	0	intron_variant	protein_coding	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_48_56_atorvastatin__K30	atorvastatin__K30	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	K30	Dyspepsja	Dyspepsia	SEL1L3	rs548799122	4-25747317-C-T	MODIFIER	0.0119154	2.19111	0.437707	6.25484	4.1382	0.543824	0.00901149	4.0	0.0887619	0.0960266	0.449398	4.69	24.69	2	weak (1/3)	1.7	0.68	enriched	22.0	UniProt SigP or TMHMM	trait_unrelated		3: gut microbiome measurement; 2: pilocytic astrocytoma; 2: COVID-19; 1: cirrhosis of liver, metabolic dysfunction-associated steatotic liver disease; 1: systolic blood pressure change measurement	11.0		GO:0005515:protein_binding,GO:0016020:membrane	Nie wskazanie. GI symptoms (nudności, dyspepsja) – często w SmPC statyn jako common ADR.	100.0	0.0	1055	364	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=4.14/Wald_z=2.61 + tissue enriched)	9	8	4	6.6	HIGH_CONFIDENCE_T3; LOW_PLEIOTROPY_n11; CURATOR_KNOWN_ADR	-0.00779367	0.025653	0.11846	0.0183148	0.0504323	0.144791	0.849193259356597	0.7692260866036281	0.5937120168543877	0.0	1.5954873747195462	1.5691401671562961	1	curated							3.5774282053195643	-0.16743979747593765	1	0.0	0.5762856541791708	1	1	1	SEL1L3	0.47830553619822963	1		HIGH replicated	0	364	2.8884		376	2464	0.0	0	2.61162	0.04	0.01157	4	0	93	0	downstream_gene_variant	protein_coding	-	-	0.0024	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_15_35_47_furosemide__E162	furosemide__E162	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	E162	Hipoglikemia	Hypoglycaemia, unspecified	LEKR1	rs147448455	3-156980109-A-G	MODIFIER	0.0211257	3.06043	0.52776	8.17557	1.46163	0.678376	0.575819	1.0	0.446412	0.16149	2.24382	4.74	6.86	2	STRONG (ROR+PRR+IC)	4.12	1.92	enriched	30.0	Database Ubiquitination	trait_unrelated		11: heel bone mineral density; 5: bone tissue density; 5: body height; 3: psoriasis; 2: sex interaction measurement, carotid artery thickness	49.0		-	Nie wskazanie. Diuretyki raczej hiperglikemia; hipoglikemia rzadki sygnał.	100.0	0.0	2004	107	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (FAERS STRONG + tissue enriched)	5	8	7	6.54	HIGH_CONFIDENCE_T3; CURATOR_NOT_INDICATION	0.00431525	0.0217657	0.0742538	0.035228	0.0579766	0.264851	0.9654261672175812	0.9417456158032654	0.4536909488696215	1.0	-0.2949544344019813	0.24885571885506075	2	curated							0.1958438833061845	-0.19209630637609698	1	0.0	0.4918152391272602	1	1	1	LEKR1	0.5678340260183449	1		MED repl-underpowered	0	107	5.4867		640	4042	0.0	0	0.559502	0.0294118	0.0190793	1	0	61	1	intron_variant	protein_coding	-	-	0.0062	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_14_30_06_citalopram__H919	citalopram__H919	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	H919	Utrata słuchu, nieokreślona	Hearing loss, unspecified	HK1	rs558138996	10-69276684-A-G	MODIFIER	0.00678518	5.58417	0.976513	7.96867	6.08099	0.806508	0.0252046	2.0	0.177559	0.113004	0.935088	5.5	31.45	2	n_too_low			enriched	13.0	UniProt loc high conf	trait_unrelated		51: HbA1c measurement; 25: hemoglobin measurement; 20: erythrocyte volume; 19: hematocrit; 12: Red cell distribution width	308.0	Brak bezpośredniej asocjacji GWAS Catalog HK1 (10q22.1) z niedosłuchem nieokreślonym (H91.9). HK1 ma szeroki profil GWAS: glycated hemoglobin (HbA1c, Paré 2008 GWS), erythrocyte phenotypes (RBC count, MCHC - Chen CHARGE), MPV; Mendlowski locus dla retinitis pigmentosa 79 (adRP), hemolytic anemia, CMT4G, neurodevelopmental disorder. Brak GWS dla fenotypów słuchowych.	GO:0000166:nucleotide_binding,GO:0001678:intracellular_glucose_homeostasis,GO:0002376:immune_system_process,GO:0003824:catalytic_activity,GO:0004340:glucokinase_activity,GO:0004396:hexokinase_activity,GO:0005515:protein_binding,GO:0005524:ATP_binding,GO:0005536:D-glucose_binding,GO:0005737:cytoplasm,GO:0005739:mitochondrion,GO:0005741:mitochondrial_outer_membrane,GO:0005829:cytosol,GO:0005975:carbohydrate_metabolic_process,GO:0006002:fructose_6-phosphate_metabolic_process,GO:0006006:glucose_metabolic_process,GO:0006013:mannose_metabolic_process,GO:0006096:glycolytic_process,GO:0006954:inflammatory_response,GO:0008865:,GO:0009298:GDP-mannose_biosynthetic_process,GO:0016020:membrane,GO:0016301:kinase_activity,GO:0016740:transferase_activity,GO:0016773:phosphotransferase_activity_-_alcohol_group_as_acceptor,GO:0019158:mannokinase_activity,GO:0019318:hexose_metabolic_process,GO:0019637:organophosphate_metabolic_process,GO:0042834:peptidoglycan_binding,GO:0045087:innate_immune_response,GO:0046835:carbohydrate_phosphorylation,GO:0047931:glucosamine_kinase_activity,GO:0051156:glucose_6-phosphate_metabolic_process,GO:0061621:canonical_glycolysis,GO:0072655:establishment_of_protein_localization_to_mitochondrion,GO:0072656:maintenance_of_protein_location_in_mitochondrion,GO:1901135:carbohydrate_derivative_metabolic_process	Nie wskazanie. Ototoksyczność SSRI opisywana (głównie duloksetyna, ale też SSRI) jako rzadkie ADR w pharmacovigilance.	91.111	8.8889	1291	135	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=6.08/Wald_z=2.24 + tissue enriched)	9	7	4	6.32	HIGH_CONFIDENCE_T3; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n308; CURATOR_NOT_INDICATION	-0.0110007	0.0243916	0.185761	-0.0376492	0.0749926	0.210673	0.5887134542521278	0.620457532827914	0.7993679604570131	0.0	-0.341253012071231		1	curated_weak							3.7692721005517607	-0.028294926532859907	1	0.0014783194187388072	0.34434530049037937	0	1	1	HK1	0.411660705235074	0		HIGH replicated	12	123	3.5346	15.628	350	2495	0.0	0	2.23825	0.0384615	0.00643087	2	0	24	0	intron_variant	protein_coding	-	-	0.0008	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_40_00_amlodipine__N309	amlodipine__N309	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	N309	Zapalenie pęcherza moczowego	Cystitis, unspecified	PTPN12		PTPN12_mpc		0.00281996	83.3404	12.5121	10.5648	8.6539	20.7636	0.917223	0.166199	4.69469	2.37397	1.31896	6.18	17.75	2	weak (1/3)	1.97	0.84	enriched	15.0	High-Quality Ligand	trait_unrelated		11: BMI-adjusted waist-hip ratio; 6: electrocardiography; 5: lymphocyte count; 5: hypothyroidism; 2: BMI-adjusted waist circumference	44.0	PTPN12 / Cystitis unspecified (N30.9). Brak asocjacji GWAS Catalog PTPN12 (7q11.23) z zapaleniem pęcherza. PTPN12 - protein tyrosine phosphatase, tumor suppressor (Src/EGFR signaling), GWS głównie dla cech immunologicznych i kilku nowotworów. Brak GWS dla fenotypów urologicznych. Cystitis jako ADR amlodypiny prawdopodobnie wtórna (obrzęki kończyn dolnych/confounding ze stylem życia).		Brak wskazania.	83.784	16.216	1425	185	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched; wymagana walidacja carrier frequency	6	8	5	6.21	BURDEN; RARE_VARIANT_LARGE_EFFECT; LIT_NO_PRIOR_HIT	0.011606	0.200891	0.0204836	0.379961	0.899897	0.172076	0.619130914400985	0.501513517274973	0.5914431569564864	0.0	0.6916787352584813	0.7122927405952041	1	curated	0.41998	Bladder	1.0	0.41998	Bladder	1.0	4.1664807106561925	-0.7917968843184326	1	0.0	0.3958653854445625	1	2	1	PTPN12	0.5874969752723457	1		MED repl-underpowered	30	155	3.9014	5.4428	590	2553	0.0	0	0.103932	0.00268062	0.00283386	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_18_42_46_simvastatin__K579	simvastatin__K579	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	K579	Uchyłkowatość jelita	Diverticular disease	SEC14L1	rs142406975	17-77212716-T-C	MODIFIER	0.00568449	2.62866	0.500138	6.8317	3.16285	0.513438	0.024918	3.0	0.129201	0.154978	0.393119	4.77	20.35	2	n_too_low			enriched	62.0	Database Ubiquitination	trait_unrelated		3: neurofibrillary tangles measurement; 2: COVID-19; 1: neuropsychological test; 1: very long-chain saturated fatty acid measurement; 1: hypothyroidism	13.0	Brak asocjacji GWAS Catalog SEC14L1 (17q25.3) z chorobą uchyłkową jelita (K57.9); query EBI-NHGRI dla SEC14L1: 0 studies / 0 traits / 0 variants. SEC14L1 (SEC14-like 1, lipid-binding cytosolic factor family, paralog SEC14L5) - rola w wewnątrzkomórkowym transporcie lipidów; powiązany z Watson syndrome i tylosis with esophageal cancer w GeneCards (mendlowskie, nie GWAS). Top loci GWAS DivD: ARHGAP15, FAM155A, COLQ (Sigurdsson 2017 Nat Commun); rozszerzona lista Schafmayer 2019 Gut (39+12 nowych loci, neuromuscular/connective tissue/epithelial); meta-GWAS 2023 Cell Genomics (Wu et al.: 150 loci priorytetyzujące SLC9A3, ANO1, ELN, mechanizmy: gut myocyte, mesothelial, enteric neurons/glia). SEC14L1 nie figuruje wśród zidentyfikowanych loci.	GO:0002376:immune_system_process,GO:0002753:cytoplasmic_pattern_recognition_receptor_signaling_pathway,GO:0005515:protein_binding,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005794:Golgi_apparatus,GO:0005829:cytosol,GO:0009968:negative_regulation_of_signal_transduction,GO:0015871:choline_transport,GO:0039532:negative_regulation_of_cytoplasmic_pattern_recognition_receptor_signaling_pathway,GO:0039536:negative_regulation_of_RIG-I_signaling_pathway,GO:0039552:RIG-I_binding,GO:0045087:innate_immune_response,GO:0140311:	Nie wskazanie. Słaba populacyjna asocjacja - nested case-control (Skajaa 2021) raportuje aOR=1.19 dla diverticular disease u statyn (bez dose-response). Skoldberg 2016 brak wpływu na ryzyko/komplikację diverticulitis. Komorbidalność wieku/zachodniej diety.	98.855	1.145	1490	524	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=3.16/Wald_z=2.24 + tissue enriched)	10	6	4	6.21	HIGH_CONFIDENCE_T3; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n13; CURATOR_NOT_INDICATION	0.0257361	0.020427	0.682556	0.0915975	0.067919	0.750909	0.6037690168000326	0.5621923566174437	0.6243416254760553	0.0	-0.8345209431781078	-1.6845117775344396	2	curated							2.8742197921520996	-0.05897536816835386	1	0.0	0.32744568897548704	0	1	1	SEC14L1	0.33800676865304263	0		HIGH replicated	6	518	4.1342	2.8446	624	2527	0.0	0	2.24267	0.0185185	0.00659322	3	0	77	1	intron_variant	protein_coding	-	-	0.0056	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_02_54_simvastatin__R13	simvastatin__R13	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	R13	Dysfagia	Dysphagia	ABTB3	rs575681638	12-107507573-C-T	MODIFIER	0.00666752	2.49378	0.458274	7.27752	3.79806	0.62822	0.03365	2.0	0.0487205	0.129183	0.151155	5.14	51.19	2	weak (1/3)	1.63	0.58	specific	3.0	UniProt SigP or TMHMM	trait_unrelated		7: body mass index; 5: smoking initiation; 3: body height; 2: triglyceride measurement; 2: FEV change measurement, response to bronchodilator	50.0		GO:0005515:protein_binding,GO:0016020:membrane,GO:0030165:PDZ_domain_binding,GO:0035249:synaptic_transmission_-_glutamatergic,GO:0035640:exploration_behavior,GO:0046982:protein_heterodimerization_activity,GO:0050821:protein_stabilization,GO:0098978:glutamatergic_synapse	Brak wskazania. Rzadko w opisach case.	96.383	0.36166	1545	553	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=3.80/Wald_z=2.12 + tissue specific)	10	6	4	6.21	HIGH_CONFIDENCE_T3	0.00108012	0.0183103	0.0209252	0.015545	0.0607355	0.098001						1.794747221042495	2	curated	0.38128	Colon - Sigmoid	3.0	0.38128	Colon - Sigmoid	3.0		-0.12088425308747255	1	0.0	0.534950782775765	1	1	1	ABTB3	0.482370040156725	1		HIGH replicated	2	533	4.23	6.0287	737	2654	3.255	0	2.12424	0.0166667	0.00657019	2	0	79	0	intron_variant	protein_coding	-	-	0.0004	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_02_10_simvastatin__N951	simvastatin__N951	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	N951	Menopauza	Menopausal state	SPRTN		SPRTN_mpc		0.00258852	69.3073	13.1364	6.8793	158345.0	6.20928	0.0538341	0.0429688	2.78107	2.44202	0.593853	4.98	24.92	2	no_signal	1.51	-0.22	enriched	86.0	Structure with Ligand	trait_unrelated		4: hematocrit; 2: hemoglobin measurement; 1: wellbeing measurement	7.0			Brak wskazania.	58.824	41.176	693	85	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched; wymagana walidacja carrier frequency	9	5	5	6.08	BURDEN; RARE_VARIANT_LARGE_EFFECT; LOW_PLEIOTROPY_n7	0.0916029	0.23554	0.156552	0.115966	0.781399	0.0545215	0.7316594041245942	0.676829268292683	0.34932339356616154	1.0	1.0203078979680669	1.4902543568698605	2	curated	0.24684	Ovary	2.0	0.24684	Ovary	2.0	1.7856692950409752	-0.7917968843184326	1	0.0	0.23764545666627485	0	4	1	SPRTN	0.3130632970677623	0		HIGH replicated	35	50	1.8973	5.4209	305	1444	0.0	0	1.92817	0.00214844	0.00265261	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_40_01_amlodipine__N390	amlodipine__N390	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	N390	ZUM	Urinary tract infection	DPP7		DPP7_lof		0.000661765	6.29707	1.21582	6.65222	7.52711	1.20249	0.0932287	1.0	0.0315987	0.237264	0.0486374	5.06	199.28	2	weak (1/3)	1.87	0.84	enriched	85.0	UniProt loc high conf	trait_unrelated		5: dipeptidyl peptidase 2 measurement; 2: protein measurement; 1: cerebrospinal fluid composition attribute; 1: waist-hip ratio; 1: BMI-adjusted waist-hip ratio	21.0			Brak wskazania.	87.534	12.466	1392	730	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched; wymagana walidacja carrier frequency	9	6	4	6.0	BURDEN; LOW_PLEIOTROPY_n21	0.00616193	0.04813	0.0466619	-0.114097	0.186613	0.26686	0.555727281932281	0.4401031894934333	0.19228587634713554	1.0	0.5354893328601843	-0.11086044932300987	3	curated	0.14862	Bladder	1.0	0.14862	Bladder	1.0	4.909878977642213	-0.0367191347046332	1	0.05504175555489434	0.5146415023245791	1	1	1	DPP7	0.44584483137728065	1		HIGH replicated	91	639	3.8905	6.9377	572	2729	0.0	0	1.67861	0.00406504	0.000439496	1	0	3	0						C7	P	Sub-threshold predisposition	P	P	model	P
dzesikahoinkis_plinktestset_2026_04_20_14_48_45_clopidogrel__K30	clopidogrel__K30	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	K30	Dyspepsja	Dyspepsia	SLC8A1	rs75077292	2-40187733-G-A	MODIFIER	0.00516267	4.97594	1.00625	6.1185	10.5455	0.876213	0.00717737	1.0	0.128123	0.142686	0.432716	4.77	38.84	2	weak (1/3)	1.59	0.53	enriched	78.0	UniProt loc high conf	trait_unrelated		17: body mass index; 11: heel bone mineral density; 10: QT interval; 9: bone tissue density; 9: diastolic blood pressure	202.0		GO:0002026:regulation_of_the_force_of_heart_contraction,GO:0002027:regulation_of_heart_rate,GO:0005432:calcium:sodium_antiporter_activity,GO:0005509:calcium_ion_binding,GO:0005515:protein_binding,GO:0005516:calmodulin_binding,GO:0005654:nucleoplasm,GO:0005886:plasma_membrane,GO:0006811:monoatomic_ion_transport,GO:0006814:sodium_ion_transport,GO:0006816:calcium_ion_transport,GO:0006874:intracellular_calcium_ion_homeostasis,GO:0006883:intracellular_sodium_ion_homeostasis,GO:0006936:muscle_contraction,GO:0007154:cell_communication,GO:0008092:cytoskeletal_protein_binding,GO:0010468:regulation_of_gene_expression,GO:0010649:regulation_of_cell_communication_by_electrical_coupling,GO:0010881:,GO:0010882:,GO:0014069:postsynaptic_density,GO:0014704:intercalated_disc,GO:0014829:vascular_associated_smooth_muscle_contraction,GO:0015297:antiporter_activity,GO:0016020:membrane,GO:0030018:Z_disc,GO:0030315:T-tubule,GO:0030424:axon,GO:0030425:dendrite,GO:0030501:positive_regulation_of_bone_mineralization,GO:0030506:ankyrin_binding,GO:0034614:cellular_response_to_reactive_oxygen_species,GO:0035725:sodium_ion_transmembrane_transport,GO:0035994:response_to_muscle_stretch,GO:0036376:,GO:0042383:,GO:0043025:neuronal_cell_body,GO:0043679:axon_terminus,GO:0044325:transmembrane_transporter_binding,GO:0044557:relaxation_of_smooth_muscle,GO:0045202:synapse,GO:0046872:metal_ion_binding,GO:0051481:negative_regulation_of_cytosolic_calcium_ion_concentration,GO:0055013:cardiac_muscle_cell_development,GO:0055074:calcium_ion_homeostasis,GO:0055085:transmembrane_transport,GO:0055119:relaxation_of_cardiac_muscle,GO:0060048:cardiac_muscle_contraction,GO:0060402:calcium_ion_transport_into_cytosol,GO:0070509:,GO:0070588:calcium_ion_transmembrane_transport,GO:0071313:cellular_response_to_caffeine,GO:0071944:cell_periphery,GO:0086012:membrane_depolarization_during_cardiac_muscle_cell_action_potential,GO:0086064:cell_communication_by_electrical_coupling_involved_in_cardiac_conduction,GO:0097553:calcium_ion_transmembrane_import_into_cytosol,GO:0098703:,GO:0098719:,GO:0098735:,GO:0098794:postsynapse,GO:1901660:calcium_ion_export,GO:1902532:negative_regulation_of_intracellular_signal_transduction,GO:1903779:regulation_of_cardiac_conduction	Nie wskazanie. Dyspepsja/ból brzucha – common ADR klopidogrelu (1–10%) w CURE.	100.0	0.0	483	120	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=10.55/Wald_z=2.69 + tissue enriched)	9	6	4	6.0	HIGH_CONFIDENCE_T3; HIGH_PLEIOTROPY_n202; CURATOR_NOT_INDICATION	-0.019943	0.0152074	0.72188	0.0390083	0.128394	0.118463	0.763181514036558	0.919681571815718	0.4230613402479539	1.0	-1.2337114948470709	-0.4826910320375941	1	curated							0.39361719798972505	-0.22935703808451374	1	0.0	0.44120263586274283	1	4	1	SLC8A1	0.36714483151258814	1		HIGH replicated	0	120	1.3224		124	2064	0.0	0	2.6885	0.0294118	0.0060015	1	0	16	0	intron_variant	protein_coding	-	-	0.0028	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_01_53_simvastatin__N40	simvastatin__N40	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	N40	BPH	Enlarged prostate	SPRED1		SPRED1_mpc		0.000236778	22.0749	4.22173	6.76818	4502.06	3.55131	0.0178466	0.475952	0.813591	1.30389	0.27356	4.81	27.13	2	n_too_low			enriched	72.0	UniProt loc high conf	trait_unrelated		9: body height; 2: birth weight; 2: gut microbiome measurement, allergen exposure measurement; 2: erosive tooth wear attribute; 1: sleep duration trait, high density lipoprotein cholesterol measurement	29.0			Brak wskazania.	89.903	1.0373	1647	1446	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched; wymagana walidacja carrier frequency	9	6	4	6.0	BURDEN; LOW_PLEIOTROPY_n29	-0.145751	0.224428	0.2873	-0.627378	0.682755	0.445932	0.6371883901490777	0.6702270815811607	0.6131593874078275	0.0	0.10386035734331334	-0.2969010099720345	1	curated	0.93511	Prostate	2.0	0.93511	Prostate	2.0	2.4274099434394754	-0.6985007467832482	1	0.01270944055832391	0.3088659808887783	0	1	1	SPRED1	0.3126385715305408	0		HIGH replicated	15	1300	4.4545	2.6229	706	2723	9.0595	0	2.36879	0.00108665	0.000154067	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_20_48_tramadol__A099	tramadol__A099	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	A099	Zapalenie żołądka i jelit	Gastroenteritis	CPED1	rs189708494	7-121161842-G-A	MODIFIER	0.00731523	2.85312	0.57519	6.15253	5.75846	0.810473	0.0307679	1.0	0.192801	0.121241	0.951625	4.53	14.8	2	weak (1/3)	1.36	-0.01	enriched	11.0	UniProt SigP or TMHMM	trait_unrelated		337: bone tissue density; 32: heel bone mineral density; 11: body height; 6: radius bone mineral density; 6: brain attribute	478.0		GO:0005783:endoplasmic_reticulum	Brak wskazania.	100.0	0.0	1395	276	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=5.76/Wald_z=2.16 + tissue enriched)	9	6	4	6.0	HIGH_CONFIDENCE_T3; HIGH_PLEIOTROPY_n478	0.0259252	0.0266538	0.48054	0.161019	0.0720934	1.59316	0.8857865733125113	0.7526309273245017	0.7753828701077707	0.0	1.2524666788584415	0.42714700553776136	4	curated							3.13392777230539	-0.21287139262127297	1	0.0	0.5226976560340548	0	1	1	CPED1	0.4457673595895522	0		HIGH replicated	0	276	3.8193		169	2931	0.0	0	2.16006	0.0135135	0.00400668	1	0	24	0	intron_variant	protein_coding	-	-	0.001	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_10_59_53_amlodipine__E669	amlodipine__E669	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	E669	Otyłość	Obesity, unspecified	LRCOL1		LRCOL1_lof		0.000551471	7.20923	1.29042	7.63569	5.11579	1.5501	0.292318	0.0	0.116651	0.340533	0.135528	5.31	61.8	1	weak (1/3)	1.45	0.33	specific	1.0	UniProt SigP or TMHMM	trait_unrelated		1: total cholesterol measurement	1.0			Nie wskazanie. Otyłość to silny driver HT → amlodypina częsta w tej populacji. Komorbidalność.	94.896	5.1044	1521	862	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=specific; wymagana walidacja carrier frequency	10	5	4	5.85	BURDEN; LOW_POWER_HIGH_OR; LOW_PLEIOTROPY_n1; CURATOR_NOT_INDICATION	0.109391	0.0594464	1.18215	-0.0513762	0.245065	0.078862	0.9420549016994827	0.9973701851183417	0.700834616319585	0.0	0.16970013684681376	-0.17115183411723328	2	curated	0.97071	Adipose - Subcutaneous	3.0	0.97071	Adipose - Subcutaneous	3.0	0.5654876575738937	-0.13988600505430554	1	0.0	0.480860095967676	1	1	1	LRCOL1	0.46646855282520205	1		MED repl-underpowered	44	818	4.1643	5.3908	533	2874	0.0	0	1.05305	0.0	0.000293341	0	0	2	0						C7	P	Sub-threshold predisposition	P	P	model	P
dzesikahoinkis_plinktestset_2026_04_20_13_45_27_bisoprolol__G439	bisoprolol__G439	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	G439	Migrena	Migraine, unspecified	ATP8A2	rs181219039	13-25972430-G-A	MODIFIER	0.00682261	4.82227	0.940806	6.52802	11.2922	1.43988	0.092268	1.0	0.231545	0.150991	0.902556	4.82	20.83	2	weak (1/3)	1.42	0.37	specific	4.0	UniProt loc high conf	trait_unrelated		2: acute myeloid leukemia; 2: cerebral cortex area attribute; 2: lifestyle measurement, alcohol consumption quality; 2: brain attribute; 2: response to corticosteroid	47.0		GO:0034204:lipid_translocation,GO:0046872:metal_ion_binding,GO:0140326:ATPase-coupled_intramembrane_lipid_transporter_activity	β-blokery selektywne β1 (propranolol, atenolol, metoprolol, timolol) – Level A/B w profilaktyce migreny (AHS/AAN 2012). Bisoprolol: niewielkie dowody RCT (Worz Cephalalgia 1992 wskazuje skuteczność), ale klasa = silny driver prescription.	75.904	24.096	1204	83	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=11.29/Wald_z=1.68 + tissue specific)	10	5	4	5.85	HIGH_CONFIDENCE_T3	0.0756288	0.0481375	0.934943	0.197245	0.0990737	1.33261	0.9318339767626289	0.8611948479035353	0.7648488777246575	0.0	1.6480061550161094	2.0323484102738005	4	curated							2.4549112522525993	-0.2600628809881026	1	0.0022174791281082107	0.43867017635839656	1	1	1	ATP8A2	0.4382239950115082	1		HIGH replicated	20	63	3.2964	8.2136	439	2422	0.0	0	1.68355	0.0555556	0.00503115	1	0	21	0	intron_variant,NMD_transcript_variant	nonsense_mediated_decay	-	-	0.001	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_15_55_32_furosemide__K30	furosemide__K30	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	K30	Dyspepsja	Dyspepsia	UQCC1	rs117783353	20-35390799-C-T	MODIFIER	0.0203461	2.87113	0.569937	6.32665	4.48277	0.576403	0.00924748	2.0	0.0364726	0.0761313	0.199362	4.93	78.72	2	weak (1/3)	1.47	0.44	enriched	38.0	Human Protein Atlas loc	trait_unrelated		54: body height; 15: BMI-adjusted hip circumference; 13: sexual dimorphism measurement; 10: BMI-adjusted waist-hip ratio; 9: amygdala volume	210.0		GO:0005515:protein_binding,GO:0005739:mitochondrion,GO:0005743:mitochondrial_inner_membrane,GO:0016020:membrane,GO:0031410:cytoplasmic_vesicle,GO:0034551:mitochondrial_respiratory_chain_complex_III_assembly	Brak wskazania.	100.0	0.0	1620	102	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=4.48/Wald_z=2.60 + tissue enriched)	8	6	4	5.77	HIGH_CONFIDENCE_T3; HIGH_PLEIOTROPY_n210	0.0222297	0.0219532	0.506886	0.0581914	0.0598058	0.480762	0.44274995722685884	0.7442070124996953	0.24268697836480022	1.0	-0.39486831593496147	-0.20465336606645787	1	curated							2.6910667960617967	-0.14036021111474623	1	0.0	0.5897072695653935	1	1	1	UQCC1	0.5344861252967975	1		HIGH replicated	0	102	4.4353		593	3198	0.0	0	2.60277	0.05	0.0197209	2	0	63	1	intron_variant	protein_coding	-	-	0.005	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_16_15_24_gabapentin__K625	gabapentin__K625	gabapentin	G40, G50.0, M79.7, R52, G62.9	Padaczka - napady ogniskowe (G40), neuralgia (G50.0), ból neuropatyczny w tym poherpetyczny i cukrzycowy (M79.7/G62.9)	K625	Krwawienie z odbytu/odbytnicy	Haemorrhage of anus and rectum	CRISPLD2	rs551836887	16-84915773-G-A	MODIFIER	0.00459812	6.25285	1.21318	6.5937	6.60664	1.13781	0.0970363	1.0	0.106587	0.112166	0.465996	5.04	58.66	2	weak (1/3)	1.82	0.7	enriched	24.0	UniProt loc med conf	trait_unrelated		35: body height; 17: Inguinal hernia; 7: diverticular disease; 6: glomerular filtration rate; 5: cysteine-rich secretory protein LCCL domain-containing 2 measurement	111.0		-	Brak wskazania.	84.821	15.179	533	112	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=6.61/Wald_z=1.66 + tissue enriched)	8	6	4	5.77	HIGH_CONFIDENCE_T3; HIGH_PLEIOTROPY_n111	-0.123698	0.084849	0.838995	-0.175671	0.109462	0.964468	0.7393412866251713	0.5909129403794038	0.8005023904059637	0.0	0.9785304957536133	0.8851823861102465	1	curated							4.522852141698376	-0.0028782888417592176	1	0.0	0.5230755287705411	1	1	1	CRISPLD2	0.4936724496366573	1		HIGH replicated	17	95	1.4593	6.4832	112	1440	0.0	0	1.65939	0.0263158	0.00665266	1	0	19	0	intron_variant,NMD_transcript_variant	nonsense_mediated_decay	-	-	0.0006	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_41_09_tramadol__N309	tramadol__N309	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	N309	Zapalenie pęcherza moczowego	Cystitis, unspecified	TPRA1		TPRA1_mpc		0.00161114	32.9766	6.64371	6.15989	315102000.0	6.68893	0.00343914	0.351685	1.16905	1.10098	0.540135	4.72	28.21	2	weak (1/3)	1.8	0.58	enriched	67.0	UniProt SigP or TMHMM	trait_unrelated		4: high density lipoprotein cholesterol measurement; 3: triglyceride measurement; 2: triglyceride:HDL cholesterol ratio; 2: low density lipoprotein cholesterol measurement; 2: body height	37.0			Nie wskazanie bezpośrednie – ból w cystitis zwykle łagodny, niewymagający opioidów.	81.356	18.644	870	118	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched; wymagana walidacja carrier frequency	8	6	4	5.77	BURDEN; RARE_VARIANT_LARGE_EFFECT; CURATOR_NOT_INDICATION	-0.00836625	0.181947	0.0162273	0.41703	0.463279	0.434117	0.5277258724226784	0.3878947004767498	0.46600761688680004	1.0	0.8634838365968527	0.2776081043085058	1	curated	0.36288	Bladder	1.0	0.36288	Bladder	1.0	3.5641435532123786	-0.7917968843184326	1	0.0	0.508091186953457	1	1	1	TPRA1	0.46821811791753337	1		HIGH replicated	22	96	2.3819	3.5975	160	2650	0.0	0	2.92549	0.0103437	0.0015124	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_46_43_atorvastatin__H931	atorvastatin__H931	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	H931	Szumy uszne	Tinnitus	RABGAP1L	rs138349984	1-174228581-A-G	MODIFIER	0.00637371	6.2674	1.10032	7.9113	3.33696	1.24957	0.334855	0.0	0.390462	0.213516	1.17108	5.24	16.05	1	weak (1/3)	1.92	0.83	enriched	20.0	Database Ubiquitination	trait_unrelated		26: body mass index; 21: hospitalisation, psychiatric disorder; 20: level of tenascin-N in blood; 17: osteoarthritis; 14: smoking initiation	248.0		GO:0005096:GTPase_activator_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005737:cytoplasm,GO:0005768:endosome,GO:0005769:early_endosome,GO:0005794:Golgi_apparatus,GO:0005929:cilium,GO:0006897:endocytosis,GO:0015031:protein_transport,GO:0031267:small_GTPase_binding,GO:0031410:cytoplasmic_vesicle,GO:0032880:regulation_of_protein_localization	Nie wskazanie. Tinnitus opisywany jako rzadkie ADR statyn w post-marketing (SmPC).	89.552	10.448	1275	134	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue enriched)	9	5	4	5.65	BORDERLINE_REPLICATION; LOW_POWER_HIGH_OR; HIGH_PLEIOTROPY_n248; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs138349984	-0.00283281	0.0351222	0.0288561	-0.0833969	0.0685526	0.650179	0.7066206610159373	0.8293532021482094	0.48966858439348504	1.0	0.9494173885224644	0.08001550114443083	2	curated_weak							2.364547172955639	-0.19235479617875878	3	0.0	0.49900845297141466	1	1	3	RABGAP1L	0.5475264210168591	1		MED repl-underpowered	14	120	3.4908	5.7741	491	2778	0.0	0	0.96438	0.0	0.00617284	0	0	50	0	intron_variant	protein_coding	-	-	0.0012	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_14_57_43_clopidogrel__R13	clopidogrel__R13	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	R13	Dysfagia	Dysphagia	SLC30A9	rs140016081	4-42078960-T-G	MODIFIER	0.0146113	3.71772	0.737589	6.33289	3.87956	0.679305	0.0459612	2.0	0.0819951	0.090811	0.435845	4.89	45.34	1	weak (1/3)	1.4	0.34	enriched	80.0	UniProt SigP or TMHMM	trait_unrelated		4: major depressive disorder; 3: PHF-tau measurement; 2: COVID-19; 1: urate measurement, bone tissue density; 1: bipolar disorder, major depressive disorder	14.0		GO:0003682:chromatin_binding,GO:0003713:transcription_coactivator_activity,GO:0005385:zinc_ion_transmembrane_transporter_activity,GO:0005634:nucleus,GO:0005739:mitochondrion,GO:0005783:endoplasmic_reticulum,GO:0005856:cytoskeleton,GO:0006289:nucleotide-excision_repair,GO:0006811:monoatomic_ion_transport,GO:0006812:monoatomic_cation_transport,GO:0006829:zinc_ion_transport,GO:0006882:intracellular_zinc_ion_homeostasis,GO:0008324:monoatomic_cation_transmembrane_transporter_activity,GO:0010821:regulation_of_mitochondrion_organization,GO:0015297:antiporter_activity,GO:0016020:membrane,GO:0016922:nuclear_receptor_binding,GO:0031410:cytoplasmic_vesicle,GO:0031966:mitochondrial_membrane,GO:0045944:positive_regulation_of_transcription_by_RNA_polymerase_II,GO:0055085:transmembrane_transport,GO:0071577:zinc_ion_transmembrane_transport	Brak wskazania.	94.545	0.90909	1065	110	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue enriched) + walidacja kierunkowa OR=3.88 (Wald|z|=2.00, low power)	9	5	4	5.65	BORDERLINE_REPLICATION; LOW_PLEIOTROPY_n14; LOCUS_LEAD_rs140016081	-0.0162427	0.00965527	1.03377	-0.00180532	0.0791202	0.0079788	0.4902118420203433	0.5420624732563115	0.1851551738108743	1.0	-0.17867525874284304	-1.0761012060243835	2	curated	0.100683	Liver	3.0	0.100683	Liver	3.0	2.9581498177240646	-0.037257516721397405	2	0.0	0.5490707866071464	1	1	2	SLC30A9	0.5185887375346141	1		HIGH replicated	1	104	2.9158	6.0287	246	2415	4.5455	0	1.99575	0.0434783	0.0146948	2	0	39	0	intron_variant	protein_coding	-	-	0.0072	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_16_48_46_losartan__N309	losartan__N309	losartan	I10, I50, E10.2, E11.2, N08, I63	Nadciśnienie tętnicze (I10), niewydolność serca przy nietolerancji ACE-I (I50), nefropatia cukrzycowa typu 2 (E11.2/N08), profilaktyka udaru przy LVH (I63)	N309	Zapalenie pęcherza moczowego	Cystitis, unspecified	DMD	rs149408540	X-32609243-G-A	MODIFIER	0.0058045	7.48876	1.19679	9.40717	1.98552	0.794908	0.388222	0.0	0.19782	0.159604	0.667197	6.04	37.86	1	weak (1/3)	1.79	0.57	enriched	14.0	UniProt loc med conf	trait_unrelated		10: COVID-19; 4: body mass index; 3: vaginal microbiome measurement; 2: influenza A (H1N1); 2: breast carcinoma	65.0	DMD / Cystitis unspecified (N30.9). Brak asocjacji GWAS Catalog DMD (Xp21.2-p21.1) z cystitis. DMD (dystrofina, największy gen ludzki - 2,2 Mb) to klasyczny locus Mendlowskiej Duchenne/Becker muscular dystrophy (X-linked recessive) oraz DMD-associated dilated cardiomyopathy (carriers kobiety). GWAS głównie dla cech mięśniowych, creatine kinase, dilated cardiomyopathy u kobiet-nosicielek. Brak GWS dla fenotypów urologicznych.	GO:0003779:actin_binding,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0043226:organelle	Brak wskazania.	73.611	26.389	1947	72	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue enriched)	9	5	4	5.65	BORDERLINE_REPLICATION; LIT_NO_PRIOR_HIT	-0.00930719	0.0424818	0.0827138	0.0571107	0.101409	0.241605	0.838207906133634	0.7806832395247029	0.6416821975528725	0.0	0.814650327211933	-0.015143011954700508	1	curated	0.077664	Bladder	1.0	0.077664	Bladder	1.0	2.490855586390411	-0.42942023987532296	1	0.0	0.41892439521371544	1	1	1	DMD	0.5294874788368523	1		MED repl-underpowered	19	53	5.3306	8.9528	1272	3303	0.0	0	0.862846	0.0	0.00547445	0	0	4	4	intron_variant	protein_coding	-	-	0.004	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_15_36_11_furosemide__I219	furosemide__I219	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	I219	Ostry zawał serca	Acute myocardial infarction	PRKG1	rs72797346	10-51675580-C-T	MODIFIER	0.00608045	5.94513	1.08069	7.42348	7.86542	1.1686	0.0775789	1.0	0.25735	0.20289	0.688997	5.17	23.1	2	weak (1/3)	1.74	0.72	enriched	6.0	Structure with Ligand	trait_match	2: coronary artery disorder; 1: stroke disorder, response to clopidogrel, cardiovascular event measurement	42: body height; 14: body mass index; 9: neutral ceramidase measurement; 6: schizophrenia; 5: systolic blood pressure	219.0		GO:0000166:nucleotide_binding,GO:0004674:protein_serine/threonine_kinase_activity,GO:0004692:cGMP-dependent_protein_kinase_activity,GO:0005524:ATP_binding,GO:0016301:kinase_activity,GO:0016740:transferase_activity	Nie wskazanie bezpośrednie. Furosemid stosowany w ostrej HF lewokomorowej powikłającej MI/STEMI – klasa I (ESC ACS 2023). Często co-prescribed w ostrej fazie.	92.381	7.619	1718	105	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=7.87/Wald_z=1.76 + tissue enriched)	5	7	5	5.59	HIGH_CONFIDENCE_T3; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n219; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs72797346	0.0359565	0.0378807	0.465317	-0.137426	0.0957365	0.820573	0.9023597907482579	0.8061807917782442	0.7645247548821003	0.0	2.2875768312594107	1.1977870539135964	3	curated	0.96857	Artery - Coronary	3.0	0.96857	Artery - Coronary	3.0	3.839196365863246	-0.07499954415558202	3	0.2548054359704634	0.539552546534571	1	1	3	PRKG1	0.5323783595558367	1		HIGH replicated	8	97	4.7036	2.2615	358	3685	0.0	0	1.76491	0.0384615	0.00785498	1	0	26	0	intron_variant	protein_coding	-	-	0.005	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_06_16_propranolol__R51	propranolol__R51	propranolol	I10, I20, I47, I48, G43, F41.0, E05, R25.1, F45.3	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie (I47/I48), profilaktyka migreny (G43), drżenie samoistne (R25.1), nadczynność tarczycy - leczenie objawowe (E05), objawy somatyczne lęku (F41.0/F45.3)	R51	Ból głowy	Headache	SLC9A2		SLC9A2_mpc		0.00162587	22.4842	4.42619	6.4227	404313000.0	8.39548	0.0182493	0.166016	0.531063	0.735345	0.327741	4.89	42.34	2	weak (1/3)	1.94	0.89	enriched	41.0	UniProt loc high conf	trait_unrelated		8: interleukin-18 receptor 1 measurement; 8: glomerular filtration rate; 6: interleukin 18 receptor 1 measurement; 5: serum creatinine amount; 5: sleep apnea measurement	98.0			Pierwsza linia profilaktyki migreny (AHS/AAN Level A; NICE CG150). Maksymalne confounding.	79.808	0.96154	653	104	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=enriched; wymagana walidacja carrier frequency	8	5	4	5.43	BURDEN; RARE_VARIANT_LARGE_EFFECT	0.0612877	0.358465	0.063363	0.270753	0.535052	0.212657	0.9321759527046241	0.9018513076697031	0.6770115873916214	0.0	-0.05293859230824716	-0.36080415771476915	4	curated	0.95899	Whole Blood	1.0	0.95899	Whole Blood	1.0	0.43275726578078716	-0.7917968843184326	1	0.0	0.5038649399236415	1	1	1	SLC9A2	0.4658588590197279	1		HIGH replicated	1	83	1.7878	0.0	82	2389	19.231	0	2.36052	0.00518799	0.00098335	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_18_44_15_simvastatin__M706	simvastatin__M706	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	M706	Zapalenie kaletki krętarzowej	Trochanteric bursitis	-	rs77119758	6-156588192-C-T	MODIFIER	0.007907	4.24139	0.822165	6.60461	5.00484	0.775055	0.0377283	1.0	-0.173685	0.170871	0.50947	5.26	24.42	2	STRONG (ROR+PRR+IC)	2.11	0.77	no_gene_symbol		Unknown	no_gene_symbol				Wariant intergeniczny w 6q25.2 (chr6:156,588,192, ~156.6 Mb) bez przypisania VEP do genu (intergenic_variant, SYMBOL=-). Najbliższe protein-coding genes w okolicy: TIAM2 (~155 Mb upstream, T-lymphoma invasion and metastasis 2), ARID1B (~156.8 Mb downstream, AT-rich interaction domain 1B; mutacje powodują Coffin-Siris syndrome). M70.6 (zapalenie kaletki krętarzowej) - rzadki fenotyp w UKB, znikoma reprezentacja w GWAS Catalog. Brak asocjacji genów regionu 6q25.2-q25.3 z bursitis trochanterica. Sygnał prawdopodobnie chance finding lub konsekwencja drobnej populacji case'ów.	-	Brak wskazania.	96.296	3.7037	1736	135	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.11) + |z|=5.26 + replikacja (OR=5.00/P_test=0.038) + amp_ratio=24.4 - prawdopodobny efektor wymaga fine-mappingu/eQTL	4	7	5	5.19	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; LIT_NO_PRIOR_HIT	0.0225988	0.0170894	0.730394	-0.0767846	0.0536466	0.817178							1	curated_weak	0.34675	Muscle - Skeletal	1.0	0.34675	Muscle - Skeletal	1.0		-0.07129630575960613	1	0.0	0.5588454015335526	0	1	1	-	0.5023064231664467	0		HIGH replicated	5	130	4.7529	3.9042	785	2777	0.0	0	2.07779	0.0277778	0.00858936	1	0	104	0	intergenic_variant	-	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_18_44_15_simvastatin__M706	simvastatin__M706	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	M706	Zapalenie kaletki krętarzowej	Trochanteric bursitis	-	rs117514239	8-98358868-C-T	MODIFIER	0.00724483	4.85515	0.98944	6.03387	5.9336	0.828703	0.0316585	1.0	0.184491	0.264512	0.313806	4.56	26.32	2	STRONG (ROR+PRR+IC)	2.13	0.78	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	96.296	3.7037	1736	135	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.13) + |z|=4.56 + replikacja (OR=5.93/P_test=0.032) + amp_ratio=26.3 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	7	5	4.72	NO_GENE_SYMBOL; NEEDS_FINEMAPPING	-0.0428293	0.0175474	1.83399	0.0657744	0.057848	0.592559							1	curated_weak	0.34675	Muscle - Skeletal	1.0	0.34675	Muscle - Skeletal	1.0		-0.07472566591122357	1	0.0	0.5410439780411087	1	1	1	-	0.464975010045514	1		HIGH replicated	5	130	4.7529	3.9042	785	2777	0.0	0	2.1487	0.0277778	0.00768087	1	0	93	0	regulatory_region_variant	enhancer	-	-	0.0022	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_04_31_simvastatin__R80	simvastatin__R80	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	R80	Izolowany białkomocz	Isolated proteinuria	NLGN1	rs139771640	3-173819694-A-G	MODIFIER	0.00579134	4.67234	0.905318	6.60969	9.32868	0.589467	0.000151664	2.0						2	weak (1/3)	1.75	0.53	enriched	27.0	UniProt loc high conf	trait_unrelated		21: body mass index; 6: smoking initiation; 6: insomnia; 5: self reported educational attainment; 4: type 2 diabetes mellitus	152.0	Brak bezpośredniej asocjacji GWAS Catalog NLGN1 (3q26.31) z izolowaną proteinurią (R80). NLGN1 (neuroligina 1, synaptic adhesion) - GWS dla: autism spectrum disorder, IQ/educational attainment, alkoholizm, depresja. Brak GWS dla fenotypów nerkowych.	GO:0001540:amyloid-beta_binding,GO:0005576:extracellular_region,GO:0005794:Golgi_apparatus,GO:0005886:plasma_membrane,GO:0006605:protein_targeting,GO:0007155:cell_adhesion,GO:0007157:heterophilic_cell-cell_adhesion_via_plasma_membrane_cell_adhesion_molecules,GO:0007158:neuron_cell-cell_adhesion,GO:0007399:nervous_system_development,GO:0007416:synapse_assembly,GO:0009986:,GO:0010841:,GO:0014069:postsynaptic_density,GO:0016020:membrane,GO:0016080:,GO:0016339:,GO:0023041:neuronal_signal_transduction,GO:0030165:PDZ_domain_binding,GO:0030425:dendrite,GO:0031175:neuron_projection_development,GO:0031594:neuromuscular_junction,GO:0032230:,GO:0032433:,GO:0035418:protein_localization_to_synapse,GO:0038023:signaling_receptor_activity,GO:0042043:neurexin_family_protein_binding,GO:0042043:,GO:0042802:identical_protein_binding,GO:0043083:synaptic_cleft,GO:0043197:dendritic_spine,GO:0043235:receptor_complex,GO:0045184:establishment_of_protein_localization,GO:0045202:synapse,GO:0045211:postsynaptic_membrane,GO:0045664:regulation_of_neuron_differentiation,GO:0048511:rhythmic_process,GO:0048789:cytoskeletal_matrix_organization_at_active_zone,GO:0048812:neuron_projection_morphogenesis,GO:0050804:modulation_of_chemical_synaptic_transmission,GO:0050839:cell_adhesion_molecule_binding,GO:0051491:positive_regulation_of_filopodium_assembly,GO:0051965:positive_regulation_of_synapse_assembly,GO:0051968:positive_regulation_of_synaptic_transmission_-_glutamatergic,GO:0060076:excitatory_synapse,GO:0060999:positive_regulation_of_dendritic_spine_development,GO:0061002:negative_regulation_of_dendritic_spine_morphogenesis,GO:0071277:cellular_response_to_calcium_ion,GO:0072553:terminal_button_organization,GO:0097060:synaptic_membrane,GO:0097091:synaptic_vesicle_clustering,GO:0097104:postsynaptic_membrane_assembly,GO:0097105:presynaptic_membrane_assembly,GO:0097110:scaffold_protein_binding,GO:0097113:AMPA_glutamate_receptor_clustering,GO:0097114:NMDA_glutamate_receptor_clustering,GO:0097115:neurexin_clustering_involved_in_presynaptic_membrane_assembly,GO:0097119:postsynaptic_density_protein_95_clustering,GO:0097120:receptor_localization_to_synapse,GO:0098635:protein_complex_involved_in_cell-cell_adhesion,GO:0098793:presynapse,GO:0098794:postsynapse,GO:0098978:glutamatergic_synapse,GO:0098982:,GO:0098984:neuron_to_neuron_synapse,GO:0098985:asymmetric_-_glutamatergic_-_excitatory_synapse,GO:0098989:,GO:0098990:,GO:0099054:,GO:0099634:,GO:0140058:neuron_projection_arborization,GO:1900029:positive_regulation_of_ruffle_assembly,GO:1900075:positive_regulation_of_neuromuscular_synaptic_transmission,GO:1900244:positive_regulation_of_synaptic_vesicle_endocytosis,GO:1902533:positive_regulation_of_intracellular_signal_transduction,GO:1904861:excitatory_synapse_assembly,GO:2000302:positive_regulation_of_synaptic_vesicle_exocytosis,GO:2000463:positive_regulation_of_excitatory_postsynaptic_potential	Nie wskazanie. Statyny w wysokich dawkach mogą powodować łagodną przejściową proteinurię (pinocytoza w tubulach), ale skuteczniej – marker CKD/DM → statyny przepisywane risk-based. Komorbidalność dominuje.	13.26	0.55249	1755	181	3	T3: Predyspozycja	Predyspozycja HIGH_CONFIDENCE: n_independent=2/3 (OR=9.33/Wald_z=3.79 + tissue enriched)	7	5	4	5.19	HIGH_CONFIDENCE_T3; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n152; CURATOR_NOT_INDICATION	-0.0102019	0.0202157	0.211971	0.00877645	0.066411	0.0482435	0.7110627573965637	0.8050830088132813	0.7340572076817112	0.0	-0.742469139368284	0.17795762539158705	2	curated							0.3880293176425814	-0.21674361856261723	1	0.0	0.17948628872487488	0	1	1	NLGN1	0.2371939069579135	0		HIGH replicated	1	24	4.8049	1.3799	955	2259	86.188	0	3.78833	0.037037	0.00496278	2	0	58	1	intron_variant	protein_coding	-	-	0.0032	C5	E	Drug-triggered, no pharmacovigilance support	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_16_15_08_gabapentin__I251	gabapentin__I251	gabapentin	G40, G50.0, M79.7, R52, G62.9	Padaczka - napady ogniskowe (G40), neuralgia (G50.0), ból neuropatyczny w tym poherpetyczny i cukrzycowy (M79.7/G62.9)	I251	Miażdżycowa choroba serca	Atherosclerotic heart disease	CPNE4	rs80201980	3-131654696-C-T	MODIFIER	0.0335663	2.32352	0.443016	6.80558	3.06841	0.660543	0.0896341	3.0	0.0388946	0.0423733	0.445305	5.13	59.74	1	weak (1/3)	1.51	0.39	enriched	9.0	GO CC med conf	trait_unrelated		58: body mass index; 7: body fat percentage; 7: body weight; 7: educational attainment; 6: metabolic syndrome	208.0		GO:0005515:protein_binding,GO:0005544:calcium-dependent_phospholipid_binding,GO:0005886:plasma_membrane,GO:0045202:synapse,GO:0046872:metal_ion_binding,GO:0070062:,GO:0071277:cellular_response_to_calcium_ion,GO:0098978:glutamatergic_synapse	Brak wskazania.	96.581	3.4188	631	117	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue enriched) + walidacja kierunkowa OR=3.07 (Wald|z|=1.70, low power)	8	4	4	5.04	BORDERLINE_REPLICATION; HIGH_PLEIOTROPY_n208	-0.0077847	0.0321623	0.0921878	-0.0609989	0.0451236	0.75342	0.9479584133449706	0.9490382708705135	0.7593387894011829	0.0	1.0530446648114111	-0.03942448232591686	2	curated	0.30723	Artery - Coronary	2.0	0.30723	Artery - Coronary	2.0	1.4096958967264968	-0.07271140611055454	1	0.18239955165716296	0.557530322412789	1	1	1	CPNE4	0.5735983062460349	1		HIGH replicated	4	113	1.7276	6.7871	259	1652	0.0	0	1.69733	0.0714286	0.0322581	3	0	92	0	intron_variant	protein_coding	-	-		C7	P	Sub-threshold predisposition	P	P	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_41_30_amlodipine__R529	amlodipine__R529	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R529	Ból, nieokreślony	Pain, unspecified	NPAS3	rs143340101	14-33568506-A-G	MODIFIER	0.00605068	6.7889	1.25563	7.19268	4.0666	1.24523	0.259934	0.0	0.0808607	0.24982	0.127155	5.24	83.96	1	weak (1/3)	1.2	0.23	specific	3.0	Unknown	trait_unrelated		16: insomnia; 10: body height; 5: PHF-tau measurement; 4: schizophrenia; 3: self reported educational attainment	146.0		GO:0000785:chromatin,GO:0000977:RNA_polymerase_II_transcription_regulatory_region_sequence-specific_DNA_binding,GO:0000981:DNA-binding_transcription_factor_activity_-_RNA_polymerase_II-specific,GO:0003677:DNA_binding,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0006355:regulation_of_DNA-templated_transcription,GO:0006357:regulation_of_transcription_by_RNA_polymerase_II,GO:0045893:positive_regulation_of_DNA-templated_transcription,GO:0046982:protein_heterodimerization_activity,GO:0046983:protein_dimerization_activity	Brak wskazania.	94.318	5.6818	1342	88	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue specific) + walidacja kierunkowa OR=4.07 (Wald|z|=1.13, low power)	10	4	3	4.93	BORDERLINE_REPLICATION; LOW_POWER_HIGH_OR; HIGH_PLEIOTROPY_n146	-0.0180151	0.018079	0.496175	-0.0144036	0.0719593	0.0750216	0.7814979397259099	0.829077743902439	0.7919131350781945	0.0	1.6848186298590513	2.305210398509371	3	curated	0.31025	Whole Blood	1.0	0.31025	Whole Blood	1.0	2.0557378149806005	-0.17434296211798261	1	0.03817108592891665	0.4893535920718921	1	1	1	NPAS3	0.5146763043488586	1		MED repl-underpowered	5	83	3.6742	5.5222	502	2164	0.0	0	1.12655	0.0	0.00520405	0	0	38	0	intron_variant	protein_coding	-	-	0.0016	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_41_30_amlodipine__R529	amlodipine__R529	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R529	Ból, nieokreślony	Pain, unspecified	LINC01019	rs115731173	5-3525655-C-T	MODIFIER	0.00526765	7.51345	1.31552	7.95056	4.18591	1.2317	0.245074	0.0	0.214191	0.280728	0.351178	5.43	35.08	0	weak (1/3)	1.2	0.23	low	2.0	Unknown	trait_unrelated		10: body mass index; 8: smoking initiation; 7: educational attainment; 6: self reported educational attainment; 5: body height	91.0		-	Brak wskazania.	94.318	5.6818	1342	88	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	5	1	3.11		0.00441333	0.019494	0.0857123	-0.137088	0.0741141	1.19139	0.9994180466028021				-0.1477206135158251		3	curated	0.31025	Whole Blood	1.0	0.31025	Whole Blood	1.0	0.0	-0.21920096854546997	1	0.0	0.4907699269532331	1	1	1	LINC01019	0.5345867488512435	1		MED repl-underpowered	5	83	3.6742	5.5222	502	2164	0.0	0	1.1624	0.0	0.0050671	0	0	37	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.002	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_48_18_lisinopril__R600	lisinopril__R600	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	R600	Obrzęk zlokalizowany	Localised oedema	ENSG00000232389	rs150583919	6-70607996-A-G	MODIFIER	0.00954719	5.74294	1.16865	6.0498	13.9182	0.824426	0.00140326	1.0	0.277418	0.167971	1.00604	4.63	20.7	2	STRONG (ROR+PRR+IC)	12.81	3.51	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie (odwrotnie). R60.0 = obrzęk zlokalizowany silnie sugeruje obrzęk naczynioruchowy (angioedema) – KLASYCZNE ADR ACEi (0.1–0.7% u osób pochodzenia europejskiego, ~5× częściej u Afroamerykanów). FAERS signal silny.	90.0	10.0	1360	80	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=12.81) + |z|=4.63 + replikacja (OR=13.92/P_test=0.001) + amp_ratio=20.7 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	8	5	4.93	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	-0.0402141	0.0520697	0.356617	0.0359237	0.0854938	0.171117							2	curated								-0.2520558316628935	1	0.0	0.6652921267521137	1	1	1	ENSG00000232389	0.5511971788904364	1		HIGH replicated	8	72	3.7235	1.3799	694	3486	0.0	0	3.19398	0.05	0.0100764	1	0	29	0	downstream_gene_variant	processed_pseudogene	-	-	0.0058	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_16_48_18_lisinopril__R600	lisinopril__R600	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	R600	Obrzęk zlokalizowany	Localised oedema	ENSG00000287526	rs73031262	19-34040164-G-A	MODIFIER	0.0140025	4.45265	0.848978	6.80542	17.4767	0.788175	0.00028371	1.0	0.00328329	0.147542	0.00777976	5.16	445.26	2	STRONG (ROR+PRR+IC)	12.81	3.51	no_gene_symbol		Unknown	no_gene_symbol				Gen bez symbolu HGNC (ENSG00000287526) - niemożliwe cross-reference w GWAS Catalog. R60.0 (obrzęk miejscowy) jako fenotyp ADR po lizynoprylu - angioobrzęk ACE-i. Klasyczne loci ACEi-angioobrzęku: KCNMA1, ETV6/BDKRB2, XPNPEP2 - żaden nie odpowiada tej ENSG.	-	Nie wskazanie (odwrotnie). R60.0 = obrzęk zlokalizowany silnie sugeruje obrzęk naczynioruchowy (angioedema) – KLASYCZNE ADR ACEi (0.1–0.7% u osób pochodzenia europejskiego, ~5× częściej u Afroamerykanów). FAERS signal silny.	90.0	10.0	1360	80	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=12.81) + |z|=5.16 + replikacja (OR=17.48/P_test=0.000) + amp_ratio=445.3 - prawdopodobny efektor wymaga fine-mappingu/eQTL	2	8	5	4.31	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	-0.000589525	0.0437546	0.0046939	0.0266845	0.0747531	0.141995							2	curated								-0.4113010892838437	1	0.0	0.6653987184046395	1	1	1	ENSG00000287526	0.5876821025781859	1		HIGH replicated	8	72	3.7235	1.3799	694	3486	0.0	0	3.62974	0.05	0.00972898	1	0	28	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0026	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_26_06_ramipril__J90	ramipril__J90	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	J90	Wysięk opłucnowy	Pleural effusion	ENSG00000293906	rs143383919	13-28735638-G-A	MODIFIER	0.00542192	3.3482	0.628827	6.99471	3.6817	0.754669	0.0841528	2.0	0.0842831	0.144041	0.25301	5.06	39.73	2	STRONG (ROR+PRR+IC)	2.79	1.32	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie bezpośrednie. Wysięk wtórny do HF → indication dla ACEi. Dodatkowo rzadkie ADR ACEi (eosinophilic pneumonitis z wysiękiem).	97.578	1.0381	1468	289	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.79) + |z|=5.06 + replikacja (OR=3.68/P_test=0.084) + amp_ratio=39.7 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	8	5	4.93	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	0.0694062	0.0409847	1.04399	0.102157	0.076159	0.745207							1	curated	0.451	Lung	1.0	0.451	Lung	1.0		-0.04944628096990669	1	0.0	0.5738752573903306	1	1	1	ENSG00000293906	0.5091539827719614	1		HIGH replicated	3	282	4.0192	4.6379	448	2820	1.3841	0	1.72708	0.0208333	0.00653789	2	0	44	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0038	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_41_11_tramadol__N328	tramadol__N328	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	N328	Inne zaburzenia pęcherza	Other specified disorders of bladder	-	rs142163545	10-76769795-G-T	MODIFIER	0.00559152	4.64274	0.903331	6.56012	5.40166	0.760789	0.0266198	1.0	0.276496	0.159219	1.08375	4.76	16.79	2	STRONG (ROR+PRR+IC)	2.68	1.03	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Opioidy (w tym tramadol) znany czynnik zaburzeń mikcji/retencji.	97.778	2.2222	925	135	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.68) + |z|=4.76 + replikacja (OR=5.40/P_test=0.027) + amp_ratio=16.8 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	8	5	4.93	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	-0.0630948	0.0296333	1.47835	-0.00471078	0.0753943	0.0221945							1	curated	0.49352	Bladder	1.0	0.49352	Bladder	1.0		-0.06358532057703295	1	0.0	0.592101686315876	1	1	1	-	0.5087182437888986	1		HIGH replicated	3	132	2.5325	3.3046	149	2339	0.0	0	2.21705	0.0192308	0.00681969	1	0	41	0	intergenic_variant	-	-	-	0.0022	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_59_10_zopiclone__R074	zopiclone__R074	zopiclone	F51.0	Krótkotrwałe leczenie bezsenności (F51.0) - max 4 tygodnie	R074	Ból w klatce piersiowej	Chest pain, unspecified	-	rs74612175	10-91124837-C-T	MODIFIER	0.00825417	3.86796	0.786863	6.05318	10.1212	0.697689	0.000908039	2.0	0.150224	0.0953495	0.938781	4.69	25.75	2	STRONG (ROR+PRR+IC)	2.92	1.44	no_gene_symbol		Unknown	no_gene_symbol				Brak symbolu VEP dla wariantu - niemożliwe cross-reference w GWAS Catalog dla bólu w klatce piersiowej (R07.4). Top loci GWAS chest pain (UKB) głównie pokrywają się z CAD (9p21.3) i fenotypami psychiatrycznymi (anxiety).	-	Brak wskazania.	100.0	0.0	948	146	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.92) + |z|=4.69 + replikacja (OR=10.12/P_test=0.001) + amp_ratio=25.7 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	8	5	4.93	NO_GENE_SYMBOL; NEEDS_FINEMAPPING	0.00788456	0.0272447	0.112227	0.210334	0.0875519	1.78812							3	curated								-0.2988500015872349	1	0.0	0.6507933723778607	1	1	1	-	0.5137869843599864	1		HIGH replicated	0	146	2.5955		148	2726	0.0	0	3.31757	0.0454545	0.00491703	2	0	16	0	intergenic_variant	-	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_46_32_atorvastatin__H919	atorvastatin__H919	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	H919	Utrata słuchu	Hearing loss	A2ML1	rs116952594	12-8831374-C-G	MODIFIER	0.00538082	3.08606	0.571667	7.17228	2.715	0.754184	0.185391	2.0	0.280052	0.141778	1.31662	4.76	11.02	1	n_too_low			enriched	33.0	UniProt loc high conf	trait_unrelated		6: reticulocyte count; 4: level of pregnancy zone protein in blood; 3: microfibrillar-associated protein 5 measurement; 3: reticulocyte amount; 3: venous thromboembolism	48.0		GO:0004866:endopeptidase_inhibitor_activity,GO:0004867:serine-type_endopeptidase_inhibitor_activity,GO:0005576:extracellular_region,GO:0005615:extracellular_space,GO:0030414:peptidase_inhibitor_activity,GO:0052548:regulation_of_endopeptidase_activity,GO:0070062:	Nie wskazanie. Rzadkie case reports ototoksyczności statyn; większość bez silnego sygnału.	89.125	10.875	1163	377	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue enriched) + walidacja kierunkowa OR=2.71 (Wald|z|=1.32, low power)	7	4	4	4.82	BORDERLINE_REPLICATION; CURATOR_NOT_INDICATION	-0.00937205	0.0381016	0.0938258	-0.0292165	0.0741909	0.158811	0.987160154139725	0.9114466047131212	0.7076411960132889	0.0	0.5599475449337344		1	curated_weak							1.5064190972986538	-0.01793670447378376	1	0.0	0.29541109309810665	0	1	1	A2ML1	0.34264043176520065	0		MED repl-underpowered	41	336	3.1869	6.1958	462	2656	0.0	0	1.32434	0.015625	0.00649189	2	0	52	0	intron_variant	protein_coding	-	-		C7	P	Sub-threshold predisposition	P	P	model	P
dzesikahoinkis_plinktestset_2026_04_20_13_26_41_atorvastatin__R529	atorvastatin__R529	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	R529	Ból, nieokreślony	Pain, unspecified	RBMS1	rs145098727	2-160292652-G-A	MODIFIER	0.0073666	6.47979	1.22967	6.86403	5.10348	1.16103	0.160361	0.0	0.818961	0.265049	2.6984	4.5	7.91	1	weak (1/3)	1.08	0.07	enriched	93.0	Database Ubiquitination	trait_unrelated		13: blood protein amount; 12: type 2 diabetes mellitus; 12: body height; 10: body mass index; 10: self reported educational attainment	256.0		GO:0003676:nucleic_acid_binding,GO:0003677:DNA_binding,GO:0003690:double-stranded_DNA_binding,GO:0003697:single-stranded_DNA_binding,GO:0003723:RNA_binding,GO:0003730:mRNA_3'-UTR_binding,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005829:cytosol,GO:0006260:DNA_replication,GO:0006396:RNA_processing,GO:0008143:poly(A)_binding,GO:0008266:poly(U)_RNA_binding,GO:1990904:ribonucleoprotein_complex	Nie wskazanie. Może odzwierciedlać statin-associated muscle pain (SAMS) kodowane jako 'ból niesprecyzowany'.	82.178	17.822	1351	101	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (tissue enriched) + walidacja kierunkowa OR=5.10 (Wald|z|=1.40, low power)	7	4	4	4.82	BORDERLINE_REPLICATION; LOW_POWER_HIGH_OR; HIGH_PLEIOTROPY_n256; CURATOR_NOT_INDICATION	-0.0384842	0.032085	0.637603	0.0601604	0.0650463	0.44974	0.6669086399109433	0.6812977099236641	0.704724090430273	0.0	0.9087859391361353	1.1356782491250863	3	curated	0.65202	Whole Blood	1.0	0.65202	Whole Blood	1.0	4.046232168314504	-0.08713418012694567	1	0.0	0.3939165015728156	1	1	1	RBMS1	0.42362174699731586	1		MED repl-underpowered	18	83	3.6988	1.5633	547	2959	0.0	0	1.40386	0.0	0.00677841	0	0	55	0	intron_variant	protein_coding	-	-	0.0012	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_10_23_34_amitriptyline__G470	amitriptyline__G470	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	G470	Bezsenność	Insomnia	-	rs186140708	X-4781444-T-G	MODIFIER	0.00475757	4.15533	0.83733	6.15766	9.23441	0.888384	0.0123415	0.0	0.343896	0.31464	0.561614	4.26	12.08	2	STRONG (ROR+PRR+IC)	2.25	1.08	no_gene_symbol		Unknown	no_gene_symbol					-	Szeroko stosowana off-label w niskich dawkach (10–25 mg) w bezsenności, zwł. u starszych i w chronic pain. Confounding by indication.	49.167	50.833	1145	120	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.25) + |z|=4.26 + replikacja (OR=9.23/P_test=0.012) + amp_ratio=12.1 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	7	5	4.72	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; LOW_POWER_HIGH_OR; CURATOR_GENERAL_CONFOUNDING; EXPERT_DISAGREEMENT	-0.044323	0.0265475	1.02226	-0.0278973	0.0600398	0.19234							2	curated								-0.2517309328776793	1	0.0	0.26443101864250135	1	2	1	-	0.2694553627519118	1		HIGH replicated	61	59	3.1348	0.0	181	3061	0.0	0	2.50223	0.0	0.00595403	0	0	27	8	intergenic_variant	-	-	-	0.0011	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_41_07_amlodipine__R410	amlodipine__R410	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R410	Dezorientacja	Disorientation	ENSG00000294396	rs142170134	11-44992783-A-G	MODIFIER	0.00530325	5.11622	1.01738	6.30671	5.96989	0.779537	0.0219034	1.0	0.126955	0.202612	0.274966	4.81	40.3	2	STRONG (ROR+PRR+IC)	2.04	0.96	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Hipotensja → hipoperfuzja mózgu u starszych może dać dezorientację.	99.219	0.78125	1855	128	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.04) + |z|=4.81 + replikacja (OR=5.97/P_test=0.022) + amp_ratio=40.3 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	7	5	4.72	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	0.00726597	0.0187822	0.155607	-0.0106852	0.077157	0.0506803							2	curated	0.60462	Brain - Cortex	2.0	0.60462	Brain - Cortex	2.0		-0.05733378202879964	1	0.0	0.5280932148196688	1	2	1	ENSG00000294396	0.4466771036850869	1		HIGH replicated	1	127	5.0787	2.9295	498	3233	0.0	0	2.29204	0.0238095	0.00507963	1	0	37	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0006	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_32_41_atorvastatin__G473	atorvastatin__G473	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	G473	Bezdech senny	Sleep apnoea	ENSG00000298364	rs114063754	2-78427035-T-C	MODIFIER	0.0073666	3.35992	0.531307	9.5933	3.01329	0.718735	0.124861	2.0	0.457487	0.158551	2.40794	5.23	7.34	2	STRONG (ROR+PRR+IC)	2.14	0.93	no_gene_symbol		Unknown	no_gene_symbol				Gen bez symbolu HGNC (ENSG00000298364) - niemożliwe cross-reference w GWAS Catalog (który indeksuje po symbolach/rsID). Top loci GWAS OSA (Chen 2024, Nat Commun): TMEM117, IL15RA, CSNK1D; brak odniesienia do tego ENSG.	-	Nie wskazanie formalne. OSA to silny marker zespołu metabolicznego (~70% koincydencja z otyłością, HT, dyslipidemią) → statyny często przepisywane. Silna komorbidalność napędzająca prescription.	97.966	2.0339	1321	295	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.14) + |z|=5.23 + replikacja (OR=3.01/P_test=0.125) + amp_ratio=7.3 - prawdopodobny efektor wymaga fine-mappingu/eQTL	1	9	5	3.56	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs114063754	0.00678097	0.033019	0.0771258	-0.0464734	0.0639482	0.330323							2	curated								-0.008365453843536985	2	0.0	0.4493660504831707	1	2	2	ENSG00000227088;ENSG00000298364	0.46918502641422516	1		MED repl-underpowered	6	289	3.6167	0.9473	523	3097	0.0	0	1.53468	0.0227273	0.00645963	2	0	50	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.001	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_06_27_ramipril__B379	ramipril__B379	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	B379	Kandydoza, nieokreślona	Candidiasis, unspecified	WWC3	rs148811762	X-10077376-T-C	MODIFIER	0.00924017	5.88672	1.05511	7.61701	3.98998	0.78413	0.0776075	0.0	-0.00696844	0.165207	0.0148633	5.52	588.67	1	n/a (skip)			icd_not_mapped		Database Ubiquitination	icd_not_mapped		2: FEV/FVC ratio; 1: fear of medical pain measurement; 1: cardiac troponin I change measurement; 1: body height; 1: influenza A (H1N1)	7.0		GO:0000122:negative_regulation_of_transcription_by_RNA_polymerase_II,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0006355:regulation_of_DNA-templated_transcription,GO:0008285:negative_regulation_of_cell_population_proliferation,GO:0016477:cell_migration,GO:0019900:kinase_binding,GO:0035329:hippo_signaling,GO:0035330:regulation_of_hippo_signaling,GO:0035331:negative_regulation_of_hippo_signaling,GO:0035591:signaling_adaptor_activity,GO:0046621:negative_regulation_of_organ_growth,GO:0060090:molecular_adaptor_activity	Brak związku.	87.209	12.791	1287	86	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (OR=3.99)	5	7	3	4.72	BORDERLINE_REPLICATION; LOW_POWER_HIGH_OR; TISSUE_UNCERTAIN; LOW_PLEIOTROPY_n7	0.0263019	0.0259305	0.508038	0.0233873	0.0481806	0.202465	0.6042326912827907	0.572783584978707	0.596953245279961	0.0	0.6763921085710063	0.46592174684795257	4	curated							3.2453658455426635	-0.11365911163652553	1	0.0	0.31555215003948023	0	1	1	WWC3	0.40125191694810375	0		HIGH replicated	11	75	3.5236	3.4716	475	2637	0.0	0	1.76474	0.0	0.00853192	0	0	22	18	intron_variant	protein_coding	-	-	0.0021	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_06_27_ramipril__B379	ramipril__B379	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	B379	Kandydoza, nieokreślona	Candidiasis, unspecified	ENSG00000287409	rs186243613	7-10083001-G-A	MODIFIER	0.00568919	6.19954	1.21205	6.50329	22.7412	1.19483	0.00892938	2.0	0.212236	0.218909	0.478486	4.86	29.21	1	n/a (skip)			no_gene_symbol		Unknown	no_gene_symbol					-	Brak związku.	87.209	12.791	1287	86	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000287409') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL	0.0199875	0.0427472	0.193759	0.103109	0.0775879	0.735492							4	curated								-0.358182446175898	1	0.0	0.3236202120597578	0	1	1	ENSG00000287409	0.3496129091086144	0		HIGH replicated	11	75	3.5236	3.4716	475	2637	0.0	0	2.61475	0.0714286	0.00470727	2	0	30	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0012	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_46_52_lisinopril__N309	lisinopril__N309	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	N309	Zapalenie pęcherza moczowego	Cystitis, unspecified	ENSG00000285679	rs192999440	X-8312268-A-G	MODIFIER	0.00718443	4.88641	0.845016	8.13346	3.55276	0.948253	0.181254	1.0	0.0686594	0.170017	0.163466	5.59	71.17	1	STRONG (ROR+PRR+IC)	2.2	0.97	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	87.209	12.791	1706	86	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.20) + |z|=5.59 + replikacja (OR=3.55/P_test=0.181) + amp_ratio=71.2 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	6	5	4.48	NO_GENE_SYMBOL; NEEDS_FINEMAPPING	0.00389194	0.0502662	0.0276656	0.0293572	0.0896846	0.12877							1	curated	0.41445	Bladder	1.0	0.41445	Bladder	1.0		-0.07337313725292663	1	0.0	0.5107542231362497	1	1	1	ENSG00000285679	0.5427693200042796	1		MED repl-underpowered	11	75	4.6708	7.0144	877	3367	0.0	0	1.3369	0.0294118	0.00768156	1	0	10	6	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0011	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_25_59_ramipril__I802	ramipril__I802	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	I802	Zakrzepowe zapalenie żył	Phlebitis and thrombophlebitis	RPL32P14	rs549725833	5-19038101-T-C	MODIFIER	0.00992745	4.06345	0.757264	7.09409	7.03634	0.811181	0.0161617	2.0	0.0688266	0.170127	0.163801	5.15	59.04	1	weak (1/3)	1.97	0.81	no_data		Unknown	trait_unrelated		1: head and neck cancer; 1: erectile dysfunction; 1: coronary artery calcification; 1: brain connectivity attribute; 1: type 2 diabetes mellitus	11.0		-	Nie wskazanie. Komorbidalność naczyniowa słaba.	93.162	6.8376	1101	117	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (OR=7.04)	7	6	2	4.38	BORDERLINE_REPLICATION; TISSUE_UNCERTAIN; LOW_PLEIOTROPY_n11; CURATOR_NOT_INDICATION	-0.0152957	0.0323381	0.196394	0.0399405	0.0593186	0.300385					0.0		2	curated	0.75745	Artery - Tibial	2.0	0.75745	Artery - Tibial	2.0	0.0	-0.1811808105580014	1	0.0	0.5567224963316043	1	1	1	RPL32P14	0.5211954140014621	1		HIGH replicated	8	109	3.0144	5.7084	453	2703	0.0	0	2.40524	0.0666667	0.0108888	2	0	74	0	upstream_gene_variant	processed_pseudogene	-	-	0.001	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_11_55_05_amlodipine__T810	amlodipine__T810	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	T810	Krwotok powikłanie procedury	Haemorrhage complicating procedure	PARP6		PARP6_mpc		0.000302236	37.9298	6.82391	7.56495	44.6603	2.8142	0.177025	0.0	1.01705	1.32429	0.354096	5.31	37.29	0	weak (1/3)	1.31	-0.04	icd_not_mapped		High-Quality Ligand	icd_not_mapped		3: erythrocyte count; 2: body height; 1: cognitive decline measurement, disease progression measurement; 1: size; 1: amount of CD276 antigen (human) in blood	12.0			Brak wskazania.	99.531	0.46948	1332	213	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=icd_not_mapped; wymagana walidacja carrier frequency	4	5	4	4.31	BURDEN; LOW_POWER_HIGH_OR; TISSUE_UNCERTAIN; LOW_PLEIOTROPY_n12	-0.101241	0.150885	0.299097	0.159207	0.520484	0.119361	0.6133208384622056	0.61335347866753	0.051940685519812	1.0	-1.3444459897518337	0.3612685191162572	1	curated							3.109168095978751	-0.7917968843184326	1	0.0	0.5021070177292994	0	1	1	PARP6	0.4867123746389968	0		MED repl-underpowered	1	212	3.6468	3.7125	482	2590	0.0	0	1.34997	0.0	0.000431511	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_15_29_atenolol__M549	atenolol__M549	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	M549	Bóle pleców, nieokreślone	Dorsalgia, unspecified	ENSG00000288545	rs72912279	18-45707749-T-A	MODIFIER	0.0134051	3.35443	0.674939	6.17416	9.59041	0.668999	0.000726649	3.0	0.010787	0.0990058	0.0394152	4.9	310.97	2	STRONG (ROR+PRR+IC)	2.22	1.06	no_gene_symbol		Unknown	no_gene_symbol				ENSG00000288545 / Dorsalgia unspecified (M54.9). Gen bez symbolu HGNC - niemożliwe cross-reference w GWAS Catalog. Top loci GWAS back/spinal pain (Freidin 2019, Suri 2018): SOX5, CCDC26/GSDMC, CHST3, GFPT2.	-	Brak wskazania.	94.495	5.5046	2447	109	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.22) + |z|=4.90 + replikacja (OR=9.59/P_test=0.001) + amp_ratio=311.0 - prawdopodobny efektor wymaga fine-mappingu/eQTL	2	8	5	4.31	NO_GENE_SYMBOL; NEEDS_FINEMAPPING	0.00942526	0.0217544	0.177291	0.037872	0.0598495	0.278295							2	curated	0.67521	Muscle - Skeletal	1.0	0.67521	Muscle - Skeletal	1.0		-0.3211560126152653	1	0.0	0.6148255848337453	1	1	1	ENSG00000288545	0.5175889597019142	1		HIGH replicated	6	103	6.6995	9.87	1043	3929	0.0	0	3.37932	0.0882353	0.011725	1	1	59	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.003	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_15_29_atenolol__M549	atenolol__M549	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	M549	Bóle pleców, nieokreślone	Dorsalgia, unspecified	LINC02934	rs138843581	2-65932155-T-C	MODIFIER	0.00596369	6.25364	1.02698	8.94554	1.64294	1.29787	0.702063	0.0	-0.0351528	0.15765	0.0843098	6.05	177.9	1	STRONG (ROR+PRR+IC)	2.22	1.06	low		Unknown	trait_unrelated		32: body height; 28: BMI-adjusted waist-hip ratio; 26: BMI-adjusted waist circumference; 8: brain attribute; 7: monocyte count	269.0		-	Brak wskazania.	94.495	5.5046	2447	109	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	5	8	4	5.43	HIGH_PLEIOTROPY_n269; LOCUS_LEAD_rs138843581	0.0830923	0.0325922	1.96701	0.0680314	0.0908274	0.343091							2	curated	0.67521	Muscle - Skeletal	1.0	0.67521	Muscle - Skeletal	1.0		-0.39277955980134865	2	0.0	0.46133721887681717	0	2	2	LINC02934	0.5449170114999954	0		MED repl-underpowered	6	103	6.6995	9.87	1043	3929	0.0	0	0.382538	0.0	0.00695548	0	0	35	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0032	C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_28_32_lisinopril__E871	lisinopril__E871	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	E871	Hipoosmolarność/hiponatremia	Hypo-osmolality and hyponatraemia	ENSG00000309049	rs183950360	8-97427479-C-T	MODIFIER	0.00527369	6.75778	1.25005	7.19079	3.76542	1.20095	0.269588	0.0	0.169467	0.183003	0.450473	5.21	39.88	1	STRONG (ROR+PRR+IC)	2.14	0.97	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Hiponatremia z ACEi (szczególnie + diuretyk) udokumentowana (SIADH-like).	100.0	0.0	2017	79	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.14) + |z|=5.21 + replikacja (OR=3.77/P_test=0.270) + amp_ratio=39.9 - prawdopodobny efektor wymaga fine-mappingu/eQTL	3	5	5	4.22	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; LOW_POWER_HIGH_OR; CURATOR_NOT_INDICATION	0.0174582	0.0685635	0.0974474	-0.0901841	0.112118	0.375529							2	curated	0.534465	Adipose - Subcutaneous	3.0	0.534465	Adipose - Subcutaneous	3.0		-0.19393790233759112	1	0.0	0.5620297491183238	1	1	1	ENSG00000309049	0.5599306324074096	1		MED repl-underpowered	0	79	5.5222		554	4117	0.0	0	1.10401	0.0	0.00799166	0	0	23	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0012	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_20_06_simvastatin__Z980	simvastatin__Z980	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	Z980	Stan po wyłączeniu jelitowym	Intestinal bypass/anastomosis status	RNF167		RNF167_mpc		0.00026846	103.079	19.0779	7.18364	1.44038e+19	10.4895	2.60465e-05	0.0855103	5.47473	5.92963	0.448722	4.89	18.83	1	n/a (skip)			icd_not_mapped		UniProt loc high conf	icd_not_mapped		1: platelet volume; 1: protein measurement	2.0	Z98.0 to fenotyp proceduralny (stan po bypassie jelitowym/zespoleniu), nie jednostka chorobowa - brak GWAS-owych asocjacji ze statusem post-operacyjnym. RNF167 (17p13.2) znany z asocjacji TWAS/SMR z intraocular pressure (IOP, Liu 2023) oraz regulacji surface AMPA receptors. Brak bezpośrednich hitów w GWAS Catalog dla fenotypów przewodu pokarmowego.		Z98.0 (WHO) = status po bariatrii/zespoleniu jelitowym – NIE CABG (to Z95.1). Pacjenci bariatryczni to typowo populacja z wysokim wyjściowym ryzykiem kardiometabolicznym → statyny często kontynuowane. Słabe confounding komorbidalne.	100.0	0.0	2067	162	3	T3: Predyspozycja	Predyspozycja (BURDEN): tissue=icd_not_mapped; wymagana walidacja carrier frequency	4	6	3	4.16	BURDEN; RARE_VARIANT_LARGE_EFFECT; TISSUE_UNCERTAIN; LOW_PLEIOTROPY_n2	0.231213	0.468283	0.206569	-0.488923	1.53429	0.12495	0.3917804633656914	0.41875307513882065	-0.1668422332063852	1.0	0.9975188013977027	0.3191740631771501	3	curated							4.905756144044895	-0.7917968843184326	1	0.0	0.350134988301268	0	1	1	RNF167	0.36246390551069385	0		HIGH replicated	0	162	5.6591		1076	2857	0.0	0	4.20554	0.00203596	0.000310907	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	P
dzesikahoinkis_plinktestset_2026_04_20_18_04_06_simvastatin__H353	simvastatin__H353	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	H353	Zwyrodnienie plamki żółtej (AMD)	Degeneration of macula	ENSG00000232153	rs57314774	2-34757937-C-T	MODIFIER	0.164133	0.634613	0.125465	6.37319	1.48954	0.199377	0.045655	28.0	-0.0130917	0.0360813	0.144648	4.96	48.47	1	STRONG (ROR+PRR+IC)	5.44	2.22	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Wspólne czynniki ryzyka naczyniowego. Niektóre obserwacyjne – słabe protekcyjne działanie statyn w AMD (Barbosa BMJ Open 2014), RCT niekonkluzywne.	94.828	5.1724	1668	406	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=5.44) + |z|=4.96 + replikacja (OR=1.49/P_test=0.046) + amp_ratio=48.5 - prawdopodobny efektor wymaga fine-mappingu/eQTL	2	7	5	4.12	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	-0.00368711	0.00413579	0.428694	0.0130886	0.0133528	0.485483							1	curated_weak								-0.009010662705992933	1	0.0	0.5850507630070673	0	1	1	ENSG00000232153	0.5605449235724148	0		HIGH replicated	21	385	4.5667	2.0862	759	2922	0.0	0	1.99857	0.222222	0.159529	22	3	1597	144	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.1264	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_19_21_09_tramadol__E785	tramadol__E785	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	E785	Hiperlipidemia	Hyperlipidaemia	-	rs9529353	13-68503449-C-T	MODIFIER	0.0254772	2.19528	0.43435	6.36428	3.45834	0.515905	0.0161693	4.0	0.128556	0.0666424	1.26981	4.7	17.08	2	STRONG (ROR+PRR+IC)	2.01	0.59	no_gene_symbol		Unknown	no_gene_symbol					-	Brak związku.	93.631	6.3694	1121	157	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.01) + |z|=4.70 + replikacja (OR=3.46/P_test=0.016) + amp_ratio=17.1 - prawdopodobny efektor wymaga fine-mappingu/eQTL	2	7	5	4.12	NO_GENE_SYMBOL; NEEDS_FINEMAPPING	0.00342912	0.0144535	0.0901976	-0.0273353	0.0353851	0.356731							3	curated	0.99216	Adipose - Subcutaneous	3.0	0.99216	Adipose - Subcutaneous	3.0		-0.11611403754253691	1	0.0	0.5634222298371877	1	1	1	-	0.519615771926851	1		HIGH replicated	10	147	3.0691	3.9754	364	2653	0.0	0	2.40507	0.0833333	0.0275931	4	0	156	5	intergenic_variant	-	-	-		C7	P	Sub-threshold predisposition	P	P	model	P
dzesikahoinkis_plinktestset_2026_04_20_14_46_59_citalopram__Z966	citalopram__Z966	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	Z966	Obecność protezy stawowej	Presence of orthopedic joint implant	TP63	rs186308256	3-189833228-G-A	MODIFIER	0.00671733	4.60615	0.844363	7.31048	4.90756	1.09773	0.147294	1.0	-0.0308323	0.111583	0.106624	5.44	149.39	0	n/a (skip)			icd_not_mapped		Structure with Ligand	icd_not_mapped		10: lung adenocarcinoma; 8: lung carcinoma; 5: psoriasis; 5: urinary bladder carcinoma; 4: protein measurement	128.0		GO:0000122:negative_regulation_of_transcription_by_RNA_polymerase_II,GO:0000785:chromatin,GO:0000976:transcription_cis-regulatory_region_binding,GO:0000978:RNA_polymerase_II_cis-regulatory_region_sequence-specific_DNA_binding,GO:0000981:DNA-binding_transcription_factor_activity_-_RNA_polymerase_II-specific,GO:0001228:DNA-binding_transcription_activator_activity_-_RNA_polymerase_II-specific,GO:0001501:skeletal_system_development,GO:0001736:establishment_of_planar_polarity,GO:0001738:morphogenesis_of_a_polarized_epithelium,GO:0001942:hair_follicle_development,GO:0002039:p53_binding,GO:0002064:epithelial_cell_development,GO:0003677:DNA_binding,GO:0003682:chromatin_binding,GO:0003684:damaged_DNA_binding,GO:0003690:double-stranded_DNA_binding,GO:0003700:DNA-binding_transcription_factor_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0006338:chromatin_remodeling,GO:0006355:regulation_of_DNA-templated_transcription,GO:0006366:transcription_by_RNA_polymerase_II,GO:0006915:apoptotic_process,GO:0006974:DNA_damage_response,GO:0007219:Notch_signaling_pathway,GO:0007283:spermatogenesis,GO:0007389:pattern_specification_process,GO:0007499:ectoderm_and_mesoderm_interaction,GO:0008284:positive_regulation_of_cell_population_proliferation,GO:0008340:determination_of_adult_lifespan,GO:0008544:epidermis_development,GO:0009887:animal_organ_morphogenesis,GO:0009913:epidermal_cell_differentiation,GO:0009954:proximal/distal_pattern_formation,GO:0010481:,GO:0010482:,GO:0010838:,GO:0019904:protein_domain_specific_binding,GO:0030216:keratinocyte_differentiation,GO:0030326:embryonic_limb_morphogenesis,GO:0030425:dendrite,GO:0030850:prostate_gland_development,GO:0030855:epithelial_cell_differentiation,GO:0030859:polarized_epithelial_cell_differentiation,GO:0031069:hair_follicle_morphogenesis,GO:0032991:protein-containing_complex,GO:0033147:negative_regulation_of_intracellular_estrogen_receptor_signaling_pathway,GO:0035115:embryonic_forelimb_morphogenesis,GO:0035116:embryonic_hindlimb_morphogenesis,GO:0036342:,GO:0042475:odontogenesis_of_dentin-containing_tooth,GO:0042771:intrinsic_apoptotic_signaling_pathway_in_response_to_DNA_damage_by_p53_class_mediator,GO:0042802:identical_protein_binding,GO:0042981:regulation_of_apoptotic_process,GO:0043565:sequence-specific_DNA_binding,GO:0043589:skin_morphogenesis,GO:0043616:keratinocyte_proliferation,GO:0045597:positive_regulation_of_cell_differentiation,GO:0045617:,GO:0045669:,GO:0045747:,GO:0045892:negative_regulation_of_DNA-templated_transcription,GO:0045893:positive_regulation_of_DNA-templated_transcription,GO:0045944:positive_regulation_of_transcription_by_RNA_polymerase_II,GO:0046872:metal_ion_binding,GO:0048485:sympathetic_nervous_system_development,GO:0048646:anatomical_structure_formation_involved_in_morphogenesis,GO:0048807:female_genitalia_morphogenesis,GO:0048863:stem_cell_differentiation,GO:0050699:WW_domain_binding,GO:0051262:protein_tetramerization,GO:0051402:neuron_apoptotic_process,GO:0060197:cloacal_septation,GO:0060513:prostatic_bud_formation,GO:0060529:squamous_basal_epithelial_stem_cell_differentiation_involved_in_prostate_gland_acinus_development,GO:0061436:establishment_of_skin_barrier,GO:0072089:stem_cell_proliferation,GO:0090398:cellular_senescence,GO:0097371:MDM2/MDM4_family_protein_binding,GO:0098773:skin_epidermis_development,GO:1904674:positive_regulation_of_somatic_stem_cell_population_maintenance,GO:1904888:cranial_skeletal_system_development,GO:1990841:promoter-specific_chromatin_binding,GO:2000271:positive_regulation_of_fibroblast_apoptotic_process,GO:2000381:negative_regulation_of_mesoderm_development,GO:2000648:positive_regulation_of_stem_cell_proliferation,GO:2001235:positive_regulation_of_apoptotic_signaling_pathway	Brak wskazania. Koincydencja wiekowa.	100.0	0.0	1152	157	3	T3: Predyspozycja	Predyspozycja NEEDS_REPLICATION: tissue=icd_not_mapped + walidacja kierunkowa OR=4.91 (low-power)	4	4	4	4.0	NEEDS_REPLICATION; TISSUE_UNCERTAIN; HIGH_PLEIOTROPY_n128	0.0444594	0.0270545	0.998633	0.035332	0.0872788	0.163922	0.9541250779131163	0.8841275218307738	0.7405396645328578	0.0	1.5076754306484215	1.3158365054229948	1	curated_weak							2.704276422682636	-0.038995022101744437	1	0.0	0.34269228945394636	0	1	1	TP63	0.40086884914498994	0		MED repl-underpowered	0	157	3.154		446	2117	0.0	0	1.44916	0.02	0.005624	1	0	21	0	intron_variant	protein_coding	-	-	0.0012	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_10_41_02_amitriptyline__M069	amitriptyline__M069	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	M069	Reumatoidalne zapalenie stawów	Rheumatoid arthritis, unspecified	-	rs79676622	7-82561437-T-C	MODIFIER	0.0146575	2.46476	0.483711	6.45867	3.242	0.603457	0.0512854	3.0	0.218706	0.13568	0.970702	4.47	11.27	1	STRONG (ROR+PRR+IC)	2.24	1.03	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. TCA off-label w bólu przewlekłym u RA (EULAR 2018 – niski poziom dowodów). Słabe confounding.	91.525	8.4746	1970	177	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.24) + |z|=4.47 + replikacja (OR=3.24/P_test=0.051) + amp_ratio=11.3 - prawdopodobny efektor wymaga fine-mappingu/eQTL	2	6	5	3.91	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	0.0358871	0.0188975	1.23988	-0.0376234	0.0428553	0.42023							2	curated_weak	0.53873	Muscle - Skeletal	1.0	0.53873	Muscle - Skeletal	1.0		-0.07800872715574009	1	0.0	0.5280637743636581	1	1	1	-	0.4790550465525634	1		HIGH replicated	15	162	5.3936	4.6215	500	3346	0.0	0	1.94908	0.0535714	0.016129	3	0	112	2	intergenic_variant	-	-	-	0.0048	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_12_26_01_atenolol__R53	atenolol__R53	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R53	Złe samopoczucie i zmęczenie	Malaise and fatigue	GPR37	rs139716193	7-124766405-G-A	MODIFIER	0.00823306	4.91884	0.82307	8.64133	2.06963	1.20361	0.545629	0.0	0.145678	0.138589	0.532851	5.72	33.77	0	weak (1/3)	1.55	0.57	icd_not_mapped		UniProt loc high conf	icd_not_mapped		3: cutaneous melanoma; 3: chromosome, telomeric region length; 3: level of prosaposin receptor GPR37 in blood; 2: thyroid gland carcinoma; 1: protein measurement	23.0		GO:0000151:ubiquitin_ligase_complex,GO:0004930:G_protein-coupled_receptor_activity,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005783:endoplasmic_reticulum,GO:0005789:endoplasmic_reticulum_membrane,GO:0005886:plasma_membrane,GO:0007165:signal_transduction,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007193:adenylate_cyclase-inhibiting_G_protein-coupled_receptor_signaling_pathway,GO:0007218:neuropeptide_signaling_pathway,GO:0008188:neuropeptide_receptor_activity,GO:0008528:G_protein-coupled_peptide_receptor_activity,GO:0009986:,GO:0016020:membrane,GO:0016358:dendrite_development,GO:0030165:PDZ_domain_binding,GO:0030425:dendrite,GO:0030544:Hsp70_protein_binding,GO:0031072:heat_shock_protein_binding,GO:0031625:ubiquitin_protein_ligase_binding,GO:0031987:locomotion_involved_in_locomotory_behavior,GO:0034614:cellular_response_to_reactive_oxygen_species,GO:0036505:,GO:0042277:peptide_binding,GO:0042416:dopamine_biosynthetic_process,GO:0042923:neuropeptide_binding,GO:0042995:cell_projection,GO:0043235:receptor_complex,GO:0043410:positive_regulation_of_MAPK_cascade,GO:0045202:synapse,GO:0045964:positive_regulation_of_dopamine_metabolic_process	Nie wskazanie. Fatigue to flagowe ADR β-blokerów (10–25% użytkowników) – mechanizm via obniżony rzut, zmniejszona perfuzja mięśni, CNS.	60.833	0.0	2211	120	3	T3: Predyspozycja	Predyspozycja NEEDS_REPLICATION: tissue=icd_not_mapped	5	4	3	3.91	NEEDS_REPLICATION; LOW_POWER_HIGH_OR; TISSUE_UNCERTAIN; LOW_PLEIOTROPY_n23; CURATOR_NOT_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[GPR37|POT1]	-0.00906768	0.0269918	0.132583	0.104143	0.0766864	0.758322	0.9603831019090759	0.8546119011678714	0.9155659995138156	0.0	-0.7940902518148275	-0.2673453325957699	2	curated	0.2167	Whole Blood	1.0	0.2167	Whole Blood	1.0	0.27609798524519774	-0.22936071941820768	3	0.0	0.33140148876031317	1	1	3	GPR37;POT1	0.44822378021216264	1		MED repl-underpowered	0	73	6.0534		1034	4136	39.167	0	0.604323	0.0	0.00736172	0	0	37	0	upstream_gene_variant	protein_coding	-	-	0.0034	C6	E	Unreplicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_07_17_ramipril__D509	ramipril__D509	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	D509	Niedokrwistość z niedoboru żelaza	Iron deficiency anaemia	ENSG00000266906	rs79143240	19-27981026-T-C	MODIFIER	0.0114548	2.59945	0.497534	6.7583	3.17354	0.620275	0.0626272	3.0	0.154078	0.0982093	0.933018	4.82	16.87	1	STRONG (ROR+PRR+IC)	2.75	1.07	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. ACEi mogą powodować anemię (↓EPO), ale rzadko IDA.	98.86	1.1396	1711	351	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=2.75) + |z|=4.82 + replikacja (OR=3.17/P_test=0.063) + amp_ratio=16.9 - prawdopodobny efektor wymaga fine-mappingu/eQTL	2	6	5	3.91	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; CURATOR_NOT_INDICATION	-0.00225533	0.0300794	0.0267652	0.0764131	0.0553565	0.776065							2	curated	0.7754	Spleen	2.0	0.7754	Spleen	2.0		-0.062074415742190414	1	0.0	0.5798478568635197	1	1	1	ENSG00000266906	0.5205412972607333	1		HIGH replicated	4	347	4.6845	12.616	736	3143	0.0	0	1.86183	0.0272727	0.0105718	3	0	71	0	downstream_gene_variant	transcribed_processed_pseudogene	-	-	0.0056	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_17_07_15_ramipril__C787	ramipril__C787	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	C787	Wtórne nowotwory wątroby	Secondary malignant neoplasm of liver	TRERNA1	rs116976563	20-50041241-G-A	MODIFIER	0.00996564	3.25617	0.663839	6.02965	4.67707	0.564584	0.00628745	2.0	0.169768	0.167229	0.508609	4.51	19.18	1	n/a (skip)			icd_not_mapped		Unknown	icd_not_mapped		2: body height; 1: cytokine measurement; 1: monocyte percentage of leukocytes; 1: age of onset of Parkinson disease; 1: blood copper level	10.0		-	Brak wskazania.	99.27	0.72993	1794	137	3	T3: Predyspozycja	Predyspozycja BORDERLINE: n_independent=1/3 (OR=4.68)	4	6	2	3.63	BORDERLINE_REPLICATION; TISSUE_UNCERTAIN; LOW_PLEIOTROPY_n10	0.0259824	0.0323634	0.374614	0.0527134	0.0587836	0.431963	0.9921297788110764				-0.196010399875371		1	curated							0.0	-0.12421544992342215	1	0.050810009947791744	0.3411498139843397	0	1	1	TRERNA1	0.33938587344442783	0		HIGH replicated	1	136	4.9117	1.3881	811	3139	0.0	0	2.7324	0.0526316	0.00987036	2	0	63	2	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0062	C3	E	Replicated drug-triggered signal	E	E	model	P
dzesikahoinkis_plinktestset_2026_04_20_15_55_10_furosemide__J441	furosemide__J441	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	J441	POChP z zaostrzeniem	COPD with acute exacerbation	ENSG00000289368	rs73739788	6-23533888-C-T	MODIFIER	0.0101341	3.84871	0.761404	6.36557	7.82842	1.12321	0.0669458	0.0	0.569312	0.245969	1.68536	4.1	6.76	1	STRONG (ROR+PRR+IC)	3.68	1.76	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie formalne. Furosemid stosowany w prawokomorowej HF/cor pulmonale (częste w zaawansowanej POChP) i w obrzęku płuc współistniejącym.	84.848	15.152	893	99	3	T3: Predyspozycja	Predyspozycja CANDIDATE_NO_SYMBOL: brak symbolu, ale FAERS STRONG (PRR=3.68) + |z|=4.10 + replikacja (OR=7.83/P_test=0.067) + amp_ratio=6.8 - prawdopodobny efektor wymaga fine-mappingu/eQTL	0	6	5	2.47	NO_GENE_SYMBOL; NEEDS_FINEMAPPING; LOW_POWER_HIGH_OR; CURATOR_NOT_INDICATION	-0.00907132	0.0301602	0.11714	0.0997993	0.0837915	0.631459							1	curated	0.90924	Lung	1.0	0.90924	Lung	1.0		-0.22723687872159007	1	0.0	0.4892650384192217	1	1	1	ENSG00000289368	0.4496862102073811	1		HIGH replicated	15	84	2.4449	6.9706	258	2890	0.0	0	1.83204	0.0	0.00602773	0	0	20	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0178	C4	I	Pre-existing condition (timing only)	I	I	model	P
dzesikahoinkis_plinktestset_2026_04_20_18_03_05_simvastatin__G309	simvastatin__G309	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	G309	Choroba Alzheimera, nieokreślona	Alzheimer disease, unspecified	APOC1	rs4420638	19-44919689-A-G	MODIFIER	0.201693	1.39925	0.214279	10.182	2.86605	0.295853	0.000372295	13.0	1.22599	0.057698	99.4678	0.78	1.14	2	n_too_low			enriched	29.0	UniProt loc med conf	trait_match	653: memory performance; 277: memory impairment; 55: Alzheimer disease; 42: Alzheimer disease, family history of Alzheimerâ_x0080__x0099_s disease; 20: Alzheimer's disease biomarker measurement	653: memory performance; 277: memory impairment; 112: fatty acid amount; 102: protein measurement; 99: triglyceride measurement	3434.0	TAK - rs4420638 (APOC1) jest GWS w GWAS choroby Alzheimera (G30.x) jako część haplotypu APOE-TOMM40-APOC1 na 19q13.32. Asocjacja z AD, hippocampal atrophy rate (p=9.3e-9, Guo 2019), cognitive decline, hipometabolizm mózgu. Zhou 2019 (Nat Commun): niezależne od APOE-e4 haplotypy ryzyka w rejonie APOC1. Uwaga: silne LD z APOE komplikuje przypisanie kauzalności.	GO:0005576:extracellular_region,GO:0006869:lipid_transport,GO:0042157:lipoprotein_metabolic_process	Nie wskazanie. Meta-analiza obserwacyjna (Olmastroni 2022, n=7M) wykazała RR=0.82 (CI 0.74–0.90) dla AD u statyn. Kierunek 'protective' – potencjalne confounding by healthy-user i indirect prevention via CAD. Statyny lipofilne (simva) lepiej przechodzą BBB. RCT (PROSPER, HPS) nie potwierdzają.	89.32	10.68	1560	103	1	T1: Wskazanie	Wskazanie/komorbidalność genetyczna: curator GWAS Catalog identyfikuje gen jako kanoniczny locus choroby + amp_ratio=1.14<1.5 (efekt plejotropowy, nie farmakologiczny)	0	9	3	2.38	CANONICAL_DISEASE_LOCUS_T1; PHEWAS_ATLAS_MATCH; CANONICAL_DISEASE_LOCUS; HIGH_PLEIOTROPY_n3434; CURATOR_NOT_INDICATION; EXPERT_DISAGREEMENT; LOCUS_HETEROGENEOUS_MULTI_GENE[APOC1|APOE|NECTIN2]	-0.00040358	0.00376179	0.0387861	0.156251	0.0124947	35.1567	0.9864392651112257	0.9925425057175562	0.800826513248521	0.0	0.4641676850413462	0.6255981662778989	3	curated							3.2962664033695748	-0.1210259057057429	5	0.30102114337283636	0.0854586813299675	0	15	5	APOC1;APOE;NECTIN2	0.12680778061228337	0		HIGH replicated	11	92	4.271	1.8973	955	3127	0.0	0	3.55898	0.40625	0.202526	7	3	1937	258	downstream_gene_variant	protein_coding	-	-	0.151	C8	C	Prescription-driving locus (APOE)	C	C	model	I
dzesikahoinkis_plinktestset_2026_04_20_12_16_32_atenolol__R030	atenolol__R030	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R030	Podwyższone BP bez diagnozy HT	Elevated BP reading, without diagnosis of HT	SATB2	rs113236683	2-199394154-T-C	MODIFIER	0.00549044	7.03617	1.2717	7.50168	6.1646	0.906379	0.0447826	1.0	0.245762	0.19133	0.701217	5.28	28.63	3	STRONG (ROR+PRR+IC)	3.56	1.74	enriched	73.0	UniProt Ubiquitination	trait_unrelated		15: body height; 7: schizophrenia; 6: heel bone mineral density; 6: mathematical ability; 6: testosterone measurement	103.0		GO:0000785:chromatin,GO:0000977:RNA_polymerase_II_transcription_regulatory_region_sequence-specific_DNA_binding,GO:0000978:RNA_polymerase_II_cis-regulatory_region_sequence-specific_DNA_binding,GO:0000981:DNA-binding_transcription_factor_activity_-_RNA_polymerase_II-specific,GO:0001228:DNA-binding_transcription_activator_activity_-_RNA_polymerase_II-specific,GO:0003677:DNA_binding,GO:0003700:DNA-binding_transcription_factor_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0006325:chromatin_organization,GO:0006338:chromatin_remodeling,GO:0006357:regulation_of_transcription_by_RNA_polymerase_II,GO:0016363:,GO:0031981:,GO:0042826:histone_deacetylase_binding,GO:0045944:positive_regulation_of_transcription_by_RNA_polymerase_II	Bezpośrednie wskazanie – β-bloker jako terapia nadciśnieniowa. R03.0 często poprzedza rozpoznanie I10 w UKB. SILNE confounding.	84.034	15.966	1771	119	1	T1: Wskazanie	Wskazanie (CURATOR): Bezpośrednie wskazanie – β-bloker jako terapia nadciśnieniowa. R03.0 często poprzedza rozpoznanie I10 w UKB. SILNE confounding.	8	10	6	7.83	CURATOR_STRONG_INDICATION; HIGH_PLEIOTROPY_n103; CURATOR_STRONG_INDICATION	0.00287775	0.0339247	0.0303985	-0.0700087	0.0901885	0.35892	0.8624252480172748	0.8904022806461829	0.7074791345920103	0.0	0.8630400414169286	-1.0543746918172991	4	curated	0.55052	Artery - Aorta	2.0	0.55052	Artery - Aorta	2.0	1.6930269398604496	-0.07419242480025263	1	0.0036957985468470188	0.5623347144075908	1	1	1	SATB2	0.5502469250941868	1		HIGH replicated	19	100	4.8487	0.15606	501	3496	0.0	0	2.00669	0.0238095	0.0053742	1	0	27	0	intron_variant	protein_coding	-	-	0.0008	C4	I	Pre-existing condition (timing only)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_12_16_32_atenolol__R030	atenolol__R030	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R030	Podwyższone BP bez diagnozy HT	Elevated BP reading, without diagnosis of HT	RPL13P	rs185398807	6-28864488-G-A	MODIFIER	0.00971079	4.41422	0.780443	7.80994	8.24565	0.828704	0.0109039	1.0	0.206738	0.15232	0.757714	5.29	21.35	2	STRONG (ROR+PRR+IC)	3.56	1.74	no_data		Unknown	no_gwas_hits			0.0	RPL13P (pseudogen RPL13) - pseudogeny zazwyczaj nie mają własnych asocjacji GWAS. Brak cross-reference z R03.0 (podwyższone BP bez rozpoznania nadciśnienia). Sygnał prawdopodobnie artefakt mapowania lub LD z rzeczywistym locus BP w sąsiedztwie.	-	Bezpośrednie wskazanie – β-bloker jako terapia nadciśnieniowa. R03.0 często poprzedza rozpoznanie I10 w UKB. SILNE confounding.	84.034	15.966	1771	119	1	T1: Wskazanie	Wskazanie (CURATOR): Bezpośrednie wskazanie – β-bloker jako terapia nadciśnieniowa. R03.0 często poprzedza rozpoznanie I10 w UKB. SILNE confounding.	7	10	4	6.54	CURATOR_STRONG_INDICATION; LOW_PLEIOTROPY_n0; CURATOR_STRONG_INDICATION	0.0501267	0.0254992	1.30698	0.0918177	0.0720228	0.693864					0.0		4	curated	0.55052	Artery - Aorta	2.0	0.55052	Artery - Aorta	2.0	0.0	-0.2005704613706809	1	0.0	0.5670328014317839	1	1	1	RPL13P	0.5541972012932869	1		HIGH replicated	19	100	4.8487	0.15606	501	3496	0.0	0	2.54576	0.0238095	0.00736465	1	0	37	0	downstream_gene_variant	processed_pseudogene	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_12_16_32_atenolol__R030	atenolol__R030	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R030	Podwyższone BP bez diagnozy HT	Elevated BP reading, without diagnosis of HT	-	rs557049009	21-20375273-A-T	MODIFIER	0.00517205	6.66591	1.16359	7.99498	10.5869	0.772382	0.0022507	1.0	0.178154	0.192227	0.450953	5.5	37.42	2	STRONG (ROR+PRR+IC)	3.56	1.74	no_gene_symbol		Unknown	no_gene_symbol				Brak mapowania VEP do genu - cross-reference niemożliwy.	-	Bezpośrednie wskazanie – β-bloker jako terapia nadciśnieniowa. R03.0 często poprzedza rozpoznanie I10 w UKB. SILNE confounding.	84.034	15.966	1771	119	1	T1: Wskazanie	Wskazanie (CURATOR): Bezpośrednie wskazanie – β-bloker jako terapia nadciśnieniowa. R03.0 często poprzedza rozpoznanie I10 w UKB. SILNE confounding.	3	9	4	4.76	CURATOR_STRONG_INDICATION; CURATOR_STRONG_INDICATION	0.0271382	0.0336215	0.377195	0.0175172	0.0891687	0.073525							4	curated	0.55052	Artery - Aorta	2.0	0.55052	Artery - Aorta	2.0		-0.10666848471690013	1	0.0	0.5873390825604764	1	1	1	-	0.5563350984189672	1		HIGH replicated	19	100	4.8487	0.15606	501	3496	0.0	0	3.05499	0.0238095	0.00875796	1	0	44	0	intergenic_variant	-	-	-		C7	P	Sub-threshold predisposition	P	P	model	I
dzesikahoinkis_plinktestset_2026_04_20_13_05_45_atorvastatin__K760	atorvastatin__K760	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	K760	Stłuszczenie wątroby (NAFLD)	Fatty liver NEC	FBLIM1	rs142961571	1-15757809-G-A	MODIFIER	0.00384344	6.69408	1.05122	9.71758	1.64075	1.26457	0.695385	0.0	0.0540575	0.223043	0.0923206	6.18	123.83	2	STRONG (ROR+PRR+IC)	2.54	1.18	enriched	58.0	Unknown	trait_unrelated		3: heel bone mineral density; 1: alcoholic pancreatitis; 1: gut microbiome measurement, taxonomic microbiome measurement; 1: bone tissue density; 1: facial morphology	11.0		GO:0001650:fibrillar_center,GO:0001725:stress_fiber,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0005856:cytoskeleton,GO:0005925:focal_adhesion,GO:0007155:cell_adhesion,GO:0008360:regulation_of_cell_shape,GO:0030054:cell_junction,GO:0031005:filamin_binding,GO:0033623:regulation_of_integrin_activation,GO:0046872:metal_ion_binding,GO:0070161:anchoring_junction,GO:0071944:cell_periphery,GO:0098609:cell-cell_adhesion	Nie formalne wskazanie. ALE: NAFLD = silny marker zespołu metabolicznego; kilka metanaliz (Tziomalos 2010, Bril JHep 2017) sugeruje wręcz korzyść statyn w NAFLD (redukcja ALT, aterogennego profilu). Silne confounding – statyny częściej przepisywane u NAFLD.	96.818	3.1818	1048	220	1	T1: Wskazanie	Wskazanie (CURATOR): Nie formalne wskazanie. ALE: NAFLD = silny marker zespołu metabolicznego; kilka metanaliz (Tziomalos 2010, Bril JHep 2017) sugeruje wręcz ko	10	9	5	7.66	CURATOR_STRONG_INDICATION; LOW_PLEIOTROPY_n11; CURATOR_STRONG_INDICATION	-0.0822423	0.0418034	1.30855	-0.178852	0.0770945	1.69152	0.9358822930888032	0.6348991267690456	0.753504578235151	0.0	-0.8720205007227299	1.0559762167535574	1	curated	0.082663	Liver	1.0	0.082663	Liver	1.0	1.4042619724703407	-0.42542413485201563	1	0.0022174791281082107	0.5152038367201383	1	1	1	FBLIM1	0.5919840802015803	1		MED repl-underpowered	7	213	2.8693	3.6605	351	2572	0.0	0	0.391557	0.0	0.00433598	0	0	35	0	upstream_gene_variant	protein_coding	-	-	0.002	C6	E	Unreplicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_23_37_amitriptyline__H931	amitriptyline__H931	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	H931	Szumy uszne	Tinnitus	OGT	rs144678540	X-71569459-G-A	MODIFIER	0.0115091	4.39657	0.75895	8.16018	2.01877	0.95213	0.460631	0.0	0.0157029	0.122438	0.0467479	5.7	279.98	2	STRONG (ROR+PRR+IC)	3.39	1.59	enriched	17.0	UniProt loc med conf	trait_unrelated		1: Red cell distribution width	1.0		GO:0000122:negative_regulation_of_transcription_by_RNA_polymerase_II,GO:0000123:histone_acetyltransferase_complex,GO:0000423:mitophagy,GO:0002181:cytoplasmic_translation,GO:0005515:protein_binding,GO:0005547:phosphatidylinositol-3-4-5-trisphosphate_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005739:mitochondrion,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0006110:regulation_of_glycolytic_process,GO:0006111:regulation_of_gluconeogenesis,GO:0006325:chromatin_organization,GO:0006357:regulation_of_transcription_by_RNA_polymerase_II,GO:0006486:protein_glycosylation,GO:0006493:protein_O-linked_glycosylation,GO:0006915:apoptotic_process,GO:0007165:signal_transduction,GO:0007584:response_to_nutrient,GO:0008289:lipid_binding,GO:0008375:acetylglucosaminyltransferase_activity,GO:0016020:membrane,GO:0016485:protein_processing,GO:0016740:transferase_activity,GO:0016757:glycosyltransferase_activity,GO:0017122:,GO:0017148:negative_regulation_of_translation,GO:0030097:hemopoiesis,GO:0030336:negative_regulation_of_cell_migration,GO:0030512:negative_regulation_of_transforming_growth_factor_beta_receptor_signaling_pathway,GO:0031397:negative_regulation_of_protein_ubiquitination,GO:0031669:cellular_response_to_nutrient_levels,GO:0031966:mitochondrial_membrane,GO:0032435:negative_regulation_of_proteasomal_ubiquitin-dependent_protein_catabolic_process,GO:0032868:,GO:0032922:circadian_regulation_of_gene_expression,GO:0032991:protein-containing_complex,GO:0035020:regulation_of_Rac_protein_signal_transduction,GO:0038202:TORC1_signaling,GO:0042995:cell_projection,GO:0044545:NSL_complex,GO:0045727:positive_regulation_of_translation,GO:0045862:positive_regulation_of_proteolysis,GO:0045893:positive_regulation_of_DNA-templated_transcription,GO:0045944:positive_regulation_of_transcription_by_RNA_polymerase_II,GO:0045947:negative_regulation_of_translational_initiation,GO:0045948:positive_regulation_of_translational_initiation,GO:0046626:regulation_of_insulin_receptor_signaling_pathway,GO:0048511:rhythmic_process,GO:0051604:protein_maturation,GO:0060544:regulation_of_necroptotic_process,GO:0061462:protein_localization_to_lysosome,GO:0070269:pyroptotic_inflammatory_response,GO:0070822:Sin3-type_complex,GO:0071333:cellular_response_to_glucose_stimulus,GO:0097363:protein_O-acetylglucosaminyltransferase_activity,GO:0120162:,GO:0140694:membraneless_organelle_assembly,GO:0160075:non-canonical_inflammasome_complex_assembly,GO:0160076:negative_regulation_of_non-canonical_inflammasome_complex_assembly,GO:1902455:negative_regulation_of_stem_cell_population_maintenance,GO:1902459:positive_regulation_of_stem_cell_population_maintenance,GO:1904263:positive_regulation_of_TORC1_signaling	Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dowodów, ale praktyka kliniczna istnieje).	80.682	19.318	1101	88	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dow	9	8	6	7.56	CURATOR_MODERATE_INDICATION; LOW_PLEIOTROPY_n1; CURATOR_MODERATE_INDICATION	-0.00606377	0.0182095	0.131277	-0.0230019	0.0410621	0.240059	0.5357510321790253	0.5067109250974167	0.8184912081678956	0.0	1.2669798607169618	-0.8869602470755413	2	curated_weak							5.476488656218906	-0.19817398381520115	1	0.0	0.4831383144175727	1	1	1	OGT	0.5665315310017062	1		MED repl-underpowered	17	71	3.0144	2.0397	203	3284	0.0	0	0.737808	0.0	0.00900028	0	0	45	10	intron_variant	protein_coding	-	-	0.0021	C4	I	Pre-existing condition (timing only)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_23_37_amitriptyline__H931	amitriptyline__H931	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	H931	Szumy uszne	Tinnitus	LINC01449	rs17623175	7-41114148-A-G	MODIFIER	0.0068565	6.95448	1.07586	9.99186	3.4962	1.18338	0.290185	0.0	0.21382	0.190908	0.580529	6.17	32.52	1	STRONG (ROR+PRR+IC)	3.39	1.59	low	42.0	Unknown	trait_unrelated		9: body height; 8: glomerular filtration rate; 8: serum creatinine amount; 7: hospitalisation, psychiatric disorder; 6: testosterone measurement	79.0	LINC01449 (long intergenic non-coding RNA) - brak asocjacji w GWAS Catalog z tinnitus (H93.1) ani z innymi fenotypami słuchowymi. Top loci tinnitus w UKB GWAS (Maas 2017, Wells 2019): RCOR1, AC047065, liczne loci blisko genów słuchowych - brak LINC01449.	-	Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dowodów, ale praktyka kliniczna istnieje).	80.682	19.318	1101	88	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dow	6	9	4	6.0	CURATOR_MODERATE_INDICATION; LIT_NO_PRIOR_HIT; CURATOR_MODERATE_INDICATION; LOCUS_LEAD_rs17623175	0.00295001	0.026644	0.0400819	-0.00581603	0.0608264	0.0344103	0.9591052520245557				-0.08523537351908146		2	curated_weak							0.08658880438506834	-0.22943622317661477	2	0.0	0.49964944739165185	1	1	2	ENSG00000302868;LINC01449	0.5938058996878982	1		MED repl-underpowered	17	71	3.0144	2.0397	203	3284	0.0	0	1.05772	0.0	0.00761562	0	0	55	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0026	C4	I	Pre-existing condition (timing only)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_23_37_amitriptyline__H931	amitriptyline__H931	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	H931	Szumy uszne	Tinnitus	ENSG00000304974	rs558639365	14-43334081-A-G	MODIFIER	0.00528231	6.39766	1.11935	7.96115	2.07598	1.31607	0.578887	0.0	0.0866986	0.195033	0.182661	5.55	73.79	1	STRONG (ROR+PRR+IC)	3.39	1.59	no_gene_symbol		Unknown	no_gene_symbol					-	Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dowodów, ale praktyka kliniczna istnieje).	80.682	19.318	1101	88	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dow	3	7	4	4.38	CURATOR_MODERATE_INDICATION; CURATOR_MODERATE_INDICATION; LOCUS_LEAD_rs558639365	0.0422677	0.0304139	0.783555	-0.0432339	0.0669733	0.285186							2	curated_weak								-0.336823989710557	2	0.0	0.47052787167444077	1	1	2	ENSG00000304974	0.5360381942230237	1		MED repl-underpowered	17	71	3.0144	2.0397	203	3284	0.0	0	0.555011	0.0	0.0052617	0	0	36	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0004	C4	I	Pre-existing condition (timing only)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_23_37_amitriptyline__H931	amitriptyline__H931	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	H931	Szumy uszne	Tinnitus	F11-AS1	rs111252999	4-186367191-A-C	MODIFIER	0.00972504	4.93515	0.996472	6.13537	15.2516	1.22848	0.0265602	1.0	-0.0691949	0.161536	0.174968	4.96	71.32	3	STRONG (ROR+PRR+IC)	3.39	1.59	expressed	16.0	Unknown	trait_match	7: Tinnitus; 1: Tinnitus, wellbeing measurement	2174: body height; 669: blood protein amount; 642: fatty acid amount; 638: body mass index; 584: BMI-adjusted waist-hip ratio	47767.0		-	Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dowodów, ale praktyka kliniczna istnieje).	80.682	19.318	1101	88	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Umiarkowane off-label. Amitryptylina niskie dawki stosowane w tinnitus z komponentą depresyjną/bezsenności (Cochrane 2019 – słaba jakość dow	0	10	4	2.71	CURATOR_MODERATE_INDICATION; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n47767; TISSUE_RESCUE_BY_LIT_n7; CURATOR_MODERATE_INDICATION	-0.0468531	0.0229799	1.38234	-0.0336987	0.0514645	0.290221	0.9898699444564412				0.29436787606537673		2	curated_weak							0.3411974836081189	-0.33724014009137415	1	0.0	0.5337224880203201	0	1	1	F11-AS1	0.48677179119664965	0		HIGH replicated	17	71	3.0144	2.0397	203	3284	0.0	0	2.21792	0.0384615	0.0098338	1	0	71	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0046	C4	I	Pre-existing condition (timing only)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_15_35_23_fluoxetine__N951	fluoxetine__N951	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	N951	Menopauza/stany klimakteryczne	Menopausal state	TERF2IP		TERF2IP_mpc		0.000684561	104.465	20.4733	6.47472	5293.49	3.50776	0.0145109	0.385559	0.123996	2.00296	0.0219851	5.07	842.49	3	STRONG (ROR+PRR+IC)	7.24	2.36	enriched	52.0	UniProt Ubiquitination	trait_unrelated		5: smoking initiation; 3: smoking status measurement; 3: chymotrypsinogen B measurement; 1: smoking behavior; 1: Epstein-Barr virus seropositivity	25.0			Off-label udokumentowane. SSRI/SNRI (paroksetyna FDA-approved, fluoksetyna off-label) efektywne w uderzeniach gorąca (NAMS position 2023). Umiarkowane confounding.	54.023	45.977	814	87	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Off-label udokumentowane. SSRI/SNRI (paroksetyna FDA-approved, fluoksetyna off-label) efektywne w uderzeniach gorąca (NAMS position 2023). U	9	8	6	7.56	CURATOR_MODERATE_INDICATION; BURDEN; LOW_PLEIOTROPY_n25; CURATOR_MODERATE_INDICATION	-0.0271448	0.102867	0.101346	0.115507	0.697452	0.0612491	0.7491958517149451	0.6502101435319975	0.7112065472814195	0.0	0.6852674912578801	0.10711878479658182	2	curated	0.55423	Ovary	2.0	0.55423	Ovary	2.0	4.624963009314643	-0.7917968843184326	1	0.028827228665406743	0.13953572993948832	0	1	1	TERF2IP	0.15263051399570213	0	indication: SSRIs used for menopausal vasomotor symptoms (off-label)	HIGH replicated	40	47	2.2286	0.21355	151	2019	0.0	0	2.44436	0.0148292	0.000745487	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	confounder	I
dzesikahoinkis_plinktestset_2026_04_20_18_02_54_simvastatin__E785	simvastatin__E785	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	E785	Hiperlipidemia, nieokreślona	Hyperlipidaemia, unspecified	EXOSC8		EXOSC8_lof		0.000529101	6.90114	1.26205	7.34235	7.54023	0.741927	0.00646958	2.0	1.18695	0.460243	2.00393	4.25	5.81	3	STRONG (ROR+PRR+IC)	6.7	2.53	enriched	56.0	Structure with Ligand	trait_unrelated		1: soluble triggering receptor expressed on myeloid cells 2 measurement	1.0	Brak asocjacji GWAS Catalog EXOSC8 (13q13.3) z hiperlipidemią (E78.5). EXOSC8 - podjednostka kompleksu exosome RNA; Mendlowska leukoencefalopatia pontocerebellarna. Top loci GWAS E78 (lipid traits): LDLR, APOE, APOB, PCSK9, HMGCR - brak EXOSC8.		BEZPOŚREDNIE wskazanie – najsilniejsze confounding by indication w całym atlasie. E78.5 to par excellence wskazanie statynowe.	77.034	22.966	1061	1450	1	T1: Wskazanie	Wskazanie (CURATOR): BEZPOŚREDNIE wskazanie – najsilniejsze confounding by indication w całym atlasie. E78.5 to par excellence wskazanie statynowe.	7	8	7	7.32	CURATOR_STRONG_INDICATION; BURDEN; CONFIRMED_BY_BNF; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n1; CURATOR_STRONG_INDICATION	0.0327968	0.0701376	0.193775	0.160603	0.221919	0.328597	0.6689071766858543	0.5140264713227337	0.18612754233854628	1.0	0.576343858356373	0.9050045646621574	3	curated	0.88347	Adipose - Subcutaneous	3.0	0.88347	Adipose - Subcutaneous	3.0	3.2489238278199126	-0.007038241827685135	1	0.0	0.47145401032290846	0	1	1	EXOSC8	0.40662014355224574	0		HIGH replicated	333	1117	2.8474	0.0	290	2146	0.0	0	2.72298	0.00492611	0.000702864	2	0	8	0						C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_23_35_amitriptyline__G500	amitriptyline__G500	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	G500	Neuralgia nerwu trójdzielnego	Trigeminal neuralgia	NPAS3	rs117645447	14-33500816-A-G	MODIFIER	0.00654166	6.84411	1.14202	8.68604	4.07894	1.19104	0.237864	0.0	0.576182	0.404282	0.812197	5.17	11.88	2	STRONG (ROR+PRR+IC)	6.2	2.21	specific	3.0	Unknown	trait_unrelated		16: insomnia; 10: body height; 5: PHF-tau measurement; 4: schizophrenia; 3: self reported educational attainment	146.0	NPAS3 / Trigeminal neuralgia (G50.0). Brak bezpośredniej asocjacji GWAS Catalog NPAS3 (14q13.1) z nerwobólem nerwu trójdzielnego. NPAS3 (Neuronal PAS domain 3, bHLH-PAS TF) - GWS w cross-disorder psychiatric GWAS (schizofrenia, bipolar, major depressive disorder; Ferreira 2008 meta-GWAS bipolar; Huckins 2014), także związany z odpowiedzią na iloperidone. Brak GWS dla bólu neuropatycznego/G50.	GO:0000785:chromatin,GO:0000977:RNA_polymerase_II_transcription_regulatory_region_sequence-specific_DNA_binding,GO:0000981:DNA-binding_transcription_factor_activity_-_RNA_polymerase_II-specific,GO:0003677:DNA_binding,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0006355:regulation_of_DNA-templated_transcription,GO:0006357:regulation_of_transcription_by_RNA_polymerase_II,GO:0045893:positive_regulation_of_DNA-templated_transcription,GO:0046982:protein_heterodimerization_activity,GO:0046983:protein_dimerization_activity	Off-label standard II linii po karbamazepinie (NICE CG173, EAN 2019). Umiarkowane confounding.	65.476	34.524	1265	84	1	T1: Wskazanie	Wskazanie kliniczne (BNF): amitriptyline stosowany w G50.x według wytycznych - confounding by indication	9	7	5	6.8	INDICATION_LIST; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n146; CURATOR_MODERATE_INDICATION	0.0152727	0.0283603	0.228989	0.079838	0.0674462	0.626131	0.7814979397259099	0.829077743902439	0.7919131350781945	0.0	1.6848186298590513	2.305210398509371	2	curated							2.0557378149806005	-0.17752615675309727	1	0.0	0.3931959786677979	1	1	1	NPAS3	0.47573987955824343	1		MED repl-underpowered	29	55	3.4634	0.0	244	2756	0.0	0	1.18034	0.0	0.00581556	0	0	42	0	intron_variant	protein_coding	-	-	0.0018	C4	I	Pre-existing condition (timing only)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_42_18_amitriptyline__M797	amitriptyline__M797	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	M797	Fibromialgia	Fibromyalgia	GRIA1	rs114846642	5-153805544-A-G	MODIFIER	0.0124536	2.548	0.432492	8.41695	4.23957	0.552043	0.00888175	4.0	0.611266	0.181864	3.10998	4.13	4.17	2	STRONG (ROR+PRR+IC)	9.71	3.11	low		Approved Drug	trait_unrelated		15: insomnia; 13: body mass index; 11: schizophrenia; 9: taste liking measurement; 6: pain measurement	146.0	Brak bezpośredniej asocjacji GWAS Catalog dla GRIA1 z fibromialgią (M79.7). GRIA1 (5q33.2, GluA1/AMPAR) to GWS locus dla schizofrenii (PGC2 2014, Nature 511:421) oraz zaburzenia dwubiegunowego. Biologicznie wysoce plauzybilny dla bólu ośrodkowego/fibromialgii (glutamatergiczna transmisja, sensytyzacja centralna, mechanizm amitryptyliny), ale bez raportowanego GWS sygnału dla FM w GWAS Catalog.	GO:0001540:amyloid-beta_binding,GO:0001919:regulation_of_receptor_recycling,GO:0001965:G-protein_alpha-subunit_binding,GO:0004970:glutamate-gated_receptor_activity,GO:0004971:AMPA_glutamate_receptor_activity,GO:0005216:monoatomic_ion_channel_activity,GO:0005515:protein_binding,GO:0005768:endosome,GO:0005769:early_endosome,GO:0005783:endoplasmic_reticulum,GO:0005789:endoplasmic_reticulum_membrane,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0005911:cell-cell_junction,GO:0006811:monoatomic_ion_transport,GO:0007165:signal_transduction,GO:0007268:chemical_synaptic_transmission,GO:0007416:synapse_assembly,GO:0007616:long-term_memory,GO:0008021:synaptic_vesicle,GO:0008179:adenylate_cyclase_binding,GO:0008328:ionotropic_glutamate_receptor_complex,GO:0009410:response_to_xenobiotic_stimulus,GO:0009636:response_to_toxic_substance,GO:0009744:response_to_sucrose,GO:0009897:,GO:0009986:,GO:0010226:response_to_lithium_ion,GO:0010628:positive_regulation_of_gene_expression,GO:0012507:ER_to_Golgi_transport_vesicle_membrane,GO:0014069:postsynaptic_density,GO:0015276:ligand-gated_monoatomic_ion_channel_activity,GO:0016020:membrane,GO:0019228:neuronal_action_potential,GO:0019722:calcium-mediated_signaling,GO:0019865:immunoglobulin_binding,GO:0019901:protein_kinase_binding,GO:0019904:protein_domain_specific_binding,GO:0021510:spinal_cord_development,GO:0021987:cerebral_cortex_development,GO:0022849:glutamate-gated_calcium_ion_channel_activity,GO:0030165:PDZ_domain_binding,GO:0030425:dendrite,GO:0030666:endocytic_vesicle_membrane,GO:0030672:synaptic_vesicle_membrane,GO:0031267:small_GTPase_binding,GO:0031489:myosin_V_binding,GO:0031594:neuromuscular_junction,GO:0031623:receptor_internalization,GO:0031667:response_to_nutrient_levels,GO:0031681:G-protein_beta-subunit_binding,GO:0031698:beta-2_adrenergic_receptor_binding,GO:0031901:early_endosome_membrane,GO:0032279:asymmetric_synapse,GO:0032281:,GO:0032355:response_to_estradiol,GO:0032590:,GO:0032591:,GO:0032809:,GO:0032991:protein-containing_complex,GO:0033116:endoplasmic_reticulum-Golgi_intermediate_compartment_membrane,GO:0034220:monoatomic_ion_transmembrane_transport,GO:0034765:regulation_of_monoatomic_ion_transmembrane_transport,GO:0035235:ionotropic_glutamate_receptor_signaling_pathway,GO:0035249:synaptic_transmission_-_glutamatergic,GO:0035254:glutamate_receptor_binding,GO:0036477:,GO:0038023:signaling_receptor_activity,GO:0042220:response_to_cocaine,GO:0042734:presynaptic_membrane,GO:0042802:identical_protein_binding,GO:0042995:cell_projection,GO:0043005:neuron_projection,GO:0043025:neuronal_cell_body,GO:0043197:dendritic_spine,GO:0043198:dendritic_shaft,GO:0043278:response_to_morphine,GO:0043434:response_to_peptide_hormone,GO:0044297:cell_body,GO:0044308:axonal_spine,GO:0044309:neuron_spine,GO:0045202:synapse,GO:0045211:postsynaptic_membrane,GO:0045471:response_to_ethanol,GO:0045838:,GO:0046685:response_to_arsenic-containing_substance,GO:0048167:regulation_of_synaptic_plasticity,GO:0048266:behavioral_response_to_pain,GO:0048787:presynaptic_active_zone_membrane,GO:0050804:modulation_of_chemical_synaptic_transmission,GO:0050806:positive_regulation_of_synaptic_transmission,GO:0051018:protein_kinase_A_binding,GO:0051428:peptide_hormone_receptor_binding,GO:0051602:response_to_electrical_stimulus,GO:0055037:recycling_endosome,GO:0055038:recycling_endosome_membrane,GO:0060076:excitatory_synapse,GO:0060078:regulation_of_postsynaptic_membrane_potential,GO:0060291:long-term_synaptic_potentiation,GO:0060292:long-term_synaptic_depression,GO:0060992:response_to_fungicide,GO:0071230:cellular_response_to_amino_acid_stimulus,GO:0071242:cellular_response_to_ammonium_ion,GO:0071359:cellular_response_to_dsRNA,GO:0071363:cellular_response_to_growth_factor_stimulus,GO:0071375:cellular_response_to_peptide_hormone_stimulus,GO:0071418:cellular_response_to_amine_stimulus,GO:0090326:positive_regulation_of_locomotion_involved_in_locomotory_behavior,GO:0097060:synaptic_membrane,GO:0097110:scaffold_protein_binding,GO:0098793:presynapse,GO:0098794:postsynapse,GO:0098839:,GO:0098978:glutamatergic_synapse,GO:0099092:,GO:0099505:,GO:0099507:,GO:0099544:,GO:1904315:transmitter-gated_monoatomic_ion_channel_activity_involved_in_regulation_of_postsynaptic_membrane_potential,GO:1905232:cellular_response_to_L-glutamate,GO:1990416:cellular_response_to_brain-derived_neurotrophic_factor_stimulus,GO:1990635:proximal_dendrite,GO:1990708:conditioned_place_preference,GO:1990911:response_to_psychosocial_stress,GO:2000463:positive_regulation_of_excitatory_postsynaptic_potential	Amitryptylina to uznany lek w fibromialgii (ACR/EULAR guidelines, SIGN 136). Meta-analizy (Häuser 2011) potwierdzają skuteczność niskich dawek. SILNE confounding by indication.	84.228	15.772	2560	298	1	T1: Wskazanie	Wskazanie (CURATOR): Amitryptylina to uznany lek w fibromialgii (ACR/EULAR guidelines, SIGN 136). Meta-analizy (Häuser 2011) potwierdzają skuteczność niskich daw	3	10	7	5.94	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n146; CURATOR_STRONG_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[GRIA1|LINC01861|MFAP3]	0.0381512	0.0202998	1.22047	-0.0313815	0.046198	0.30368	0.9111090291916905	0.8863717286807905	0.7377846203711206	0.0	1.6111157111705798	2.0260790775638187	3	curated	0.25696	Muscle - Skeletal	1.0	0.25696	Muscle - Skeletal	1.0	3.3090382321433642	-0.14817488079149704	38	0.0014783194187388072	0.4783396391932659	0	1	18	-;GRIA1;LINC01861;MFAP3	0.4607135170834522	0		HIGH replicated	47	251	7.0089	0.03833	899	4534	0.0	0	2.61657	0.04	0.0114717	4	0	82	0	intron_variant	protein_coding	-	-	0.0136	C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_42_18_amitriptyline__M797	amitriptyline__M797	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	M797	Fibromialgia	Fibromyalgia	GPC4	rs73239386	X-133395658-G-A	MODIFIER	0.0148674	1.99746	0.387761	6.58714	4.88547	0.351651	6.45494e-06	8.0	0.492876	0.165915	2.52699	3.57	4.05	2	STRONG (ROR+PRR+IC)	9.71	3.11	low		UniProt loc med conf	no_gwas_hits			0.0	Brak asocjacji GWAS Catalog dla fibromialgii (M79.7) w GPC4. Najnowsza multi-ancestry GWAS fibromialgii (2.5M individuals, 54 629 przypadków, 2025) nie raportuje GPC4 - top loci to HTT, GPR52, CAMKV, DCC, DRD2/NCAM1, MDGA2, CELF4. GPC4 związany z Mendlowskim zespołem Keiperta (Xq26.2, LoF); astrocytarny ligand klastrowania GluA1/AMPAR - biologicznie powiązany z glutamatergiczną transmisją ważną dla amitryptyliny, ale bez GWS sygnału.	GO:0005515:protein_binding,GO:0005576:extracellular_region,GO:0005634:nucleus,GO:0005796:Golgi_lumen,GO:0005886:plasma_membrane,GO:0009897:,GO:0009966:regulation_of_signal_transduction,GO:0009986:,GO:0015026:coreceptor_activity,GO:0016020:membrane,GO:0016055:Wnt_signaling_pathway,GO:0016477:cell_migration,GO:0043202:lysosomal_lumen,GO:0045202:synapse,GO:0062023:collagen-containing_extracellular_matrix,GO:0070062:,GO:0098552:side_of_membrane,GO:0098696:,GO:0098978:glutamatergic_synapse,GO:0099560:,GO:1905606:regulation_of_presynapse_assembly	Amitryptylina to uznany lek w fibromialgii (ACR/EULAR guidelines, SIGN 136). Meta-analizy (Häuser 2011) potwierdzają skuteczność niskich dawek. SILNE confounding by indication.	84.228	15.772	2560	298	1	T1: Wskazanie	Wskazanie (CURATOR): Amitryptylina to uznany lek w fibromialgii (ACR/EULAR guidelines, SIGN 136). Meta-analizy (Häuser 2011) potwierdzają skuteczność niskich daw	5	9	5	6.08	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n0; CURATOR_STRONG_INDICATION; LOCUS_LEAD_rs73239386	0.00433157	0.015681	0.106588	0.017326	0.0363236	0.198344	0.7790400561687948	0.6494237469847226	0.6672879021149014	0.0	1.3112786681451665	1.5088309070970842	3	curated	0.25696	Muscle - Skeletal	1.0	0.25696	Muscle - Skeletal	1.0	3.6110881684201575	-0.22881775481465907	2	0.0	0.498360419518989	0	1	2	GPC4	0.4129125165004757	0		HIGH replicated	47	251	7.0089	0.03833	899	4534	0.0	0	4.51091	0.08	0.0145495	6	1	62	21	intron_variant	protein_coding	-	-	0.0013	C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_42_18_amitriptyline__M797	amitriptyline__M797	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	M797	Fibromialgia	Fibromyalgia	GRIA1	rs143889705	5-153797151-C-T	MODIFIER	0.0124195	2.56033	0.433237	8.46521	4.23957	0.552043	0.00888175	4.0	0.611564	0.181881	3.11205	4.15	4.19	2	STRONG (ROR+PRR+IC)	9.71	3.11	low		Approved Drug	trait_unrelated		15: insomnia; 13: body mass index; 11: schizophrenia; 9: taste liking measurement; 6: pain measurement	146.0	Brak bezpośredniej asocjacji GWAS Catalog dla GRIA1 z fibromialgią (M79.7). GRIA1 (5q33.2, GluA1/AMPAR) to GWS locus dla schizofrenii (PGC2 2014, Nature 511:421) oraz zaburzenia dwubiegunowego. Biologicznie wysoce plauzybilny dla bólu ośrodkowego/fibromialgii (glutamatergiczna transmisja, sensytyzacja centralna, mechanizm amitryptyliny), ale bez raportowanego GWS sygnału dla FM w GWAS Catalog.	GO:0001540:amyloid-beta_binding,GO:0001919:regulation_of_receptor_recycling,GO:0001965:G-protein_alpha-subunit_binding,GO:0004970:glutamate-gated_receptor_activity,GO:0004971:AMPA_glutamate_receptor_activity,GO:0005216:monoatomic_ion_channel_activity,GO:0005515:protein_binding,GO:0005768:endosome,GO:0005769:early_endosome,GO:0005783:endoplasmic_reticulum,GO:0005789:endoplasmic_reticulum_membrane,GO:0005829:cytosol,GO:0005886:plasma_membrane,GO:0005911:cell-cell_junction,GO:0006811:monoatomic_ion_transport,GO:0007165:signal_transduction,GO:0007268:chemical_synaptic_transmission,GO:0007416:synapse_assembly,GO:0007616:long-term_memory,GO:0008021:synaptic_vesicle,GO:0008179:adenylate_cyclase_binding,GO:0008328:ionotropic_glutamate_receptor_complex,GO:0009410:response_to_xenobiotic_stimulus,GO:0009636:response_to_toxic_substance,GO:0009744:response_to_sucrose,GO:0009897:,GO:0009986:,GO:0010226:response_to_lithium_ion,GO:0010628:positive_regulation_of_gene_expression,GO:0012507:ER_to_Golgi_transport_vesicle_membrane,GO:0014069:postsynaptic_density,GO:0015276:ligand-gated_monoatomic_ion_channel_activity,GO:0016020:membrane,GO:0019228:neuronal_action_potential,GO:0019722:calcium-mediated_signaling,GO:0019865:immunoglobulin_binding,GO:0019901:protein_kinase_binding,GO:0019904:protein_domain_specific_binding,GO:0021510:spinal_cord_development,GO:0021987:cerebral_cortex_development,GO:0022849:glutamate-gated_calcium_ion_channel_activity,GO:0030165:PDZ_domain_binding,GO:0030425:dendrite,GO:0030666:endocytic_vesicle_membrane,GO:0030672:synaptic_vesicle_membrane,GO:0031267:small_GTPase_binding,GO:0031489:myosin_V_binding,GO:0031594:neuromuscular_junction,GO:0031623:receptor_internalization,GO:0031667:response_to_nutrient_levels,GO:0031681:G-protein_beta-subunit_binding,GO:0031698:beta-2_adrenergic_receptor_binding,GO:0031901:early_endosome_membrane,GO:0032279:asymmetric_synapse,GO:0032281:,GO:0032355:response_to_estradiol,GO:0032590:,GO:0032591:,GO:0032809:,GO:0032991:protein-containing_complex,GO:0033116:endoplasmic_reticulum-Golgi_intermediate_compartment_membrane,GO:0034220:monoatomic_ion_transmembrane_transport,GO:0034765:regulation_of_monoatomic_ion_transmembrane_transport,GO:0035235:ionotropic_glutamate_receptor_signaling_pathway,GO:0035249:synaptic_transmission_-_glutamatergic,GO:0035254:glutamate_receptor_binding,GO:0036477:,GO:0038023:signaling_receptor_activity,GO:0042220:response_to_cocaine,GO:0042734:presynaptic_membrane,GO:0042802:identical_protein_binding,GO:0042995:cell_projection,GO:0043005:neuron_projection,GO:0043025:neuronal_cell_body,GO:0043197:dendritic_spine,GO:0043198:dendritic_shaft,GO:0043278:response_to_morphine,GO:0043434:response_to_peptide_hormone,GO:0044297:cell_body,GO:0044308:axonal_spine,GO:0044309:neuron_spine,GO:0045202:synapse,GO:0045211:postsynaptic_membrane,GO:0045471:response_to_ethanol,GO:0045838:,GO:0046685:response_to_arsenic-containing_substance,GO:0048167:regulation_of_synaptic_plasticity,GO:0048266:behavioral_response_to_pain,GO:0048787:presynaptic_active_zone_membrane,GO:0050804:modulation_of_chemical_synaptic_transmission,GO:0050806:positive_regulation_of_synaptic_transmission,GO:0051018:protein_kinase_A_binding,GO:0051428:peptide_hormone_receptor_binding,GO:0051602:response_to_electrical_stimulus,GO:0055037:recycling_endosome,GO:0055038:recycling_endosome_membrane,GO:0060076:excitatory_synapse,GO:0060078:regulation_of_postsynaptic_membrane_potential,GO:0060291:long-term_synaptic_potentiation,GO:0060292:long-term_synaptic_depression,GO:0060992:response_to_fungicide,GO:0071230:cellular_response_to_amino_acid_stimulus,GO:0071242:cellular_response_to_ammonium_ion,GO:0071359:cellular_response_to_dsRNA,GO:0071363:cellular_response_to_growth_factor_stimulus,GO:0071375:cellular_response_to_peptide_hormone_stimulus,GO:0071418:cellular_response_to_amine_stimulus,GO:0090326:positive_regulation_of_locomotion_involved_in_locomotory_behavior,GO:0097060:synaptic_membrane,GO:0097110:scaffold_protein_binding,GO:0098793:presynapse,GO:0098794:postsynapse,GO:0098839:,GO:0098978:glutamatergic_synapse,GO:0099092:,GO:0099505:,GO:0099507:,GO:0099544:,GO:1904315:transmitter-gated_monoatomic_ion_channel_activity_involved_in_regulation_of_postsynaptic_membrane_potential,GO:1905232:cellular_response_to_L-glutamate,GO:1990416:cellular_response_to_brain-derived_neurotrophic_factor_stimulus,GO:1990635:proximal_dendrite,GO:1990708:conditioned_place_preference,GO:1990911:response_to_psychosocial_stress,GO:2000463:positive_regulation_of_excitatory_postsynaptic_potential	Amitryptylina to uznany lek w fibromialgii (ACR/EULAR guidelines, SIGN 136). Meta-analizy (Häuser 2011) potwierdzają skuteczność niskich dawek. SILNE confounding by indication.	84.228	15.772	2560	298	1	T1: Wskazanie	Wskazanie (CURATOR): Amitryptylina to uznany lek w fibromialgii (ACR/EULAR guidelines, SIGN 136). Meta-analizy (Häuser 2011) potwierdzają skuteczność niskich daw	3	10	7	5.94	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n146; CURATOR_STRONG_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[GRIA1|LINC01861|MFAP3]	0.0385531	0.020351	1.23529	-0.0338887	0.0462317	0.333906	0.9111090291916905	0.8863717286807905	0.7377846203711206	0.0	1.6111157111705798	2.0260790775638187	3	curated	0.25696	Muscle - Skeletal	1.0	0.25696	Muscle - Skeletal	1.0	3.3090382321433642	-0.14727161998542154	37	0.0014783194187388072	0.47877983150978953	0	1	20	GRIA1	0.46203152149195614	0		HIGH replicated	47	251	7.0089	0.03833	899	4534	0.0	0	2.61657	0.04	0.0114717	4	0	82	0	intron_variant	protein_coding	-	-	0.0138	C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_14_48_33_clopidogrel__I639	clopidogrel__I639	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	I639	Zawał mózgu	Cerebral infarction	RPS2P55	rs145901271	X-40936652-T-A	MODIFIER	0.0054549	4.51402	0.802516	7.73124	2.10041	0.805822	0.357071	0.0	0.0632896	0.17985	0.139715	5.41	71.32	1	STRONG (ROR+PRR+IC)	4.58	2.02	expressed	12.0	Unknown	trait_unrelated		6: reticulocyte amount; 4: reticulocyte count; 1: mean reticulocyte volume; 1: Red cell distribution width; 1: memory performance	16.0		-	BEZPOŚREDNIE wskazanie – prewencja wtórna udaru niedokrwiennego (CAPRIE, MATCH; ESO guidelines). Klasa I.	84.848	15.152	621	99	1	T1: Wskazanie	Wskazanie (CURATOR): BEZPOŚREDNIE wskazanie – prewencja wtórna udaru niedokrwiennego (CAPRIE, MATCH; ESO guidelines). Klasa I.	7	8	4	6.07	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; LOW_PLEIOTROPY_n16; CURATOR_STRONG_INDICATION	0.00594763	0.0119995	0.207514	0.0287801	0.0999217	0.111637	0.7496635014399688				0.17516953316186748		4	curated	0.29936	Artery - Aorta	4.0	0.29936	Artery - Aorta	4.0	0.6360777627597317	-0.19550801678071525	1	0.0	0.5104148926285744	0	1	1	RPS2P55	0.5273239873469296	0		MED repl-underpowered	15	84	1.7002	0.013689	152	1349	0.0	0	0.920961	0.0	0.00261194	0	0	1	3	upstream_gene_variant	processed_pseudogene	-	-	0.0024	C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_19_41_21_tramadol__R101	tramadol__R101	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	R101	Ból w nadbrzuszu	Pain localized to upper abdomen	SCD5	rs139368799	4-82803473-T-C	MODIFIER	0.00781973	2.95031	0.558906	6.88574	3.58022	0.645149	0.0480478	3.0	0.0835379	0.0903947	0.44927	5.06	35.32	2	weak (1/3)	1.87	0.8	enriched	37.0	High-Quality Ligand	trait_unrelated		16: leukocyte quantity; 16: eosinophil count; 15: monocyte count; 14: lymphocyte count; 14: Premature atrial contractions	149.0		GO:0004768:stearoyl-CoA_9-desaturase_activity,GO:0005506:iron_ion_binding,GO:0005783:endoplasmic_reticulum,GO:0005789:endoplasmic_reticulum_membrane,GO:0006629:lipid_metabolic_process,GO:0006631:fatty_acid_metabolic_process,GO:0006633:fatty_acid_biosynthetic_process,GO:0006636:unsaturated_fatty_acid_biosynthetic_process,GO:0016020:membrane,GO:0016215:acyl-CoA_desaturase_activity,GO:0016491:oxidoreductase_activity,GO:0016717:oxidoreductase_activity_-_acting_on_paired_donors_-_with_oxidation_of_a_pair_of_donors_resulting_in_the_reduction_of_molecular_oxygen_to_two_molecules_of_water,GO:0032896:palmitoyl-CoA_9-desaturase_activity,GO:0046872:metal_ion_binding	Off-label dla bólu brzusznego umiarkowanego/silnego (postoperacyjny, pankreatyczny, niesprecyzowany). Umiarkowane confounding.	85.498	14.502	1086	331	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Off-label dla bólu brzusznego umiarkowanego/silnego (postoperacyjny, pankreatyczny, niesprecyzowany). Umiarkowane confounding.	8	6	4	5.77	CURATOR_MODERATE_INDICATION; HIGH_PLEIOTROPY_n149; CURATOR_MODERATE_INDICATION	0.0109702	0.0270926	0.163967	-0.0479555	0.0664469	0.327467	0.8082713810242921	0.7987343441001977	0.7757069929503281	0.0	-0.41190061896995883	-0.5884332723667464	2	curated	0.3896599999999999	Colon - Sigmoid	3.0	0.3896599999999999	Colon - Sigmoid	3.0	2.473727731196566	-0.07064885995005524	1	0.0	0.5234815085056919	1	1	1	SCD5	0.48390001408167327	1		HIGH replicated	48	283	2.9733	3.0062	212	2281	0.0	0	1.97695	0.0348837	0.008364	3	0	48	1	upstream_gene_variant	protein_coding	-	-	0.0012	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_17_25_36_ramipril__I64	ramipril__I64	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	I64	Udar	Stroke	FDX1		FDX1_mpc		0.000336101	57.8891	11.2527	6.57145	47885.2	4.8042	0.0248867	0.0	7.93237	4.33546	1.17197	4.14	7.3	2	weak (1/3)	1.67	0.62	enriched	32.0	Structure with Ligand	trait_unrelated		2: serum metabolite level; 2: FEV/FVC ratio; 1: 3beta-hydroxy-5-cholestenoate measurement; 1: renal sinus adipose tissue measurement; 1: lactate measurement	13.0			SILNE confounding. ACEi w prewencji udaru + kontrola BP post-stroke (PROGRESS, HOPE). Klasa I ESC/ESO.	43.689	1.9417	1371	103	1	T1: Wskazanie	Wskazanie (CURATOR): SILNE confounding. ACEi w prewencji udaru + kontrola BP post-stroke (PROGRESS, HOPE). Klasa I ESC/ESO.	9	5	4	5.65	CURATOR_STRONG_INDICATION; BURDEN; LOW_PLEIOTROPY_n13; CURATOR_STRONG_INDICATION	0.18281	0.4285	0.174152	0.975016	0.967807	0.503459	0.9658811250721291	0.9605241791432559	0.6129973259865488	0.0	0.023529476693821678	-0.6470783074007349	4	curated	0.31489	Artery - Aorta	4.0	0.31489	Artery - Aorta	4.0	2.544393369537411	-0.7917968843184326	1	0.3957324252715818	0.22812358044096676	1	2	1	FDX1	0.2558024479008688	1		HIGH replicated	2	45	3.7536	0.83504	467	2426	54.369	0	2.24316	0.0	0.000310407	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	I
dzesikahoinkis_plinktestset_2026_04_20_14_59_06_clopidogrel__T828	clopidogrel__T828	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	T828	Powikłania protez sercowo-naczyniowych	Complications of cardiac/vascular prosthetic devices	HPSE2	rs151015017	10-99237313-A-G	MODIFIER	0.00691603	4.59386	0.909058	6.36257	8.4996	0.913927	0.0192032	1.0	0.891636	0.342155	2.03799	3.81	5.15	2	STRONG (ROR+PRR+IC)	11.82	1.94	icd_not_mapped		UniProt loc high conf	icd_not_mapped		5: aspartate aminotransferase measurement; 5: migraine disorder; 2: gut microbiome measurement; 2: COVID-19; 2: diet measurement, alanine aminotransferase 1 measurement	51.0		GO:0005576:extracellular_region,GO:0005615:extracellular_space,GO:0005886:plasma_membrane,GO:0016020:membrane,GO:0016798:hydrolase_activity_-_acting_on_glycosyl_bonds,GO:0030198:extracellular_matrix_organization,GO:0030305:heparanase_activity,GO:0031012:extracellular_matrix,GO:0043395:heparan_sulfate_proteoglycan_binding	BEZPOŚREDNIE wskazanie – DAPT (aspirin+clopidogrel) po stentach (DES min. 6–12 mies., BMS min. 1 mies.). Klasa I ESC ACS 2023. Maksymalne confounding.	98.214	1.7857	368	112	1	T1: Wskazanie	Wskazanie (CURATOR): BEZPOŚREDNIE wskazanie – DAPT (aspirin+clopidogrel) po stentach (DES min. 6–12 mies., BMS min. 1 mies.). Klasa I ESC ACS 2023. Maksymalne co	2	9	5	4.48	CURATOR_STRONG_INDICATION; CURATOR_STRONG_INDICATION	-0.0139764	0.0142057	0.487868	0.0143202	0.115751	0.0450146	0.8656376461098232	0.7925181278839815	0.8933635847986385	0.0	1.2459321957182303	-1.376029517696932	5	curated							2.8838896834602914	-0.19603368590504597	1	0.0	0.5349310547983256	1	1	1	HPSE2	0.4495995983481037	1		HIGH replicated	2	110	1.0075	8.0712	104	1926	0.0	0	2.34156	0.0277778	0.00563063	1	0	15	0	upstream_gene_variant	protein_coding	-	-	0.0012	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_15_34_07_fluoxetine__I48	fluoxetine__I48	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	I48	Migotanie przedsionków	Atrial fibrillation	PCLO	rs534970958	7-82781217-A-C	MODIFIER	0.0104774	3.78103	0.737125	6.53667	3.83821	0.80684	0.0955138	1.0	0.000593565	0.10101	0.00204101	5.08	378.1	1	no_signal	0.93	-0.31	enriched	14.0	Med-Quality Pocket	trait_unrelated		12: major depressive disorder; 12: insomnia; 8: memory performance; 6: wellbeing measurement; 6: semaphorin-3E measurement	125.0		GO:0005509:calcium_ion_binding,GO:0005515:protein_binding,GO:0005522:profilin_binding,GO:0005544:calcium-dependent_phospholipid_binding,GO:0005856:cytoskeleton,GO:0007010:cytoskeleton_organization,GO:0008270:zinc_ion_binding,GO:0014069:postsynaptic_density,GO:0016079:synaptic_vesicle_exocytosis,GO:0017157:regulation_of_exocytosis,GO:0030073:insulin_secretion,GO:0030424:axon,GO:0035418:protein_localization_to_synapse,GO:0042995:cell_projection,GO:0043226:organelle,GO:0045202:synapse,GO:0046872:metal_ion_binding,GO:0048786:presynaptic_active_zone,GO:0048788:cytoskeleton_of_presynaptic_active_zone,GO:0048790:maintenance_of_presynaptic_active_zone_structure,GO:0051049:regulation_of_transport,GO:0065008:regulation_of_biological_quality,GO:0070062:,GO:0097091:synaptic_vesicle_clustering,GO:0098882:,GO:0098978:glutamatergic_synapse,GO:0098982:,GO:0099140:,GO:0099172:presynapse_organization,GO:1904071:presynaptic_active_zone_assembly	Nie wskazanie. SSRI (fluoksetyna) blokują hERG K⁺ → QT prolongation → teoretyczne ryzyko arytmii. Dodatkowo: SILNE confounding by indication (depresja sama w sobie jest czynnikiem ryzyka AF; Fenger-Gron EJPC 2019).	100.0	0.0	1307	106	1	T1: Wskazanie	Wskazanie (CURATOR): Nie wskazanie. SSRI (fluoksetyna) blokują hERG K⁺ → QT prolongation → teoretyczne ryzyko arytmii. Dodatkowo: SILNE confounding by indication	7	4	3	4.38	CURATOR_STRONG_INDICATION; HIGH_PLEIOTROPY_n125; CURATOR_STRONG_INDICATION	0.000782118	0.011443	0.0243348	-0.0253835	0.0696224	0.14544	0.9333527726987884	0.8368614818223652	0.9167004294627663	0.0	-0.6057018081443217	-0.688765448772268	2	curated	0.91505	Heart - Atrial Appendage	2.0	0.91505	Heart - Atrial Appendage	2.0	0.36063788111999323	-0.029573370474368282	1	0.0	0.5090260330649364	0	1	1	PCLO	0.4925144242224244	0		HIGH replicated	0	106	3.5784		462	3148	0.0	0	1.667	0.0333333	0.0100304	1	0	33	0	intron_variant	protein_coding	-	-	0.0014	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_17_25_29_ramipril__I219	ramipril__I219	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	I219	Ostry zawał serca	Acute myocardial infarction	KLF12	rs138042714	13-74048448-C-A	MODIFIER	0.0207331	2.12822	0.401672	6.93248	1.96356	0.487606	0.166415	5.0	0.189132	0.12422	0.893228	4.61	11.25	1	weak (1/3)	1.92	0.83	enriched	25.0	Database Ubiquitination	trait_unrelated		67: electrocardiography; 17: lymphocyte count; 8: PHF-tau measurement; 7: QRS duration; 6: heel bone mineral density	245.0		GO:0000122:negative_regulation_of_transcription_by_RNA_polymerase_II,GO:0000785:chromatin,GO:0000978:RNA_polymerase_II_cis-regulatory_region_sequence-specific_DNA_binding,GO:0000981:DNA-binding_transcription_factor_activity_-_RNA_polymerase_II-specific,GO:0001227:DNA-binding_transcription_repressor_activity_-_RNA_polymerase_II-specific,GO:0003677:DNA_binding,GO:0003700:DNA-binding_transcription_factor_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005829:cytosol,GO:0006357:regulation_of_transcription_by_RNA_polymerase_II,GO:0008270:zinc_ion_binding,GO:0046872:metal_ion_binding,GO:1990837:sequence-specific_double-stranded_DNA_binding	BEZPOŚREDNIE wskazanie – ACEi po MI (prewencja remodelingu; AIRE, HOPE, SAVE). Klasa I ESC.	88.968	11.032	1076	281	1	T1: Wskazanie	Wskazanie (CURATOR): BEZPOŚREDNIE wskazanie – ACEi po MI (prewencja remodelingu; AIRE, HOPE, SAVE). Klasa I ESC.	7	4	3	4.38	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; HIGH_PLEIOTROPY_n245; CURATOR_STRONG_INDICATION	0.0605288	0.0225061	2.14526	0.0121907	0.0410012	0.115648	0.6668349533530047	0.6456511734928669	0.12162709666963778	1.0	1.5318598598450819	0.6836704175208773	3	curated	0.6390899999999999	Heart - Atrial Appendage	3.0	0.6390899999999999	Heart - Atrial Appendage	3.0	2.395742047180147	-0.03988396296219621	1	0.0014783194187388072	0.4836444803546195	0	1	1	KLF12	0.49005175718694177	0		LOW unreplicated	31	250	2.9459	0.030116	340	2294	0.0	0	1.38382	0.0480769	0.0227611	5	0	151	1	intron_variant	protein_coding	-	-	0.004	C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_14_59_16_dextropropoxyphene__M796	dextropropoxyphene__M796	dextropropoxyphene	R52, M79.7	Ból łagodny do umiarkowanego (R52) - w UK od 2007 wycofany; dostępny tylko jako 'named patient' w przewlekłym bólu (M79.7)	M796	Ból kończyny	Pain in limb	PLPP3	rs72666457	1-56627480-C-T	MODIFIER	0.00775406	4.64031	0.902376	6.56646	10.8303	1.40909	0.0908954	0.0	0.0631868	0.0935463	0.301566	5.05	73.44	1	no_signal	1.19	-0.88	low		UniProt loc high conf	trait_unrelated		22: coronary artery disorder; 10: reticulocyte count; 10: neutrophil count; 9: lymphocyte count; 8: reticulocyte amount	189.0		-	Bezpośrednie wskazanie (słaby opioid stosowany do 2010 w UK/USA do bólu). Obecnie wycofany w większości krajów, ale w UK Biobank historycznie obecny.	57.237	42.763	902	152	1	T1: Wskazanie	Wskazanie (CURATOR): Bezpośrednie wskazanie (słaby opioid stosowany do 2010 w UK/USA do bólu). Obecnie wycofany w większości krajów, ale w UK Biobank historyczni	5	5	2	3.68	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; HIGH_PLEIOTROPY_n189; CURATOR_STRONG_INDICATION	-0.0311173	0.0241127	0.7058	-0.071288	0.0863098	0.388458	0.7806079046523453	0.7056582508552062	0.7710072117332468	0.0	1.0434091842128594	-0.32951020674625836	2	curated	0.11745	Muscle - Skeletal	1.0	0.11745	Muscle - Skeletal	1.0	5.159790660953706	-0.2615199722081808	1	0.0	0.29112234748901605	0	1	1	PLPP3	0.34521057906925967	0		HIGH replicated	65	87	2.4695	2.6475	343	1820	0.0	0	1.69069	0.0	0.00474453	0	0	13	0	intron_variant,non_coding_transcript_variant	protein_coding_CDS_not_defined	-	-	0.0022	C2	I	On-label indication (BNF-confirmed)	I	I	model	I
dzesikahoinkis_plinktestset_2026_04_20_12_16_31_atenolol__R002	atenolol__R002	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R002	Kołatanie serca	Palpitations	ENSG00000303889	rs142183691	9-136606925-C-T	MODIFIER	0.00474984	4.96969	0.930997	7.02704	7.51516	0.802636	0.0119753	2.0	0.571587	0.208785	2.20849	4.61	8.69	2	STRONG (ROR+PRR+IC)	2.59	1.26	no_gene_symbol		Unknown	no_gene_symbol				ENSG00000303889 / Palpitations (R00.2). Gen bez symbolu HGNC - niemożliwe cross-reference w GWAS Catalog. R00.2 to fenotyp subiektywny; blisko związany z GWAS heart rate, heart rate variability (top loci: CHRM2, RNF220, GNG11, SYT10).	-	Bezpośrednie wskazanie β-blokera – SVT, SR tachy, IST, objawowe kołatania. Silne confounding.	97.5	2.5	2266	160	1	T1: Wskazanie	Wskazanie (CURATOR): Bezpośrednie wskazanie β-blokera – SVT, SR tachy, IST, objawowe kołatania. Silne confounding.	1	8	4	3.17	CURATOR_STRONG_INDICATION; CURATOR_STRONG_INDICATION	0.000266531	0.0338581	0.00273635	-0.0253911	0.0931063	0.105089							2	curated								-0.13350754690752537	1	0.0	0.5577529035129382	1	1	1	ENSG00000303889	0.4841016804972535	1		HIGH replicated	4	156	6.204	0.3258	351	3485	0.0	0	2.51287	0.0285714	0.00440352	2	0	22	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.001	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_10_42_55_amitriptyline__R103	amitriptyline__R103	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	R103	Ból w dole brzucha	Pain localized to other parts of lower abdomen	LINC02934	rs181365610	2-65832689-A-G	MODIFIER	0.00552718	3.58673	0.720038	6.19959	5.71388	0.765192	0.022743	2.0	0.0134412	0.12897	0.0376331	4.88	266.85	1	weak (1/3)	1.66	0.42	low	62.0	Unknown	trait_unrelated		32: body height; 28: BMI-adjusted waist-hip ratio; 26: BMI-adjusted waist circumference; 8: brain attribute; 7: monocyte count	269.0		-	Off-label STANDARD w IBS/bólu brzusznym czynnościowym (ACG 2021 conditional recommend; NICE CG61). Umiarkowane confounding.	94.821	5.1793	1305	251	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Off-label STANDARD w IBS/bólu brzusznym czynnościowym (ACG 2021 conditional recommend; NICE CG61). Umiarkowane confounding.	5	6	1	3.11	CURATOR_MODERATE_INDICATION; HIGH_PLEIOTROPY_n269; CURATOR_MODERATE_INDICATION	-0.0337921	0.0296456	0.594583	-0.127606	0.0635761	1.34935							3	curated	0.61479	Colon - Sigmoid	3.0	0.61479	Colon - Sigmoid	3.0		-0.15691984931170302	1	0.0	0.5454631876172962	1	1	1	LINC02934	0.45905177034372374	1		HIGH replicated	13	238	3.5729	1.2293	290	2668	0.0	0	2.27772	0.0232558	0.00586428	2	0	42	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_18_22_47_simvastatin__I251	simvastatin__I251	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I251	Miażdżycowa choroba serca	Atherosclerotic heart disease	LPA	rs10455872	6-160589086-A-G	MODIFIER	0.0898833	0.316521	0.0634755	6.21127	1.35486	0.110984	0.00621205	102.0	0.384958	0.0288177	39.9755	0.98	0.82	3	STRONG (ROR+PRR+IC)	4.75	2.1	low	101.0	Structure with Ligand	trait_match	45: coronary artery disorder; 8: family history, coronary artery disorder; 6: atherosclerosis; 3: lipoprotein A measurement; 2: drug use measurement, coronary artery disorder	299: fatty acid amount; 111: lipoprotein A measurement; 61: low density lipoprotein cholesterol measurement; 57: saturated fatty acids measurement; 52: total cholesterol measurement	2501.0		GO:0001968:fibronectin_binding,GO:0004252:serine-type_endopeptidase_activity,GO:0004866:endopeptidase_inhibitor_activity,GO:0005515:protein_binding,GO:0005576:extracellular_region,GO:0006508:proteolysis,GO:0006629:lipid_metabolic_process,GO:0006869:lipid_transport,GO:0008015:blood_circulation,GO:0008201:heparin_binding,GO:0008233:peptidase_activity,GO:0008236:serine-type_peptidase_activity,GO:0016787:hydrolase_activity,GO:0034185:apolipoprotein_binding,GO:0034358:plasma_lipoprotein_particle	SILNE confounding by indication. Statyny to klasa I wskazanie w stabilnej CAD (prewencja wtórna) – ESC/ACC guidelines. Wszyscy pacjenci z ASCVD powinni otrzymać wysoko-intensywną statynę.	98.611	1.3893	373	3023	1	T1: Wskazanie	Wskazanie (CURATOR): SILNE confounding by indication. Statyny to klasa I wskazanie w stabilnej CAD (prewencja wtórna) – ESC/ACC guidelines. Wszyscy pacjenci z AS	0	10	6	3.11	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n2501; TISSUE_RESCUE_BY_LIT_n45; CURATOR_STRONG_INDICATION	0.00532618	0.00532413	0.498771	0.194428	0.017906	26.7395	0.996458904888356	0.9978599089612067	0.6577262782594603	0.0	-0.24173250295816362	-0.33354468348957317	2	curated	0.81843	Artery - Coronary	2.0	0.81843	Artery - Coronary	2.0	0.007054091292532423	-0.012649096504769364	1	0.5546141822145201	0.13272457583121755	0	33	1	LPA	0.11471908904524881	0		HIGH replicated	42	2981	1.0322	0.10404	69	1606	0.0	0	2.73637	0.111597	0.0871772	90	6	903	38	intron_variant	protein_coding	-	-	0.0222	C9	C	Coronary-risk locus (LPA, 9p21)	C	C	model	I
dzesikahoinkis_plinktestset_2026_04_20_18_22_47_simvastatin__I251	simvastatin__I251	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I251	Miażdżycowa choroba serca	Atherosclerotic heart disease	CDKN2B-AS1	rs10757270	9-22072720-A-G	MODIFIER	0.430333	0.196252	0.0372454	6.86309	1.36735	0.0691996	6.14475e-06	441.0	0.180731	0.0159963	28.8737	0.38	1.09	3	STRONG (ROR+PRR+IC)	4.75	2.1	low	110.0	Unknown	trait_match	184: coronary artery disorder; 17: type 2 diabetes mellitus, coronary artery disorder; 7: educational attainment; 7: protocadherin-10 measurement; 6: atherosclerosis	2174: body height; 661: blood protein amount; 642: fatty acid amount; 638: body mass index; 584: BMI-adjusted waist-hip ratio	47690.0	TAK - 9p21.3/CDKN2B-AS1 (ANRIL) to najsilniejszy i najczęściej replikowany locus GWAS dla CAD/MI/miażdżycy (I25.x). rs10757278, rs4977574, rs1333049, rs10757274 wszystkie GWS dla CAD, niezależne od tradycyjnych czynników ryzyka. Plejotropia: T2D, udar niedokrwienny, tętniak aorty brzusznej, tętniak wewnątrzczaszkowy, periodontitis, glejak, inne nowotwory. rs10757270 z tego wiersza mapuje się w core risk haplotype.	GO:0031507:heterochromatin_formation	SILNE confounding by indication. Statyny to klasa I wskazanie w stabilnej CAD (prewencja wtórna) – ESC/ACC guidelines. Wszyscy pacjenci z ASCVD powinni otrzymać wysoko-intensywną statynę.	98.611	1.3893	373	3023	1	T1: Wskazanie	Wskazanie (CURATOR): SILNE confounding by indication. Statyny to klasa I wskazanie w stabilnej CAD (prewencja wtórna) – ESC/ACC guidelines. Wszyscy pacjenci z AS	0	10	4	2.71	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; PHEWAS_ATLAS_MATCH; CANONICAL_DISEASE_LOCUS; HIGH_PLEIOTROPY_n47690; TISSUE_RESCUE_BY_LIT_n184; CURATOR_STRONG_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[9-22115027-G-A|9-22116221-C-T|CDKN2B-AS1]	-0.000722861	0.00306516	0.0896088	0.0426331	0.0099519	4.73604	0.928267262643309				-0.12020079965632656		2	curated	0.81843	Artery - Coronary	2.0	0.81843	Artery - Coronary	2.0	0.17615172915802696	-0.001229858920156257	3	0.008261752329335018	0.16421480083753404	0	16	3	9-22115027-G-A;9-22116221-C-T;CDKN2B-AS1	0.1585276073460176	0		HIGH replicated	42	2981	1.0322	0.10404	69	1606	0.0	0	4.52135	0.482495	0.40837	225	108	2716	935	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C9	C	Coronary-risk locus (LPA, 9p21)	C	C	model	I
dzesikahoinkis_plinktestset_2026_04_20_11_57_49_atenolol__I251	atenolol__I251	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	I251	Miażdżycowa choroba serca	Atherosclerotic heart disease	9-22083405-T-C		9-22083405-T-C		0.411178	-0.260019	0.0508133	6.50839	0.756284	0.0997916	0.00512269	188.0	-0.166954	0.0160086	24.7381	1.75	1.56	2	STRONG (ROR+PRR+IC)	6.31	2.5	no_gene_symbol		Unknown	no_gene_symbol				TAK - wariant 9-22083405-T-C bez przypisania genowego VEP, ale lokalizacja w core risk haplotype 9p21.3 (chr9:22,074,000-22,127,000) - najsilniejszy locus GWAS dla CAD/MI/miażdżycy (I25.x). Region zawiera CDKN2A, CDKN2B, CDKN2B-AS1/ANRIL i ich elementy regulatorowe (enhancery STAT1/IFNγ-responsive). Kanoniczne SNPs: rs10757278, rs4977574, rs1333049, rs10757274 - wszystkie GWS dla CAD niezależnie od tradycyjnych czynników ryzyka (Helgadottir 2007 Science; CARDIoGRAMplusC4D 2015 Nat Genet). Plejotropia: T2D, udar, tętniak aorty, glejak, periodontitis. Patrz pokrewne analizy CDKN2B-AS1×simvastatin×I25.1 i CDKN2B-AS1×atenolol×I25.1 (oba rs10757270) dla pełnego opisu locus.		SILNE confounding by indication. β-blokery (w tym atenolol) są first-line w chronic coronary syndrome / stabilnej angina pectoris zgodnie z ESC 2024 guidelines. Wszyscy pacjenci z CAD i objawami niedokrwienia powinni otrzymać β-bloker (klasa I rekomendacja w obecności AMI/HFrEF/arytmii; rola w stabilnej CAD bez tych wskazań kwestionowana w nowszych meta-analizach).	99.014	0.98551	402	1725	1	T1: Wskazanie	Wskazanie (CURATOR): SILNE confounding by indication. β-blokery (w tym atenolol) są first-line w chronic coronary syndrome / stabilnej angina pectoris zgodnie z 	0	9	4	2.62	CURATOR_STRONG_INDICATION; CONFIRMED_BY_BNF; CANONICAL_DISEASE_LOCUS; CURATOR_STRONG_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[9-22083405-T-C|CDKN2B-AS1]	0.00406321	0.0050351	0.377082	-0.0148847	0.0137355	0.555155							2	curated	0.26119	Artery - Coronary	2.0	0.26119	Artery - Coronary	2.0		-0.136158748335499	2	0.0	0.18585591350031744	0	14	2	9-22083405-T-C;CDKN2B-AS1	0.1816510391385976	0		HIGH replicated	17	1708	1.0541	1.0979	80	2396	0.0	0	-2.79922	0.361538	0.424989	124	32	1132	400						C9	C	Coronary-risk locus (LPA, 9p21)	C	C	model	I
dzesikahoinkis_plinktestset_2026_04_20_17_42_54_ramipril__N189	ramipril__N189	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	N189	Przewlekła choroba nerek	Chronic kidney disease, unspecified	-	rs117308443	13-62873344-A-G	MODIFIER	0.00668194	2.87003	0.556396	6.60333	6.02125	0.646228	0.00546758	3.0	0.0679784	0.157719	0.176225	4.85	42.22	1	no_signal	1.11	-0.06	no_gene_symbol		Unknown	no_gene_symbol					-	BEZPOŚREDNIE wskazanie – renoprotekcja ACEi w CKD z albuminurią (KDIGO 2024). Klasa I.	98.377	1.6234	1916	308	1	T1: Wskazanie	Wskazanie (CURATOR): BEZPOŚREDNIE wskazanie – renoprotekcja ACEi w CKD z albuminurią (KDIGO 2024). Klasa I.	3	5	1	2.47	CURATOR_STRONG_INDICATION; CURATOR_STRONG_INDICATION	-0.0601651	0.0391584	0.905084	-0.105563	0.0693673	0.892588							2	curated	0.95808	Kidney - Cortex	2.0	0.95808	Kidney - Cortex	2.0		-0.22431853232933616	1	0.0	0.5140085377539991	0	1	1	-	0.4424378297563167	0		HIGH replicated	5	303	5.1663	0.0	699	3244	0.0	0	2.77811	0.0294118	0.00594884	3	0	40	0	intergenic_variant	-	-	-	0.0046	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_11_02_19_amlodipine__I64	amlodipine__I64	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	I64	Udar mózgu, nieokreślony	Stroke, not specified as haemorrhage or infarction	ENSG00000249998	rs13113983	4-17056292-C-T	MODIFIER	0.0431734	2.22779	0.444854	6.25945	5.26212	0.498075	0.000856349	6.0	0.228258	0.118494	1.2671	4.34	9.76	1	weak (1/3)	1.44	0.46	no_gene_symbol		Unknown	no_gene_symbol				ENSG00000249998 / Stroke, not specified as haemorrhage or infarct (I64). Gen bez symbolu HGNC - niemożliwe cross-reference w GWAS Catalog. I64 jako fenotyp mieszany; top loci udaru (MEGASTROKE 2018, Mishra 2022): HDAC9, ZFHX3, PITX2, NINJ2, FOXF2, CDK6.	-	SILNE confounding by indication. Amlodypina + perindopril (ASCOT) i kontrola BP post-stroke to klasa I wskazanie (ESO 2022).	38.462	3.8462	1755	104	1	T1: Wskazanie	Wskazanie (CURATOR): SILNE confounding by indication. Amlodypina + perindopril (ASCOT) i kontrola BP post-stroke to klasa I wskazanie (ESO 2022).	2	4	1	2.0	CURATOR_STRONG_INDICATION; CURATOR_STRONG_INDICATION	0.00205571	0.00685711	0.116716	-0.0135431	0.0275885	0.205164							4	curated	0.66846	Artery - Aorta	4.0	0.66846	Artery - Aorta	4.0		-0.23305744655432334	1	0.0	0.24852769238036457	1	1	1	ENSG00000249998	0.31065684241233227	1		HIGH replicated	4	40	4.8049	0.17248	569	3044	57.692	0	3.33391	0.142857	0.0384404	6	0	272	4	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0208	C5	E	Drug-triggered, no pharmacovigilance support	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_11_58_02_atenolol__I500	atenolol__I500	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	I500	Zastoinowa niewydolność serca	Congestive heart failure	-	rs116844059	18-64650136-A-G	MODIFIER	0.00897192	5.8504	0.932499	9.45332	7.64616	0.784231	0.00948988	2.0	0.329261	0.163111	1.36125	5.83	17.77	1	weak (1/3)	1.75	0.65	no_gene_symbol		Unknown	no_gene_symbol				Brak mapowania VEP do genu - nie można wykonać cross-reference w GWAS Catalog.	-	SILNE confounding by indication. β-blokery (preferowany bisoprolol/carvedilol/metoprolol, ale atenolol wciąż w UK) to klasa podstawowa HFrEF (ESC HF 2021, NYHA II–IV). W UK Biobank atenolol historycznie szeroko przepisywany u pacjentów z HF.	100.0	0.0	3006	94	1	T1: Wskazanie	Wskazanie (CURATOR): SILNE confounding by indication. β-blokery (preferowany bisoprolol/carvedilol/metoprolol, ale atenolol wciąż w UK) to klasa podstawowa HFrEF	1	7	1	1.91	CURATOR_STRONG_INDICATION; CURATOR_STRONG_INDICATION	-0.0233001	0.0260989	0.429475	0.00921521	0.0710605	0.0472954							2	curated	0.85976	Heart - Atrial Appendage	2.0	0.85976	Heart - Atrial Appendage	2.0		-0.0739019370424925	1	0.0	0.6017131236788177	1	1	1	-	0.6246750204266202	1		HIGH replicated	0	94	8.23		1234	4864	0.0	0	2.59388	0.0526316	0.00815434	2	0	39	1	intergenic_variant	-	-	-	0.002	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_19_40_33_tramadol__L409	tramadol__L409	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	L409	Łuszczyca, nieokreślona	Psoriasis, unspecified	HLA-C		C_0602_hla		0.0899139	1.69134	0.315526	7.08072	5.77874	0.413327	2.19506e-05	12.0	1.23037	0.0512963	126.406	1.44	1.37	1	no_signal	0.92	-0.31	low		UniProt loc high conf	trait_match	149: psoriasis; 8: psoriatic arthritis; 3: psoriasis vulgaris; 1: psoriasis vulgaris, age at onset; 1: psoriasis, cutaneous psoriasis measurement	728: rheumatoid arthritis, hypothyroidism; 266: BMI-adjusted waist-hip ratio; 181: fatty acid amount; 160: hematological measurement; 159: blood protein amount	9735.0	TAK - HLA-C (6p21.33) to najsilniejszy locus GWAS dla psoriasis. HLA-C*06:02 daje p=1.7e-364 w fine-mappingu PsV (Okada 2014). Definiuje wczesny początek, ciężkość i agregację rodzinną psoriasis. Plejotropia MHC: psoriatic arthritis, HIV viral control (elite controllers), AS, Behçet, Crohn's, Graves, Takayasu arteritis. Również predyktor odpowiedzi na ustekinumab/adalimumab (pharmakogenetyka).		Tramadol stosowany w bólu w łuszczycowym zapaleniu stawów (PsA). Do 30% pacjentów z łuszczycą skórną rozwija PsA, a kodowanie UKB często nie rozróżnia L40.5 (PsA) od L40.9. Tramadol w PsA: umiarkowane off-label przy niepowodzeniu NSAID/DMARD (Arthritis Australia, Cochrane 2022). Nakłada się z sygnałem HLA-B×tramadol – confounding przez PsA wzmacnia pleiotropię.	80.769	19.231	1806	78	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Tramadol stosowany w bólu w łuszczycowym zapaleniu stawów (PsA). Do 30% pacjentów z łuszczycą skórną rozwija PsA, a kodowanie UKB często nie	0	7	2	1.91	CURATOR_MODERATE_INDICATION; BURDEN; PHEWAS_ATLAS_MATCH; CANONICAL_DISEASE_LOCUS; HIGH_PLEIOTROPY_n9735; CURATOR_MODERATE_INDICATION	0.000412916	0.00793466	0.0184091	0.0064175	0.0199062	0.126587	0.8540612379105939	0.738924025425754	0.7129892229154848	0.0	0.5820693569323255	0.4530655167983105	2	curated							6.764370933620187	-0.2989795079263573	1	0.3953915992315448	0.22153860352132057	0	3	1	HLA-C	0.2506299444444892	0		HIGH replicated	15	63	4.9446	11.307	649	2774	0.0	0	4.24407	0.333333	0.0939254	10	1	529	20						C10	P	Major-effect disease locus (Factor V Leiden)	P	P	model	I
dzesikahoinkis_plinktestset_2026_04_20_19_40_33_tramadol__L409	tramadol__L409	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	L409	Łuszczyca, nieokreślona	Psoriasis, unspecified	RPL3P2	rs12189871	6-31284147-C-T	MODIFIER	0.0898007	1.70175	0.316325	7.12731	5.73303	0.413743	2.43654e-05	12.0	1.23806	0.0513467	127.725	1.45	1.37	1	no_signal	0.92	-0.31	low		Unknown	trait_match	26: psoriasis; 1: psoriatic arthritis; 1: psoriasis, type 2 diabetes mellitus	26: psoriasis; 12: BMI-adjusted waist-hip ratio; 7: hematological measurement; 6: fatty acid amount; 5: leukocyte quantity	109.0	RPL3P2 to pseudogen (processed pseudogene) - nie ma własnych asocjacji GWAS. Wariant rs12189871 w tym regionie (6p21.33) leży w rozszerzonym locus MHC - ryzyko psoriasis w tym wierszu może odzwierciedlać LD z HLA-C*06:02 lub innymi klasycznymi allelami HLA (patrz pokrewną analizę HLA-C×tramadol×L40.9). Annotacja do pseudogenu może być artefaktem mapowania VEP.	-	Tramadol stosowany w bólu w łuszczycowym zapaleniu stawów (PsA). Do 30% pacjentów z łuszczycą skórną rozwija PsA, a kodowanie UKB często nie rozróżnia L40.5 (PsA) od L40.9. Tramadol w PsA: umiarkowane off-label przy niepowodzeniu NSAID/DMARD (Arthritis Australia, Cochrane 2022). Nakłada się z sygnałem HLA-B×tramadol – confounding przez PsA wzmacnia pleiotropię.	80.769	19.231	1806	78	1	T1: Wskazanie	Wskazanie umiarkowane (CURATOR): Tramadol stosowany w bólu w łuszczycowym zapaleniu stawów (PsA). Do 30% pacjentów z łuszczycą skórną rozwija PsA, a kodowanie UKB często nie	0	7	1	1.52	CURATOR_MODERATE_INDICATION; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n109; CURATOR_MODERATE_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[LINC02571|PSORS1C1|RPL3P2]	0.000575344	0.0079704	0.0257396	0.00519688	0.0199725	0.0997922	0.6946780984719864				1.5529953564654675		2	curated							1.0300157671955414	-0.29595930078726534	3	0.0	0.22150747795829678	0	3	3	LINC02571;PSORS1C1;RPL3P2	0.2514575947147859	0		HIGH replicated	15	63	4.9446	11.307	649	2774	0.0	0	4.2206	0.333333	0.0932316	10	1	522	20	downstream_gene_variant	processed_pseudogene	-	-	0.0811	C10	P	Major-effect disease locus (Factor V Leiden)	P	P	model	I
dzesikahoinkis_plinktestset_2026_04_20_13_27_36_atorvastatin__Z955	atorvastatin__Z955	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	Z955	Obecność implantu/pomostu po angioplastyce wieńcowej	Presence of coronary angioplasty implant/graft	PCDH15	rs116987503	10-55628926-G-T	MODIFIER	0.0168471	1.18134	0.213872	7.47865	2.32218	0.335481	0.0120275	11.0	0.301981	0.0940613	2.87773	3.76	3.91	1	n/a (skip)			icd_not_mapped		UniProt loc med conf	icd_not_mapped		7: gut microbiome measurement, allergen exposure measurement; 7: smoking initiation; 6: PHF-tau measurement; 4: schizophrenia; 4: serum metabolite level	138.0	PCDH15 / Presence of coronary angioplasty implant/graft (Z95.5). Z95.5 to fenotyp stanu proceduralnego (post-PCI) - silnie confounding, odzwierciedla leczone wskazanie (CAD). PCDH15 (10q21.1) znany z Mendlowskich: Usher syndrome type 1F (USH1F), DFNB23 (niesyndromowy niedosłuch). GWAS asocjacje: lipid traits w familial combined hyperlipidemia (FCHL, nonsynonimous SNP z TG, Tikkanen 2010), neurocognitive processes, EEG oscillations w SCZ/bipolar, nicotine withdrawal severity (clustered PCDH). Pośredni związek z CAD poprzez lipidy/FCHL.	GO:0007155:cell_adhesion,GO:0007605:sensory_perception_of_sound,GO:0032420:stereocilium,GO:0032420:,GO:0048839:inner_ear_development	Statyna obowiązkowa po PCI (DAPT + high-intensity statin) – klasa I wskazanie ESC/ACC. Maksymalne confounding.	99.641	0.35939	890	1113	1	T1: Wskazanie	Wskazanie (CURATOR): Statyna obowiązkowa po PCI (DAPT + high-intensity statin) – klasa I wskazanie ESC/ACC. Maksymalne confounding.	0	6	2	1.82	CURATOR_STRONG_INDICATION; EFFICACY_CONCERN; CONFIRMED_BY_BNF; HIGH_PLEIOTROPY_n138; CURATOR_STRONG_INDICATION; LOCUS_LEAD_rs116987503	-0.00500405	0.0216777	0.0875439	-0.0134835	0.0420897	0.125691	0.8486087230300504	0.9021665076985966	0.6915971153067011	0.0	-0.6697458375638313	-0.3550503224697362	2	curated							0.008994349295901167	-0.07716889025265627	2	0.0014783194187388072	0.2781078152187819	0	1	2	ENSG00000236744;PCDH15	0.3020749561869074	0		HIGH replicated	4	1109	2.4148	0.0	245	2291	0.0	0	2.51134	0.0345912	0.0157289	11	0	123	0	upstream_gene_variant	protein_coding	-	-	0.0062	C3	E	Replicated drug-triggered signal	E	E	model	I
dzesikahoinkis_plinktestset_2026_04_20_18_25_38_simvastatin__J90	simvastatin__J90	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	J90	Wysięk opłucnowy	Pleural effusion	OARD1		OARD1_lof		0.00242504	3.98289	0.75521	6.87429	8.42368	0.670289	0.00147634	2.0	-0.3689	0.224122	1.00101	5.52	10.8	3	STRONG (ROR+PRR+IC)	2.38	1.12	enriched	100.0	Structure with Ligand	trait_unrelated		2: blood protein amount; 2: body mass index; 2: acute myeloid leukemia; 2: gastric carcinoma; 1: progression free survival, metastatic colorectal cancer, response to cetuximab, response to CAPOX-B	21.0	OARD1 / Pleural effusion (J90.0). Brak asocjacji GWAS Catalog OARD1 (6p21.1, NIE 6p21.33!) z wysiękiem opłucnowym. OARD1 (TARG1, dawniej C6orf130) - ADP-ribose glycohydrolase / O-acyl-ADP-ribose deacylase, hydrolizuje mono-ADP-rybozylację reszt glutaminianu (Peterson 2011 JBC, Sharifi 2013), rola w odpowiedzi na uszkodzenia DNA i sygnalizacji PARP. Zero studies/0 traits dla OARD1 w GWAS Catalog. J90 jako fenotyp wtórny do różnych chorób (CHF, infekcje, nowotwory) - brak prostego signału GWAS; znaczące loci dla niewydolności serca: TTN, BAG3, PLN, MYH7. Wariant burden _lof - prawdopodobnie chance finding.		Nie wskazanie. Wysięk opłucnowy opisany jako rzadkie ADR statyn (case reports DIEPE - drug-induced eosinophilic pleural effusion, ILD z efuzją). Częściej komorbidalność CV (HF/CAD) w populacji statynowej. Mieszany charakter: rzadkie ADR + częsta komorbidalność.	96.101	0.38986	1715	513	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=6.9<7.5 (artefakt opposite-sign)	9	9	7	8.28	BURDEN; LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n21; CURATOR_NOT_INDICATION	0.0306121	0.0325467	0.459758	0.0168986	0.10703	0.0582171	0.7510081003107708	0.5261324041811847	0.208978202738838	1.0	-0.04556059419674359	-1.5508870952803697	1	curated	0.87495	Lung	1.0	0.87495	Lung	1.0	2.4118340388986743	-0.2382409681159782	1	0.0	0.5804136460654042	0	1	1	OARD1	0.4685550494237173	0		HIGH replicated	2	493	4.6954	8.0548	735	2803	3.5088	0	3.17929	0.0126582	0.00180567	2	0	21	0						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_57_15_atenolol__H609	atenolol__H609	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	H609	Zapalenie ucha zewnętrznego	Otitis externa	ANOS1	rs73199009	X-8578630-C-T	MODIFIER	0.00749499	5.76313	1.03973	7.52654	4.83394	0.77011	0.0407544	0.0	0.122965	0.18939	0.287211	5.34	46.87	2	STRONG (ROR+PRR+IC)	4.8	1.5	low		UniProt loc high conf	trait_unrelated		3: protein measurement; 1: response to radiation, toxicity; 1: blood protein amount; 1: severe acute respiratory syndrome, COVID-19; 1: lip morphology trait	7.0		GO:0004867:serine-type_endopeptidase_inhibitor_activity,GO:0005201:extracellular_matrix_structural_constituent,GO:0005515:protein_binding,GO:0005576:extracellular_region,GO:0005615:extracellular_space,GO:0005886:plasma_membrane,GO:0006935:chemotaxis,GO:0007155:cell_adhesion,GO:0007411:axon_guidance,GO:0008201:heparin_binding,GO:0009986:,GO:0016020:membrane,GO:0030182:neuron_differentiation,GO:0030414:peptidase_inhibitor_activity,GO:0031012:extracellular_matrix	Brak wskazania.	78.75	21.25	2561	80	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	8	9	5	7.11	PRE_EXISTING; LOW_PLEIOTROPY_n7	-0.0213194	0.0246365	0.412467	-0.0176719	0.0662924	0.102485	0.7816987270232887	0.8986037034817523	0.757880236609675	0.0	0.16794569269595577	-0.03240385782348861	2	curated							1.1962047106602245	-0.05005893533269555	1	0.0	0.5145192280681324	1	1	1	ANOS1	0.5230206211668281	1		HIGH replicated	17	63	7.0116	2.6475	809	4140	0.0	0	2.04602	0.0	0.00475624	0	0	14	5	intron_variant	protein_coding	-	-	0.0011	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_27_30_atenolol__R739	atenolol__R739	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R739	Hiperglikemia	Hyperglycaemia	SLC38A8	rs144889482	16-84041941-C-T	MODIFIER	0.00474984	6.68666	1.13897	8.36277	3.22529	1.38316	0.397204	0.0	0.325506	0.264554	0.660449	5.44	20.54	1	STRONG (ROR+PRR+IC)	2.0	0.9	low	24.0	UniProt SigP or TMHMM	trait_unrelated		1: metabolic dysfunction-associated steatotic liver disease; 1: adiponectin measurement; 1: carotid artery thickness; 1: alcoholic liver disease; 1: drug use measurement, gut microbiome measurement	10.0		GO:0003333:amino_acid_transmembrane_transport,GO:0003406:retinal_pigment_epithelium_development,GO:0005737:cytoplasm,GO:0005938:cell_cortex,GO:0006531:aspartate_metabolic_process,GO:0006865:amino_acid_transport,GO:0007601:visual_perception,GO:0009615:response_to_virus,GO:0015179:L-amino_acid_transmembrane_transporter_activity,GO:0016020:membrane,GO:0019079:viral_genome_replication,GO:0021554:optic_nerve_development,GO:0030424:axon,GO:0031175:neuron_projection_development,GO:0042995:cell_projection,GO:0060041:retina_development_in_camera-type_eye,GO:1902475:L-alpha-amino_acid_transmembrane_transport	Nie wskazanie. β-blokery nieselektywne > selektywne zwiększają insulinooporność, maskują hipoglikemię w DM. Metaanalizy – ryzyko new-onset DM.	97.71	2.2901	3302	131	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	8	7	5	6.54	LOW_PLEIOTROPY_n10; CURATOR_NOT_INDICATION	0.0169911	0.0343976	0.206675	-0.0876069	0.0916506	0.46963	0.9127833134682796	0.8121951219512196	0.7463738756988898	0.0	-0.3602745404276667	0.09854180729180562	2	curated	0.5462	Whole Blood	1.0	0.5462	Whole Blood	1.0	0.03718335067755942	-0.23274471471486546	1	0.0	0.5202390462710544	1	1	1	SLC38A8	0.5630263071050599	1		MED repl-underpowered	3	128	9.0404	1.2621	1701	4743	0.0	0	0.846626	0.0	0.00496426	0	0	25	0	intron_variant	protein_coding	-	-	0.006	C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_42_25_ramipril__M109	ramipril__M109	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	M109	Dna moczanowa	Gout, unspecified	MATN4		MATN4_lof		0.00133585	7.43763	1.31001	7.86442	3.02544	1.41757	0.43483	0.0	0.730202	0.413762	1.11014	4.88	10.19	1	STRONG (ROR+PRR+IC)	4.48	1.93	low	50.0	UniProt loc med conf	trait_unrelated		4: amount of WAP four-disulfide core domain protein 12 (human) in blood; 3: blood protein amount; 1: parental longevity; 1: matrilin-4 measurement; 1: protein measurement	12.0			Nie wskazanie. ACEi neutralne/obniżające kwas moczowy (w przeciwieństwie do tiazydów); nie powinny nasilać dny. Koincydencja HT.	100.0	0.0	2230	190	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	8	5	6.54	BURDEN; LOW_PLEIOTROPY_n12; CURATOR_NOT_INDICATION	0.117184	0.0795165	0.852132	-0.0548259	0.14729	0.148913	0.9203711424478063	0.9825932874713362	0.8121708127380276	0.0	-0.011785264254980945	-0.28324546656061117	3	curated_weak	0.64077	Muscle - Skeletal	1.0	0.64077	Muscle - Skeletal	1.0	0.23950024820608967	-0.30594296591359027	1	0.0	0.5424965943289146	1	1	1	MATN4	0.5251930058656483	1		MED repl-underpowered	0	190	6.1054		1123	3403	0.0	0	0.780953	0.0	0.00167683	0	0	11	0						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_42_25_ramipril__M109	ramipril__M109	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	M109	Dna moczanowa	Gout, unspecified	LINC01376	rs189976197	2-19047295-A-G	MODIFIER	0.0104238	2.96884	0.579858	6.5148	5.16273	0.77931	0.0351776	2.0	0.221076	0.155549	0.808992	4.58	13.43	2	STRONG (ROR+PRR+IC)	4.48	1.93	expressed	95.0	Unknown	trait_unrelated		25: cold-induced vasodilation; 23: response to cold; 12: cup-to-disc ratio measurement; 7: breast carcinoma; 7: open-angle glaucoma	166.0		-	Nie wskazanie. ACEi neutralne/obniżające kwas moczowy (w przeciwieństwie do tiazydów); nie powinny nasilać dny. Koincydencja HT.	100.0	0.0	2230	190	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	4	9	4	5.24	HIGH_PLEIOTROPY_n166; CURATOR_NOT_INDICATION	-0.023419	0.0316936	0.337283	-0.00968345	0.058546	0.0611652	0.6449138342312419				-0.2826527484077248		3	curated_weak	0.64077	Muscle - Skeletal	1.0	0.64077	Muscle - Skeletal	1.0	0.3390439269890307	-0.17334944841325572	1	0.0	0.6060399864226453	1	1	1	LINC01376	0.515891259092229	1		HIGH replicated	0	190	6.1054		1123	3403	0.0	0	2.10631	0.0294118	0.00902634	2	0	61	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0004	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_02_42_simvastatin__R030	simvastatin__R030	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	R030	Podwyższone BP bez diagnozy HT	Elevated BP reading	ACOT12		ACOT12_lof		0.000970018	6.2996	1.21791	6.63638	18.8021	1.44632	0.0425015	0.0	1.04218	0.422841	1.86289	4.08	6.04	2	STRONG (ROR+PRR+IC)	2.13	1.0	low	93.0	Structure with Ligand	trait_unrelated		2: diet measurement, glomerular filtration rate; 2: hospitalisation, psychiatric disorder; 1: orofacial cleft; 1: soluble triggering receptor expressed on myeloid cells 2 measurement; 1: smoking initiation	13.0			Nie wskazanie statynowe, ale dyslipidemia i HT współwystępują w ~60–70% przypadków. Silna komorbidalność – pacjent z podwyższonym BP jest profilowany kardiometabolicznie → statyna.	83.274	16.726	963	281	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	5	9	6	6.46	BURDEN; LOW_PLEIOTROPY_n13; CURATOR_NOT_INDICATION	0.0276917	0.0485592	0.245272	-0.214459	0.149058	0.823278	0.9973753317351559	0.9982115549104483	0.465035248359128	1.0	-0.16997764752765931	-0.28253181058590937	4	curated	0.33376	Artery - Aorta	2.0	0.33376	Artery - Aorta	2.0	0.07213608640714206	-0.29677960927986863	1	0.0	0.44937575196736834	1	1	1	ACOT12	0.38883434547913964	1		HIGH replicated	47	234	2.6366	0.94182	399	2131	0.0	0	2.02858	0.0	0.000512558	0	0	6	0						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_43_27_ramipril__R101	ramipril__R101	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	R101	Ból w nadbrzuszu	Pain localized to upper abdomen	RSU1P1	rs182945706	10-42722542-G-T	MODIFIER	0.00584192	2.84407	0.567486	6.26801	4.3613	0.763216	0.0536451	2.0	0.182714	0.102181	1.13222	4.62	15.57	2	STRONG (ROR+PRR+IC)	3.98	1.91	low	12.0	Unknown	trait_unrelated		1: gut microbiome measurement, breastfeeding duration; 1: proto-oncogene tyrosine-protein kinase receptor Ret measurement; 1: bone mineral content measurement; 1: blood nickel amount	4.0		-	Nie wskazanie. Ból brzucha/dyspepsja listed w SmPC ACEi (rzadkie).	89.263	10.737	1407	475	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	9	4	6.32	LOW_PLEIOTROPY_n4; CURATOR_NOT_INDICATION	-0.0253058	0.0426565	0.257262	-0.0846416	0.0762789	0.573233	1.0				-0.13736056288075635		2	curated	0.62863	Colon - Sigmoid	3.0	0.62863	Colon - Sigmoid	3.0	0.0	-0.13453311187446887	1	0.0	0.47020057261381465	1	3	1	RSU1P1	0.39477253804813306	1		HIGH replicated	51	424	3.8138	5.681	473	2551	0.0	0	1.92969	0.0142857	0.00493569	2	0	33	0	upstream_gene_variant	unprocessed_pseudogene	-	-		C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_19_43_amlodipine__K922	amlodipine__K922	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	K922	Krwawienie GI	GI haemorrhage	GRM7	rs141129125	3-7458237-T-A	MODIFIER	0.00662016	3.74661	0.60883	9.12118	0.907016	1.27896	0.939174	0.0	0.221409	0.144382	0.902554	5.63	16.92	1	STRONG (ROR+PRR+IC)	2.01	0.91	low	90.0	UniProt loc high conf	trait_unrelated		25: memory performance; 7: COVID-19; 6: diastolic blood pressure; 5: systolic blood pressure; 5: neurofibrillary tangles measurement	184.0		GO:0001642:group_III_metabotropic_glutamate_receptor_activity,GO:0004930:G_protein-coupled_receptor_activity,GO:0005509:calcium_ion_binding,GO:0005886:plasma_membrane,GO:0005938:cell_cortex,GO:0007165:signal_transduction,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007196:adenylate_cyclase-inhibiting_G_protein-coupled_glutamate_receptor_signaling_pathway,GO:0007216:G_protein-coupled_glutamate_receptor_signaling_pathway,GO:0007268:chemical_synaptic_transmission,GO:0007605:sensory_perception_of_sound,GO:0008066:glutamate_receptor_activity,GO:0010855:,GO:0014050:negative_regulation_of_glutamate_secretion,GO:0016020:membrane,GO:0030165:PDZ_domain_binding,GO:0030424:axon,GO:0030425:dendrite,GO:0032279:asymmetric_synapse,GO:0043198:dendritic_shaft,GO:0043235:receptor_complex,GO:0045211:postsynaptic_membrane,GO:0046983:protein_dimerization_activity,GO:0048786:presynaptic_active_zone,GO:0051966:regulation_of_synaptic_transmission_-_glutamatergic,GO:0061564:axon_development,GO:0070085:glycosylation,GO:0070905:serine_binding	Brak wskazania.	99.593	0.4065	1846	246	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	8	5	6.21	HIGH_PLEIOTROPY_n184	0.0188394	0.0169815	0.573077	0.0819679	0.0703917	0.612182	0.8928919712444837	0.8462954440865165	0.6875455797747345	0.0	-0.6266038799847616	-0.44775667780605555	4	curated							0.043772549349052635	-0.37800716450166544	1	0.0	0.4788294536342379	1	1	1	GRM7	0.5722930976802798	1		MED repl-underpowered	1	245	5.0541	4.9856	801	3344	0.0	0	-0.0763087	0.0	0.00675117	0	0	49	0	intron_variant	protein_coding	-	-	0.0018	C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_22_48_simvastatin__I48	simvastatin__I48	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I48	Migotanie przedsionków	Atrial fibrillation and flutter	RASGEF1C		RASGEF1C_cnv_gene_down		0.000427405	6.75847	1.14286	8.47548	1.79697	1.48261	0.69261	0.0	0.617899	0.476487	0.710618	4.96	10.94	1	STRONG (ROR+PRR+IC)	3.38	1.66	expressed	26.0	GO CC med conf	trait_unrelated		6: body height; 5: FEV/FVC ratio; 3: Alzheimer disease; 2: gut microbiome measurement; 2: forced expiratory volume	43.0			Nie wskazanie formalne. AF często współwystępuje z CAD/HF → populacja statynowa. Obserwacyjne badania sugerują ochronny wpływ statyn na AF (meta-analiza Fauchier JACC 2008), ale RCT (SPARCL) neutralne.	100.0	0.0	1545	1708	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	6	8	5	6.21	BURDEN; CURATOR_NOT_INDICATION	-0.0609478	0.073914	0.387628	0.239736	0.251773	0.467246	0.9429346900327976	0.9238473889441088	0.8547929665343164	0.0	-0.37872398025305387	-0.043333918032671705	2	curated	0.12432	Heart - Atrial Appendage	2.0	0.12432	Heart - Atrial Appendage	2.0	0.5264442160650593	-0.40428637669495154	1	0.0	0.4970196392306118	1	1	1	RASGEF1C	0.5055750478534818	1		MED repl-underpowered	0	1708	4.219		584	2762	0.0	0	0.395316	0.0	0.000516085	0	0	6	0						C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_43_18_simvastatin__M513	simvastatin__M513	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	M513	Zwyrodnienie krążków międzykręgowych	Intervertebral disc degeneration	MEF2D		MEF2D_mpc		0.000661812	23.5503	4.38546	7.10403	275.373	3.20637	0.0797435	0.0	1.76256	0.917279	1.26227	4.86	13.36	2	STRONG (ROR+PRR+IC)	3.19	1.38	low		UniProt Ubiquitination	trait_unrelated		9: migraine disorder; 9: platelet count; 8: body height; 7: body mass index; 7: BMI-adjusted waist circumference	176.0	Brak asocjacji GWAS Catalog MEF2D (1q22) z dyskopatią lędźwiową (M51.3). MEF2D (myocyte enhancer factor 2D) - czynnik transkrypcyjny rodziny MEF2 (paraloga MEF2A/B/C), regulator różnicowania mięśni i neuronów; somatyczne fuzje MEF2D-BCL9 i MEF2D-HNRNPUL1 w pediatrycznej B-cell ALL (Gu 2016 Nat Genet, Suzuki 2016); dziedziczne mutacje w padaczce. LDD jest słabo charakteryzowana w GWAS Catalog (heterogeniczność fenotypu, wymóg MRI grading, małe próby). Top loci szlaków powiązanych z LDD/IVD: PARK2, CHST3 (Williams 2013 Ann Rheum Dis), ADAMTS5, COL11A1, GDF5; dla low back pain: SOX5, GSDMC, FOXP2 (Suri 2018 PLoS Genet). Wariant burden _mpc - missense burden bez merytorycznego linku biologicznego do struktury IVD.		Nie wskazanie. Dyslipidemia (TC, LDL-C) jako czynnik ryzyka IVDD - retrospektywne badania populacyjne. MR i obserwacyjne dane sugerują brak kauzalnego związku statyn (HMGCR target) z IVDD; możliwy mały efekt protekcyjny przez NPC1L1/PCSK9. Komorbidalność przez wspólny czynnik ryzyka (dyslipidemia).	99.187	0.81301	1597	246	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	5	9	5	6.08	BURDEN; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n176; CURATOR_NOT_INDICATION	0.134142	0.145901	0.446258	-0.658172	0.44974	0.84362	0.7271907149516754	0.7984059067949768	0.4726521351592253	1.0	1.4969792899569967	3.494922261053367	1	curated_weak	0.81182	Muscle - Skeletal	1.0	0.81182	Muscle - Skeletal	1.0	4.646379305565771	-0.20390649542309802	1	0.0022174791281082107	0.5304425274108928	1	2	1	MEF2D	0.4692051618763078	1		HIGH replicated	2	244	4.3723	8.5476	753	2585	0.0	0	1.75218	0.0	0.000677974	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_18_54_diltiazem__M255	diltiazem__M255	diltiazem	I10, I20.1, I20.8	Nadciśnienie tętnicze (I10), dusznica bolesna stabilna i Prinzmetala (I20)	M255	Ból stawu	Pain in joint	SQSTM1	rs75363646	5-179825265-C-A	MODIFIER	0.0191589	5.63258	1.06245	6.93984	8.28761	1.5345	0.16816	1.0	0.0181853	0.0640929	0.109795	5.27	309.73	1	STRONG (ROR+PRR+IC)	2.08	0.96	low		Structure with Ligand	trait_unrelated		5: gut microbiome measurement, allergen exposure measurement; 4: bone Paget disease; 2: neutrophil count; 1: Alzheimer disease; 1: monocyte percentage of leukocytes	22.0		GO:0000407:,GO:0000422:autophagy_of_mitochondrion,GO:0000423:mitophagy,GO:0000425:,GO:0000932:P-body,GO:0002376:immune_system_process,GO:0005080:protein_kinase_C_binding,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005764:lysosome,GO:0005768:endosome,GO:0005770:late_endosome,GO:0005776:autophagosome,GO:0005783:endoplasmic_reticulum,GO:0005829:cytosol,GO:0006511:ubiquitin-dependent_protein_catabolic_process,GO:0006914:autophagy,GO:0006915:apoptotic_process,GO:0007032:endosome_organization,GO:0008104:protein_localization,GO:0008270:zinc_ion_binding,GO:0010508:positive_regulation_of_autophagy,GO:0010821:regulation_of_mitochondrion_organization,GO:0016197:endosomal_transport,GO:0016234:inclusion_body,GO:0016235:,GO:0016236:macroautophagy,GO:0016605:,GO:0019899:enzyme_binding,GO:0019901:protein_kinase_binding,GO:0030017:sarcomere,GO:0030154:cell_differentiation,GO:0030163:protein_catabolic_process,GO:0030674:protein-macromolecule_adaptor_activity,GO:0030971:receptor_tyrosine_kinase_binding,GO:0031397:negative_regulation_of_protein_ubiquitination,GO:0031410:cytoplasmic_vesicle,GO:0031625:ubiquitin_protein_ligase_binding,GO:0033554:cellular_response_to_stress,GO:0034142:toll-like_receptor_4_signaling_pathway,GO:0034144:negative_regulation_of_toll-like_receptor_4_signaling_pathway,GO:0035255:ionotropic_glutamate_receptor_binding,GO:0035556:intracellular_signal_transduction,GO:0035591:signaling_adaptor_activity,GO:0035973:aggrephagy,GO:0038023:signaling_receptor_activity,GO:0042169:,GO:0042802:identical_protein_binding,GO:0043065:positive_regulation_of_apoptotic_process,GO:0043122:regulation_of_canonical_NF-kappaB_signal_transduction,GO:0043130:ubiquitin_binding,GO:0043232:intracellular_membraneless_organelle,GO:0044753:amphisome,GO:0044754:autolysosome,GO:0045944:positive_regulation_of_transcription_by_RNA_polymerase_II,GO:0046578:regulation_of_Ras_protein_signal_transduction,GO:0046872:metal_ion_binding,GO:0061635:regulation_of_protein_complex_stability,GO:0070062:,GO:0070530:,GO:0070534:,GO:0071211:protein_targeting_to_vacuole_involved_in_autophagy,GO:0098780:,GO:0110076:negative_regulation_of_ferroptosis,GO:0140036:ubiquitin-modified_protein_reader_activity,GO:0140311:,GO:0140313:molecular_sequestering_activity,GO:0140693:molecular_condensate_scaffold_activity,GO:0140694:membraneless_organelle_assembly,GO:1900273:positive_regulation_of_long-term_synaptic_potentiation,GO:1903078:positive_regulation_of_protein_localization_to_plasma_membrane,GO:1905719:protein_localization_to_perinuclear_region_of_cytoplasm	Brak wskazania.	76.25	23.75	1498	80	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	5	6	5.94	PRE_EXISTING; LOW_PLEIOTROPY_n22	-0.130832	0.263662	0.207786	-0.0618608	0.0982373	0.276638	0.5637238022336538	0.78734686953764	0.6661534721659508	0.0	1.7670206574016454	4.13131458214812	1	curated	0.55651	Muscle - Skeletal	1.0	0.55651	Muscle - Skeletal	1.0	5.050913140594826	-0.11275982307811477	1	0.0073915970936940375	0.4383568076013975	1	1	1	SQSTM1	0.5065609280813713	1		MED repl-underpowered	19	61	4.1013	8.7967	729	2872	0.0	0	1.37814	0.03125	0.0177903	1	0	19	0	intron_variant	protein_coding	-	-	0.0068	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_22_50_simvastatin__I517	simvastatin__I517	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I517	Kardiomegalia	Cardiomegaly	HOXD10		HOXD10_mpc		0.000128417	44.5137	7.53231	8.46506	108.893	2.85659	0.100602	0.0	5.82074	2.44764	1.7594	4.89	7.65	2	STRONG (ROR+PRR+IC)	3.93	1.74	low	68.0	Database Ubiquitination	trait_unrelated		10: hemoglobin measurement; 8: hematocrit; 6: erythrocyte count; 4: serum creatinine amount; 2: cystatin C measurement	42.0	HOXD10 / Cardiomegaly (I51.7). Brak asocjacji GWAS Catalog HOXD10 (2q31.1) z kardiomegalią. HOXD10 znany z Mendlowskiej congenital vertical talus (pes convexus) i zespołu przypominającego CMT (Shrimpton 2004), zaangażowany w rozwój kończyn; somatyczne w glioblastoma i raku piersi (z miR-10a/b). Brak GWS dla fenotypów kardiologicznych. Top loci cech strukturalnych serca: TTN, BAG3, PLN, MYH7.		Nie wskazanie. Kardiomegalia wtórna do HTN/CAD/HF – populacja statynowa. Silna komorbidalność.	97.087	2.9126	1581	412	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	4	10	5	5.85	BURDEN; LIT_NO_PRIOR_HIT; CURATOR_NOT_INDICATION	0.15685	0.25528	0.268463	-0.320121	0.79078	0.163921	0.9502209943468086	0.8683943089430893	0.9491127137184991	0.0	-0.628655387140442	-0.834100501544055	2	curated	0.77977	Heart - Atrial Appendage	2.0	0.77977	Heart - Atrial Appendage	2.0	0.008638064267284326	-0.7917968843184326	1	0.0	0.4902510242805315	1	2	1	HOXD10	0.453358110183227	1		MED repl-underpowered	12	400	4.3285	1.3196	546	2770	0.0	0	1.64194	0.0	0.00026198	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_06_13_propranolol__R31	propranolol__R31	propranolol	I10, I20, I47, I48, G43, F41.0, E05, R25.1, F45.3	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie (I47/I48), profilaktyka migreny (G43), drżenie samoistne (R25.1), nadczynność tarczycy - leczenie objawowe (E05), objawy somatyczne lęku (F41.0/F45.3)	R31	Krwiomocz	Unspecified haematuria	LINC01258	rs750141766	4-38455849-C-A	MODIFIER	0.00571429	5.96443	1.00445	8.53986	2.33508	1.27163	0.504837	0.0	-0.0827117	0.113584	0.331156	5.98	72.11	1	STRONG (ROR+PRR+IC)	3.43	1.57	low	13.0	Unknown	trait_unrelated		8: body height; 4: systolic blood pressure; 3: lymphocyte count; 2: lymphocyte:monocyte ratio; 2: Diuretic use measurement	39.0		-	Brak wskazania.	80.412	2.0619	2249	97	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	8	4	5.77		0.0134368	0.0674815	0.0746001	0.131288	0.103222	0.69163	0.9830026345048787				-0.02144439599723924		3	curated	0.70238	Bladder	2.0	0.70238	Bladder	2.0	0.012494616164998187	-0.2716518699676002	1	0.0	0.49024143808669507	0	1	1	LINC01258	0.5657837161420812	0		MED repl-underpowered	2	78	6.1574	15.943	477	3761	17.526	0	0.666898	0.0	0.00681636	0	0	17	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_52_46_amlodipine__R80	amlodipine__R80	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R80	Izolowany białkomocz	Isolated proteinuria	LINC02545	rs190050073	11-13850299-A-C	MODIFIER	0.00754556	5.81736	1.17181	6.16176	7.69262	0.846146	0.0158984	2.0						2	STRONG (ROR+PRR+IC)	3.25	1.54	low	5.0	Unknown	trait_unrelated		2: vitamin D level; 1: spondin-1 measurement; 1: carotid artery thickness; 1: body height; 1: response to TNF antagonist	7.0		-	Nie wskazanie bezpośrednie. HT i CKD (częste w populacji amlodypinowej) – marker proteinurii. Komorbidalność.	20.492	0.0	714	122	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	5	8	4	5.43	LOW_PLEIOTROPY_n7; CURATOR_NOT_INDICATION	-0.00225582	0.0163527	0.0504726	0.048646	0.0669066	0.330515							2	curated								-0.07804448127431333	1	0.0	0.21590903850921922	0	1	1	LINC02545	0.27640518308741324	0		HIGH replicated	0	25	1.9548		119	1401	79.508	0	2.41124	0.0416667	0.00796922	2	0	56	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.003	C5	E	Drug-triggered, no pharmacovigilance support	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_07_46_ramipril__G439	ramipril__G439	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	G439	Migrena, nieokreślona	Migraine, unspecified	CCDC192	rs78407439	5-127900586-T-C	MODIFIER	0.0311951	2.5392	0.474695	7.05366	5.41289	0.53728	0.00167107	5.0	-0.0513872	0.066723	0.355359	5.4	49.41	2	STRONG (ROR+PRR+IC)	4.8	2.16	low	73.0	Unknown	trait_unrelated		7: attention deficit-hyperactivity disorder; 7: hematocrit; 7: hemoglobin measurement; 7: hematological measurement; 6: erythrocyte count	51.0	Brak asocjacji GWAS Catalog CCDC192 (5q23.2, chr5:~127.9 Mb) z migreną (G43.x). CCDC192 - coiled-coil domain containing 192, słabo scharakteryzowany; brak GWS dla fenotypów bólowych/migreny. Top loci GWAS migreny (Hautakangas 2022 Nat Genet, meta-analiza ~873k): PRDM16 (1p36), TRPM8 (2q37.1), LRP1 (12q13.3), FHL5 (6q16.1), MEF2D (1q22), HMGCR (5q13.3) - brak CCDC192 w sygnałach migrenowych. Wariant rs78407439 intronowy - prawdopodobnie chance finding.	-	Off-label Level C (AHS/AAN 2012). Lisinopril (nie ramipril) ma RCT Schrader BMJ 2001 – redukcja dni z migreną o 22%. Klasa ACEi prawdopodobnie efekt wspólny. Ramipril mniej danych → Tier 3.	73.214	26.786	1141	112	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=7.1<7.5 (artefakt opposite-sign)	5	8	4	5.43	PRE_EXISTING; LIT_NO_PRIOR_HIT	-0.0034576	0.0180911	0.0713835	-0.0225537	0.032957	0.306482	0.9737798515344217	0.975779132791328	0.5504416173729842	0.0	-0.07213671979863837	-0.4450537134133033	4	curated							0.3313591872343899	-0.21827509187780514	1	0.0	0.5326516261504189	0	1	1	CCDC192	0.5392696953187995	0		HIGH replicated	30	82	3.1239	12.753	388	2242	0.0	0	3.14321	0.125	0.0303566	5	0	196	5	intron_variant	protein_coding	-	-	0.0114	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_07_46_ramipril__G439	ramipril__G439	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	G439	Migrena, nieokreślona	Migraine, unspecified	DELEC1	rs72748106	9-115342430-T-G	MODIFIER	0.00572913	5.2982	0.959964	7.46773	3.71661	1.11343	0.238368	1.0	0.283937	0.147576	1.26477	5.16	18.66	1	STRONG (ROR+PRR+IC)	4.8	2.16	expressed	8.0	Unknown	trait_partial	1: migraine disorder	42: body height; 28: protein measurement; 26: lipid measurement; 25: tenascin measurement; 19: eosinophil count	378.0		-	Off-label Level C (AHS/AAN 2012). Lisinopril (nie ramipril) ma RCT Schrader BMJ 2001 – redukcja dni z migreną o 22%. Klasa ACEi prawdopodobnie efekt wspólny. Ramipril mniej danych → Tier 3.	73.214	26.786	1141	112	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	2	7	4	3.83	PRE_EXISTING; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n378; LOCUS_LEAD_rs72748106	-0.0369319	0.0429697	0.408855	-0.047565	0.0756526	0.276112							4	curated								-0.09072233614226116	2	0.0	0.47386779643218363	1	1	2	DELEC1	0.5015831196088373	1		MED repl-underpowered	30	82	3.1239	12.753	388	2242	0.0	0	1.17908	0.025	0.00678066	1	0	46	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.001	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_14_39_gabapentin__E780	gabapentin__E780	gabapentin	G40, G50.0, M79.7, R52, G62.9	Padaczka - napady ogniskowe (G40), neuralgia (G50.0), ból neuropatyczny w tym poherpetyczny i cukrzycowy (M79.7/G62.9)	E780	Czysta hipercholesterolemia	Pure hypercholesterolaemia	TSPAN8	rs118173562	12-71284188-C-T	MODIFIER	0.0185764	1.75219	0.353168	6.1549	2.98396	0.527997	0.0383998	5.0	-0.0706662	0.0425817	1.0132	5.12	24.8	2	weak (1/3)	1.53	0.26	enriched	23.0	UniProt loc high conf	trait_unrelated		22: level of tetraspanin-8 in blood; 20: type 2 diabetes mellitus; 7: asthma; 3: HbA1c measurement; 3: body height	103.0		GO:0005515:protein_binding,GO:0005886:plasma_membrane,GO:0016020:membrane,GO:0070062:	Brak wskazania.	92.754	7.2464	532	345	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=6.2<7.5 (artefakt opposite-sign)	7	6	3	5.01	HIGH_PLEIOTROPY_n103	0.0632789	0.0420877	0.877097	0.00814276	0.0601468	0.0494841	0.9449990817999608	0.9092095328759481	0.8016368203549143	0.0	0.22546124499186854	1.4212536693349782	3	curated	0.9559	Adipose - Subcutaneous	3.0	0.9559	Adipose - Subcutaneous	3.0	2.1699630011159794	-0.10663168005006607	1	0.0	0.5237407095356773	0	1	1	TSPAN8	0.4661939804132124	0		HIGH replicated	25	320	1.399	6.7214	139	1458	0.0	0	2.07056	0.0471698	0.0164993	5	0	44	1	intron_variant	protein_coding	-	-	0.0076	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_35_21_fluoxetine__M549	fluoxetine__M549	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	M549	Bóle pleców	Dorsalgia	GUCY2F	rs184784451	X-109371201-A-G	MODIFIER	0.00464787	5.02893	0.906972	7.53108	4.3333	0.841081	0.0812661	0.0	-0.0833031	0.131523	0.27861	5.58	60.37	1	weak (1/3)	1.14	0.07	low		Druggable Family	trait_unrelated		1: COVID-19; 1: gallbladder disorder; 1: non-melanoma skin carcinoma; 1: basal cell carcinoma	4.0		GO:0000166:nucleotide_binding,GO:0001653:peptide_receptor_activity,GO:0004383:guanylate_cyclase_activity,GO:0004672:protein_kinase_activity,GO:0005524:ATP_binding,GO:0005525:GTP_binding,GO:0005640:nuclear_outer_membrane,GO:0005886:plasma_membrane,GO:0006182:cGMP_biosynthetic_process,GO:0006468:protein_phosphorylation,GO:0007168:receptor_guanylyl_cyclase_signaling_pathway,GO:0007601:visual_perception,GO:0009190:cyclic_nucleotide_biosynthetic_process,GO:0016020:membrane,GO:0016829:lyase_activity,GO:0016849:phosphorus-oxygen_lyase_activity,GO:0019934:cGMP-mediated_signaling,GO:0022400:regulation_of_opsin-mediated_signaling_pathway,GO:0035556:intracellular_signal_transduction,GO:0038023:signaling_receptor_activity,GO:0042802:identical_protein_binding,GO:0042995:cell_projection,GO:0044877:protein-containing_complex_binding,GO:0050908:detection_of_light_stimulus_involved_in_visual_perception,GO:0097381:photoreceptor_disc_membrane,GO:0120200:	Off-label chronic pain. SSRI umiarkowane dowody w przewlekłym bólu z depresją; SNRI silniejsze. Confounding przez współwystępującą depresję + ból.	87.805	12.195	1316	82	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	8	7	2	4.82	LOW_PLEIOTROPY_n4	0.000347681	0.0137407	0.00885672	-0.023393	0.0827231	0.109389	0.9791460869149857	0.9390243902439024	0.7611214650352482	0.0	-0.2928395198593215	-0.34707266208193377	2	curated	0.90084	Muscle - Skeletal	1.0	0.90084	Muscle - Skeletal	1.0	0.0	-0.027354519018834705	1	0.0	0.49311203521971336	0	1	1	GUCY2F	0.49271109149687264	0		HIGH replicated	10	72	3.603	6.976	534	3752	0.0	0	1.74339	0.0	0.00393462	0	0	9	2	downstream_gene_variant	protein_coding	-	-	0.0016	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_35_21_fluoxetine__M549	fluoxetine__M549	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	M549	Bóle pleców	Dorsalgia	LINC03070	rs749501023	X-5671475-T-C	MODIFIER	0.00527975	4.93221	0.986187	6.24454	8.02051	0.93208	0.0255018	0.0	0.188974	0.121145	0.925248	4.77	26.1	1	weak (1/3)	1.14	0.07	low		Unknown	trait_unrelated		1: facial morphology trait; 1: pelvic organ prolapse, age at assessment; 1: alpha-hydroxybutyric acid measurement; 1: Alzheimer disease; 1: brain connectivity attribute	7.0		-	Off-label chronic pain. SSRI umiarkowane dowody w przewlekłym bólu z depresją; SNRI silniejsze. Confounding przez współwystępującą depresję + ból.	87.805	12.195	1316	82	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	6	1	3.48	LOW_PLEIOTROPY_n7	0.0031298	0.0127846	0.0933402	-0.0337042	0.0740606	0.187725							2	curated	0.90084	Muscle - Skeletal	1.0	0.90084	Muscle - Skeletal	1.0		-0.15475405226188763	1	0.0	0.5099818211972816	1	1	1	LINC03070	0.45513956683103296	1		HIGH replicated	10	72	3.603	6.976	534	3752	0.0	0	2.23372	0.0	0.00423729	0	0	10	2	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_42_11_ramipril__L409	ramipril__L409	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	L409	Łuszczyca	Psoriasis	GLP1R	rs112794418	6-39093427-A-G	MODIFIER	0.00794196	4.30063	0.734213	8.32793	2.07077	1.17617	0.535989	0.0	0.179986	0.16696	0.551253	5.47	23.89	0	weak (1/3)	1.91	0.81	low		Approved Drug	trait_unrelated		17: type 2 diabetes mellitus; 12: glucose measurement; 9: body mass index; 9: blood glucose amount; 6: HbA1c measurement	74.0		GO:0004888:transmembrane_signaling_receptor_activity,GO:0004930:G_protein-coupled_receptor_activity,GO:0004967:glucagon_receptor_activity,GO:0005515:protein_binding,GO:0005886:plasma_membrane,GO:0007165:signal_transduction,GO:0007166:cell_surface_receptor_signaling_pathway,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007189:adenylate_cyclase-activating_G_protein-coupled_receptor_signaling_pathway,GO:0007190:activation_of_adenylate_cyclase_activity,GO:0007204:positive_regulation_of_cytosolic_calcium_ion_concentration,GO:0007611:learning_or_memory,GO:0008016:regulation_of_heart_contraction,GO:0008528:G_protein-coupled_peptide_receptor_activity,GO:0016020:membrane,GO:0017046:peptide_hormone_binding,GO:0031204:post-translational_protein_targeting_to_membrane_-_translocation,GO:0038023:signaling_receptor_activity,GO:0044508:glucagon-like_peptide_1_receptor_activity,GO:0045776:negative_regulation_of_blood_pressure,GO:0045777:positive_regulation_of_blood_pressure,GO:0046879:hormone_secretion,GO:0065008:regulation_of_biological_quality,GO:0071377:cellular_response_to_glucagon_stimulus,GO:1990911:response_to_psychosocial_stress	Nie wskazanie. ACEi (w tym ramipril) UDOKUMENTOWANIE związane z induction/aggravation psoriasis: MR study + FAERS (ramipril ROR 1.63; Song Sci Rep 2021 meta OR 1.52). Mechanizm bradykininowy.	78.947	21.053	1382	133	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	4	4	4.82	PRE_EXISTING; CURATOR_NOT_INDICATION	0.0177056	0.036239	0.204022	-0.0340989	0.0640355	0.225936	0.9652437226853958	0.9520703346568349	0.78397212543554	0.0	0.1364603919731584	-0.2506829473658212	2	curated							0.19776092071615914	-0.1839158647373425	1	0.04093571025836034	0.426069459538352	1	1	1	GLP1R	0.506151882158456	1		MED repl-underpowered	28	105	3.7837	15.368	717	2532	0.0	0	0.61889	0.0	0.00779871	0	0	53	0	downstream_gene_variant	protein_coding	-	-	0.0018	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_42_47_ramipril__M791	ramipril__M791	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	M791	Mialgia	Myalgia	LINC00944	rs150777996	12-126690358-C-A	MODIFIER	0.0107675	5.60174	0.999679	7.67775	3.48692	1.15722	0.280442	0.0	-0.409873	0.199426	1.39954	5.9	13.67	1	STRONG (ROR+PRR+IC)	2.01	0.9	low		Unknown	trait_unrelated		2: malaria; 1: trait in response to efavirenz, virologic response measurement; 1: peripheral arterial disease, traffic air pollution measurement; 1: Alzheimer disease, dementia, family history of Alzheimerâ_x0080__x0099_s disease; 1: neuritic plaque measurement	16.0		-	Nie wskazanie. Mialgia i bóle stawowe w 'ACEi symptom complex' (SmPC Altace) obok arthralgia, positive ANA, fever, vasculitis.	89.024	10.976	1092	82	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	4	7	4	4.82	LOW_PLEIOTROPY_n16; CURATOR_NOT_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[LINC00944|LINC02824]	-0.0672244	0.0308985	1.52898	-0.0374	0.0557376	0.299106	0.9833799077799846				-0.1835916971508341		1	curated	0.086732	Muscle - Skeletal	1.0	0.086732	Muscle - Skeletal	1.0	0.10306548408643423	-0.13109389936724686	4	0.0	0.5003503195573974	0	1	4	LINC00944;LINC02824	0.5597439089392579	0		MED repl-underpowered	9	73	2.9897	1.5606	264	2163	0.0	0	1.07933	0.0	0.0125037	0	0	85	0	upstream_gene_variant	lncRNA	-	-	0.0036	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_15_07_atenolol__L409	atenolol__L409	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	L409	Łuszczyca	Psoriasis	MICAL3	rs566280265	22-17908089-G-A	MODIFIER	0.00554148	6.62336	1.23859	7.04977	10.5489	1.13385	0.0377193	1.0	0.155993	0.209506	0.340532	5.15	42.46	1	no_signal	1.02	-0.13	low		Structure with Ligand	trait_unrelated		13: body height; 12: serum gamma-glutamyl transferase measurement; 11: forced expiratory volume; 10: diastolic blood pressure; 6: vaginal microbiome measurement	128.0		GO:0003779:actin_binding,GO:0004497:monooxygenase_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005819:spindle,GO:0005829:cytosol,GO:0005856:cytoskeleton,GO:0005886:plasma_membrane,GO:0005938:cell_cortex,GO:0006887:exocytosis,GO:0007010:cytoskeleton_organization,GO:0016491:oxidoreductase_activity,GO:0016709:oxidoreductase_activity_-_acting_on_paired_donors_-_with_incorporation_or_reduction_of_molecular_oxygen_-_NAD(P)H_as_one_donor_-_and_incorporation_of_one_atom_of_oxygen,GO:0030042:actin_filament_depolymerization,GO:0030496:midbody,GO:0042995:cell_projection,GO:0045171:intercellular_bridge,GO:0046872:metal_ion_binding,GO:0051301:cell_division,GO:0060090:molecular_adaptor_activity,GO:0071949:FAD_binding,GO:0090543:Flemming_body,GO:0120501:	Nie wskazanie. β-blokery (atenolol, metoprolol) STROŃGO związane z drug-induced/aggravated psoriasis – duże dowody (Cohen BJD 2008; Brauchli BJD 2008 OR 1.31). Mechanizm: ↓cAMP, zmiany kalcyjowe, degranulacja neutrofili.	83.721	16.279	2315	86	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	6	3	4.76	HIGH_PLEIOTROPY_n128; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs566280265	0.032292	0.033609	0.472827	-0.0444423	0.0933433	0.197917	0.7880438533687131	0.5645370170515865	0.4451016935418523	1.0	-0.39850942140743534	-0.08747675466021336	2	curated							2.2541183265259392	-0.10876336492772257	2	0.0	0.4641794236850156	0	1	2	MICAL3	0.4683803063373727	0		HIGH replicated	14	72	6.3381	11.343	717	3893	0.0	0	2.07789	0.0277778	0.00417495	1	0	21	0	upstream_gene_variant	protein_coding	-	-	0.0008	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_13_06_33_atorvastatin__L918	atorvastatin__L918	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	L918	Inne przerostowe zmiany skóry	Other hypertrophic disorders of skin	-	rs76043071	9-98724864-C-T	MODIFIER	0.0396836	2.05269	0.410648	6.23859	3.51971	0.534342	0.0185225	2.0	0.0762637	0.0888086	0.408398	4.7	26.92	1	weak (1/3)	1.75	0.36	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	89.744	10.256	1077	117	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	5	1	2.15	NO_GENE_SYMBOL; LOCUS_LEAD_rs76043071	0.00382223	0.0144641	0.101503	0.0187223	0.0284701	0.29176							2	curated								-0.1315602235794005	2	0.0	0.5125650194462115	1	1	2	-;GALNT12	0.49838628276418884	1		HIGH replicated	12	105	2.9487	2.9843	457	2219	0.0	0	2.355	0.0714286	0.0362515	2	0	288	3	intergenic_variant	-	-	-	0.0232	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_13_06_33_atorvastatin__L918	atorvastatin__L918	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	L918	Inne przerostowe zmiany skóry	Other hypertrophic disorders of skin	ENSG00000288098	rs190148947	X-142016244-C-T	MODIFIER	0.00984164	3.28167	0.663778	6.11596	3.05913	0.472605	0.0179871	1.0	0.239838	0.138892	1.07466	4.49	13.68	1	weak (1/3)	1.75	0.36	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	89.744	10.256	1077	117	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000288098') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL	0.0128893	0.0223382	0.24877	-0.0498801	0.0431698	0.605705							2	curated								-0.0016589878207152742	1	0.0	0.5139598263031161	1	1	1	ENSG00000288098	0.4509843677400691	1		HIGH replicated	12	105	2.9487	2.9843	457	2219	0.0	0	2.36588	0.0384615	0.0124661	1	0	37	32	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_57_12_clopidogrel__K922	clopidogrel__K922	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	K922	Krwawienie GI	GI haemorrhage	OR9Q1	rs181975950	11-58060137-C-T	MODIFIER	0.00574713	4.61617	0.912208	6.37853	9.45819	0.912035	0.0137553	1.0	-0.0425024	0.143855	0.114838	5.04	108.61	2	STRONG (ROR+PRR+IC)	6.04	2.49	low	101.0	UniProt loc med conf	trait_match	2: ulcerative colitis; 1: platelet volume	6: memory performance; 2: plasma protease C1 inhibitor measurement; 2: ulcerative colitis; 2: body height; 1: platelet volume	29.0		GO:0004930:G_protein-coupled_receptor_activity,GO:0004984:olfactory_receptor_activity,GO:0005549:odorant_binding,GO:0005886:plasma_membrane,GO:0007165:signal_transduction,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007608:sensory_perception_of_smell,GO:0016020:membrane,GO:0050911:detection_of_chemical_stimulus_involved_in_sensory_perception_of_smell	Nie wskazanie (dokładnie przeciwnie). GI bleeding – DEFINICYJNE ADR klopidogrelu (CURE: 2.0% vs 1.3%; SmPC common). Silne confounding ADR.	98.261	1.7391	775	115	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	2	10	5	4.64	PHEWAS_ATLAS_MATCH; LOW_PLEIOTROPY_n29; CURATOR_KNOWN_ADR; EXPERT_DISAGREEMENT	0.0127435	0.0147699	0.410893	0.0331564	0.119033	0.107576	0.9517319692293688	1.0	0.44753261486103224	1.0	-0.33646472574061137	-0.15617375977831843	4	curated							0.0	-0.22477797963540452	1	0.0	0.6641302065491894	0	1	1	OR9Q1	0.5373764858850857	0		HIGH replicated	2	113	2.1218	2.0205	228	2374	0.0	0	2.46359	0.0333333	0.00486891	1	0	13	0	intron_variant	protein_coding	-	-	0.0012	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_13_26_30_atorvastatin__R21	atorvastatin__R21	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	R21	Wysypka i wykwity skórne	Rash	RTN4R	rs113110884	22-20273295-C-T	MODIFIER	0.00986484	3.18183	0.57389	7.53004	3.92162	0.795146	0.0856948	2.0	0.0454935	0.132312	0.136101	5.33	69.94	1	weak (1/3)	1.06	0.04	low		UniProt loc high conf	trait_unrelated		8: reticulon-4 receptor measurement; 1: amino acid measurement; 1: blood protein amount; 1: delivery measurement, gut microbiome measurement; 1: level of catechol O-methyltransferase in blood	17.0		GO:0005515:protein_binding,GO:0005783:endoplasmic_reticulum,GO:0005886:plasma_membrane,GO:0007166:cell_surface_receptor_signaling_pathway,GO:0007409:axonogenesis,GO:0008201:heparin_binding,GO:0008289:lipid_binding,GO:0009897:,GO:0009986:,GO:0010977:negative_regulation_of_neuron_projection_development,GO:0016020:membrane,GO:0022038:corpus_callosum_development,GO:0023041:neuronal_signal_transduction,GO:0030424:axon,GO:0030425:dendrite,GO:0030426:growth_cone,GO:0030517:negative_regulation_of_axon_extension,GO:0035025:positive_regulation_of_Rho_protein_signal_transduction,GO:0035374:chondroitin_sulfate_binding,GO:0038023:signaling_receptor_activity,GO:0038131:neuregulin_receptor_activity,GO:0042995:cell_projection,GO:0043005:neuron_projection,GO:0043025:neuronal_cell_body,GO:0043198:dendritic_shaft,GO:0043204:perikaryon,GO:0043547:positive_regulation_of_GTPase_activity,GO:0044295:axonal_growth_cone,GO:0045121:membrane_raft,GO:0048681:negative_regulation_of_axon_regeneration,GO:0051963:regulation_of_synapse_assembly,GO:0070062:,GO:0098552:side_of_membrane,GO:0098978:glutamatergic_synapse,GO:0150052:,GO:1905573:ganglioside_GM1_binding,GO:1905576:ganglioside_GT1b_binding	Nie wskazanie. Wysypka (maculopapular, lichenoid, fotowrażliwość) – znane ADR statyn, w SmPC common/uncommon.	33.163	0.0	1768	196	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	8	6	2	4.58	LOW_PLEIOTROPY_n17; CURATOR_KNOWN_ADR; EXPERT_DISAGREEMENT	0.0301135	0.0278576	0.553298	-0.0820077	0.0532141	0.909054	0.9341902857843846	0.8845744994980216	0.782513572644032	0.0	0.6789065827311885	0.40799033795247414	2	curated							2.052639299134197	-0.07958070876344606	1	0.0	0.20643786598062835	1	1	1	RTN4R	0.2866836805356232	1		HIGH replicated	0	65	4.8405		498	2796	66.837	0	1.71856	0.0344828	0.00940594	2	0	76	0	upstream_gene_variant	protein_coding	-	-	0.002	C5	E	Drug-triggered, no pharmacovigilance support	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_14_19_bisoprolol__R252	bisoprolol__R252	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	R252	Kurcze i skurcze mięśni	Cramp and spasm	INTS7		INTS7_mpc		0.00115306	42.1116	6.71246	9.45259	413227.0	5.75861	0.0247273	0.0	1.53663	1.18431	0.711168	5.95	27.41	1	weak (1/3)	1.22	0.18	low		Database Ubiquitination	trait_unrelated		7: body height; 7: urate measurement; 3: lean body mass; 2: BMI-adjusted hip circumference; 2: gout	38.0	Brak raportowanych asocjacji GWAS Catalog dla INTS7 (1q32.3) z R25.2 (kurcze/skurcze) ani skurczami mięśni. INTS7 (Integrator Complex Subunit 7) - funkcja w przetwarzaniu snRNA; znany m.in. z roli w DNA damage response. Brak GWS hitów fenotypów mięśniowo-szkieletowych.		Nie wskazanie. Skurcze mięśni opisywane w SmPC bisoprololu jako niezbyt częste ADR. Raczej sygnał ADR lub koincydencja.	82.222	17.778	1100	90	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	8	2	4.58	BURDEN; CURATOR_NOT_INDICATION	0.330877	0.266968	0.667155	0.56654	0.52603	0.550559	0.7935938187530686	0.7124390243902438	0.43424357831618177	1.0	-0.8106630576453469	0.4075101544386571	1	curated							1.578155685949778	-0.5154595908921005	1	0.0	0.48556910081353893	1	1	1	INTS7	0.5469091267629629	1		HIGH replicated	16	74	3.0116	5.5578	488	1754	0.0	0	2.24564	0.0	0.000907214	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_56_53_tramadol__R31	tramadol__R31	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	R31	Krwiomocz	Unspecified haematuria	KCNIP2	rs144335349	10-101828941-G-A	MODIFIER	0.00588582	3.06393	0.625502	6.01481	6.37021	0.647086	0.00421651	3.0	0.10006	0.109652	0.441901	4.67	30.62	1	weak (1/3)	1.48	0.28	expressed	91.0	UniProt loc med conf	trait_unrelated		2: sex hormone-binding globulin measurement; 1: level of protein O-GlcNAcase in blood; 1: cholesterol to total lipids in large VLDL percentage; 1: cholesteryl esters to total lipids in large VLDL percentage; 1: alkaline phosphatase measurement	7.0		GO:0001508:action_potential,GO:0005250:A-type_(transient_outward)_potassium_channel_activity,GO:0005267:potassium_channel_activity,GO:0005509:calcium_ion_binding,GO:0005513:detection_of_calcium_ion,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005886:plasma_membrane,GO:0006811:monoatomic_ion_transport,GO:0006813:potassium_ion_transport,GO:0006936:muscle_contraction,GO:0007165:signal_transduction,GO:0007268:chemical_synaptic_transmission,GO:0008016:regulation_of_heart_contraction,GO:0008076:voltage-gated_potassium_channel_complex,GO:0009966:regulation_of_signal_transduction,GO:0015459:potassium_channel_regulator_activity,GO:0016020:membrane,GO:0034220:monoatomic_ion_transmembrane_transport,GO:0034702:monoatomic_ion_channel_complex,GO:0044325:transmembrane_transporter_binding,GO:0045163:clustering_of_voltage-gated_potassium_channels,GO:0045202:synapse,GO:0046872:metal_ion_binding,GO:0046923:ER_retention_sequence_binding,GO:0060306:regulation_of_membrane_repolarization,GO:0071193:Kv4.2-KChIP2_channel_complex,GO:0071805:potassium_ion_transmembrane_transport,GO:0086009:membrane_repolarization,GO:0086013:membrane_repolarization_during_cardiac_muscle_cell_action_potential,GO:1901379:regulation_of_potassium_ion_transmembrane_transport,GO:1903764:regulation_of_potassium_ion_export_across_plasma_membrane,GO:1903766:positive_regulation_of_potassium_ion_export_across_plasma_membrane	Nie wskazanie. Opioidy mogą powodować retencję, nie krwiomocz.	93.385	0.77821	802	257	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	8	6	2	4.58	LOW_PLEIOTROPY_n7; CURATOR_NOT_INDICATION	0.0189801	0.0300632	0.277516	-0.0502414	0.0743313	0.301816	0.8834423367260503	0.8811113852331408	0.8329146746616967	0.0	-0.46469310814869913	-0.7107626435493027	3	curated	0.66655	Bladder	2.0	0.66655	Bladder	2.0	1.8467131395914766	-0.2261295839426679	1	0.0	0.5451473776177646	1	1	1	KCNIP2	0.44199243764752943	1		HIGH replicated	2	240	2.1958	14.357	138	2059	5.8366	0	2.86149	0.0348837	0.0058548	3	0	35	0	intron_variant	protein_coding	-	-	0.0016	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_57_25_clopidogrel__M139	clopidogrel__M139	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	M139	Zapalenie stawów, nieokreślone	Arthritis, unspecified	PHEX	rs141297234	X-22300612-C-T	MODIFIER	0.014809	2.32596	0.449718	6.63536	5.29592	0.571245	0.003522	3.0	0.0809388	0.0661827	0.65493	4.94	28.74	1	weak (1/3)	1.17	0.06	low		UniProt loc high conf	trait_unrelated		1: phosphorus measurement; 1: Tourette syndrome; 1: fetal hemoglobin measurement; 1: response to vaccine, cytokine measurement; 1: alkaline phosphatase measurement	11.0	PHEX / Arthritis unspecified (M13.9). Brak asocjacji GWAS Catalog PHEX (Xp22.11) z niespecyficznym zapaleniem stawów. PHEX to klasyczny locus Mendlowskiej X-linked hypophosphatemia (XLH, OMIM 307800) - loss-of-function variants powodują nerkowe marnotrawstwo fosforanu, krzywicę, osteomalację; leczone burosumabem. Artralgia/artropatia występuje jako powikłanie XLH u dorosłych, ale to efekt fenotypu, nie common variant GWAS M13.9.	GO:0004222:metalloendopeptidase_activity,GO:0006508:proteolysis,GO:0008237:metallopeptidase_activity	Nie wskazanie. UWAGA: zapalenie stawów opisywane jako ADR klopidogrelu (case reports migrującego polyarthritis; PMC4586816, PMC6474151, PMC10724009). Ustępuje po odstawieniu, nawrót przy rechallengu. Mechanizm immunologiczny (typ B).	98.0	2.0	930	100	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	6	2	4.38	LIT_NO_PRIOR_HIT; LOW_PLEIOTROPY_n11; CURATOR_NOT_INDICATION	0.00806029	0.00715161	0.585499	-0.00620739	0.0588995	0.0380729	0.8965581286936901	0.8744918699186991	0.5413661777813791	0.0	-0.9683085903552152	1.430470225143408	2	curated_weak	0.46053	Muscle - Skeletal	1.0	0.46053	Muscle - Skeletal	1.0	0.029601325609257847	-0.22768595485965465	1	0.06792253773623753	0.5613523134212287	1	1	1	PHEX	0.499000087446136	1		HIGH replicated	2	98	2.5462	6.4257	281	2587	0.0	0	2.91808	0.125	0.0142003	1	1	16	11	intron_variant,NMD_transcript_variant	nonsense_mediated_decay	-	-	0.0124	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_29_38_lisinopril__K20	lisinopril__K20	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	K20	Zapalenie przełyku	Oesophagitis	GNG13	rs563549874	16-804252-G-A	MODIFIER	0.0131842	2.67135	0.54373	6.04724	5.74597	0.822062	0.0334227	2.0	0.0827785	0.09027	0.444739	4.7	32.27	1	weak (1/3)	1.93	0.67	low	39.0	UniProt loc high conf	trait_unrelated		2: mean reticulocyte volume; 1: mean corpuscular hemoglobin; 1: mesothelin measurement; 1: erythrocyte volume	5.0		GO:0005515:protein_binding,GO:0005834:heterotrimeric_G-protein_complex,GO:0005886:plasma_membrane,GO:0007165:signal_transduction,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007200:phospholipase_C-activating_G_protein-coupled_receptor_signaling_pathway,GO:0016020:membrane,GO:0030425:dendrite,GO:0031681:G-protein_beta-subunit_binding,GO:0045202:synapse,GO:0050909:sensory_perception_of_taste	Nie wskazanie. Kaszel ACEi może symulować GERD/esophagitis. Confounding diagnostyczny.	90.217	0.0	2113	184	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	6	2	4.38	LOW_PLEIOTROPY_n5; CURATOR_NOT_INDICATION	0.0414075	0.045339	0.442381	0.041914	0.0759841	0.235665	0.9842555721462597	0.9529347780613311	0.8933635847986385	0.0	-0.4261254230245969	-0.49093115641523666	3	curated							0.0	-0.22557007985758107	1	0.0	0.5389848979751877	1	1	1	GNG13	0.4728565539191742	1		HIGH replicated	0	166	5.7851		1115	3439	9.7826	0	2.12697	0.0384615	0.0108925	2	0	31	0	upstream_gene_variant	protein_coding	-	-	0.0022	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_48_01_lisinopril__R21	lisinopril__R21	lisinopril	I10, I50, I21, I25, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), po zawale serca (I21/I25), nefropatia cukrzycowa (E10.2/E11.2/N08)	R21	Wysypka	Rash	MED15	rs75946839	22-20508261-C-T	MODIFIER	0.0113657	5.59815	0.9232	8.87647	0.816985	1.57506	0.897884	0.0	-0.10186	0.125944	0.378153	6.12	54.96	0	weak (1/3)	1.63	0.65	low		Structure with Ligand	trait_unrelated		3: mathematical ability; 2: FEV/FVC ratio; 2: scavenger receptor class F member 2 measurement; 1: frailty measurement; 1: forced expiratory volume	13.0		GO:0003712:transcription_coregulator_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0006355:regulation_of_DNA-templated_transcription,GO:0016020:membrane,GO:0032968:positive_regulation_of_transcription_elongation_by_RNA_polymerase_II,GO:0035019:somatic_stem_cell_population_maintenance,GO:0051123:RNA_polymerase_II_preinitiation_complex_assembly,GO:0060261:positive_regulation_of_transcription_initiation_by_RNA_polymerase_II,GO:0070847:core_mediator_complex	Nie wskazanie. Wysypka/pokrzywka/erythema multiforme – udokumentowane ADR ACEi (SmPC common).	32.877	0.0	2931	73	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	4	3	4.38	LOW_PLEIOTROPY_n13; CURATOR_KNOWN_ADR; EXPERT_DISAGREEMENT	-0.0174424	0.0493283	0.140478	0.0760725	0.0827345	0.446304	0.48111335556410145	0.4864004494171621	0.5444453447856736	0.0	0.7848135078027099	1.0035402174011376	2	curated							4.192807343110856	-0.5433641308682776	1	0.0	0.1943941193292154	0	1	1	MED15	0.35690535958747693	0		MED repl-underpowered	0	24	8.0246		2007	3513	67.123	0	-0.128335	0.0	0.00799166	0	0	23	0	intron_variant	protein_coding	-	-	0.0044	C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_21_28_tramadol__F419	tramadol__F419	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	F419	Zaburzenia lękowe	Anxiety disorder	-	rs6829799	4-82119215-G-A	MODIFIER	0.00681073	4.49041	0.751458	8.63969	1.10516	1.28265	0.937862	0.0	0.0811114	0.116441	0.313311	5.8	55.36	1	STRONG (ROR+PRR+IC)	2.9	1.46	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie formalne. Tramadol nadużywany z powodu działania serotoninergicznego w komorbidalnej depresji/lęku – znaczący sygnał misuse. Pośrednie confounding.	100.0	0.0	1412	172	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	7	4	4.38	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	-0.000242961	0.0277312	0.00304656	-0.0978617	0.0658415	0.862665							3	curated	0.5535	Brain - Cortex	3.0	0.5535	Brain - Cortex	3.0		-0.37632637897628324	1	0.0	0.5287043865329101	1	1	1	-	0.6103200470779755	1		MED repl-underpowered	0	172	3.8658		203	3324	0.0	0	0.0779577	0.0	0.00716428	0	0	43	0	intergenic_variant	-	-	-	0.002	C6	E	Unreplicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_40_29_amlodipine__R13	amlodipine__R13	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R13	Dysfagia	Dysphagia	TICAM2	rs183450691	5-115581344-T-C	MODIFIER	0.00523206	3.43099	0.617648	7.55636	3.77992	1.05333	0.206811	1.0	0.268633	0.142288	1.22892	4.99	12.77	0	weak (1/3)	1.71	0.69	low	105.0	UniProt loc high conf	trait_unrelated		2: conotruncal heart malformations; 1: lingual gyrus volume; 1: response to antidepressant; 1: body height; 1: susceptibility to chronic sinus infection measurement	6.0		GO:0001891:phagocytic_cup,GO:0002376:immune_system_process,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005768:endosome,GO:0005769:early_endosome,GO:0005770:late_endosome,GO:0005783:endoplasmic_reticulum,GO:0005794:Golgi_apparatus,GO:0005886:plasma_membrane,GO:0006909:phagocytosis,GO:0006954:inflammatory_response,GO:0007165:signal_transduction,GO:0010008:endosome_membrane,GO:0016020:membrane,GO:0030667:secretory_granule_membrane,GO:0031901:early_endosome_membrane,GO:0031902:late_endosome_membrane,GO:0032481:,GO:0034142:toll-like_receptor_4_signaling_pathway,GO:0034145:positive_regulation_of_toll-like_receptor_4_signaling_pathway,GO:0035591:signaling_adaptor_activity,GO:0035666:TRIF-dependent_toll-like_receptor_signaling_pathway,GO:0035669:TRAM-dependent_toll-like_receptor_4_signaling_pathway,GO:0042995:cell_projection,GO:0043123:positive_regulation_of_canonical_NF-kappaB_signal_transduction,GO:0045087:innate_immune_response,GO:0051707:response_to_other_organism,GO:0060090:molecular_adaptor_activity,GO:0071222:cellular_response_to_lipopolysaccharide,GO:0071651:positive_regulation_of_chemokine_(C-C_motif)_ligand_5_production,GO:2000494:positive_regulation_of_interleukin-18-mediated_signaling_pathway	Brak wskazania.	96.691	0.0	1323	272	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	8	5	2	4.31	LOW_PLEIOTROPY_n6	0.00811231	0.0190594	0.173682	-0.0864203	0.0757575	0.59521	0.8129747099352588	0.7118198874296435	0.516732841747022	0.0	0.5317833576641031	-1.0873319022183248	2	curated	0.83137	Colon - Sigmoid	3.0	0.83137	Colon - Sigmoid	3.0	1.9169373179562834	-0.05086590167231214	1	0.0	0.5230079166451022	1	1	1	TICAM2	0.5091732421839262	1		MED repl-underpowered	0	263	3.6222		546	2534	3.3088	0	1.26238	0.016129	0.0059196	1	0	43	0	intron_variant	protein_coding	-	-	0.0018	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_33_50_fluoxetine__G560	fluoxetine__G560	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	G560	Zespół cieśni nadgarstka	Carpal tunnel syndrome	GFOD1	rs11756572	6-13455966-A-G	MODIFIER	0.0073263	4.80221	0.814438	8.42987	4.58482	1.12531	0.175997	1.0	0.174205	0.119173	0.842238	5.62	27.57	0	weak (1/3)	1.48	0.15	low		UniProt loc high conf	trait_unrelated		3: aspartate aminotransferase measurement; 3: hemoglobin measurement; 2: gout; 2: lymphocyte count; 1: hypertensive disorder	27.0		GO:0000166:nucleotide_binding,GO:0005515:protein_binding,GO:0005576:extracellular_region,GO:0042802:identical_protein_binding	Brak wskazania.	98.462	1.5385	1572	130	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	8	5	2	4.31	LOW_PLEIOTROPY_n27	-0.0225931	0.0129584	1.09021	0.0720504	0.0827813	0.415558	0.7785150902149703	0.6542710270152029	0.7441050158009884	0.0	0.5873878752331138		1	curated							2.452831016315515	-0.005293814754392778	1	0.0	0.5264608194707019	1	1	1	GFOD1	0.5646850007675066	1		MED repl-underpowered	2	128	4.3039	3.7454	605	3146	0.0	0	1.35318	0.0238095	0.00518609	1	0	17	0	intron_variant	protein_coding	-	-	0.0052	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_23_22_ramipril__H609	ramipril__H609	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	H609	Zapalenie ucha zewnętrznego	Otitis externa	-	rs147786361	X-118271931-T-C	MODIFIER	0.00530737	6.03111	1.15651	6.73546	3.60454	0.737808	0.0822386	0.0	0.0682553	0.214614	0.124675	5.07	88.36	1	no_signal	1.08	-1.45	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	71.622	28.378	1241	74	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	4	1	2.29	NO_GENE_SYMBOL; LOCUS_LEAD_rs147786361	0.0426133	0.0346275	0.660619	-0.0927619	0.0617916	0.875163							2	curated								-0.15311725715008004	2	0.0	0.316976680225551	0	1	2	-;WDR44	0.3592561524114057	0		HIGH replicated	21	53	3.3977	6.1027	603	2511	0.0	0	1.73784	0.0	0.00748679	0	0	19	16	regulatory_region_variant	enhancer	-	-	0.0026	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_23_22_ramipril__H609	ramipril__H609	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	H609	Zapalenie ucha zewnętrznego	Otitis externa	ENSG00000287566	rs147431255	10-5550285-C-T	MODIFIER	0.0113402	6.78212	1.06684	9.68719	1.5746	1.17595	0.699443	0.0	0.23051	0.171948	0.744589	6.06	29.42	0	no_signal	1.08	-1.45	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	71.622	28.378	1241	74	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000287566') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	4	1	2.0	NO_GENE_SYMBOL	0.0190979	0.0294168	0.287185	-0.0253125	0.0529713	0.198764							2	curated								-0.44357241927794727	1	0.0	0.28956070217383706	0	1	1	ENSG00000287566	0.4592913188953637	0		MED repl-underpowered	21	53	3.3977	6.1027	603	2511	0.0	0	0.386072	0.0	0.0135056	0	0	92	0	non_coding_transcript_exon_variant	lncRNA	-	-	0.0032	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_20_47_temazepam__N390	temazepam__N390	temazepam	F51.0, Z51.4	Krótkotrwałe leczenie bezsenności (F51.0), premedykacja przed zabiegiem (Z51.4)	N390	ZUM	Urinary tract infection	SPANXA2-OT1	rs782188154	X-141412320-G-A	MODIFIER	0.0050671	5.22367	0.998366	6.77602	8.29835	1.0186	0.0377624	1.0	0.0182257	0.0838119	0.0820481	5.2	286.61	2	STRONG (ROR+PRR+IC)	2.57	1.17	low	88.0	Unknown	trait_partial	1: cognitive decline measurement	14: body height; 12: rho guanine nucleotide exchange factor 10 measurement; 6: heel bone mineral density; 6: bone tissue density; 5: intelligence	178.0		-	Brak wskazania.	89.423	10.577	1166	104	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	2	10	4	4.31	PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n178	0.0188702	0.0261347	0.32765	-0.165876	0.105183	0.940094	0.9229841714305249				-0.08911100170219116		3	curated	0.76268	Bladder	1.0	0.76268	Bladder	1.0	0.056374851379493295	-0.14308357146826195	1	0.0	0.582479819786922	1	1	1	SPANXA2-OT1	0.5218732852473913	1		HIGH replicated	11	93	3.1923	2.2505	83	3459	0.0	0	2.07742	0.0357143	0.00479744	1	0	5	2	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_38_02_amlodipine__M751	amlodipine__M751	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	M751	Rotator cuff syndrome	Rotator cuff syndrome	PTPN14	rs191380573	1-214349697-G-A	MODIFIER	0.00487614	4.418	0.828031	7.02112	5.26379	1.00498	0.0984098	1.0	0.151613	0.198715	0.351168	5.01	29.14	1	weak (1/3)	1.67	0.52	low		UniProt Ubiquitination	trait_unrelated		33: body height; 14: glomerular filtration rate; 10: serum creatinine amount; 5: body weight; 3: neuroticism measurement	108.0		GO:0001946:lymphangiogenesis,GO:0003712:transcription_coregulator_activity,GO:0004721:phosphoprotein_phosphatase_activity,GO:0004725:protein_tyrosine_phosphatase_activity,GO:0005515:protein_binding,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005856:cytoskeleton,GO:0006470:protein_dephosphorylation,GO:0008285:negative_regulation_of_cell_population_proliferation,GO:0016311:dephosphorylation,GO:0016787:hydrolase_activity,GO:0030971:receptor_tyrosine_kinase_binding,GO:0046825:regulation_of_protein_export_from_nucleus	Brak wskazania.	94.366	5.6338	1306	213	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	6	2	4.16	HIGH_PLEIOTROPY_n108	0.0089444	0.0196334	0.187957	-0.0230819	0.0777354	0.115476	0.8000943335373923	0.7125724295916993	0.8324284903978607	0.0	0.9515490973182582	2.0968481708980677	1	curated_weak	0.3853	Muscle - Skeletal	1.0	0.3853	Muscle - Skeletal	1.0	2.5696919397723677	-0.0726990833951632	1	0.0	0.5165814226600748	1	1	1	PTPN14	0.4830099284918624	1		HIGH replicated	12	201	3.5756	3.0253	544	2658	0.0	0	1.65261	0.0192308	0.00494913	1	0	34	1	3_prime_UTR_variant	protein_coding	-	-	0.0044	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_40_05_amlodipine__R060	amlodipine__R060	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R060	Duszność	Dyspnoea	GRM8	rs117700515	7-127192312-G-A	MODIFIER	0.00729641	3.12642	0.551807	7.83459	2.25409	0.738475	0.271082	2.0	0.0330627	0.125334	0.10131	5.47	94.56	0	weak (1/3)	1.92	0.89	expressed	38.0	UniProt loc med conf	trait_unrelated		17: smoking initiation; 17: neuroticism measurement; 9: type 2 diabetes mellitus; 8: educational attainment; 6: self reported educational attainment	169.0		GO:0001642:group_III_metabotropic_glutamate_receptor_activity,GO:0004930:G_protein-coupled_receptor_activity,GO:0005886:plasma_membrane,GO:0007165:signal_transduction,GO:0007186:G_protein-coupled_receptor_signaling_pathway,GO:0007193:adenylate_cyclase-inhibiting_G_protein-coupled_receptor_signaling_pathway,GO:0007196:adenylate_cyclase-inhibiting_G_protein-coupled_glutamate_receptor_signaling_pathway,GO:0007216:G_protein-coupled_glutamate_receptor_signaling_pathway,GO:0007601:visual_perception,GO:0008066:glutamate_receptor_activity,GO:0016020:membrane,GO:0051966:regulation_of_synaptic_transmission_-_glutamatergic	Nie wskazanie. Duszność jest UDOKUMENTOWANYM ADR amlodypiny (FAERS – jeden z top-10 sygnałów; SmPC UK: 'common'). Ryzyko zwłaszcza u pacjentów HF (PRAISE-2 – więcej przypadków obrzęku płuc).	96.884	3.1161	1325	353	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	6	5	2	3.91	HIGH_PLEIOTROPY_n169; CURATOR_KNOWN_ADR; EXPERT_DISAGREEMENT; LOCUS_LEAD_rs117700515	0.0116782	0.016417	0.321601	-0.0651193	0.0647539	0.502259	0.916201274890123	0.8180112570356474	0.6980795721578478	0.0	-0.27961127791105517	-0.4097894241194328	1	curated							0.15039821957497454	-0.073782325424677	2	0.0	0.5284204173556387	1	1	2	GRM8	0.5332315920717045	1		MED repl-underpowered	11	342	3.6687	2.6749	421	2754	0.0	0	1.10057	0.0181818	0.00859202	2	0	62	0	intron_variant	protein_coding	-	-	0.0048	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_03_15_simvastatin__G629	simvastatin__G629	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	G629	Polineuropatia	Polyneuropathy, unspecified	PLB1	rs75944756	2-28457902-C-T	MODIFIER	0.00645382	3.92167	0.793463	6.11274	5.60214	0.588632	0.00341835	2.0	0.135615	0.264565	0.215929	4.53	28.92	1	weak (1/3)	1.34	0.28	low		UniProt loc med conf	trait_unrelated		32: level of phospholipase B1, membrane-associated in blood; 19: eosinophil count; 4: triglyceride measurement; 3: cataract; 3: eosinophil percentage of leukocytes	124.0		GO:0004620:phospholipase_activity,GO:0016787:hydrolase_activity	Nie wskazanie. Polineuropatia to udokumentowane rzadkie ADR statyn (Gaist 2002 – OR 14.2 dla neuropatii przy długotrwałym użyciu).	97.126	2.8736	1702	174	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	6	2	4.16	HIGH_PLEIOTROPY_n124; CURATOR_NOT_INDICATION	-0.0201456	0.0183942	0.563166	-0.0182177	0.0586512	0.121423	0.8756525978747948	0.9492922177178175	0.7763552386354428	0.0	-0.14389843402394398		1	curated							0.8969937367244936	-0.12676867820443363	1	0.0	0.5188372337671028	1	1	1	PLB1	0.43009830814581096	1		HIGH replicated	5	169	4.6598	0.846	657	2869	0.0	0	2.92738	0.0285714	0.00629452	2	0	74	1	intron_variant	protein_coding	-	-	0.008	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_22_18_simvastatin__I10	simvastatin__I10	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I10	Pierwotne nadciśnienie tętnicze	Essential (primary) hypertension	ENSG00000293732	rs12413893	10-64775221-G-A	MODIFIER	0.0370988	0.328308	0.0581899	7.77452	1.09074	0.105051	0.408344	135.0	0.0172525	0.0237153	0.330749	4.95	19.03	0	weak (1/3)	1.92	0.86	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie formalne. ~60–70% pacjentów z dyslipidemią ma HT – obydwa schorzenia współistnieją. SCORE2 + ASCVD calculators rekomendują statyny u pacjentów HT z wysokim ryzykiem. BARDZO silne komorbidalne confounding.	91.343	1.9548	1317	11459	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000293732') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	4	1	2.0	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs12413893; LOCUS_HETEROGENEOUS_SAME_GENE	0.0126533	0.00794173	0.954286	0.00161936	0.0258324	0.0222693							6	curated	0.41424	Heart - Left Ventricle	4.0	0.41424	Heart - Left Ventricle	4.0		-0.07515625716512897	7	0.0	0.45167705255875557	1	1	7	CYP2C61P;ENSG00000293732	0.46041989226594116	1		LOW unreplicated	224	10467	3.5346	2.3436	501	2401	6.7022	0	0.826812	0.0387041	0.0363909	131	2	301	7	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0639	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_13_45_13_bisoprolol__A099	bisoprolol__A099	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	A099	Zapalenie żołądka i jelit	Gastroenteritis	-	rs55854447	14-97288492-T-C	MODIFIER	0.0141326	2.31061	0.38225	8.82497	1.89033	0.53878	0.237271	5.0	0.138413	0.0770407	1.14029	5.57	16.69	1	STRONG (ROR+PRR+IC)	3.08	1.38	no_gene_symbol		Unknown	no_gene_symbol				Brak symbolu VEP dla wariantu - niemożliwe cross-reference w GWAS Catalog dla gastroenteritis (A09.9). A09 jako ADR bisoprololu to prawdopodobnie niespecyficzne GI - brak solidnej bazy GWAS (efekty infekcyjne/środowiskowe dominują).	-	Brak wskazania.	100.0	0.0	1262	329	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	7	4	3.83	NO_GENE_SYMBOL	0.0295984	0.0319537	0.450635	-0.0533659	0.0596643	0.430523							4	curated								-0.06405015853576668	1	0.0	0.5761156970322364	1	1	1	-	0.6030895055853507	1		LOW unreplicated	0	329	3.4606		420	2313	0.0	0	1.18184	0.0454545	0.0203332	5	0	83	0	intergenic_variant	-	-	-	0.0024	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_10_23_42_amitriptyline__J189	amitriptyline__J189	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	J189	Zapalenie płuc	Pneumonia	EYS	rs186348321	6-64665130-C-T	MODIFIER	0.005877	4.74811	0.808685	8.36436	2.26046	0.998212	0.413912	1.0	0.0327353	0.146965	0.0842118	5.74	145.05	0	weak (1/3)	1.92	0.86	expressed	73.0	UniProt loc high conf	trait_unrelated		8: schizophrenia; 8: environmental exposure measurement; 5: mathematical ability; 5: retinal vasculature measurement; 4: adolescent idiopathic scoliosis	154.0		-	Nie wskazanie. TCA (antycholinergiczne, sedatywne) zwiększają ryzyko aspiracji i pneumonii u starszych (AGS Beers Criteria).	98.87	1.1299	1496	177	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	5	5	2	3.68	HIGH_PLEIOTROPY_n154; CURATOR_KNOWN_ADR; EXPERT_DISAGREEMENT	-0.0225231	0.0287187	0.363628	-0.0632072	0.0625043	0.505986	0.9082531400759762	0.8699186991869918	0.17056964589579449	1.0	-0.14199430968475002	-0.5546330176460225	1	curated	0.23051	Lung	1.0	0.23051	Lung	1.0	0.08161159939597137	-0.1917804986523787	1	0.2519541707794922	0.5328338934172776	1	1	1	EYS	0.5709577157654662	1		MED repl-underpowered	2	175	4.0958	38.07	248	3153	0.0	0	0.817029	0.0166667	0.00820812	1	0	57	1	intron_variant,non_coding_transcript_variant	protein_coding_CDS_not_defined	-	-	0.0024	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_56_04_furosemide__L089	furosemide__L089	furosemide	I50, R60.0, R60.9, N04, J81, I10	Niewydolność serca z obrzękami (I50/J81), obrzęki obwodowe (R60), zespół nerczycowy (N04), oporne nadciśnienie tętnicze (I10)	L089	Miejscowe zakażenie skóry	Local skin infection	DMD	rs148880129	X-31603867-G-A	MODIFIER	0.0186311	2.40465	0.443357	7.23384	3.3217	0.874373	0.169766	1.0	0.00298637	0.0779304	0.0134828	5.34	240.47	0	weak (1/3)	1.79	0.53	low		UniProt loc med conf	trait_unrelated		10: COVID-19; 4: body mass index; 3: vaginal microbiome measurement; 2: influenza A (H1N1); 2: breast carcinoma	65.0		GO:0002027:regulation_of_heart_rate,GO:0002162:dystroglycan_binding,GO:0003779:actin_binding,GO:0005200:structural_constituent_of_cytoskeleton,GO:0005515:protein_binding,GO:0005737:cytoplasm,GO:0005829:cytosol,GO:0005856:cytoskeleton,GO:0005886:plasma_membrane,GO:0006936:muscle_contraction,GO:0007010:cytoskeleton_organization,GO:0007517:muscle_organ_development,GO:0007519:skeletal_muscle_tissue_development,GO:0008104:protein_localization,GO:0008270:zinc_ion_binding,GO:0008307:structural_constituent_of_muscle,GO:0009986:,GO:0010880:regulation_of_release_of_sequestered_calcium_ion_into_cytosol_by_sarcoplasmic_reticulum,GO:0010881:,GO:0014809:regulation_of_skeletal_muscle_contraction_by_regulation_of_release_of_sequestered_calcium_ion,GO:0014819:regulation_of_skeletal_muscle_contraction,GO:0016010:,GO:0016013:,GO:0016020:membrane,GO:0016328:,GO:0017022:myosin_binding,GO:0017166:,GO:0030016:myofibril,GO:0030018:Z_disc,GO:0030055:cell-substrate_junction,GO:0030175:filopodium,GO:0031527:filopodium_membrane,GO:0032991:protein-containing_complex,GO:0035633:maintenance_of_blood-brain_barrier,GO:0035994:response_to_muscle_stretch,GO:0042383:,GO:0043034:costamere,GO:0043043:peptide_biosynthetic_process,GO:0044057:regulation_of_system_process,GO:0044306:neuron_projection_terminus,GO:0045121:membrane_raft,GO:0045202:synapse,GO:0045211:postsynaptic_membrane,GO:0046716:muscle_cell_cellular_homeostasis,GO:0046872:metal_ion_binding,GO:0048666:neuron_development,GO:0050998:nitric-oxide_synthase_binding,GO:0055001:muscle_cell_development,GO:0060048:cardiac_muscle_contraction,GO:0065003:protein-containing_complex_assembly,GO:0086001:cardiac_muscle_cell_action_potential,GO:0090257:regulation_of_muscle_system_process,GO:0099536:synaptic_signaling,GO:1902305:regulation_of_sodium_ion_transmembrane_transport,GO:1903169:regulation_of_calcium_ion_transmembrane_transport	Nie wskazanie. Cellulitis na tle obrzęków u pacjentów HF – populacja furosemidowa. Pośrednia komorbidalność.	90.0	10.0	1751	90	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	4	2	3.63	CURATOR_NOT_INDICATION	0.0130124	0.018134	0.325117	0.0782666	0.0507986	0.908742	0.838207906133634	0.7806832395247029	0.6416821975528725	0.0	-0.09172159740405925	-0.22012432773344334	2	curated							1.7871823434849416	-0.08931630694947007	1	0.06420566248887018	0.5058578674082458	1	1	1	DMD	0.5264042826651232	1		MED repl-underpowered	9	81	4.794	1.3771	413	3329	0.0	0	1.37296	0.0333333	0.015124	1	0	22	14	intron_variant	protein_coding	-	-	0.0053	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_30_59_citalopram__K635	citalopram__K635	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	K635	Polip okrężnicy	Polyp of colon	LINC02015	rs145844567	3-177816736-G-A	MODIFIER	0.00922785	3.13371	0.596227	6.83179	4.64832	0.918286	0.0942815	2.0	0.0708785	0.0878647	0.376904	5.08	44.21	1	no_signal	0.89	-1.46	low	31.0	Unknown	trait_unrelated		2: body mass index; 1: neuropsychological test; 1: lobe attachment; 1: Alzheimer disease, gastroesophageal reflux disease; 1: progression free survival, ovarian carcinoma	13.0		-	Brak wskazania.	97.619	2.381	1204	210	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	6	1	3.48	LOW_PLEIOTROPY_n13	-0.0074227	0.0221592	0.132152	-0.0419231	0.0667187	0.275913	0.9786212539935727				0.378763309394884		2	curated							0.15104672468167266	-0.13143365953221312	1	0.0	0.41928580789573383	0	1	1	LINC02015	0.4325101951198071	0		HIGH replicated	5	205	3.2964	0.30664	430	2516	0.0	0	1.67323	0.0434783	0.00749064	2	0	28	0	upstream_gene_variant	lncRNA	-	-	0.0098	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_00_18_simvastatin__N328	simvastatin__N328	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	N328	Inne zaburzenia pęcherza	Other specified disorders of bladder	RN7SL278P	rs143118039	15-76974556-T-C	MODIFIER	0.00698808	2.27573	0.4344	6.79146	2.50012	0.528629	0.0830206	3.0	0.21392	0.145693	0.847642	4.5	10.64	1	weak (1/3)	1.36	0.03	low	8.0	Unknown	trait_unrelated		2: self reported educational attainment; 2: Alzheimer disease, gastroesophageal reflux disease; 1: Alzheimer disease, peptic ulcer disease; 1: serum creatinine amount; 1: glomerular filtration rate	13.0		-	Brak wskazania.	98.025	1.9749	1419	557	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	7	6	1	3.48	LOW_PLEIOTROPY_n13	-0.0145059	0.0178422	0.380687	0.0356506	0.05928	0.261554	1.0				-0.13736056265567495		1	curated	0.24262	Bladder	1.0	0.24262	Bladder	1.0	0.0	-0.01798600660140176	1	0.0	0.4805173733261922	1	1	1	RN7SL278P	0.43822076390738235	1		HIGH replicated	11	546	3.7536	5.1362	644	2488	0.0	0	1.73342	0.0176471	0.00718223	3	0	84	1	downstream_gene_variant	misc_RNA	-	-	0.003	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_18_01_amlodipine__J310	amlodipine__J310	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	J310	Przewlekły nieżyt nosa	Chronic rhinitis	chr6:76600001-76700001_cnv_region_down		chr6:76600001-76700001_cnv_region_down		0.000640661	7.4397	1.30411	7.9338	20.5248	1.79071	0.091527	0.0	2.2297	0.736522	2.6078	3.48	3.34	2	STRONG (ROR+PRR+IC)	2.88	1.29	no_gene_symbol		Unknown	no_gene_symbol						Nie wskazanie. CCB mogą powodować nasilone przekrwienie nosowe (nitrogen oxide → vasodilation) – udokumentowana ADR.	84.259	15.741	1331	108	2	T2: Komorbidalność	Komorbidalność: tissue=no_gene_symbol (brak biologii w tkance ADR)	1	10	4	3.42	BURDEN; CURATOR_NOT_INDICATION	0.00103246	0.046145	0.00782247	0.385353	0.237756	0.978553							1	curated	0.98564	Lung	1.0	0.98564	Lung	1.0		-0.2381805838137102	1	0.0	0.40023797006944767	1	1	1	chr6:76600001-76700001_cnv_region_down	0.3795518265431218	1		HIGH replicated	17	91	3.6441	5.4209	484	2843	0.0	0	1.6874	0.0	0.000136986	0	0	1	0						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_19_21_amlodipine__K589	amlodipine__K589	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	K589	IBS bez biegunki	IBS without diarrhoea	AGBL4	rs148355896	1-48632540-T-G	MODIFIER	0.00647779	4.02526	0.800331	6.30823	4.84722	0.801736	0.0489834	2.0	-0.068719	0.114575	0.260699	5.06	58.58	1	no_signal	0.88	-0.4	expressed	77.0	Unknown	trait_unrelated		34: body mass index; 10: reaction time measurement; 8: atrial fibrillation; 8: body fat percentage; 6: smoking initiation	154.0		GO:0004180:carboxypeptidase_activity,GO:0004181:metallocarboxypeptidase_activity,GO:0005829:cytosol,GO:0006508:proteolysis,GO:0008237:metallopeptidase_activity,GO:0008270:zinc_ion_binding	Brak wskazania.	81.667	18.333	1404	180	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=6.3<7.5 (artefakt opposite-sign)	6	6	1	3.3	HIGH_PLEIOTROPY_n154	-0.0219476	0.017588	0.673509	-0.100833	0.0664762	0.888367	0.899949861530989	0.8140921409214091	0.7580422980309536	0.0	-0.48472090537722196	-0.7934688009253402	3	curated							0.08401388900787306	-0.0780324023208725	1	0.0	0.4381936774507685	0	1	1	AGBL4	0.41825404422036533	0		HIGH replicated	33	147	3.8439	3.729	521	2716	0.0	0	1.96874	0.03125	0.00660975	2	0	48	0	downstream_gene_variant	protein_coding	-	-	0.0024	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_01_40_simvastatin__N390	simvastatin__N390	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	N390	ZUM	Urinary tract infection	DUSP9		DUSP9_mpc		0.000286347	14.6756	2.95164	6.17877	551.03	2.50698	0.0118129	0.497559	1.72833	0.857081	1.35908	4.21	8.49	1	weak (1/3)	1.96	0.88	expressed	22.0	Database Ubiquitination	trait_unrelated		93: neuroimaging measurement; 10: type 2 diabetes mellitus; 8: white matter integrity; 5: uric acid measurement; 3: glomerular filtration rate	145.0			Brak wskazania.	90.443	9.5568	1551	1444	2	T2: Komorbidalność	Komorbidalność: tissue=expressed (brak biologii w tkance ADR)	3	6	2	3.3	BURDEN; HIGH_PLEIOTROPY_n145	-0.0783823	0.169657	0.191062	-0.108652	0.534615	0.0762626	0.9853562472432374	0.9545762953969218	0.7196337411879101	0.0	4.6753660279232845	3.210665188507963	3	curated	0.19847	Bladder	1.0	0.19847	Bladder	1.0	4.3248052776765835	-0.6434229617715417	1	0.0036957985468470188	0.5268527048603654	1	1	1	DUSP9	0.41499310075452894	1		HIGH replicated	138	1306	4.2875	8.3833	674	2689	0.0	0	2.51768	0.00113081	0.000197945	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_04_03_simvastatin__R31	simvastatin__R31	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	R31	Krwiomocz	Unspecified haematuria	COL4A4		COL4A4_lof		0.00108025	4.6109	0.842855	7.34815	3.49506	0.865217	0.148097	1.0	3.19746	0.279241	29.6315	1.59	1.44	2	STRONG (ROR+PRR+IC)	4.21	1.93	specific	2.0	Approved Drug	trait_match	3: urinary albumin to creatinine ratio; 2: albuminuria	3: body mass index; 3: systolic blood pressure; 3: urinary albumin to creatinine ratio; 2: albuminuria; 2: diastolic blood pressure	30.0			Nie wskazanie. Rzadka ADR statyn (rhabdomyolysis → myoglobinuria może być mylona z krwiomoczem).	89.817	1.2729	1287	1257	2	T2: Komorbidalność	Komorbidalność: amp_ratio=1.44<1.5 (gen reaguje podobnie z lekiem i bez)	0	8	8	3.17	BORDERLINE_RATIO; BURDEN; PHEWAS_ATLAS_MATCH; CURATOR_NOT_INDICATION	0.0576386	0.0486047	0.627684	0.325255	0.170814	1.24496	0.8348368914278899	0.7467166979362101	0.8017988817761931	0.0	1.8663942368753237	1.8642120508584337	3	curated	0.37848	Bladder	2.0	0.37848	Bladder	2.0	2.7744182975457106	-0.05784491338536593	1	0.0	0.3047239360483198	1	2	1	COL4A4	0.2805293080232221	1		MED repl-underpowered	16	1129	3.5647	5.9384	534	2289	8.9101	0	1.44629	0.0025641	0.00105282	1	0	12	0						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_25_27_atenolol__R252	atenolol__R252	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	R252	Kurcze mięśni	Cramp and spasm	LYL1		LYL1_mpc		0.000567002	66.5776	10.7457	9.23656	0.0430801	26.1216	0.904177	0.0113525	4.5711	1.72788	2.08846	5.7	14.56	0	weak (1/3)	1.84	0.78	low		Unknown	trait_unrelated		5: monocyte count; 3: platelet volume; 2: mean reticulocyte volume; 2: monocyte percentage of leukocytes; 2: self reported educational attainment	21.0			Nie wskazanie. β-blokery mogą powodować fatigue mięśniowe/kurcze u aktywnych fizycznie.	94.792	5.2083	2436	96	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	5	6	1	3.11	BURDEN; LOW_PLEIOTROPY_n21; CURATOR_NOT_INDICATION	0.514364	0.213408	1.79745	0.202699	0.650852	0.121783	0.9226491874984508	0.8191114489048572	0.829835507657402	0.0	-1.374133759232348	-0.9517448978294167	1	curated							0.8833666333699217	-0.7917968843184326	1	0.0	0.3670100209439617	1	3	1	LYL1	0.47009794928099674	1		MED repl-underpowered	5	91	6.6694	10.675	880	3588	0.0	0	-0.120387	0.000405448	0.000645548	0	0	0	0						C1	C	Carrier-depleted (weak confounder)	C	C	model	C
dzesikahoinkis_plinktestset_2026_04_20_13_04_23_atorvastatin__K589	atorvastatin__K589	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	K589	IBS bez biegunki	IBS without diarrhoea	LINC01968	rs111407300	3-194777159-C-T	MODIFIER	0.00980078	3.6198	0.600983	8.76683	2.78899	0.74177	0.166742	2.0	0.146749	0.102603	0.816322	5.7	24.67	0	no_signal	0.8	-0.55	low	72.0	Unknown	trait_unrelated		12: hemoglobin measurement; 8: erythrocyte count; 8: hematocrit; 5: body height; 4: reticulocyte amount	79.0	LINC01968 / IBS without diarrhoea (K58.9). LINC01968 (lincRNA). Brak bezpośredniej asocjacji GWAS Catalog z IBS. Top loci IBS (Eijsbouts 2021, Nat Genet): NCAM1, CADM2, PHF2/FAM120AOS, DOCK9, CKAP2L, BAG6 - brak LINC01968.	-	Brak wskazania.	82.879	17.121	1029	257	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	6	5	1	3.11	LIT_NO_PRIOR_HIT	-0.0456131	0.0285955	0.955904	0.0169164	0.0560419	0.11761	0.9985687299065551				-0.1587412833828451		3	curated							0.0	-0.049393395872227186	1	0.0	0.4179799762470109	0	1	1	LINC01968	0.4916971872952654	0		MED repl-underpowered	44	213	2.8172	8.3532	406	2395	0.0	0	1.38275	0.0222222	0.00907058	2	0	73	0	upstream_gene_variant	lncRNA	-	-	0.0018	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_26_29_ramipril__K589	ramipril__K589	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	K589	IBS bez biegunki	IBS without diarrhoea	ENSG00000301403	rs151129650	14-74395271-G-C	MODIFIER	0.0061092	3.84461	0.683261	7.73629	2.78278	1.02476	0.317929	1.0	0.328356	0.125765	2.04424	5.06	11.71	1	STRONG (ROR+PRR+IC)	24.82	4.44	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	87.097	12.903	1268	186	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000301403') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	1	7	4	3.04	NO_GENE_SYMBOL	0.0189173	0.0395482	0.198999	0.088852	0.0737599	0.641392							3	curated								-0.06649602458176929	1	0.0	0.5438052149168566	1	1	1	ENSG00000301403	0.5391511545808475	1		MED repl-underpowered	24	162	3.4716	7.9918	555	2155	0.0	0	0.998722	0.016129	0.00635719	1	0	41	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_57_39_clopidogrel__M542	clopidogrel__M542	clopidogrel	I21, I25.2, I63, I65, I70.2, I73.9	Profilaktyka zdarzeń miażdżycowych po zawale (I21/I25), udarze niedokrwiennym (I63), choroba tętnic obwodowych (I70/I73), ostre zespoły wieńcowe	M542	Bóle szyi	Cervicalgia	NR2F1-AS1	rs116458234	5-93360700-G-A	MODIFIER	0.00701344	6.96311	1.28767	7.19452	9.42382	1.48478	0.130833	1.0	-0.177	0.128639	0.772531	5.52	39.34	1	weak (1/3)	1.3	0.19	low		Unknown	trait_unrelated		2174: body height; 661: blood protein amount; 642: fatty acid amount; 638: body mass index; 584: BMI-adjusted waist-hip ratio	47702.0		-	Nie wskazanie. Arthralgia/myalgia – listed ADR klopidogrelu (post-marketing).	68.657	31.343	832	67	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=7.2<7.5 (artefakt opposite-sign)	5	5	1	2.92	PRE_EXISTING; HIGH_PLEIOTROPY_n47702; CURATOR_NOT_INDICATION	-0.0266681	0.0135773	1.3053	-0.160663	0.10293	0.926108	0.7530908650966606				1.1576122181870196		2	curated	0.92118	Muscle - Skeletal	1.0	0.92118	Muscle - Skeletal	1.0	2.2023348310524677	-0.05181289463376313	1	0.0	0.39938297118303856	0	1	1	NR2F1-AS1	0.45879940704175276	0		MED repl-underpowered	21	46	2.2779	5.8508	239	1422	0.0	0	1.51083	0.0416667	0.0104634	1	0	26	1	downstream_gene_variant	lncRNA	-	-	0.0046	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_25_27_simvastatin__J449	simvastatin__J449	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	J449	POChP, nieokreślona	COPD, unspecified	CADM2		CADM2_cnv_gene_down		0.000642041	5.10194	1.01689	6.28039	10.6448	0.933218	0.0112667	1.0	-0.31706	0.630014	0.211278	4.53	16.09	3	STRONG (ROR+PRR+IC)	3.2	1.54	expressed	74.0	UniProt loc high conf	trait_match	11: forced expiratory volume, response to bronchodilator; 7: FEV/FVC ratio, response to bronchodilator; 1: chronic obstructive pulmonary disease, irritable bowel syndrome	72: body mass index; 43: risk-taking behaviour; 38: taste liking measurement; 27: alcohol consumption quality; 19: cigarettes per day measurement	646.0	Brak bezpośredniej asocjacji GWAS Catalog CADM2 (3p12.1) z POChP (J44.9). CADM2 (cell adhesion molecule 2, SynCAM) - jeden z najczęściej powtarzanych genów w GWAS behawioralnych: risk-taking propensity (Strawbridge 2018 Comm Biol, Karlsson Linnér 2019 Nat Genet), BMI/otyłość (Morris 2019), aktywność fizyczna, użycie alkoholu i cannabis, lifetime smoking (Liu 2019 GSCAN), educational attainment, neurotyczność, mood instability, depresja, autism. Indirect link do POChP możliwy przez asocjację z paleniem (FTND, smoking initiation/cessation - top SNPs CADM2 są GWS dla cech smoking phenotype). Top loci GWAS COPD/lung function: SERPINA1, CHRNA3/5 (15q25), HHIP (4q31), FAM13A, MMP3/12, RIN3, AGER. CADM2 nie figuruje w bezpośrednich GWAS POChP. Wariant burden _cnv_gene_down - sygnał prawdopodobnie pleiotropowy via behawioralne mediatory.		Nie wskazanie. Wspólne czynniki ryzyka (palenie). Badanie STATCOPE (Criner NEJM 2014) – simvastatin nie zapobiegał zaostrzeniom u biorców 40 mg/d × 12-36 mies., RCT zakończony jako futile. Statyny przepisywane CV-comorbid u palaczy. Komorbidalność populacyjna.	93.67	6.3302	1719	1169	2	T2: Komorbidalność	Komorbidalność: przeciwny znak BETA + L10P_disc=6.3<7.5 (artefakt opposite-sign)	0	10	5	2.92	BURDEN; PHEWAS_ATLAS_MATCH; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n646; TISSUE_RESCUE_BY_LIT_n11; CURATOR_NOT_INDICATION	0.0699287	0.05904	0.626641	-0.373634	0.184671	1.36604	0.8490665952460198	0.8815690218757858	0.7295194878859087	0.0	-0.758172887628777	-0.7943412564094484	1	curated	0.15587	Lung	1.0	0.15587	Lung	1.0	0.25288874395097544	-0.22279098360134372	1	0.0	0.5077198329156513	0	1	1	CADM2	0.3925672719706426	0		HIGH replicated	74	1095	4.627	3.3758	750	2720	0.0	0	2.53432	0.00333333	0.000507185	1	0	6	0						C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_29_55_citalopram__H612	citalopram__H612	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	H612	Zaleganie woskowiny	Impacted cerumen	-	rs80144718	11-75024965-T-C	MODIFIER	0.00671824	6.01471	1.20935	6.18213	18.2913	1.30199	0.0255957	0.0	-0.182268	0.187559	0.479969	5.06	33.0	1	moderate (ROR+PRR)	2.19	-0.01	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	72.131	27.869	1129	61	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	4	2	2.88	NO_GENE_SYMBOL	0.0497574	0.0247846	1.34982	-0.0409329	0.0769362	0.225701							2	curated								-0.30981992234863265	1	0.0	0.4128106958265322	0	1	1	-	0.40865844770110143	0		HIGH replicated	17	44	3.091	7.0773	180	2170	0.0	0	2.23229	0.0	0.00371353	0	0	14	0	intergenic_variant	-	-	-	0.002	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_23_58_simvastatin__I802	simvastatin__I802	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I802	Zakrzepowe zapalenie żył głębokich	Phlebitis and thrombophlebitis deep vessels lower extr.	F5	rs6025	1-169549811-C-T	MODERATE	0.0228021	1.81615	0.355222	6.49821	3.24493	0.432694	0.00652071	4.0	1.90365	0.102119	76.8293	0.24	0.95	2	weak (1/3)	1.48	0.41	specific	4.0	Approved Drug	trait_match	23: venous thromboembolism; 15: prothrombin time measurement; 11: coagulation factor V amount; 5: deep vein thrombosis; 3: phlebitis, Thrombophlebitis	43: blood protein amount; 23: venous thromboembolism; 21: protein measurement; 15: prothrombin time measurement; 14: tissue factor pathway inhibitor amount	347.0		GO:0005507:copper_ion_binding,GO:0005576:extracellular_region,GO:0030134:COPII-coated_ER_to_Golgi_transport_vesicle,GO:0031093:platelet_alpha_granule_lumen,GO:0033116:endoplasmic_reticulum-Golgi_intermediate_compartment_membrane,GO:0046872:metal_ion_binding	Nie wskazanie. Statyny mają słabe efekty antytrombotyczne (JUPITER – redukcja VTE o ~40% w wysokim ryzyku), ale nie wskazanie primarne. Komorbidalność naczyniowa.	89.163	10.837	1616	203	2	T2: Komorbidalność	Komorbidalność/plejotropia: |z|=0.24<2 + amp_ratio=0.95<1.3 (BETA tożsame; gen reaguje tak samo z lekiem i bez)	0	8	5	2.71	SHARED_RISK_LOCUS; PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n347; CURATOR_NOT_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[F5|NME7]	-0.0105718	0.0102278	0.520993	0.0534734	0.0330789	0.974786	0.9652233740978311	0.9863988870471229	0.6081354833481889	0.0	3.472639293180049	0.7040534885769905	2	curated	0.7644	Artery - Tibial	2.0	0.7644	Artery - Tibial	2.0	3.0063853277363037	-0.12578086026830615	1	0.5458235568971362	0.16622002644186631	1	8	1	F5	0.16041857947044458	1		HIGH replicated	22	181	4.4244	6.9843	724	2498	0.0	0	2.72038	0.0625	0.0208609	2	1	248	2	missense_variant	protein_coding	deleterious(0)	probably_damaging(0.936)		C10	P	Major-effect disease locus (Factor V Leiden)	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_23_58_simvastatin__I802	simvastatin__I802	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	I802	Zakrzepowe zapalenie żył głębokich	Phlebitis and thrombophlebitis deep vessels lower extr.	NME7	rs144737447	1-169191220-C-T	MODIFIER	0.0232081	2.00086	0.351991	7.88188	2.44505	0.480014	0.0625213	3.0	1.7706	0.102223	66.485	0.63	1.13	1	weak (1/3)	1.48	0.41	enriched	101.0	Structure with Ligand	trait_match	6: venous thromboembolism; 2: coagulation factor V amount; 1: D dimer measurement; 1: coronary artery disorder, factor VII measurement; 1: factor VIII measurement, coronary artery disorder	31: electrocardiography; 7: QT interval; 6: venous thromboembolism; 5: pulse pressure measurement; 4: blood coagulation disease	107.0	NME7 / Phlebitis and thrombophlebitis of deep vessels of lower extremities (I80.2). Brak bezpośredniej asocjacji GWAS Catalog NME7 (1q24.2) z głęboką zakrzepicą żylną (DVT). NME7 (nucleoside diphosphate kinase 7) - rola w biogenezie rzęsek i lewo-prawej asymetrii; brak GWS hitów naczyniowych. Top loci GWAS VTE (Lindström 2019, Thibord 2022): F5 (Leiden), F2 (prothrombin), ABO, FGG, F11, SLC44A2.	GO:0000931:gamma-tubulin_ring_complex,GO:0003351:epithelial_cilium_movement_involved_in_extracellular_fluid_movement,GO:0004550:nucleoside_diphosphate_kinase_activity,GO:0004672:protein_kinase_activity,GO:0005515:protein_binding,GO:0005524:ATP_binding,GO:0005576:extracellular_region,GO:0005634:nucleus,GO:0005654:nucleoplasm,GO:0005737:cytoplasm,GO:0005813:centrosome,GO:0005819:spindle,GO:0005829:cytosol,GO:0005856:cytoskeleton,GO:0005879:axonemal_microtubule,GO:0005886:plasma_membrane,GO:0005929:cilium,GO:0006183:GTP_biosynthetic_process,GO:0006228:UTP_biosynthetic_process,GO:0006241:CTP_biosynthetic_process,GO:0006308:DNA_catabolic_process,GO:0007224:smoothened_signaling_pathway,GO:0007368:determination_of_left/right_symmetry,GO:0007420:brain_development,GO:0008296:3'-5'-DNA_exonuclease_activity,GO:0010968:regulation_of_microtubule_nucleation,GO:0016301:kinase_activity,GO:0016740:transferase_activity,GO:0016787:hydrolase_activity,GO:0030317:flagellated_sperm_motility,GO:0031514:motile_cilium,GO:0036064:ciliary_basal_body,GO:0036126:,GO:0042073:intraciliary_transport,GO:0042995:cell_projection,GO:0043113:receptor_clustering,GO:0060271:cilium_assembly,GO:0060972:left/right_pattern_formation,GO:0160111:axonemal_A_tubule_inner_sheath,GO:1990830:cellular_response_to_leukemia_inhibitory_factor	Nie wskazanie. Statyny mają słabe efekty antytrombotyczne (JUPITER – redukcja VTE o ~40% w wysokim ryzyku), ale nie wskazanie primarne. Komorbidalność naczyniowa.	89.163	10.837	1616	203	2	T2: Komorbidalność	Komorbidalność/plejotropia: |z|=0.63<2 + amp_ratio=1.13<1.3 (BETA tożsame; gen reaguje tak samo z lekiem i bez)	0	6	4	2.29	SHARED_RISK_LOCUS; PHEWAS_ATLAS_MATCH; LIT_NO_PRIOR_HIT; HIGH_PLEIOTROPY_n107; CURATOR_NOT_INDICATION; LOCUS_HETEROGENEOUS_MULTI_GENE[F5|NME7]	-0.00995916	0.0101847	0.48393	0.0535727	0.032841	0.987872	0.5641010537823824	0.6576923076923078	0.5160845960619074	0.0	1.0545674423488673	0.4241891821716691	2	curated	0.7644	Artery - Tibial	2.0	0.7644	Artery - Tibial	2.0	2.796732403707223	-0.03179039935759381	1	0.35200224151486503	0.17502712912157806	1	7	1	NME7	0.19421022233065455	1		HIGH replicated	22	181	4.4244	6.9843	724	2498	0.0	0	1.86258	0.046875	0.0219371	1	1	261	2	intron_variant	protein_coding	-	-	0.0054	C10	P	Major-effect disease locus (Factor V Leiden)	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_46_07_atorvastatin__H409	atorvastatin__H409	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	H409	Jaskra, nieokreślona	Glaucoma, unspecified	-	rs190862969	4-130925968-C-T	MODIFIER	0.00589328	3.967	0.711106	7.61544	5.39947	0.78223	0.0311024	2.0	-0.0538579	0.183692	0.113863	5.47	73.66	1	weak (1/3)	1.17	0.02	no_gene_symbol		Unknown	no_gene_symbol				Brak symbolu VEP dla wariantu - niemożliwe cross-reference w GWAS Catalog dla glaucoma (H40.9). Top loci GWAS POAG/glaucoma (Gharahkhani 2021): CAV1/2, TMCO1, CDKN2B-AS1, SIX6, ABCA1, AFAP1, GAS7.	-	Brak wskazania.	89.14	10.86	902	221	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	6	1	2.62	NO_GENE_SYMBOL; LOCUS_LEAD_rs190862969	0.0256836	0.0371934	0.309934	0.0453749	0.0728176	0.273111							1	curated_weak								-0.11297283606081256	1	0.0	0.4820560725825801	0	1	1	-	0.47160187120010194	0		HIGH replicated	24	197	2.4695	8.0794	364	2412	0.0	0	2.15576	0.0344828	0.00594059	2	0	48	0	intergenic_variant	-	-	-	0.0014	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_46_07_atorvastatin__H409	atorvastatin__H409	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	H409	Jaskra, nieokreślona	Glaucoma, unspecified	-	rs368321957	4-131232615-T-C	MODIFIER	0.00563705	3.96103	0.748249	6.92139	6.22326	0.786983	0.02017	2.0	-0.0823451	0.186889	0.180788	5.24	48.1	1	weak (1/3)	1.17	0.02	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	89.14	10.86	902	221	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL; LOCUS_TAGGED_BY_rs190862969	0.0290347	0.038031	0.35145	0.0249154	0.074372	0.132169							1	curated_weak								-0.15377591130818657	2	0.0	0.48470882468735454	0	1	2	-	0.44888546191277756	0		HIGH replicated	24	197	2.4695	8.0794	364	2412	0.0	0	2.32317	0.0344828	0.00556931	2	0	45	0	intergenic_variant	-	-	-	0.0006	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_57_16_atenolol__H931	atenolol__H931	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	H931	Szumy uszne	Tinnitus	-	rs73236614	X-140839067-C-T	MODIFIER	0.00633312	5.53306	1.11122	6.19502	5.68381	0.789002	0.0276438	0.0	0.0130374	0.159657	0.0292265	4.92	424.4	1	weak (1/3)	1.94	0.76	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Tinnitus opisywany jako ADR β-blokerów w FAERS/VigiBase.	91.667	8.3333	2700	72	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	-0.0342752	0.0233617	0.846688	0.0781233	0.0696421	0.581774							2	curated_weak								-0.01283723068380277	1	0.0	0.5608549651869542	1	1	1	-	0.491774537731249	1		HIGH replicated	6	66	7.3922	2.4449	1245	4666	0.0	0	2.2023	0.0	0.00376238	0	0	11	4	intergenic_variant	-	-	-	0.0005	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_02_51_bisoprolol__L989	bisoprolol__L989	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	L989	Choroba skóry	Disorder of skin, unspecified	ENSG00000302198	rs570854059	20-57987672-A-G	MODIFIER	0.00596979	6.00034	1.17487	6.48556	7.97242	0.848213	0.0143857	2.0	-0.0379105	0.147251	0.0986358	5.1	158.28	1	no_signal	1.06	-0.18	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. β-blokery mogą powodować różne wykwity skórne (lichen planus-like, psoriasiform, eczematous) – udokumentowane ADR.	86.957	13.043	1099	92	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000302198') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.0522873	0.0502743	0.525316	0.0306943	0.0977667	0.122885							2	curated								-0.07479624390252708	1	0.0	0.495597624685606	0	1	1	ENSG00000302198	0.4647139868887814	0		HIGH replicated	12	80	3.0089	3.5756	522	2399	0.0	0	2.44749	0.0555556	0.00577478	2	0	24	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.001	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_02_51_bisoprolol__L989	bisoprolol__L989	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	L989	Choroba skóry	Disorder of skin, unspecified	-	rs114012253	2-157159365-C-T	MODIFIER	0.0112086	4.17477	0.812643	6.55479	8.06565	0.716414	0.00356857	2.0	0.0827366	0.108631	0.350391	4.99	50.46	1	no_signal	1.06	-0.18	no_gene_symbol		Unknown	no_gene_symbol				Brak symbolu VEP dla wariantu - niemożliwe cross-reference w GWAS Catalog dla nieokreślonego zaburzenia skóry (L98.9).	-	Nie wskazanie. β-blokery mogą powodować różne wykwity skórne (lichen planus-like, psoriasiform, eczematous) – udokumentowane ADR.	86.957	13.043	1099	92	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	5	1	2.15	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.00769673	0.0375044	0.0770678	0.0385501	0.0717706	0.228281							2	curated								-0.21183741697311992	1	0.0	0.5029081859077218	0	1	1	-	0.4774589387978816	0		HIGH replicated	12	80	3.0089	3.5756	522	2399	0.0	0	2.91398	0.0555556	0.0115496	2	0	48	0	intergenic_variant	-	-	-	0.0048	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_44_40_citalopram__R074	citalopram__R074	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	R074	Ból w klatce piersiowej	Chest pain	ENSG00000295630	rs139074265	2-122983571-C-T	MODIFIER	0.00766725	2.84122	0.570389	6.19935	3.44286	0.609641	0.0425684	2.0	0.0567127	0.0860344	0.29262	4.83	50.1	1	weak (1/3)	1.63	0.61	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Objawy somatyczne lęku. SSRI związane z kołataniem/bólem w klatce jako łagodne ADR.	99.273	0.72727	831	275	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000295630') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.0105172	0.0236947	0.18234	-0.0537321	0.0729772	0.335775							3	curated								-0.06751897607559915	1	0.0	0.573880752106349	1	1	1	ENSG00000295630	0.48365281359119183	1		HIGH replicated	2	273	2.2752	6.6612	233	1822	0.0	0	2.02792	0.0263158	0.00782093	2	0	27	1	downstream_gene_variant	lncRNA	-	-	0.0028	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_34_17_fluoxetine__K20	fluoxetine__K20	fluoxetine	F32, F33, F42, F50.2	Epizody depresyjne (F32/F33), zaburzenia obsesyjno-kompulsyjne (F42), bulimia (F50.2)	K20	Zapalenie przełyku	Oesophagitis	-	rs138483345	9-27719841-A-G	MODIFIER	0.00858673	4.78024	0.920253	6.68763	9.46873	0.867245	0.00953889	2.0	-0.0767434	0.106659	0.326225	5.24	62.29	1	weak (1/3)	1.98	0.58	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. SSRI zwiększają ryzyko krwawienia GI (OR ~1.5) i uszkodzeń esophageal (interakcja z NSAID). Sygnał ADR.	87.5	0.96154	1849	104	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.0177235	0.0120051	0.854318	-0.0836241	0.0724868	0.60442							3	curated								-0.21307529561002608	1	0.0	0.5526084171504348	0	1	1	-	0.5111268632758253	0		HIGH replicated	1	91	5.0623	6.0561	734	3899	11.538	0	2.59211	0.0666667	0.0106383	2	0	35	0	intergenic_variant	-	-	-	0.0072	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_48_43_losartan__L089	losartan__L089	losartan	I10, I50, E10.2, E11.2, N08, I63	Nadciśnienie tętnicze (I10), niewydolność serca przy nietolerancji ACE-I (I50), nefropatia cukrzycowa typu 2 (E11.2/N08), profilaktyka udaru przy LVH (I63)	L089	Miejscowe zakażenie skóry	Local skin infection	-	rs573957134	20-56216436-A-G	MODIFIER	0.00661406	8.51985	1.39436	9.00225	0.788408	1.46593	0.871167	0.0	0.049382	0.148775	0.130799	6.04	172.53	0	no_signal	1.13	-0.4	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	87.654	12.346	1237	81	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL	0.0926	0.0518214	1.13105	0.0626293	0.117383	0.226466							2	curated								-0.7675213576297772	1	0.0	0.3952807046613108	0	1	1	-	0.5583866433397252	0		MED repl-underpowered	10	71	3.3867	14.631	502	2988	0.0	0	-0.162177	0.0	0.0105023	0	0	23	0	intergenic_variant	-	-	-	0.001	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_02_56_simvastatin__F03	simvastatin__F03	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	F03	Demencja, nieokreślona	Unspecified dementia	-	rs145266573	2-198790131-G-A	MODIFIER	0.00792837	4.02719	0.819324	6.05224	9.59606	0.753419	0.00268693	1.0	-0.00571366	0.246437	0.00810852	4.71	402.72	1	weak (1/3)	1.99	0.78	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Jak dla G30.9 – observational meta-analiza pokazuje RR~0.85 (protective) u statyn, potencjalne healthy-user bias. RCT neutralne (PROSPER, HPS).	94.059	0.0	1759	101	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.0107164	0.017036	0.276283	0.0313065	0.0561071	0.23893							4	curated	0.81282	Brain - Cortex	3.0	0.81282	Brain - Cortex	3.0		-0.27203895273250234	1	0.0	0.5444871260749433	0	1	1	-	0.4505406469203663	0		HIGH replicated	0	95	4.8159		927	3248	5.9406	0	3.00145	0.0294118	0.00751445	1	0	89	1	intergenic_variant	-	-	-	0.0036	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_18_03_27_simvastatin__H000	simvastatin__H000	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	H000	Jęczmień	Hordeolum	ENSG00000308003	rs139975518	4-140225948-A-G	MODIFIER	0.00846262	4.46242	0.897999	6.17264	5.00953	0.775914	0.0378291	1.0	0.352817	0.254012	0.782939	4.4	12.65	1	no_signal	0.73	-1.32	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	94.167	5.8333	1463	120	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000308003') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL	-0.00730864	0.0163245	0.184181	-0.0242885	0.0532454	0.188241							2	curated								-0.05537054687132667	1	0.0	0.39853211128698696	0	1	1	ENSG00000308003	0.3906011525687781	0		HIGH replicated	7	113	4.0055	0.90897	735	2428	0.0	0	2.0767	0.0384615	0.00924245	1	0	112	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0038	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_19_41_simvastatin__Z501	simvastatin__Z501	simvastatin	E78.0, E78.2, E78.5, I25, I63, I65, E11	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka chorób sercowo-naczyniowych (I25/I63), wysokie ryzyko CV w cukrzycy (E11)	Z501	Inne formy fizjoterapii	Other physical therapy	-	rs142781610	5-29231711-A-G	MODIFIER	0.0063256	3.99898	0.80316	6.19454	5.66919	0.733654	0.0180331	1.0	0.180485	0.110616	0.988195	4.71	22.16	1	n/a (skip)			no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	100.0	0.0	1474	162	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	5	1	2.47	NO_GENE_SYMBOL	-0.0278591	0.0187846	0.859954	-0.00441947	0.0614379	0.0256475							1	curated_weak								-0.1244874064839773	1	0.0	0.35954532491916524	0	1	1	-	0.35982727775929074	0		HIGH replicated	0	162	4.0356		516	2451	0.0	0	2.36494	0.0192308	0.00611975	1	0	72	1	intergenic_variant	-	-	-	0.0022	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_17_26_07_ramipril__K20	ramipril__K20	ramipril	I10, I50, I21, I25, I70, E10.2, E11.2, N08	Nadciśnienie tętnicze (I10), niewydolność serca (I50), profilaktyka po zawale (I21/I25), profilaktyka sercowo-naczyniowa u pacjentów wysokiego ryzyka (I70), nefropatia (E10.2/E11.2/N08)	K20	Zapalenie przełyku	Oesophagitis	-	rs182355394	X-89108942-C-T	MODIFIER	0.0225379	1.41098	0.2409	8.32703	1.76306	0.401403	0.157753	4.0	0.139919	0.0582921	1.78565	5.13	10.08	1	STRONG (ROR+PRR+IC)	3.39	1.44	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie bezpośrednie. Kaszel ACEi (10–12%) może być mylnie kodowany jako GERD, ACEi rzadko opisywane jako przyczyna zmian przełykowych. Słaba komorbidalność/misklasyfikacja.	89.971	0.29499	1400	339	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	0	7	4	2.41	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.00340725	0.0178088	0.071465	0.00989171	0.0328444	0.117313							3	curated								-0.017960239337441675	1	0.0	0.5166658397925541	1	1	1	-	0.5344242811982244	1		LOW unreplicated	1	305	3.833	4.6105	637	2616	9.7345	0	1.41267	0.0408163	0.0188039	0	2	60	31	intergenic_variant	-	-	-	0.0058	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_15_53_atenolol__N920	atenolol__N920	atenolol	I10, I20, I47, I48, I25	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), arytmie nadkomorowe (I47/I48), profilaktyka po zawale (I25)	N920	Obfite miesiączki	Excessive menstruation	-	rs112437286	4-29761337-A-T	MODIFIER	0.00580536	6.66799	1.15008	8.17278	5.41838	1.29551	0.192115	0.0	0.105031	0.128163	0.384581	5.67	63.49	0	no_signal	0.48	-1.64	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	94.0	6.0	794	100	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	4	1	2.29	NO_GENE_SYMBOL; LOCUS_LEAD_rs112437286	0.00117487	0.0319308	0.0129378	-0.0816394	0.0818131	0.49711							1	curated	0.10815	Ovary	2.0	0.10815	Ovary	2.0		-0.0839001623837895	2	0.0	0.3961893756670917	0	1	2	-	0.47460395470356276	0		MED repl-underpowered	6	94	2.1739	1.0732	262	1753	0.0	0	1.30435	0.0	0.00794913	0	0	40	0	intergenic_variant	-	-	-	0.002	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_17_41_citalopram__B351	citalopram__B351	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	B351	Grzybica paznokci	Tinea unguium	-	rs189578781	1-116222102-C-T	MODIFIER	0.00664948	7.92766	1.34294	8.44796	5.77847	1.26297	0.164862	0.0	-0.214737	0.162469	0.729869	6.02	36.92	0	n/a (skip)			no_gene_symbol		Unknown	no_gene_symbol				Brak symbolu VEP dla wariantu - niemożliwe cross-reference w GWAS Catalog dla tinea unguium (B35.1). B35.1 jako ADR citalopramu to prawdopodobnie confounding/zbieżność (infekcja grzybicza paznokci nie ma predyktorów genetycznych common-variant).	-	Brak związku.	80.0	20.0	644	90	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	4	1	2.29	NO_GENE_SYMBOL; LOCUS_LEAD_rs189578781	-0.00422852	0.0251769	0.062171	-0.0408661	0.0766262	0.22635							2	curated								-0.1578888785975091	2	0.0	0.29081721409091293	0	1	2	-	0.4046152977541199	0		MED repl-underpowered	18	72	1.7632	5.358	357	1821	0.0	0	1.3889	0.0	0.00505051	0	0	19	0	intergenic_variant	-	-	-	0.0022	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_59_20_diazepam__D649	diazepam__D649	diazepam	F41.1, F10.3, R56.8, G40, M62.4, F51.0, Z51.4	Krótkotrwałe leczenie lęku (F41.1), zespół odstawienny alkoholu (F10.3), drgawki/stan padaczkowy (G40/R56.8), spastyczność mięśni (M62.4), bezsenność krótkotrwała (F51.0), premedykacja (Z51.4)	D649	Niedokrwistość, nieokreślona	Anaemia, unspecified	-	rs117410228	20-9059027-G-A	MODIFIER	0.0203243	3.28667	0.581307	7.8046	5.27335	0.506145	0.00101999	3.0	0.0871365	0.0588232	0.858491	5.48	37.72	1	no_signal	1.07	-0.06	no_gene_symbol		Unknown	no_gene_symbol				Brak mapowania VEP do genu - cross-reference niemożliwy.	-	Brak wskazania. Koincydencja – pacjenci starsi/przewlekle chorzy częściej otrzymują BDZ i mają anemię niespecyficzną.	98.131	1.8692	657	107	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	6	1	2.29	NO_GENE_SYMBOL	-0.00766031	0.0160527	0.198444	0.00494935	0.0409604	0.0439164							2	curated	0.5367	Spleen	2.0	0.5367	Spleen	2.0		-0.15609294343408947	1	0.0	0.5780891940849504	0	1	1	-	0.5867172751533333	0		HIGH replicated	2	105	1.7988	14.313	37	2676	0.0	0	3.28496	0.1	0.0174077	3	0	81	1	intergenic_variant	-	-	-	0.0072	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_16_29_bisoprolol__R634	bisoprolol__R634	bisoprolol	I10, I20, I50, I48	Nadciśnienie tętnicze (I10), dusznica bolesna (I20), niewydolność serca - przewlekła stabilna (I50), migotanie przedsionków (I48)	R634	Nieprawidłowa utrata masy ciała	Abnormal weight loss	ENSG00000242880	rs4277658	3-115339675-G-A	MODIFIER	0.0571394	1.60378	0.299312	7.07544	3.14071	0.411316	0.00539576	8.0	-0.00292198	0.0458397	0.0226539	5.31	160.38	1	weak (1/3)	1.47	0.48	no_gene_symbol		Unknown	no_gene_symbol				ENSG00000242880 / Abnormal weight loss (R63.4). Gen bez symbolu HGNC - niemożliwe cross-reference w GWAS Catalog (indeksowanym po symbolach/rsID). R63.4 jako fenotyp ADR bisoprololu - głównie efekt farmakologiczny ?-blokera, brak solidnej bazy GWAS.	-	Nie wskazanie. Niespecyficzne.	98.718	1.2821	1006	156	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000242880') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	5	1	2.15	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	-0.0287953	0.0170443	1.04031	-0.0289326	0.0314745	0.446153							3	curated								-0.13205820935493173	1	0.0	0.5892986283082231	0	1	1	ENSG00000242880	0.5865497857314618	0		HIGH replicated	2	154	2.7543	5.744	292	2214	0.0	0	2.78241	0.148148	0.0618656	6	1	244	6	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0627	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_10_44_13_amlodipine__B349	amlodipine__B349	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	B349	Zakażenie wirusowe	Viral infection, unspecified	ENSG00000295272	rs191054889	5-2555671-T-C	MODIFIER	0.00704727	5.67081	1.06272	7.02247	5.05406	1.12327	0.149193	1.0	0.270484	0.178317	0.888405	5.01	20.97	0	n/a (skip)			no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	97.03	2.9703	1315	101	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000295272') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	3	1	2.08	NO_GENE_SYMBOL	-0.0396825	0.0163642	1.81502	-0.0748614	0.0647671	0.606003							2	curated								-0.03063686284806838	1	0.0	0.3293188279462284	0	1	1	ENSG00000295272	0.3901347551757147	0		MED repl-underpowered	3	98	3.6003	3.5127	584	2327	0.0	0	1.44239	0.0384615	0.00684932	1	0	50	0	downstream_gene_variant	lncRNA	-	-	0.0022	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_12_32_03_atorvastatin__F419	atorvastatin__F419	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	F419	Zaburzenia lękowe	Anxiety disorder	-	rs193041764	9-68662929-A-G	MODIFIER	0.00531676	4.14181	0.758894	7.31662	2.65421	0.777367	0.209221	1.0	0.0280116	0.139041	0.0755468	5.33	147.86	0	weak (1/3)	1.09	0.07	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Niektóre doniesienia o związku statyn z nastrojem/lękiem (mechanizm neurosteroidowy), ale słabe dowody.	99.608	0.39216	1043	255	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	3	1	2.08	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	-0.0242817	0.0377378	0.284044	-0.0271407	0.0741959	0.145988							3	curated	0.87948	Brain - Cortex	3.0	0.87948	Brain - Cortex	3.0		-0.10171543359615612	1	0.0	0.5069445686512865	1	1	1	-	0.5019238648694375	1		MED repl-underpowered	1	254	2.8556	0.0	363	2808	0.0	0	1.25571	0.0125	0.00670141	1	0	54	0	intergenic_variant	-	-	-	0.0024	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_16_14_31_gabapentin__A419	gabapentin__A419	gabapentin	G40, G50.0, M79.7, R52, G62.9	Padaczka - napady ogniskowe (G40), neuralgia (G50.0), ból neuropatyczny w tym poherpetyczny i cukrzycowy (M79.7/G62.9)	A419	Sepsa, nieokreślona	Sepsis, unspecified	ENSG00000287907	rs117452116	18-68414441-C-T	MODIFIER	0.0113114	4.53111	0.785919	8.08894	7.50007	1.12664	0.0737065	1.0	0.136082	0.11428	0.631265	5.53	33.3	0	n/a (skip)			no_gene_symbol		Unknown	no_gene_symbol				ENSG00000287907 / Sepsis unspecified (A41.9). Gen bez symbolu HGNC - niemożliwe cross-reference w GWAS Catalog. Top loci GWAS sepsy (Scherag 2016, Dubourg 2022): IVD, TIMM40, VPS13A.	-	Brak wskazania. Możliwe pośrednie konfundowanie: gabapentyna u hospitalizowanych (bóle, neuropatia) ↔ większa ekspozycja na infekcje szpitalne. Niska specyficzność.	100.0	0.0	469	109	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000287907') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	4	1	2.0	NO_GENE_SYMBOL	0.0505393	0.0542727	0.453772	-0.104901	0.0761868	0.773285							2	curated								-0.16506528247576285	1	0.0	0.3507983470456873	0	1	1	ENSG00000287907	0.43720550343852055	0		HIGH replicated	0	109	1.2841		127	1374	0.0	0	1.78843	0.0294118	0.00734266	1	0	21	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-		C7	P	Sub-threshold predisposition	P	P	model	C
dzesikahoinkis_plinktestset_2026_04_20_19_58_03_tramadol__R53	tramadol__R53	tramadol	R52, M79.7, M54, M25.5	Ból umiarkowany do silnego (R52), ból neuropatyczny (M79.7), bóle mięśniowo-szkieletowe (M54/M25.5)	R53	Złe samopoczucie i zmęczenie	Malaise and fatigue	ENSG00000225718	rs79486133	7-69273320-C-T	MODIFIER	0.0103002	3.41076	0.674927	6.36278	7.07341	0.799133	0.014362	2.0	-0.14389	0.112099	0.700523	5.2	23.7	1	weak (1/3)	1.45	0.48	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. Somnolencja/zmęczenie – najczęstsze ADR tramadolu (>10%). Możliwe subtelne confounding (opioidy przepisywane w chronic illness z fatigue).	79.339	0.82645	865	121	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000225718') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	4	1	2.0	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION; LOCUS_LEAD_rs79486133	-0.0247033	0.0221317	0.577841	-0.0230883	0.0549116	0.171245							2	curated	0.8485	Whole Blood	1.0	0.8485	Whole Blood	1.0		-0.23048878429494168	3	0.0	0.48267685226326895	0	1	3	ENSG00000225718	0.4482601280802382	0		HIGH replicated	1	96	2.3682	4.5038	131	1670	19.835	0	2.44808	0.047619	0.00929924	2	0	56	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.007	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_41_29_citalopram__N390	citalopram__N390	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	N390	ZUM	Urinary tract infection	-	rs143913044	3-192014844-G-A	MODIFIER	0.0170308	2.14635	0.405385	6.92342	2.5859	0.503376	0.0591057	5.0	0.0252638	0.0581435	0.177884	5.18	84.96	0	weak (1/3)	1.91	0.84	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	87.22	12.78	942	313	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	2	3	1	1.82	NO_GENE_SYMBOL	0.00306321	0.0160074	0.0714803	0.0498817	0.051905	0.47296							3	curated	0.6178	Bladder	1.0	0.6178	Bladder	1.0		-0.03705415441372473	1	0.0	0.5367874681315851	1	1	1	-	0.5149456725266511	1		HIGH replicated	40	273	2.5791	10.771	282	2305	0.0	0	1.88741	0.0454545	0.0190528	5	0	68	1	intergenic_variant	-	-	-	0.0056	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_14_41_51_citalopram__R05	citalopram__R05	citalopram	F32, F33, F40, F41.0, F42	Epizody depresyjne (F32/F33), zespół lęku napadowego z agorafobią lub bez (F41.0/F40), zaburzenia obsesyjno-kompulsyjne (F42)	R05	Kaszel	Cough	ENSG00000287292	rs116595899	4-148774352-C-T	MODIFIER	0.00773511	5.49473	1.04446	6.84339	4.25947	1.03695	0.162261	1.0	0.131474	0.14689	0.430908	5.08	41.79	0	weak (1/3)	1.52	0.52	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	77.011	0.0	1244	87	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000287292') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	2	1	1.82	NO_GENE_SYMBOL	-0.0282756	0.022794	0.667975	-0.107163	0.0693251	0.913105							1	curated								-0.06636294589205789	1	0.0	0.4484715334870369	1	1	1	ENSG00000287292	0.4744947239146573	1		MED repl-underpowered	0	67	3.4059		685	2585	22.989	0	1.39751	0.0384615	0.00691857	1	0	24	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.003	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_15_15_47_diazepam__M255	diazepam__M255	diazepam	F41.1, F10.3, R56.8, G40, M62.4, F51.0, Z51.4	Krótkotrwałe leczenie lęku (F41.1), zespół odstawienny alkoholu (F10.3), drgawki/stan padaczkowy (G40/R56.8), spastyczność mięśni (M62.4), bezsenność krótkotrwała (F51.0), premedykacja (Z51.4)	M255	Ból stawu	Pain in joint	ENSG00000282828	rs149121643	2-49605190-T-C	MODIFIER	0.00431761	4.80867	0.875027	7.40925	2.91465	1.12535	0.341811	0.0	0.0970648	0.128013	0.348425	5.33	49.54	0	no_signal	0.97	-0.16	no_gene_symbol		Unknown	no_gene_symbol					-	Off-label słaby. Diazepam jako miorelaksant w bólu ze skurczem mięśni (NICE LBP 2020 – NIE rekomenduje jako pierwsza linia).	56.316	43.684	1159	190	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000282828') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	3	2	1	1.82	NO_GENE_SYMBOL	-0.0109508	0.031388	0.13836	-0.0851349	0.0788649	0.552278							1	curated	0.18057	Muscle - Skeletal	1.0	0.18057	Muscle - Skeletal	1.0		-0.1239583754344481	1	0.0	0.2933495892526565	0	1	1	ENSG00000282828	0.364176594959856	0		MED repl-underpowered	83	107	3.1732	4.5832	141	3543	0.0	0	0.950593	0.0	0.00463353	0	0	20	1	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0014	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_40_02_amlodipine__N393	amlodipine__N393	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	N393	Wysiłkowe nietrzymanie moczu	Stress incontinence	-	rs147810021	X-4192675-T-G	MODIFIER	0.00537481	5.67586	1.15277	6.0709	5.60752	0.813954	0.0341589	0.0	0.398638	0.199589	1.3392	4.51	14.24	1	weak (1/3)	1.62	-0.01	no_gene_symbol		Unknown	no_gene_symbol					-	Nie wskazanie. CCB mogą pogarszać UI przez zmniejszenie kontraktylności pęcherza.	97.059	2.9412	1397	102	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	1	5	1	1.71	NO_GENE_SYMBOL; CURATOR_NOT_INDICATION	0.00586155	0.0144725	0.164012	0.104144	0.0640172	0.983894							1	curated	0.80325	Bladder	1.0	0.80325	Bladder	1.0		-0.0014654265185861381	1	0.0	0.5225758652448785	0	1	1	-	0.45851176947165506	0		HIGH replicated	3	99	3.8248	10.07	670	2953	0.0	0	2.11819	0.0	0.00438837	0	0	12	10	intergenic_variant	-	-	-	0.0019	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_13_06_50_atorvastatin__M720	atorvastatin__M720	atorvastatin	E78.0, E78.2, E78.5, I25, I63, I65	Hipercholesterolemia pierwotna i mieszana (E78), profilaktyka pierwotna i wtórna chorób sercowo-naczyniowych (I25/I63)	M720	Włókniakowatość powięzi dłoniowej (Dupuytren)	Palmar fascial fibromatosis	-	rs560768493	12-61170760-T-C	MODIFIER	0.00755877	4.21481	0.812707	6.66818	4.43753	0.750688	0.047147	2.0	0.485031	0.177046	2.211	4.48	8.69	1	n_too_low			no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	89.143	10.857	1127	175	2	T2: Komorbidalność	Brak symbolu genu ('-') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	1	5	1	1.71	NO_GENE_SYMBOL	-0.0243947	0.0314799	0.358148	-0.0319252	0.0616448	0.218579							2	curated	0.22539	Muscle - Skeletal	1.0	0.22539	Muscle - Skeletal	1.0		-0.0390425111219381	1	0.0	0.2912094482933614	0	1	1	-	0.3257207996400477	0		HIGH replicated	19	156	3.0856	5.3744	527	2875	0.0	0	1.98498	0.030303	0.00792864	2	0	62	1	intergenic_variant	-	-	-	0.0012	C4	I	Pre-existing condition (timing only)	I	I	model	C
dzesikahoinkis_plinktestset_2026_04_20_11_40_17_amlodipine__R103	amlodipine__R103	amlodipine	I10, I11, I20.1, I20.8	Nadciśnienie tętnicze (I10/I11), dusznica bolesna stabilna i Prinzmetala (I20)	R103	Ból w dole brzucha	Pain localized to other parts of lower abdomen	ENSG00000237761	rs141241625	10-104617964-A-G	MODIFIER	0.00861333	3.26663	0.602645	7.22596	2.79746	0.752367	0.171532	2.0	0.28296	0.106142	2.1147	4.88	11.54	0	weak (1/3)	1.23	0.13	no_gene_symbol		Unknown	no_gene_symbol					-	Brak wskazania.	94.718	5.2817	1409	284	2	T2: Komorbidalność	Brak symbolu genu ('ENSG00000237761') - wymagana ścieżka post-GWAS (eQTL/kolokalizacja)	1	3	1	1.44	NO_GENE_SYMBOL	-0.00485154	0.0150233	0.126827	-0.0210845	0.0588242	0.142656							3	curated	0.95485	Colon - Sigmoid	3.0	0.95485	Colon - Sigmoid	3.0		-0.02265913190514629	1	0.0	0.4737681919784743	1	1	1	ENSG00000237761	0.475662013055971	1		MED repl-underpowered	15	269	3.8576	3.6879	658	2566	0.0	0	1.3673	0.0227273	0.00911854	2	0	66	0	downstream_gene_variant	lncRNA	-	-	0.0028	C3	E	Replicated drug-triggered signal	E	E	model	C
dzesikahoinkis_plinktestset_2026_04_20_10_42_58_amitriptyline__R21	amitriptyline__R21	amitriptyline	F32, F33, F41.2, G43, G44.2, R52, M79.7, N39.4, F98.0	Depresja (F32/F33), zaburzenia lękowe (F41), profilaktyka migreny (G43), bóle głowy typu napięciowego (G44.2), ból neuropatyczny (R52/M79.7), nokturalne moczenie u dzieci (F98.0/N39.4)	R21	Wysypka	Rash	NETO1-DT	rs75178920	18-72875402-G-A	MODIFIER	0.0101098	4.05684	0.762635	6.98276	4.36352	1.08843	0.175872	1.0	0.113547	0.134155	0.400842	5.09	35.73	0	weak (1/3)	1.3	0.29	low		Unknown	trait_match	4: atopic eczema; 1: seborrheic dermatitis	569: body height; 264: body mass index; 229: high density lipoprotein cholesterol measurement; 206: fatty acid amount; 176: systolic blood pressure	15422.0		-	Nie wskazanie. Reakcje skórne (rash, photosensitivity) w SmPC amitriptyliny.	42.478	0.0	1116	113	2	T2: Komorbidalność	Komorbidalność: tissue=low (brak biologii w tkance ADR)	0	4	1	1.26	PHEWAS_ATLAS_MATCH; HIGH_PLEIOTROPY_n15422; CURATOR_KNOWN_ADR; EXPERT_DISAGREEMENT	-0.00402313	0.0217463	0.0689355	0.0445771	0.0515218	0.412374							2	curated								-0.04583369153306274	1	0.0	0.2492409868400923	1	1	1	NETO1-DT	0.32799361620562817	1		MED repl-underpowered	0	48	3.0554		333	3439	57.522	0	1.35358	0.0294118	0.00956474	1	0	69	0	intron_variant,non_coding_transcript_variant	lncRNA	-	-	0.0034	C5	E	Drug-triggered, no pharmacovigilance support	E	E	model	C